data_2kch_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2kch _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 5.4 m . . . . . 0 N--CA 1.457 -0.092 0 CA-C-O 121.038 0.447 . . . . 0.0 110.013 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 76.68 -35.45 1.4 Allowed Glycine 0 C--N 1.331 0.259 0 CA-C-N 115.849 -0.614 . . . . 0.0 113.703 179.069 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 7.3 pt-20 -58.13 143.84 42.49 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 121.615 0.721 . . . . 0.0 112.058 -178.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 53.6 m -95.11 121.35 36.65 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.034 -0.985 . . . . 0.0 110.658 179.688 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.77 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 13.7 p -88.08 61.17 6.17 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 121.258 0.552 . . . . 0.0 109.866 179.05 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 29.4 t80 -52.77 -44.5 66.56 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.368 -0.833 . . . . 0.0 110.555 -179.609 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -93.45 25.08 22.52 Favored Glycine 0 N--CA 1.449 -0.462 0 C-N-CA 120.639 -0.791 . . . . 0.0 112.399 179.223 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 75.59 -30.52 1.23 Allowed Glycine 0 CA--C 1.523 0.562 0 C-N-CA 121.485 -0.388 . . . . 0.0 113.789 179.579 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.5 m -89.1 148.95 23.42 Favored 'General case' 0 C--N 1.322 -0.59 0 O-C-N 122.367 -0.49 . . . . 0.0 111.293 -179.483 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 79.7 m -112.15 151.44 29.49 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.859 -0.61 . . . . 0.0 109.684 179.11 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -88.46 -21.64 24.1 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 120.895 0.379 . . . . 0.0 110.53 -179.214 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 4.3 m -100.71 123.38 45.98 Favored Pre-proline 0 C--N 1.323 -0.557 0 CA-C-O 121.148 0.499 . . . . 0.0 111.277 -179.1 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 29.7 Cg_endo -63.75 136.04 51.61 Favored 'Trans proline' 0 C--N 1.344 0.332 0 C-N-CA 122.823 2.348 . . . . 0.0 111.562 179.519 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 98.69 -21.39 46.19 Favored Glycine 0 N--CA 1.443 -0.834 0 C-N-CA 120.509 -0.853 . . . . 0.0 111.744 -179.228 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.534 ' SG ' ' HB3' ' A' ' 24' ' ' ARG . 71.3 m -86.73 126.35 34.52 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 121.212 0.529 . . . . 0.0 110.235 179.597 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 14.8 m -96.85 140.64 31.11 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 115.449 -0.796 . . . . 0.0 109.023 179.634 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 53.7 t -69.76 123.68 22.03 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-O 121.683 0.754 . . . . 0.0 111.92 -178.792 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 7.4 m -130.06 61.68 1.58 Allowed 'General case' 0 C--N 1.313 -0.997 0 N-CA-C 106.031 -1.84 . . . . 0.0 106.031 177.787 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . 0.478 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -27.51 125.71 0.22 Allowed Pre-proline 0 N--CA 1.463 0.198 0 CA-C-N 113.827 -1.533 . . . . 0.0 112.787 -176.576 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . 0.478 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 71.9 Cg_endo -98.03 38.07 5.82 Favored 'Cis proline' 0 N--CA 1.459 -0.533 0 C-N-CA 123.813 -1.328 . . . . 0.0 114.172 0.746 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.443 HD13 HG23 ' A' ' 21' ' ' ILE . 39.9 pt -143.44 136.9 25.21 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 O-C-N 121.6 -0.688 . . . . 0.0 112.026 -179.148 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.77 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 74.0 m -82.37 136.61 34.95 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-O 121.09 0.471 . . . . 0.0 110.236 178.923 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 67.0 p -127.3 123.47 36.47 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.857 -179.615 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.534 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 4.4 ptm180 -92.63 125.69 37.37 Favored 'General case' 0 N--CA 1.445 -0.702 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 178.519 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 58.62 26.75 14.86 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.257 0.551 . . . . 0.0 109.682 -178.941 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 84.11 3.27 89.09 Favored Glycine 0 N--CA 1.45 -0.428 0 CA-C-N 115.723 -0.671 . . . . 0.0 112.668 -179.402 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . 0.451 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 88.8 mt -102.91 121.5 48.97 Favored Pre-proline 0 C--N 1.328 -0.352 0 O-C-N 122.561 -0.376 . . . . 0.0 110.857 -179.947 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . 0.451 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 5.1 Cg_exo -76.98 47.22 2.15 Favored 'Trans proline' 0 C--N 1.343 0.246 0 C-N-CA 123.361 2.707 . . . . 0.0 112.307 179.827 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 10.7 p . . . . . 0 C--N 1.32 -0.692 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.402 -179.856 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.3 m . . . . . 0 CA--C 1.527 0.068 0 CA-C-O 120.962 0.41 . . . . 0.0 110.419 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 77.92 -36.39 1.68 Allowed Glycine 0 C--N 1.331 0.251 0 CA-C-N 115.969 -0.56 . . . . 0.0 113.166 179.415 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 11.8 pt-20 -58.27 137.26 57.26 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 121.5 0.667 . . . . 0.0 112.072 -179.244 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.493 ' HB ' ' CD1' ' A' ' 6' ' ' PHE . 10.6 p -91.15 117.52 29.68 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.37 -0.832 . . . . 0.0 109.804 179.221 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 28.2 p -88.92 57.97 4.37 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.012 0.434 . . . . 0.0 111.764 -178.521 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . 0.493 ' CD1' ' HB ' ' A' ' 4' ' ' THR . 5.3 m-85 -57.64 -38.07 74.4 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.99 179.423 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -89.9 18.06 49.6 Favored Glycine 0 CA--C 1.519 0.315 0 C-N-CA 120.639 -0.791 . . . . 0.0 112.861 179.841 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 62.31 39.48 97.79 Favored Glycine 0 C--N 1.331 0.27 0 C-N-CA 121.092 -0.575 . . . . 0.0 112.916 179.546 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 3.5 m -149.04 152.18 35.8 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 109.724 -0.473 . . . . 0.0 109.724 -179.996 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 56.8 m -129.94 143.4 50.78 Favored 'General case' 0 C--N 1.324 -0.522 0 O-C-N 123.21 0.319 . . . . 0.0 110.225 179.927 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 43.0 t30 -89.13 -18.11 27.86 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.026 -179.229 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.432 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 6.7 m -100.97 125.13 39.34 Favored Pre-proline 0 C--N 1.323 -0.558 0 CA-C-O 121.155 0.503 . . . . 0.0 111.671 -178.649 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_endo -64.41 138.52 60.61 Favored 'Trans proline' 0 C--N 1.346 0.395 0 C-N-CA 122.859 2.372 . . . . 0.0 111.626 179.541 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 93.67 -15.55 62.78 Favored Glycine 0 N--CA 1.447 -0.607 0 C-N-CA 120.726 -0.75 . . . . 0.0 111.557 -179.133 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.746 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 93.7 m -87.45 133.27 33.77 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 121.045 0.45 . . . . 0.0 110.163 179.606 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 14.6 m -110.54 136.58 49.44 Favored 'General case' 0 C--N 1.323 -0.56 0 N-CA-C 109.209 -0.663 . . . . 0.0 109.209 179.934 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.8 t -67.37 126.42 29.2 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-O 121.437 0.637 . . . . 0.0 111.914 -178.604 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 4.9 m -132.35 65.79 1.57 Allowed 'General case' 0 C--N 1.318 -0.79 0 N-CA-C 106.889 -1.523 . . . . 0.0 106.889 178.457 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . 0.45 ' CE3' ' HB3' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -27.71 126.67 0.22 Allowed Pre-proline 0 N--CA 1.465 0.289 0 CA-C-N 114.402 -1.272 . . . . 0.0 112.93 -176.684 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . 0.45 ' HB3' ' CE3' ' A' ' 19' ' ' TRP . 62.8 Cg_endo -97.68 30.72 12.97 Favored 'Cis proline' 0 N--CA 1.461 -0.43 0 C-N-CA 123.802 -1.333 . . . . 0.0 114.424 0.927 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.417 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 43.5 pt -138.65 142.58 34.32 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.36 0 CA-C-O 121.385 0.612 . . . . 0.0 111.448 -179.05 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.746 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 5.8 t -87.97 144.0 26.79 Favored 'General case' 0 C--N 1.314 -0.943 0 CA-C-O 121.137 0.494 . . . . 0.0 110.005 179.393 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 48.7 p -136.58 126.84 26.45 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-N 115.573 -0.74 . . . . 0.0 111.7 -178.58 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.659 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 9.1 ptm180 -91.47 126.9 36.71 Favored 'General case' 0 N--CA 1.445 -0.713 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 177.985 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 29.0 m-20 58.34 26.72 14.38 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 121.209 0.528 . . . . 0.0 109.911 -178.889 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 80.31 10.07 85.82 Favored Glycine 0 N--CA 1.45 -0.432 0 CA-C-N 115.864 -0.607 . . . . 0.0 112.363 -179.395 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 89.7 mt -113.15 128.54 25.52 Favored Pre-proline 0 C--O 1.236 0.379 0 CA-C-O 120.857 0.36 . . . . 0.0 110.755 -180.0 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.5 Cg_exo -73.76 52.94 2.65 Favored 'Trans proline' 0 CA--C 1.527 0.166 0 C-N-CA 123.619 2.879 . . . . 0.0 112.54 -179.839 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 39.4 t . . . . . 0 C--N 1.323 -0.57 0 CA-C-O 121.364 0.602 . . . . 0.0 110.206 -179.75 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.5 m . . . . . 0 N--CA 1.458 -0.058 0 CA-C-O 121.081 0.467 . . . . 0.0 110.191 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 77.16 -36.28 1.51 Allowed Glycine 0 C--N 1.332 0.331 0 CA-C-N 115.862 -0.608 . . . . 0.0 113.29 179.256 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 9.1 pt-20 -58.04 138.6 55.85 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 121.585 0.707 . . . . 0.0 112.181 -179.166 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.441 ' HA ' ' HA ' ' A' ' 21' ' ' ILE . 28.9 p -89.77 119.86 30.53 Favored 'General case' 0 N--CA 1.445 -0.675 0 CA-C-N 115.288 -0.869 . . . . 0.0 109.663 179.064 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 25.7 p -87.83 60.6 5.99 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 121.478 0.656 . . . . 0.0 110.507 -179.684 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 36.0 t80 -54.6 -41.5 70.01 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.353 -0.839 . . . . 0.0 110.613 179.942 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -94.33 22.93 34.26 Favored Glycine 0 N--CA 1.449 -0.492 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.733 179.611 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 75.25 -28.85 1.18 Allowed Glycine 0 CA--C 1.523 0.593 0 C-N-CA 121.192 -0.528 . . . . 0.0 113.94 179.382 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.8 m -88.43 151.05 22.82 Favored 'General case' 0 C--N 1.322 -0.616 0 O-C-N 122.522 -0.399 . . . . 0.0 111.445 -179.015 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 61.6 m -120.79 149.77 42.03 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.855 -0.611 . . . . 0.0 109.763 179.266 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 41.3 t30 -88.8 -21.33 23.81 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 121.115 0.483 . . . . 0.0 111.181 -179.227 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 6.4 m -101.08 124.2 42.4 Favored Pre-proline 0 C--N 1.323 -0.575 0 CA-C-O 121.239 0.542 . . . . 0.0 111.793 -178.424 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 33.7 Cg_endo -65.01 138.35 56.66 Favored 'Trans proline' 0 C--N 1.346 0.423 0 C-N-CA 122.897 2.398 . . . . 0.0 111.58 179.461 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 95.22 -16.22 61.75 Favored Glycine 0 N--CA 1.446 -0.655 0 C-N-CA 120.635 -0.793 . . . . 0.0 111.492 -179.224 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.644 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 91.5 m -88.07 133.81 33.89 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 120.991 0.424 . . . . 0.0 109.934 179.368 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 15.1 m -108.62 136.47 48.16 Favored 'General case' 0 C--N 1.322 -0.604 0 N-CA-C 109.201 -0.666 . . . . 0.0 109.201 -179.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.4 t -66.92 126.07 27.95 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-O 121.673 0.749 . . . . 0.0 111.91 -178.49 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 4.6 m -129.93 62.52 1.55 Allowed 'General case' 0 C--N 1.316 -0.87 0 N-CA-C 106.37 -1.715 . . . . 0.0 106.37 178.016 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . 0.434 ' CE3' ' HB3' ' A' ' 20' ' ' PRO . 0.2 OUTLIER -26.11 126.4 0.2 Allowed Pre-proline 0 N--CA 1.465 0.307 0 CA-C-N 114.052 -1.431 . . . . 0.0 113.028 -176.507 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . 0.434 ' HB3' ' CE3' ' A' ' 19' ' ' TRP . 61.0 Cg_endo -97.49 31.55 11.97 Favored 'Cis proline' 0 CA--C 1.533 0.459 0 C-N-CA 123.731 -1.362 . . . . 0.0 114.32 1.02 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.441 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 42.8 pt -138.04 140.29 40.81 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.354 0 CA-C-O 121.272 0.558 . . . . 0.0 111.362 -179.194 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.644 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 4.0 t -87.0 144.07 27.07 Favored 'General case' 0 C--N 1.315 -0.929 0 CA-C-O 121.205 0.526 . . . . 0.0 110.146 179.715 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 60.4 p -136.64 127.82 28.01 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 115.572 -0.74 . . . . 0.0 111.643 -178.553 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.593 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 1.7 ptm180 -89.07 123.42 33.35 Favored 'General case' 0 N--CA 1.446 -0.63 0 N-CA-C 108.528 -0.915 . . . . 0.0 108.528 178.197 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 69.8 m-20 57.44 30.73 19.1 Favored 'General case' 0 N--CA 1.468 0.461 0 O-C-N 123.518 0.511 . . . . 0.0 109.955 -177.627 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 78.54 9.65 86.85 Favored Glycine 0 C--N 1.333 0.415 0 CA-C-N 115.895 -0.593 . . . . 0.0 112.688 -179.656 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 90.4 mt -110.61 127.01 27.67 Favored Pre-proline 0 C--O 1.237 0.4 0 O-C-N 122.682 -0.305 . . . . 0.0 110.686 179.912 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 61.9 Cg_endo -73.57 52.45 2.46 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 123.268 2.645 . . . . 0.0 112.783 -179.837 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 39.7 t . . . . . 0 C--N 1.323 -0.56 0 CA-C-O 121.396 0.617 . . . . 0.0 110.041 -179.948 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.8 m . . . . . 0 CA--C 1.527 0.077 0 CA-C-O 120.967 0.413 . . . . 0.0 110.409 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 77.78 -36.01 1.64 Allowed Glycine 0 C--N 1.33 0.231 0 CA-C-N 115.848 -0.615 . . . . 0.0 113.405 179.278 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 11.1 pt-20 -56.6 136.22 54.61 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.523 0.678 . . . . 0.0 112.085 -179.001 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.524 ' HA ' ' HA ' ' A' ' 21' ' ' ILE . 24.6 p -89.58 114.99 26.65 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.347 -0.842 . . . . 0.0 109.951 179.424 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 28.3 p -88.9 58.34 4.54 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 120.999 0.428 . . . . 0.0 111.673 -179.006 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . 0.478 ' CD1' ' HB ' ' A' ' 4' ' ' THR . 5.1 m-85 -57.17 -38.15 73.17 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.137 179.444 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -89.43 17.52 51.55 Favored Glycine 0 CA--C 1.519 0.314 0 C-N-CA 120.656 -0.783 . . . . 0.0 112.791 179.815 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 62.57 40.23 98.87 Favored Glycine 0 C--N 1.331 0.268 0 C-N-CA 121.141 -0.552 . . . . 0.0 112.88 179.529 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.8 m -148.38 150.57 33.78 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 109.65 -0.5 . . . . 0.0 109.65 179.885 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 56.6 m -128.53 143.65 51.01 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 120.797 0.332 . . . . 0.0 110.413 -179.846 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 42.8 t30 -89.21 -18.98 26.0 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.805 -179.538 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 6.0 m -101.26 124.49 41.12 Favored Pre-proline 0 C--N 1.324 -0.521 0 CA-C-O 121.169 0.509 . . . . 0.0 111.586 -178.593 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 36.0 Cg_endo -65.54 140.43 62.84 Favored 'Trans proline' 0 C--N 1.346 0.404 0 C-N-CA 122.849 2.366 . . . . 0.0 111.72 179.468 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 93.73 -17.09 59.32 Favored Glycine 0 N--CA 1.447 -0.58 0 C-N-CA 120.608 -0.806 . . . . 0.0 111.495 -179.054 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.686 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 94.4 m -87.34 134.6 33.55 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-O 121.067 0.46 . . . . 0.0 110.087 179.714 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 14.5 m -108.71 136.3 48.51 Favored 'General case' 0 C--N 1.323 -0.57 0 N-CA-C 108.997 -0.742 . . . . 0.0 108.997 179.97 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 48.7 t -71.21 121.53 18.55 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-O 121.472 0.654 . . . . 0.0 111.856 -178.644 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 2.0 p -129.64 73.07 1.5 Allowed 'General case' 0 C--N 1.314 -0.956 0 N-CA-C 107.354 -1.35 . . . . 0.0 107.354 177.934 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . 0.482 ' CE3' ' HB3' ' A' ' 20' ' ' PRO . 0.0 OUTLIER -29.57 129.51 0.24 Allowed Pre-proline 0 N--CA 1.465 0.31 0 CA-C-N 114.379 -1.282 . . . . 0.0 112.906 -176.842 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . 0.482 ' HB3' ' CE3' ' A' ' 19' ' ' TRP . 68.2 Cg_endo -97.48 27.56 17.46 Favored 'Cis proline' 0 N--CA 1.46 -0.468 0 C-N-CA 123.696 -1.377 . . . . 0.0 114.682 1.001 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.524 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 0.2 OUTLIER -139.3 148.61 23.45 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.347 0 CA-C-O 121.309 0.576 . . . . 0.0 111.229 -179.297 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.686 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 4.6 t -88.81 144.22 26.37 Favored 'General case' 0 C--N 1.312 -1.057 0 CA-C-O 121.168 0.509 . . . . 0.0 109.783 179.635 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 21.5 p -138.13 126.58 23.32 Favored 'General case' 0 C--N 1.314 -0.954 0 CA-C-N 115.478 -0.783 . . . . 0.0 111.586 -178.486 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.616 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 4.8 ptm180 -90.18 127.52 36.14 Favored 'General case' 0 N--CA 1.446 -0.67 0 N-CA-C 108.803 -0.814 . . . . 0.0 108.803 178.445 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 58.04 27.04 14.3 Favored 'General case' 0 C--N 1.328 -0.37 0 CA-C-O 121.206 0.527 . . . . 0.0 109.873 -179.225 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 78.4 13.52 83.16 Favored Glycine 0 C--N 1.334 0.417 0 CA-C-N 115.821 -0.627 . . . . 0.0 112.201 -179.165 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 89.9 mt -114.94 129.98 24.58 Favored Pre-proline 0 C--O 1.238 0.496 0 CA-C-O 120.914 0.388 . . . . 0.0 110.751 -179.894 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 67.7 Cg_endo -74.24 53.67 3.05 Favored 'Trans proline' 0 C--N 1.344 0.291 0 C-N-CA 123.277 2.651 . . . . 0.0 112.789 -179.807 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 39.9 t . . . . . 0 C--N 1.323 -0.553 0 CA-C-O 121.416 0.627 . . . . 0.0 110.2 -179.896 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.458 -0.031 0 CA-C-O 121.07 0.462 . . . . 0.0 110.253 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 61.04 38.77 96.09 Favored Glycine 0 C--N 1.332 0.324 0 CA-C-N 115.595 -0.73 . . . . 0.0 112.776 179.33 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -127.55 143.2 51.2 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 121.15 0.5 . . . . 0.0 110.986 -179.812 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.487 ' HB ' ' CD1' ' A' ' 6' ' ' PHE . 21.0 p -89.58 111.67 22.67 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.014 179.487 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 23.8 p -88.85 59.21 4.95 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 121.096 0.474 . . . . 0.0 111.401 -179.24 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . 0.487 ' CD1' ' HB ' ' A' ' 4' ' ' THR . 4.5 m-85 -57.48 -36.41 71.45 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.739 179.382 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -88.53 16.77 52.51 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.788 179.517 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 76.39 -29.6 1.44 Allowed Glycine 0 CA--C 1.523 0.588 0 C-N-CA 121.226 -0.511 . . . . 0.0 113.612 179.536 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.9 m -88.57 150.93 22.82 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 120.844 0.354 . . . . 0.0 111.172 -179.139 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 69.5 m -117.49 148.3 41.96 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.831 -0.622 . . . . 0.0 109.893 179.396 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 66.1 m-80 -88.84 -18.81 26.87 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.819 -179.511 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.522 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 3.2 m -101.87 124.93 38.6 Favored Pre-proline 0 C--N 1.324 -0.527 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.238 -178.984 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -65.77 138.24 52.76 Favored 'Trans proline' 0 C--N 1.344 0.304 0 C-N-CA 122.804 2.336 . . . . 0.0 112.022 179.746 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 91.61 -13.01 67.77 Favored Glycine 0 N--CA 1.449 -0.499 0 C-N-CA 120.761 -0.733 . . . . 0.0 111.876 -179.495 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.684 ' SG ' ' HB3' ' A' ' 24' ' ' ARG . 99.3 m -87.34 136.08 33.07 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.108 0.48 . . . . 0.0 110.401 179.857 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 9.9 m -107.39 135.86 48.16 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 108.99 -0.744 . . . . 0.0 108.99 179.925 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.3 t -72.41 120.73 18.43 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-O 121.596 0.713 . . . . 0.0 112.17 -178.468 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 7.6 m -122.33 65.3 0.94 Allowed 'General case' 0 C--N 1.314 -0.968 0 N-CA-C 106.494 -1.669 . . . . 0.0 106.494 177.705 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . 0.468 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -27.32 126.96 0.21 Allowed Pre-proline 0 N--CA 1.466 0.359 0 CA-C-N 114.222 -1.354 . . . . 0.0 112.955 -176.51 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . 0.468 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 64.9 Cg_endo -97.2 31.07 12.73 Favored 'Cis proline' 0 N--CA 1.461 -0.42 0 C-N-CA 123.704 -1.373 . . . . 0.0 114.324 0.846 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 40.9 pt -137.21 136.02 47.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 121.481 0.658 . . . . 0.0 111.862 -179.112 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.655 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 5.7 t -86.44 144.96 27.03 Favored 'General case' 0 C--N 1.315 -0.905 0 CA-C-O 121.233 0.539 . . . . 0.0 110.064 179.577 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' THR . . . . . 0.481 HG23 ' HA ' ' A' ' 28' ' ' PRO . 9.1 p -144.11 128.79 18.21 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-N 115.288 -0.869 . . . . 0.0 111.216 -178.503 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.684 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 5.6 ptm180 -91.33 128.44 37.15 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.095 -0.706 . . . . 0.0 109.095 178.628 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 57.5 27.51 14.13 Favored 'General case' 0 N--CA 1.466 0.37 0 CA-C-O 121.243 0.544 . . . . 0.0 109.654 -179.349 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 76.2 14.53 82.21 Favored Glycine 0 C--N 1.332 0.345 0 CA-C-N 115.725 -0.67 . . . . 0.0 112.106 -178.92 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 88.2 mt -114.99 132.2 23.12 Favored Pre-proline 0 C--O 1.239 0.548 0 CA-C-O 121.071 0.462 . . . . 0.0 110.791 -179.755 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . 0.481 ' HA ' HG23 ' A' ' 23' ' ' THR . 73.2 Cg_endo -76.08 55.16 4.41 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 123.301 2.667 . . . . 0.0 112.548 179.91 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 41.8 t . . . . . 0 C--N 1.324 -0.51 0 CA-C-O 121.272 0.558 . . . . 0.0 110.236 -179.681 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.5 m . . . . . 0 N--CA 1.457 -0.079 0 CA-C-O 121.062 0.458 . . . . 0.0 110.251 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 77.33 -36.59 1.55 Allowed Glycine 0 C--N 1.331 0.287 0 CA-C-N 115.837 -0.619 . . . . 0.0 113.387 179.27 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 7.8 pt-20 -58.17 138.0 56.55 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 121.481 0.657 . . . . 0.0 112.283 -179.109 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.464 ' HA ' ' HA ' ' A' ' 21' ' ' ILE . 26.3 p -89.79 119.34 30.1 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.418 -0.81 . . . . 0.0 109.675 179.056 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 23.0 p -88.1 61.99 6.57 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 121.495 0.664 . . . . 0.0 110.552 -179.691 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 34.2 t80 -54.38 -42.14 70.04 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.281 -0.872 . . . . 0.0 110.819 -179.892 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -93.01 21.3 40.59 Favored Glycine 0 N--CA 1.45 -0.426 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.833 179.712 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 76.52 -29.49 1.47 Allowed Glycine 0 CA--C 1.521 0.433 0 C-N-CA 121.117 -0.563 . . . . 0.0 113.616 179.598 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -88.73 143.22 27.06 Favored 'General case' 0 C--N 1.321 -0.641 0 O-C-N 122.631 -0.334 . . . . 0.0 111.878 -179.127 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 64.5 m -111.03 151.49 27.95 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.895 -0.593 . . . . 0.0 109.893 179.354 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 38.9 t30 -88.6 -24.17 22.9 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 121.132 0.491 . . . . 0.0 110.897 -179.432 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 7.5 m -101.39 123.84 43.17 Favored Pre-proline 0 C--N 1.322 -0.612 0 CA-C-O 121.15 0.5 . . . . 0.0 111.813 -178.573 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -65.95 140.91 62.42 Favored 'Trans proline' 0 C--N 1.345 0.368 0 C-N-CA 122.828 2.352 . . . . 0.0 111.484 179.263 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 96.46 -19.81 53.03 Favored Glycine 0 N--CA 1.446 -0.643 0 C-N-CA 120.539 -0.839 . . . . 0.0 111.457 -179.053 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.652 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 84.7 m -87.41 134.82 33.53 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 120.991 0.424 . . . . 0.0 109.896 179.279 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 11.0 m -106.52 136.2 46.71 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 109.114 -0.699 . . . . 0.0 109.114 -179.872 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 48.2 t -70.91 121.91 18.99 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-O 121.522 0.677 . . . . 0.0 112.23 -178.596 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 18.2 m -125.76 67.63 1.17 Allowed 'General case' 0 C--N 1.314 -0.971 0 N-CA-C 106.308 -1.738 . . . . 0.0 106.308 177.572 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . 0.46 ' CE3' ' HB3' ' A' ' 20' ' ' PRO . 0.2 OUTLIER -28.27 127.84 0.22 Allowed Pre-proline 0 N--CA 1.464 0.25 0 CA-C-N 114.062 -1.427 . . . . 0.0 112.945 -176.446 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . 0.46 ' HB3' ' CE3' ' A' ' 19' ' ' TRP . 60.2 Cg_endo -97.83 31.91 11.38 Favored 'Cis proline' 0 N--CA 1.461 -0.429 0 C-N-CA 123.711 -1.37 . . . . 0.0 114.242 0.872 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.464 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 42.8 pt -138.56 139.22 41.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 121.452 0.644 . . . . 0.0 111.699 -179.019 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.652 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 3.7 t -84.3 144.42 28.89 Favored 'General case' 0 C--N 1.317 -0.839 0 CA-C-O 121.237 0.541 . . . . 0.0 109.55 179.268 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 17.9 p -141.97 130.43 22.49 Favored 'General case' 0 C--N 1.314 -0.944 0 CA-C-N 115.411 -0.813 . . . . 0.0 111.602 -178.143 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.452 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 9.6 ptm180 -93.84 128.17 39.97 Favored 'General case' 0 N--CA 1.448 -0.57 0 N-CA-C 108.729 -0.841 . . . . 0.0 108.729 178.309 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 28.6 m-20 58.4 26.71 14.45 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 121.29 0.567 . . . . 0.0 109.796 -178.876 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 77.75 10.67 86.08 Favored Glycine 0 C--N 1.333 0.411 0 CA-C-N 115.736 -0.666 . . . . 0.0 112.171 -179.118 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . 0.437 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 90.2 mt -110.39 131.04 22.25 Favored Pre-proline 0 C--O 1.24 0.578 0 CA-C-O 120.965 0.412 . . . . 0.0 110.684 -179.75 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . 0.437 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 4.9 Cg_exo -74.85 52.93 3.12 Favored 'Trans proline' 0 C--N 1.344 0.297 0 C-N-CA 123.699 2.933 . . . . 0.0 112.447 -179.832 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 40.5 t . . . . . 0 C--N 1.322 -0.613 0 CA-C-O 121.433 0.635 . . . . 0.0 110.018 -179.881 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.8 m . . . . . 0 C--O 1.23 0.032 0 CA-C-O 121.045 0.45 . . . . 0.0 110.37 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 78.11 -36.02 1.72 Allowed Glycine 0 N--CA 1.453 -0.228 0 CA-C-N 115.781 -0.645 . . . . 0.0 113.496 179.159 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 10.8 pt-20 -60.21 139.22 57.69 Favored 'General case' 0 C--O 1.238 0.471 0 CA-C-O 121.617 0.722 . . . . 0.0 111.831 -178.945 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.49 ' HB ' ' CD1' ' A' ' 6' ' ' PHE . 11.9 p -91.31 118.22 30.32 Favored 'General case' 0 N--CA 1.445 -0.699 0 CA-C-N 115.301 -0.863 . . . . 0.0 109.985 179.347 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 26.5 p -88.93 58.87 4.77 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 121.049 0.452 . . . . 0.0 111.438 -178.992 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . 0.49 ' CD1' ' HB ' ' A' ' 4' ' ' THR . 4.9 m-85 -57.67 -36.43 71.9 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.542 179.306 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -90.13 18.37 48.6 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.649 179.516 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 75.58 -30.28 1.23 Allowed Glycine 0 CA--C 1.522 0.526 0 C-N-CA 121.344 -0.455 . . . . 0.0 113.786 179.531 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.0 m -88.95 151.57 22.23 Favored 'General case' 0 C--N 1.322 -0.591 0 O-C-N 122.53 -0.394 . . . . 0.0 111.237 -179.078 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 82.8 m -118.24 149.34 41.28 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.874 -0.603 . . . . 0.0 109.661 179.29 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 65.5 m-80 -88.92 -26.06 21.76 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 116.059 -0.519 . . . . 0.0 111.659 -178.674 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.446 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 19.3 p -102.06 128.47 28.49 Favored Pre-proline 0 C--N 1.324 -0.53 0 CA-C-O 121.398 0.618 . . . . 0.0 111.841 -178.855 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.446 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 19.6 Cg_exo -66.09 141.36 63.37 Favored 'Trans proline' 0 C--N 1.346 0.402 0 C-N-CA 123.252 2.635 . . . . 0.0 112.164 -179.913 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 96.44 -20.63 49.53 Favored Glycine 0 N--CA 1.447 -0.578 0 C-N-CA 120.761 -0.733 . . . . 0.0 111.545 -179.385 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.678 ' SG ' ' HB3' ' A' ' 24' ' ' ARG . 91.8 m -88.19 135.96 33.2 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-O 121.097 0.475 . . . . 0.0 110.324 179.703 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 15.2 m -109.71 136.65 48.71 Favored 'General case' 0 C--N 1.323 -0.582 0 N-CA-C 109.044 -0.724 . . . . 0.0 109.044 179.889 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 45.4 t -66.41 127.47 32.42 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-O 121.602 0.715 . . . . 0.0 112.062 -178.448 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 5.3 m -132.32 64.61 1.6 Allowed 'General case' 0 C--N 1.316 -0.874 0 N-CA-C 106.583 -1.636 . . . . 0.0 106.583 178.337 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . 0.454 ' CE3' ' HB3' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -27.15 126.73 0.21 Allowed Pre-proline 0 N--CA 1.466 0.343 0 CA-C-N 114.231 -1.349 . . . . 0.0 112.996 -176.592 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . 0.454 ' HB3' ' CE3' ' A' ' 19' ' ' TRP . 66.8 Cg_endo -97.3 31.37 12.28 Favored 'Cis proline' 0 CA--C 1.533 0.433 0 C-N-CA 123.689 -1.38 . . . . 0.0 114.492 1.025 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.427 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 43.4 pt -139.33 141.31 35.87 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.382 0 CA-C-O 121.302 0.573 . . . . 0.0 111.565 -179.212 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.618 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 4.2 t -86.11 144.38 27.55 Favored 'General case' 0 C--N 1.316 -0.854 0 N-CA-C 109.669 -0.493 . . . . 0.0 109.669 179.406 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 61.9 p -137.15 128.24 27.72 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-N 115.661 -0.699 . . . . 0.0 112.007 -178.235 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.678 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 3.3 ptm180 -90.52 125.36 35.58 Favored 'General case' 0 N--CA 1.445 -0.705 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 177.822 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 53.0 m-20 58.59 28.1 16.63 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-O 121.148 0.499 . . . . 0.0 110.007 -178.421 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 79.37 11.27 85.11 Favored Glycine 0 C--N 1.334 0.441 0 CA-C-N 115.933 -0.576 . . . . 0.0 112.541 -179.514 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . 0.44 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 91.7 mt -113.81 127.92 26.31 Favored Pre-proline 0 C--O 1.236 0.382 0 CA-C-O 120.779 0.323 . . . . 0.0 110.777 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . 0.44 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 6.9 Cg_exo -73.29 53.66 2.61 Favored 'Trans proline' 0 C--N 1.344 0.291 0 C-N-CA 123.539 2.826 . . . . 0.0 112.695 -179.776 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 38.8 t . . . . . 0 C--N 1.323 -0.547 0 CA-C-O 121.445 0.641 . . . . 0.0 110.107 -179.926 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 4.1 m . . . . . 0 CA--C 1.527 0.089 0 CA-C-O 121.016 0.436 . . . . 0.0 110.246 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 62.86 45.41 95.75 Favored Glycine 0 C--N 1.333 0.405 0 CA-C-N 115.73 -0.668 . . . . 0.0 112.944 179.068 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 8.2 pt-20 -144.73 140.53 28.61 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 121.323 0.583 . . . . 0.0 111.346 -179.686 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.48 ' HB ' ' CD1' ' A' ' 6' ' ' PHE . 21.6 p -93.39 113.84 26.1 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 115.487 -0.779 . . . . 0.0 109.74 179.148 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 25.4 p -88.65 59.25 5.03 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 121.065 0.46 . . . . 0.0 111.459 -179.019 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . 0.48 ' CD1' ' HB ' ' A' ' 4' ' ' THR . 4.6 m-85 -57.73 -36.46 72.08 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.627 179.33 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -89.75 17.89 50.16 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.665 179.529 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 76.1 -29.57 1.37 Allowed Glycine 0 CA--C 1.524 0.609 0 C-N-CA 121.307 -0.473 . . . . 0.0 113.672 179.531 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.8 m -88.66 150.58 22.94 Favored 'General case' 0 C--N 1.323 -0.55 0 O-C-N 122.582 -0.363 . . . . 0.0 111.149 -179.232 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 67.6 m -117.12 150.87 37.97 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.094 179.517 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 42.3 t30 -88.82 -22.23 23.33 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.789 -179.605 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.423 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 4.5 m -101.42 123.35 44.85 Favored Pre-proline 0 C--N 1.324 -0.519 0 CA-C-O 121.226 0.536 . . . . 0.0 111.556 -178.62 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 22.4 Cg_exo -64.75 136.83 51.14 Favored 'Trans proline' 0 C--N 1.345 0.38 0 C-N-CA 122.96 2.44 . . . . 0.0 111.788 179.656 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 95.02 -15.12 64.09 Favored Glycine 0 N--CA 1.446 -0.648 0 C-N-CA 120.645 -0.788 . . . . 0.0 111.894 -179.436 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.664 ' SG ' ' HB3' ' A' ' 24' ' ' ARG . 88.6 m -87.31 135.5 33.29 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.583 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 13.3 m -105.7 135.25 47.45 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 109.125 -0.695 . . . . 0.0 109.125 -179.844 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.0 t -70.85 120.81 16.98 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-O 121.609 0.719 . . . . 0.0 111.994 -178.445 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 11.2 m -123.62 66.32 1.02 Allowed 'General case' 0 C--N 1.315 -0.933 0 N-CA-C 106.415 -1.698 . . . . 0.0 106.415 177.685 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . 0.458 ' CE3' ' HB3' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -27.76 127.21 0.22 Allowed Pre-proline 0 N--CA 1.466 0.345 0 CA-C-N 114.167 -1.378 . . . . 0.0 112.878 -176.561 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . 0.458 ' HB3' ' CE3' ' A' ' 19' ' ' TRP . 65.0 Cg_endo -97.37 31.29 12.35 Favored 'Cis proline' 0 N--CA 1.46 -0.442 0 C-N-CA 123.765 -1.348 . . . . 0.0 114.34 0.948 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 42.3 pt -138.2 137.34 44.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-O 121.454 0.645 . . . . 0.0 111.722 -179.155 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.594 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 4.5 t -85.05 144.38 28.29 Favored 'General case' 0 C--N 1.316 -0.861 0 CA-C-O 121.177 0.513 . . . . 0.0 109.912 179.447 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 21.5 p -143.52 127.06 16.92 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-N 115.304 -0.862 . . . . 0.0 111.127 -178.266 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.664 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 3.4 ptm180 -93.65 126.28 38.73 Favored 'General case' 0 N--CA 1.447 -0.581 0 N-CA-C 108.859 -0.793 . . . . 0.0 108.859 178.535 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 51.5 m-20 57.75 29.68 17.77 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-O 121.259 0.552 . . . . 0.0 109.657 -178.54 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 78.29 7.99 87.64 Favored Glycine 0 C--N 1.333 0.386 0 CA-C-N 115.587 -0.733 . . . . 0.0 112.67 -179.338 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . 0.463 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 88.2 mt -106.62 124.48 35.45 Favored Pre-proline 0 C--O 1.237 0.442 0 CA-C-O 120.935 0.397 . . . . 0.0 110.867 -179.829 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . 0.463 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 3.8 Cg_exo -79.75 46.35 2.2 Favored 'Trans proline' 0 N--CA 1.462 -0.374 0 C-N-CA 123.574 2.849 . . . . 0.0 112.08 179.868 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 10.5 p . . . . . 0 C--N 1.319 -0.719 0 CA-C-N 115.552 -0.749 . . . . 0.0 110.337 -179.765 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.0 m . . . . . 0 N--CA 1.456 -0.136 0 CA-C-O 121.066 0.46 . . . . 0.0 110.318 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 76.27 -34.05 1.32 Allowed Glycine 0 C--N 1.332 0.325 0 CA-C-N 115.867 -0.606 . . . . 0.0 113.575 179.111 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -55.04 138.44 44.0 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 121.813 0.816 . . . . 0.0 112.315 -178.921 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.553 HG23 ' HD2' ' A' ' 6' ' ' PHE . 81.1 m -89.0 110.86 21.5 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 114.892 -1.049 . . . . 0.0 110.008 179.607 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 28.5 p -89.13 53.42 2.66 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 121.167 0.508 . . . . 0.0 110.9 -179.459 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . 0.553 ' HD2' HG23 ' A' ' 4' ' ' THR . 18.9 p90 -58.15 -30.93 66.75 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.925 -0.58 . . . . 0.0 111.283 -179.988 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -94.32 15.57 62.95 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.687 179.699 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 65.17 40.08 96.57 Favored Glycine 0 CA--C 1.518 0.269 0 C-N-CA 121.049 -0.596 . . . . 0.0 112.79 179.676 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 3.0 m -149.91 150.75 32.35 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 179.91 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 60.1 m -129.26 142.75 50.76 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 120.758 0.313 . . . . 0.0 110.213 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 43.7 t30 -89.23 -17.82 28.29 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.964 -179.367 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.443 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 5.2 m -101.11 123.67 44.21 Favored Pre-proline 0 C--N 1.323 -0.561 0 CA-C-O 121.122 0.487 . . . . 0.0 111.611 -178.546 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.422 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 23.9 Cg_exo -63.61 136.65 55.21 Favored 'Trans proline' 0 C--N 1.345 0.359 0 C-N-CA 122.959 2.44 . . . . 0.0 111.705 179.583 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 94.39 -15.07 64.06 Favored Glycine 0 N--CA 1.447 -0.623 0 C-N-CA 120.638 -0.792 . . . . 0.0 111.594 -179.225 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.707 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 93.1 m -87.88 132.42 34.21 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 121.059 0.457 . . . . 0.0 110.053 179.524 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 15.2 m -108.96 134.78 51.16 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 109.116 -0.698 . . . . 0.0 109.116 179.892 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 41.9 t -67.43 121.98 16.96 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 121.578 0.704 . . . . 0.0 111.873 -178.504 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 4.1 m -125.3 65.96 1.14 Allowed 'General case' 0 C--N 1.317 -0.82 0 N-CA-C 106.765 -1.569 . . . . 0.0 106.765 178.023 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . 0.436 ' CE3' ' HB3' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -27.76 125.77 0.23 Allowed Pre-proline 0 N--CA 1.466 0.331 0 CA-C-N 114.347 -1.297 . . . . 0.0 112.812 -176.74 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . 0.532 ' O ' HG22 ' A' ' 4' ' ' THR . 66.6 Cg_endo -97.51 31.19 12.42 Favored 'Cis proline' 0 N--CA 1.46 -0.452 0 C-N-CA 123.656 -1.393 . . . . 0.0 114.362 0.843 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 41.8 pt -138.54 136.36 43.76 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 O-C-N 121.474 -0.766 . . . . 0.0 111.859 -179.208 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.707 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 5.7 t -83.36 142.77 30.79 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-O 121.201 0.524 . . . . 0.0 109.826 179.367 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 62.0 p -137.05 128.35 28.11 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-N 115.504 -0.771 . . . . 0.0 111.785 -178.276 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.63 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 3.0 ptm180 -89.52 124.71 34.76 Favored 'General case' 0 N--CA 1.446 -0.67 0 N-CA-C 108.483 -0.932 . . . . 0.0 108.483 178.126 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 53.8 m-20 58.11 28.37 16.31 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 121.173 0.511 . . . . 0.0 110.035 -178.434 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 80.14 10.04 85.94 Favored Glycine 0 C--N 1.334 0.426 0 CA-C-N 115.87 -0.604 . . . . 0.0 112.58 -179.423 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 90.1 mt -110.82 127.33 27.11 Favored Pre-proline 0 C--N 1.327 -0.412 0 CA-C-O 120.82 0.343 . . . . 0.0 110.63 179.967 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 62.3 Cg_endo -73.61 52.69 2.53 Favored 'Trans proline' 0 C--N 1.343 0.261 0 C-N-CA 123.202 2.601 . . . . 0.0 112.784 -179.879 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 40.4 t . . . . . 0 C--N 1.322 -0.602 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.094 -179.922 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.7 m . . . . . 0 N--CA 1.457 -0.078 0 CA-C-O 121.03 0.443 . . . . 0.0 110.232 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 75.71 -34.59 1.2 Allowed Glycine 0 C--N 1.33 0.243 0 CA-C-N 115.785 -0.643 . . . . 0.0 113.657 179.114 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 15.3 pt-20 -55.74 141.8 36.89 Favored 'General case' 0 C--O 1.238 0.478 0 CA-C-O 121.639 0.733 . . . . 0.0 112.116 -178.806 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.615 HG22 ' O ' ' A' ' 20' ' ' PRO . 87.8 m -88.68 117.03 27.36 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.157 -0.928 . . . . 0.0 110.308 -179.983 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 26.3 p -88.77 58.51 4.65 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 121.229 0.538 . . . . 0.0 110.209 179.798 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 32.3 t80 -51.76 -46.36 64.08 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 115.438 -0.801 . . . . 0.0 111.243 -179.559 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -94.45 25.41 22.9 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.59 -0.814 . . . . 0.0 112.568 179.749 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.44 38.69 96.18 Favored Glycine 0 CA--C 1.518 0.223 0 C-N-CA 121.184 -0.531 . . . . 0.0 112.742 179.65 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.3 m -139.49 150.66 45.41 Favored 'General case' 0 C--N 1.324 -0.512 0 N-CA-C 110.013 -0.365 . . . . 0.0 110.013 -179.911 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 59.3 m -133.22 140.84 47.75 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 116.404 -0.362 . . . . 0.0 110.057 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 65.0 m-80 -89.56 -13.88 36.33 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.08 -179.047 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.54 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 4.7 m -101.09 124.84 40.15 Favored Pre-proline 0 C--N 1.322 -0.605 0 CA-C-O 121.126 0.489 . . . . 0.0 111.208 -178.751 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.458 ' HD2' HG23 ' A' ' 12' ' ' THR . 28.8 Cg_endo -63.58 135.81 51.1 Favored 'Trans proline' 0 C--N 1.345 0.387 0 C-N-CA 122.88 2.387 . . . . 0.0 112.179 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 91.83 -11.32 72.43 Favored Glycine 0 N--CA 1.448 -0.556 0 C-N-CA 120.806 -0.711 . . . . 0.0 111.898 -179.508 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.743 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 89.1 m -88.08 132.9 34.12 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.056 0.455 . . . . 0.0 110.344 179.738 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 15.3 m -111.21 138.06 48.13 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 109.158 -0.682 . . . . 0.0 109.158 179.889 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 45.7 t -67.74 123.86 21.69 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-O 121.451 0.643 . . . . 0.0 111.969 -178.766 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 4.6 m -128.35 62.64 1.44 Allowed 'General case' 0 C--N 1.317 -0.815 0 N-CA-C 106.698 -1.593 . . . . 0.0 106.698 178.028 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . 0.429 ' CE3' ' HB3' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -27.48 126.33 0.22 Allowed Pre-proline 0 N--CA 1.464 0.239 0 CA-C-N 114.153 -1.385 . . . . 0.0 112.933 -176.686 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . 0.615 ' O ' HG22 ' A' ' 4' ' ' THR . 67.9 Cg_endo -97.21 33.76 9.47 Favored 'Cis proline' 0 N--CA 1.461 -0.436 0 C-N-CA 123.775 -1.344 . . . . 0.0 114.241 0.848 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 42.0 pt -140.24 137.05 37.55 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 O-C-N 121.654 -0.654 . . . . 0.0 111.582 -179.284 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.743 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 6.6 t -85.36 142.71 29.11 Favored 'General case' 0 C--N 1.316 -0.88 0 CA-C-O 121.062 0.458 . . . . 0.0 109.848 179.346 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 66.2 p -136.88 129.2 29.86 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-N 115.552 -0.749 . . . . 0.0 111.824 -178.47 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.643 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 1.7 ptm180 -90.36 123.04 33.78 Favored 'General case' 0 N--CA 1.445 -0.711 0 N-CA-C 108.634 -0.876 . . . . 0.0 108.634 178.066 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 71.1 m-20 56.85 31.27 19.31 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-O 121.214 0.53 . . . . 0.0 109.987 -177.656 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 79.38 7.31 88.57 Favored Glycine 0 C--N 1.334 0.448 0 CA-C-N 115.879 -0.6 . . . . 0.0 112.856 -179.625 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . 0.462 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 88.0 mt -107.36 126.4 30.12 Favored Pre-proline 0 C--O 1.237 0.41 0 O-C-N 122.624 -0.339 . . . . 0.0 110.697 179.982 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . 0.462 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 7.4 Cg_exo -72.91 52.98 2.29 Favored 'Trans proline' 0 C--N 1.343 0.246 0 C-N-CA 123.587 2.858 . . . . 0.0 112.581 -179.834 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 43.4 t . . . . . 0 C--N 1.323 -0.561 0 CA-C-O 121.307 0.575 . . . . 0.0 110.171 -179.774 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.6 m . . . . . 0 CA--C 1.528 0.104 0 CA-C-O 120.875 0.369 . . . . 0.0 110.763 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.68 42.97 95.08 Favored Glycine 0 N--CA 1.451 -0.321 0 CA-C-N 115.798 -0.637 . . . . 0.0 112.982 179.217 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -142.84 143.44 32.12 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 121.211 0.529 . . . . 0.0 110.864 179.906 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.521 ' HB ' ' CD1' ' A' ' 6' ' ' PHE . 7.3 p -95.97 115.08 26.88 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 115.582 -0.735 . . . . 0.0 110.381 179.506 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 25.5 p -89.11 58.84 4.69 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 121.047 0.451 . . . . 0.0 111.426 -179.248 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . 0.521 ' CD1' ' HB ' ' A' ' 4' ' ' THR . 5.2 m-85 -57.81 -36.36 72.13 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.644 179.416 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -88.36 16.83 51.49 Favored Glycine 0 N--CA 1.448 -0.508 0 C-N-CA 120.833 -0.699 . . . . 0.0 112.703 179.654 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 77.2 -30.62 1.61 Allowed Glycine 0 CA--C 1.523 0.542 0 C-N-CA 121.223 -0.513 . . . . 0.0 113.487 179.635 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.7 m -88.62 149.96 23.28 Favored 'General case' 0 C--N 1.322 -0.626 0 O-C-N 122.655 -0.32 . . . . 0.0 111.035 -179.373 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 77.0 m -113.05 150.6 31.79 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.141 179.52 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 64.8 m-80 -88.65 -27.94 20.95 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 115.818 -0.628 . . . . 0.0 111.244 -179.086 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.425 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 21.3 p -102.46 128.31 28.49 Favored Pre-proline 0 C--N 1.324 -0.509 0 CA-C-O 121.481 0.658 . . . . 0.0 111.746 -179.049 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.425 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 17.3 Cg_exo -67.25 141.09 55.61 Favored 'Trans proline' 0 C--N 1.345 0.375 0 C-N-CA 123.277 2.651 . . . . 0.0 112.172 -179.758 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 96.8 -20.1 52.05 Favored Glycine 0 N--CA 1.448 -0.565 0 C-N-CA 120.739 -0.743 . . . . 0.0 111.7 -179.509 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.723 ' SG ' ' HB3' ' A' ' 24' ' ' ARG . 91.0 m -88.22 138.82 31.1 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-O 121.066 0.46 . . . . 0.0 110.283 179.734 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 16.1 m -108.49 134.52 51.15 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 109.172 -0.677 . . . . 0.0 109.172 179.855 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.4 t -66.31 125.2 24.86 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-O 121.615 0.721 . . . . 0.0 111.893 -178.418 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 3.9 m -129.0 65.6 1.44 Allowed 'General case' 0 C--N 1.315 -0.913 0 N-CA-C 106.708 -1.589 . . . . 0.0 106.708 178.277 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . 0.453 ' CE3' ' HB3' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -27.26 126.42 0.22 Allowed Pre-proline 0 N--CA 1.465 0.312 0 CA-C-N 114.423 -1.262 . . . . 0.0 112.836 -176.571 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . 0.453 ' HB3' ' CE3' ' A' ' 19' ' ' TRP . 63.2 Cg_endo -97.17 31.03 12.79 Favored 'Cis proline' 0 CA--C 1.532 0.407 0 C-N-CA 123.776 -1.343 . . . . 0.0 114.534 0.932 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 42.5 pt -139.42 138.98 39.72 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.333 0 CA-C-O 121.319 0.581 . . . . 0.0 111.719 -179.117 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.54 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 4.4 t -84.93 145.14 27.92 Favored 'General case' 0 C--N 1.316 -0.849 0 N-CA-C 109.622 -0.51 . . . . 0.0 109.622 179.282 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 61.8 p -139.54 128.52 23.6 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-N 115.792 -0.64 . . . . 0.0 112.121 -178.026 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.723 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 3.3 ptm180 -91.68 125.57 36.46 Favored 'General case' 0 N--CA 1.445 -0.697 0 N-CA-C 108.155 -1.054 . . . . 0.0 108.155 177.588 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 54.7 m-20 58.9 28.24 17.28 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-O 121.143 0.497 . . . . 0.0 109.842 -178.319 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 78.87 10.36 86.25 Favored Glycine 0 C--N 1.333 0.374 0 CA-C-N 115.897 -0.592 . . . . 0.0 112.636 -179.413 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 92.1 mt -114.3 126.28 28.18 Favored Pre-proline 0 C--N 1.328 -0.357 0 CA-C-O 120.881 0.372 . . . . 0.0 110.759 -179.961 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -75.28 52.42 3.16 Favored 'Trans proline' 0 CA--C 1.529 0.241 0 C-N-CA 123.159 2.573 . . . . 0.0 112.876 -179.811 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 22.3 t . . . . . 0 C--N 1.323 -0.559 0 CA-C-O 121.389 0.614 . . . . 0.0 110.184 -179.883 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 63.4 m . . . . . 0 N--CA 1.458 -0.061 0 CA-C-O 120.991 0.424 . . . . 0.0 110.104 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 61.45 35.29 90.81 Favored Glycine 0 C--N 1.332 0.348 0 CA-C-N 115.674 -0.694 . . . . 0.0 113.102 179.114 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 9.5 pt-20 -115.9 148.44 40.01 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 120.9 0.381 . . . . 0.0 110.716 179.929 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.41 ' HA ' ' HA ' ' A' ' 21' ' ' ILE . 33.9 p -93.41 118.09 30.88 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.182 -179.933 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.8 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 13.5 p -88.87 61.57 6.0 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.287 0.565 . . . . 0.0 110.52 179.298 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 32.8 t80 -55.14 -41.27 71.54 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.561 -0.745 . . . . 0.0 110.235 179.892 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -92.18 22.94 29.49 Favored Glycine 0 N--CA 1.45 -0.43 0 C-N-CA 120.865 -0.683 . . . . 0.0 112.765 179.338 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 76.66 -35.81 1.4 Allowed Glycine 0 CA--C 1.521 0.446 0 C-N-CA 121.23 -0.51 . . . . 0.0 113.938 179.405 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.5 m -89.2 148.37 23.66 Favored 'General case' 0 C--N 1.322 -0.609 0 O-C-N 122.423 -0.457 . . . . 0.0 111.442 -179.093 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 59.9 m -108.69 153.67 23.11 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.711 -0.677 . . . . 0.0 109.515 179.072 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 39.1 t30 -87.53 -29.42 21.33 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-O 121.255 0.55 . . . . 0.0 110.171 179.956 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.42 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 3.8 m -102.48 118.35 58.92 Favored Pre-proline 0 C--N 1.323 -0.571 0 CA-C-N 115.877 -0.601 . . . . 0.0 111.167 -179.485 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.42 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 13.6 Cg_exo -68.76 136.95 37.19 Favored 'Trans proline' 0 N--CA 1.46 -0.479 0 C-N-CA 122.829 2.352 . . . . 0.0 111.719 179.724 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 117.33 -32.66 5.32 Favored Glycine 0 N--CA 1.439 -1.166 0 N-CA-C 111.134 -0.787 . . . . 0.0 111.134 -179.264 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 32.9 m -89.45 131.43 35.5 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 120.921 0.391 . . . . 0.0 110.36 179.05 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 16.0 m -89.67 136.15 33.2 Favored 'General case' 0 C--N 1.319 -0.724 0 N-CA-C 109.213 -0.662 . . . . 0.0 109.213 179.556 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 43.2 t -67.66 115.45 7.25 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 121.773 0.797 . . . . 0.0 111.031 -179.336 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 2.9 m -118.95 66.96 0.78 Allowed 'General case' 0 C--N 1.309 -1.172 0 N-CA-C 106.332 -1.729 . . . . 0.0 106.332 178.182 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . 0.445 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.3 OUTLIER -27.24 124.6 0.23 Allowed Pre-proline 0 N--CA 1.463 0.196 0 CA-C-N 114.213 -1.358 . . . . 0.0 112.646 -176.314 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . 0.445 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 56.7 Cg_endo -98.77 34.25 8.69 Favored 'Cis proline' 0 N--CA 1.459 -0.52 0 C-N-CA 123.732 -1.362 . . . . 0.0 114.554 1.103 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.437 HD11 HG23 ' A' ' 21' ' ' ILE . 40.8 pt -142.12 136.06 29.09 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.301 0 CA-C-N 118.753 0.706 . . . . 0.0 112.513 -178.939 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.8 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 47.2 m -82.08 131.68 35.24 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.266 178.977 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 65.4 p -142.7 136.7 29.25 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.134 179.785 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.512 ' HG3' ' O ' ' A' ' 24' ' ' ARG . 2.8 ptm180 -94.62 121.86 36.62 Favored 'General case' 0 N--CA 1.443 -0.789 0 N-CA-C 108.153 -1.054 . . . . 0.0 108.153 178.445 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 61.3 m-20 57.36 29.85 17.56 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.134 0.492 . . . . 0.0 109.775 -178.032 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 82.12 1.95 90.46 Favored Glycine 0 CA--C 1.521 0.41 0 CA-C-N 115.801 -0.636 . . . . 0.0 112.667 -179.371 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 88.0 mt -98.87 123.6 48.81 Favored Pre-proline 0 C--O 1.237 0.429 0 CA-C-O 121.074 0.464 . . . . 0.0 111.217 -179.838 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -77.13 69.81 6.93 Favored 'Trans proline' 0 N--CA 1.464 -0.242 0 C-N-CA 123.248 2.632 . . . . 0.0 112.139 179.649 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 47.2 t . . . . . 0 C--N 1.324 -0.504 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.297 -179.396 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 82.0 m . . . . . 0 CA--C 1.524 -0.026 0 CA-C-O 120.92 0.391 . . . . 0.0 110.353 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 76.46 -32.32 1.39 Allowed Glycine 0 CA--C 1.519 0.327 0 CA-C-N 116.117 -0.492 . . . . 0.0 113.85 178.878 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 14.7 pt-20 -53.95 139.31 34.47 Favored 'General case' 0 C--O 1.239 0.509 0 CA-C-O 121.447 0.641 . . . . 0.0 111.889 -178.933 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.473 ' HA ' ' HA ' ' A' ' 21' ' ' ILE . 36.2 p -89.44 120.91 31.18 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 115.276 -0.875 . . . . 0.0 110.801 -179.581 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.76 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 25.0 p -88.98 60.96 5.69 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 121.253 0.549 . . . . 0.0 110.71 179.651 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 34.4 t80 -53.33 -44.36 68.37 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.525 -0.761 . . . . 0.0 110.993 -179.896 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -92.65 22.63 32.39 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.742 179.788 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 62.55 40.68 99.43 Favored Glycine 0 CA--C 1.518 0.27 0 C-N-CA 121.257 -0.497 . . . . 0.0 112.965 179.514 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.5 m -147.99 149.28 31.87 Favored 'General case' 0 C--N 1.324 -0.513 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 179.919 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 47.2 m -124.76 143.42 50.8 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 179.837 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 63.1 m-80 -88.39 -23.24 23.4 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.276 -179.49 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 4.3 m -101.72 119.37 57.35 Favored Pre-proline 0 C--N 1.323 -0.582 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.982 -179.148 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 20.4 Cg_exo -65.55 140.93 64.87 Favored 'Trans proline' 0 N--CA 1.462 -0.324 0 C-N-CA 122.922 2.415 . . . . 0.0 111.939 179.894 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 105.76 -29.9 10.62 Favored Glycine 0 N--CA 1.441 -1.024 0 C-N-CA 120.75 -0.738 . . . . 0.0 111.489 -179.4 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.509 ' HB3' ' HB3' ' A' ' 22' ' ' CYS . 15.7 m -89.04 129.19 35.71 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 121.209 0.528 . . . . 0.0 110.708 179.289 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 19.6 m -94.39 138.51 32.26 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 115.512 -0.767 . . . . 0.0 109.036 179.372 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 43.4 t -66.43 116.16 7.13 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-O 121.593 0.711 . . . . 0.0 111.03 -179.287 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 3.0 m -120.78 68.7 0.87 Allowed 'General case' 0 C--N 1.311 -1.099 0 N-CA-C 106.597 -1.631 . . . . 0.0 106.597 178.422 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . 0.435 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -27.82 125.1 0.23 Allowed Pre-proline 0 N--CA 1.463 0.215 0 O-C-N 124.706 1.253 . . . . 0.0 112.631 -176.52 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . 0.435 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 59.8 Cg_endo -98.54 30.62 12.65 Favored 'Cis proline' 0 CA--C 1.535 0.562 0 C-N-CA 123.613 -1.411 . . . . 0.0 115.061 1.033 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.473 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 0.2 OUTLIER -141.62 141.65 29.68 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.293 0 CA-C-N 118.992 0.815 . . . . 0.0 112.122 -179.422 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.76 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 64.6 m -81.1 133.81 35.54 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.586 179.365 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 64.5 p -134.23 132.4 39.65 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.735 179.856 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.467 ' HG3' ' O ' ' A' ' 24' ' ' ARG . 1.4 ptm180 -91.93 120.25 32.43 Favored 'General case' 0 N--CA 1.443 -0.777 0 N-CA-C 108.185 -1.042 . . . . 0.0 108.185 178.305 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 72.7 m-20 56.6 31.0 18.34 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 121.144 0.497 . . . . 0.0 109.895 -177.437 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 84.0 -0.4 89.45 Favored Glycine 0 CA--C 1.521 0.447 0 CA-C-N 115.885 -0.598 . . . . 0.0 112.907 -179.624 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . 0.472 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 86.9 mt -99.3 122.34 52.31 Favored Pre-proline 0 C--O 1.237 0.41 0 CA-C-O 120.903 0.383 . . . . 0.0 111.155 -179.754 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . 0.472 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 3.4 Cg_exo -74.46 63.78 5.5 Favored 'Trans proline' 0 CA--C 1.528 0.177 0 C-N-CA 123.597 2.865 . . . . 0.0 112.143 179.66 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 48.2 t . . . . . 0 C--N 1.325 -0.479 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.485 -179.233 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 3.0 m . . . . . 0 CA--C 1.527 0.058 0 CA-C-O 120.943 0.402 . . . . 0.0 110.486 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 78.23 -37.16 1.76 Allowed Glycine 0 C--N 1.33 0.226 0 CA-C-N 115.952 -0.567 . . . . 0.0 113.022 179.59 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 8.9 pt-20 -59.77 141.66 54.81 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 121.526 0.679 . . . . 0.0 111.961 -179.331 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.424 ' HA ' ' HA ' ' A' ' 21' ' ' ILE . 14.7 p -94.87 124.73 39.08 Favored 'General case' 0 N--CA 1.444 -0.733 0 CA-C-N 115.316 -0.856 . . . . 0.0 109.695 178.982 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 24.4 p -87.98 58.8 5.01 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 121.479 0.657 . . . . 0.0 110.698 -179.419 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 35.3 t80 -56.27 -39.93 73.42 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.309 -0.859 . . . . 0.0 110.038 179.48 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -91.31 22.68 28.54 Favored Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 120.943 -0.646 . . . . 0.0 112.751 179.375 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 77.25 -36.82 1.53 Allowed Glycine 0 CA--C 1.522 0.482 0 C-N-CA 121.36 -0.448 . . . . 0.0 114.081 179.223 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 10.2 t -89.52 164.46 14.79 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-O 121.229 0.537 . . . . 0.0 111.627 -179.083 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 62.0 m -125.69 151.77 46.15 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 114.983 -1.008 . . . . 0.0 109.514 179.28 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 41.4 t30 -88.88 -22.76 22.99 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-O 121.031 0.444 . . . . 0.0 111.198 -178.983 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.431 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 7.8 m -101.14 124.46 41.42 Favored Pre-proline 0 C--N 1.322 -0.59 0 CA-C-O 121.215 0.531 . . . . 0.0 111.955 -178.375 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.431 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 23.8 Cg_exo -63.81 137.48 58.56 Favored 'Trans proline' 0 C--N 1.346 0.411 0 C-N-CA 123.059 2.506 . . . . 0.0 111.47 179.403 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 96.55 -17.39 59.36 Favored Glycine 0 N--CA 1.446 -0.67 0 C-N-CA 120.596 -0.812 . . . . 0.0 111.447 -179.06 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.681 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 81.6 m -87.61 133.06 33.87 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 109.651 -0.5 . . . . 0.0 109.651 179.39 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 15.4 m -108.87 138.11 45.72 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 -179.577 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.4 t -68.46 127.08 31.69 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 121.752 0.787 . . . . 0.0 111.948 -178.705 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 4.3 m -131.17 60.67 1.65 Allowed 'General case' 0 C--N 1.316 -0.882 0 N-CA-C 106.144 -1.799 . . . . 0.0 106.144 177.891 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . 0.433 ' CE3' ' HB3' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -26.24 126.65 0.2 Allowed Pre-proline 0 N--CA 1.464 0.265 0 CA-C-N 113.951 -1.477 . . . . 0.0 113.002 -176.487 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . 0.433 ' HB3' ' CE3' ' A' ' 19' ' ' TRP . 62.3 Cg_endo -97.01 32.32 11.16 Favored 'Cis proline' 0 CA--C 1.532 0.421 0 C-N-CA 123.684 -1.381 . . . . 0.0 114.41 0.842 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.424 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 43.8 pt -137.53 140.35 41.76 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.39 0 CA-C-O 121.255 0.55 . . . . 0.0 111.346 -179.234 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.681 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 5.4 t -89.4 144.28 26.18 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-O 121.17 0.509 . . . . 0.0 110.233 179.783 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 43.0 p -138.25 127.14 23.89 Favored 'General case' 0 C--N 1.318 -0.784 0 CA-C-N 115.527 -0.761 . . . . 0.0 111.752 -178.673 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.624 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 3.1 ptm180 -89.53 125.07 35.06 Favored 'General case' 0 N--CA 1.447 -0.618 0 N-CA-C 108.601 -0.889 . . . . 0.0 108.601 178.403 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 53.7 m-20 57.98 28.9 16.87 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.216 0.531 . . . . 0.0 109.958 -178.532 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 78.71 12.06 84.6 Favored Glycine 0 C--N 1.334 0.417 0 CA-C-N 115.875 -0.602 . . . . 0.0 112.457 -179.445 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 88.9 mt -113.72 127.71 26.53 Favored Pre-proline 0 C--O 1.237 0.405 0 CA-C-O 120.857 0.36 . . . . 0.0 110.686 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 70.9 Cg_endo -74.57 51.92 2.74 Favored 'Trans proline' 0 C--N 1.343 0.256 0 C-N-CA 123.292 2.662 . . . . 0.0 112.678 -179.949 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 39.4 t . . . . . 0 C--N 1.322 -0.601 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.222 -179.855 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . 0.506 ' HB3' ' HG2' ' A' ' 3' ' ' GLU . 82.5 m . . . . . 0 N--CA 1.458 -0.065 0 CA-C-O 120.897 0.379 . . . . 0.0 110.239 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 77.47 -34.73 1.57 Allowed Glycine 0 C--N 1.331 0.285 0 CA-C-N 116.034 -0.53 . . . . 0.0 113.436 179.188 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.506 ' HG2' ' HB3' ' A' ' 1' ' ' CYS . 7.0 pt-20 -53.8 139.88 31.76 Favored 'General case' 0 C--O 1.237 0.429 0 CA-C-O 121.528 0.68 . . . . 0.0 112.423 -179.114 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.486 ' HA ' ' HA ' ' A' ' 21' ' ' ILE . 31.5 p -89.29 121.22 31.36 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 115.271 -0.877 . . . . 0.0 110.01 179.29 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 23.5 p -88.0 61.14 6.19 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 121.382 0.611 . . . . 0.0 110.478 -179.857 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 35.1 t80 -55.11 -41.04 71.17 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.367 -0.833 . . . . 0.0 110.513 179.91 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -91.65 21.58 35.21 Favored Glycine 0 N--CA 1.449 -0.457 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.735 179.51 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 76.7 -33.47 1.41 Allowed Glycine 0 CA--C 1.522 0.51 0 C-N-CA 121.221 -0.514 . . . . 0.0 113.833 179.572 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.7 m -89.11 149.7 23.06 Favored 'General case' 0 C--N 1.321 -0.674 0 O-C-N 122.538 -0.389 . . . . 0.0 111.443 -179.184 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 58.3 m -114.76 152.68 31.66 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.761 -0.654 . . . . 0.0 109.301 179.017 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 36.4 t30 -87.8 -28.52 21.61 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-O 121.215 0.531 . . . . 0.0 110.537 -179.534 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 8.2 m -101.63 120.99 52.82 Favored Pre-proline 0 C--N 1.32 -0.681 0 CA-C-N 115.967 -0.56 . . . . 0.0 111.563 -178.871 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 17.3 Cg_exo -66.62 143.84 69.96 Favored 'Trans proline' 0 N--CA 1.463 -0.316 0 C-N-CA 123.178 2.585 . . . . 0.0 111.888 179.741 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 105.02 -29.59 11.43 Favored Glycine 0 N--CA 1.443 -0.862 0 C-N-CA 120.676 -0.774 . . . . 0.0 111.555 -179.443 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.639 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 9.2 m -87.98 138.87 31.08 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 121.131 0.491 . . . . 0.0 110.158 179.169 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 15.2 m -102.57 141.54 35.22 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 115.645 -0.707 . . . . 0.0 109.099 179.936 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 48.9 t -73.17 114.62 11.56 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-O 121.597 0.713 . . . . 0.0 111.661 -178.908 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 17.0 m -117.42 66.98 0.74 Allowed 'General case' 0 C--N 1.311 -1.103 0 N-CA-C 106.353 -1.721 . . . . 0.0 106.353 177.468 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . 0.44 ' CE3' ' HB3' ' A' ' 20' ' ' PRO . 0.4 OUTLIER -29.08 127.39 0.24 Allowed Pre-proline 0 N--CA 1.463 0.225 0 CA-C-N 114.102 -1.408 . . . . 0.0 112.753 -176.47 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . 0.44 ' HB3' ' CE3' ' A' ' 19' ' ' TRP . 59.5 Cg_endo -97.85 32.77 10.31 Favored 'Cis proline' 0 N--CA 1.46 -0.5 0 C-N-CA 123.68 -1.383 . . . . 0.0 114.304 0.918 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.486 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 42.0 pt -138.3 137.48 43.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 121.443 0.639 . . . . 0.0 111.873 -179.135 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.639 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 3.4 t -85.42 139.74 31.29 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-O 121.309 0.576 . . . . 0.0 109.498 179.284 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 11.7 p -147.85 133.38 18.71 Favored 'General case' 0 C--N 1.313 -1.012 0 CA-C-N 115.279 -0.873 . . . . 0.0 111.297 -178.259 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.508 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 3.1 ptm180 -92.25 124.47 36.34 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 108.81 -0.811 . . . . 0.0 108.81 178.774 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 46.3 m-20 57.53 30.34 18.55 Favored 'General case' 0 N--CA 1.467 0.383 0 N-CA-C 109.384 -0.599 . . . . 0.0 109.384 -178.431 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 76.89 8.53 86.68 Favored Glycine 0 CA--C 1.521 0.423 0 CA-C-N 115.511 -0.768 . . . . 0.0 112.559 -179.116 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 86.8 mt -105.41 129.13 25.23 Favored Pre-proline 0 C--O 1.239 0.545 0 CA-C-O 121.057 0.456 . . . . 0.0 111.059 -179.661 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -75.42 62.94 6.3 Favored 'Trans proline' 0 C--N 1.343 0.262 0 C-N-CA 123.372 2.715 . . . . 0.0 112.583 179.84 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 48.5 t . . . . . 0 C--N 1.323 -0.578 0 CA-C-O 121.324 0.583 . . . . 0.0 110.177 -179.661 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 3.8 m . . . . . 0 CA--C 1.528 0.101 0 CA-C-O 121.141 0.496 . . . . 0.0 109.672 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 76.15 -36.38 1.3 Allowed Glycine 0 C--N 1.333 0.366 0 CA-C-N 115.6 -0.727 . . . . 0.0 113.777 178.691 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -60.13 138.54 57.87 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 121.621 0.724 . . . . 0.0 111.953 -178.805 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.465 ' HB ' ' CD1' ' A' ' 6' ' ' PHE . 30.8 p -89.62 118.99 29.65 Favored 'General case' 0 N--CA 1.446 -0.657 0 CA-C-N 115.271 -0.877 . . . . 0.0 109.734 179.245 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 26.2 p -88.62 58.02 4.47 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 121.066 0.46 . . . . 0.0 111.489 -179.034 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . 0.465 ' CD1' ' HB ' ' A' ' 4' ' ' THR . 4.7 m-85 -58.29 -36.56 73.49 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.334 179.049 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -88.99 19.07 40.37 Favored Glycine 0 N--CA 1.45 -0.414 0 C-N-CA 120.86 -0.686 . . . . 0.0 112.611 179.426 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 76.09 -32.77 1.3 Allowed Glycine 0 CA--C 1.524 0.598 0 C-N-CA 121.379 -0.439 . . . . 0.0 113.999 179.353 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 8.9 t -89.24 165.25 14.55 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.238 0.542 . . . . 0.0 111.561 -179.059 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 70.4 m -130.74 147.53 52.41 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.092 -0.958 . . . . 0.0 109.793 179.489 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 64.0 m-80 -89.43 -17.19 29.23 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.925 -0.58 . . . . 0.0 111.212 -178.979 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.414 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 4.6 m -101.22 123.25 45.51 Favored Pre-proline 0 C--N 1.323 -0.568 0 CA-C-O 121.091 0.472 . . . . 0.0 111.335 -178.635 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -63.48 135.03 47.48 Favored 'Trans proline' 0 C--N 1.344 0.299 0 C-N-CA 122.859 2.372 . . . . 0.0 111.941 179.674 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 95.2 -16.35 61.47 Favored Glycine 0 N--CA 1.445 -0.703 0 C-N-CA 120.637 -0.792 . . . . 0.0 111.867 -179.454 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.669 ' SG ' ' HB3' ' A' ' 24' ' ' ARG . 99.6 m -87.31 133.65 33.67 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 121.073 0.463 . . . . 0.0 109.906 179.644 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 15.7 m -109.34 137.83 46.61 Favored 'General case' 0 C--N 1.324 -0.522 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 -179.925 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 44.7 t -66.71 128.2 35.35 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-O 121.718 0.77 . . . . 0.0 112.182 -178.428 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 4.4 m -132.4 61.01 1.67 Allowed 'General case' 0 C--N 1.316 -0.867 0 N-CA-C 106.221 -1.77 . . . . 0.0 106.221 177.953 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . 0.444 ' CE3' ' HB3' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -25.76 126.44 0.19 Allowed Pre-proline 0 N--CA 1.466 0.359 0 CA-C-N 113.931 -1.486 . . . . 0.0 113.037 -176.537 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . 0.444 ' HB3' ' CE3' ' A' ' 19' ' ' TRP . 67.0 Cg_endo -96.85 30.91 13.07 Favored 'Cis proline' 0 CA--C 1.532 0.421 0 C-N-CA 123.757 -1.351 . . . . 0.0 114.515 0.805 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 43.3 pt -137.34 140.92 41.16 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.424 0 CA-C-O 121.273 0.558 . . . . 0.0 111.371 -179.154 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.665 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 4.5 t -88.41 143.99 26.65 Favored 'General case' 0 C--N 1.314 -0.943 0 CA-C-O 121.259 0.552 . . . . 0.0 110.267 179.908 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 68.5 p -138.04 127.61 24.98 Favored 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 115.433 -0.803 . . . . 0.0 111.316 -178.778 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.669 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 3.2 ptm180 -92.73 124.28 36.62 Favored 'General case' 0 N--CA 1.445 -0.687 0 N-CA-C 108.794 -0.817 . . . . 0.0 108.794 178.447 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 53.7 m-20 57.76 28.94 16.64 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.172 0.511 . . . . 0.0 109.744 -178.271 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 82.44 3.65 90.45 Favored Glycine 0 N--CA 1.449 -0.447 0 CA-C-N 115.854 -0.612 . . . . 0.0 112.683 -179.461 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 86.0 mt -101.18 121.06 53.3 Favored Pre-proline 0 C--O 1.236 0.352 0 O-C-N 122.623 -0.339 . . . . 0.0 110.75 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -77.06 47.34 2.19 Favored 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 123.062 2.508 . . . . 0.0 112.601 179.828 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 11.6 p . . . . . 0 C--N 1.321 -0.667 0 CA-C-N 115.537 -0.756 . . . . 0.0 110.239 179.999 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . 0.557 ' SG ' ' HB3' ' A' ' 24' ' ' ARG . 1.8 m . . . . . 0 N--CA 1.458 -0.058 0 CA-C-O 121.007 0.432 . . . . 0.0 110.339 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 76.04 -34.37 1.27 Allowed Glycine 0 CA--C 1.519 0.31 0 CA-C-N 115.865 -0.607 . . . . 0.0 113.287 179.515 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.407 ' H ' ' C ' ' A' ' 1' ' ' CYS . 12.1 pt-20 -54.56 140.62 34.22 Favored 'General case' 0 C--O 1.239 0.528 0 CA-C-O 121.658 0.742 . . . . 0.0 112.393 -179.001 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.538 HG23 ' O ' ' A' ' 20' ' ' PRO . 67.8 m -88.89 114.5 25.58 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.059 -0.973 . . . . 0.0 109.984 179.587 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 26.6 p -88.6 58.43 4.66 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 121.324 0.583 . . . . 0.0 110.458 -179.803 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 34.0 t80 -52.69 -44.96 66.62 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.309 -0.859 . . . . 0.0 111.194 -179.726 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -94.06 24.46 26.64 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.582 -0.818 . . . . 0.0 112.781 179.764 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.48 40.38 98.61 Favored Glycine 0 CA--C 1.518 0.264 0 C-N-CA 121.136 -0.554 . . . . 0.0 112.88 179.595 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.3 m -142.45 150.19 40.23 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 179.996 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 57.5 m -132.82 142.02 48.76 Favored 'General case' 0 C--N 1.324 -0.539 0 N-CA-C 110.025 -0.361 . . . . 0.0 110.025 179.869 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 43.6 t30 -89.31 -15.0 34.48 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.842 -0.617 . . . . 0.0 111.229 -179.081 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.624 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 5.7 m -100.67 125.3 39.33 Favored Pre-proline 0 C--N 1.323 -0.549 0 CA-C-O 121.252 0.549 . . . . 0.0 111.509 -178.754 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.469 ' HD2' HG22 ' A' ' 12' ' ' THR . 28.7 Cg_endo -63.58 131.93 33.5 Favored 'Trans proline' 0 C--N 1.347 0.457 0 C-N-CA 122.999 2.466 . . . . 0.0 112.438 -179.819 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 95.08 -8.62 70.08 Favored Glycine 0 N--CA 1.447 -0.587 0 C-N-CA 120.894 -0.67 . . . . 0.0 111.737 -179.472 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.79 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 84.7 m -88.06 131.62 34.6 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-O 121.127 0.489 . . . . 0.0 110.133 179.63 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 13.3 m -109.49 136.45 48.86 Favored 'General case' 0 C--N 1.324 -0.538 0 N-CA-C 108.925 -0.769 . . . . 0.0 108.925 179.906 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 50.2 t -71.89 119.92 16.76 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-O 121.366 0.603 . . . . 0.0 112.106 -178.631 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 18.4 m -123.89 67.21 1.03 Allowed 'General case' 0 C--N 1.315 -0.903 0 N-CA-C 106.624 -1.621 . . . . 0.0 106.624 177.697 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . 0.452 ' CE3' ' HB3' ' A' ' 20' ' ' PRO . 0.2 OUTLIER -29.03 127.51 0.23 Allowed Pre-proline 0 N--CA 1.464 0.234 0 CA-C-N 114.092 -1.413 . . . . 0.0 112.862 -176.721 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . 0.538 ' O ' HG23 ' A' ' 4' ' ' THR . 65.6 Cg_endo -97.71 33.24 9.85 Favored 'Cis proline' 0 N--CA 1.46 -0.484 0 C-N-CA 123.767 -1.347 . . . . 0.0 114.23 0.822 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 41.8 pt -139.59 137.37 40.02 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-O 121.425 0.631 . . . . 0.0 111.632 -179.182 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.79 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 6.2 t -84.27 143.18 29.72 Favored 'General case' 0 C--N 1.316 -0.885 0 CA-C-O 121.311 0.576 . . . . 0.0 109.791 179.222 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' THR . . . . . 0.446 HG22 ' HA ' ' A' ' 28' ' ' PRO . 14.9 p -138.28 125.82 22.04 Favored 'General case' 0 C--N 1.314 -0.943 0 CA-C-N 115.239 -0.892 . . . . 0.0 111.378 -178.497 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.557 ' HB3' ' SG ' ' A' ' 1' ' ' CYS . 0.0 OUTLIER -91.1 129.3 37.11 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 178.864 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.433 ' CG ' ' HD3' ' A' ' 24' ' ' ARG . 54.8 m-20 54.6 30.03 12.48 Favored 'General case' 0 C--N 1.324 -0.529 0 O-C-N 123.85 0.719 . . . . 0.0 110.382 -178.844 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 77.46 13.97 82.98 Favored Glycine 0 C--N 1.335 0.498 0 CA-C-N 115.803 -0.635 . . . . 0.0 112.652 -179.583 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 90.2 mt -117.46 132.23 23.67 Favored Pre-proline 0 C--O 1.236 0.354 0 CA-C-O 120.825 0.345 . . . . 0.0 110.831 -179.888 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . 0.446 ' HA ' HG22 ' A' ' 23' ' ' THR . 70.8 Cg_endo -74.6 53.68 3.22 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 123.116 2.544 . . . . 0.0 112.673 -179.95 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 40.9 t . . . . . 0 C--N 1.323 -0.58 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.404 -179.85 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 67.9 m . . . . . 0 N--CA 1.458 -0.051 0 CA-C-O 120.905 0.383 . . . . 0.0 110.195 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 60.14 38.11 93.9 Favored Glycine 0 C--N 1.333 0.381 0 CA-C-N 115.74 -0.663 . . . . 0.0 112.694 179.299 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -117.87 151.77 36.72 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 120.86 0.362 . . . . 0.0 110.848 -179.789 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.462 HG22 ' O ' ' A' ' 20' ' ' PRO . 28.2 m -96.66 118.67 33.63 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-N 115.893 -0.594 . . . . 0.0 111.051 179.811 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.718 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 7.6 p -88.45 61.2 6.02 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 121.262 0.553 . . . . 0.0 109.699 178.826 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 13.2 t80 -54.26 -41.51 68.91 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.35 -0.841 . . . . 0.0 110.28 -179.548 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -91.94 22.98 28.65 Favored Glycine 0 N--CA 1.449 -0.488 0 C-N-CA 120.926 -0.654 . . . . 0.0 112.611 179.325 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 78.71 -38.28 1.91 Allowed Glycine 0 CA--C 1.522 0.483 0 C-N-CA 121.251 -0.5 . . . . 0.0 113.631 179.447 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.4 m -89.49 147.38 24.02 Favored 'General case' 0 C--N 1.321 -0.65 0 O-C-N 122.498 -0.413 . . . . 0.0 111.49 -179.348 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 62.9 m -104.49 154.82 19.41 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.759 -0.655 . . . . 0.0 109.394 178.834 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 39.7 t30 -87.64 -26.7 22.89 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-O 121.135 0.493 . . . . 0.0 110.496 -179.717 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 3.7 m -102.12 120.42 53.7 Favored Pre-proline 0 C--N 1.324 -0.54 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.283 -179.268 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_exo -65.71 140.62 62.67 Favored 'Trans proline' 0 N--CA 1.461 -0.385 0 C-N-CA 122.943 2.428 . . . . 0.0 111.846 179.693 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 105.1 -28.91 12.74 Favored Glycine 0 N--CA 1.441 -0.976 0 C-N-CA 120.717 -0.754 . . . . 0.0 111.66 -179.356 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.532 ' HB3' ' HB3' ' A' ' 22' ' ' CYS . 2.0 m -87.64 131.55 34.4 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 121.273 0.559 . . . . 0.0 110.546 179.402 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 13.6 m -91.53 140.52 29.67 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.482 -0.781 . . . . 0.0 109.168 179.59 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 39.9 t -75.52 111.14 10.51 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-O 121.645 0.736 . . . . 0.0 111.598 -179.121 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 11.7 m -114.47 65.43 0.67 Allowed 'General case' 0 C--N 1.308 -1.197 0 N-CA-C 106.254 -1.758 . . . . 0.0 106.254 177.385 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . 0.473 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.5 OUTLIER -28.66 125.78 0.24 Allowed Pre-proline 0 N--CA 1.464 0.252 0 CA-C-N 114.072 -1.422 . . . . 0.0 112.574 -176.583 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . 0.473 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 65.0 Cg_endo -98.4 38.03 5.84 Favored 'Cis proline' 0 N--CA 1.459 -0.54 0 C-N-CA 123.963 -1.265 . . . . 0.0 114.109 0.899 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 2.3 pp -143.43 133.02 20.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 121.541 0.686 . . . . 0.0 112.457 -178.938 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.718 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 63.8 m -83.0 134.46 35.05 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.411 179.225 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 5.2 p -138.56 130.56 28.22 Favored 'General case' 0 C--N 1.317 -0.843 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.038 -179.746 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.433 ' HG3' ' O ' ' A' ' 24' ' ' ARG . 9.6 ptm180 -97.5 127.82 43.77 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 178.764 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 27.9 m-20 58.52 27.43 15.61 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.439 0.637 . . . . 0.0 109.504 -178.692 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 77.38 7.86 87.02 Favored Glycine 0 N--CA 1.449 -0.471 0 CA-C-N 115.411 -0.813 . . . . 0.0 112.389 -178.984 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . 0.414 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 91.6 mt -109.59 131.57 21.82 Favored Pre-proline 0 C--O 1.238 0.451 0 CA-C-O 121.158 0.504 . . . . 0.0 111.293 -179.666 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . 0.414 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 5.0 Cg_exo -77.06 65.4 7.81 Favored 'Trans proline' 0 N--CA 1.463 -0.32 0 C-N-CA 123.656 2.904 . . . . 0.0 111.95 179.594 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 47.8 t . . . . . 0 C--N 1.325 -0.465 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.594 -179.166 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 CA--C 1.526 0.035 0 CA-C-O 121.046 0.45 . . . . 0.0 110.299 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 60.37 38.63 94.99 Favored Glycine 0 C--N 1.332 0.348 0 CA-C-N 115.535 -0.757 . . . . 0.0 112.796 179.353 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -125.0 143.19 51.03 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 121.187 0.517 . . . . 0.0 111.259 -179.731 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.417 HG21 ' O ' ' A' ' 20' ' ' PRO . 87.9 m -89.18 111.46 22.25 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.376 179.85 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 25.3 p -88.77 58.98 4.87 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 121.287 0.565 . . . . 0.0 110.468 -179.995 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 33.6 t80 -52.92 -46.01 67.88 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.378 -0.828 . . . . 0.0 111.233 -179.688 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -92.56 24.04 25.15 Favored Glycine 0 C--O 1.227 -0.291 0 C-N-CA 120.579 -0.82 . . . . 0.0 112.728 179.73 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.83 36.72 93.2 Favored Glycine 0 C--O 1.228 -0.252 0 C-N-CA 121.2 -0.524 . . . . 0.0 112.666 179.694 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.7 m -136.06 148.95 48.56 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 60.3 m -129.33 141.57 51.05 Favored 'General case' 0 C--N 1.322 -0.628 0 O-C-N 123.218 0.324 . . . . 0.0 110.246 179.9 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 44.0 t30 -89.06 -17.3 29.6 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.804 -0.635 . . . . 0.0 110.614 -179.592 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.512 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 4.3 m -101.31 123.46 44.62 Favored Pre-proline 0 C--N 1.322 -0.596 0 CA-C-O 121.14 0.495 . . . . 0.0 111.33 -178.939 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.416 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 23.4 Cg_exo -64.18 136.65 52.77 Favored 'Trans proline' 0 C--N 1.345 0.349 0 C-N-CA 123.017 2.478 . . . . 0.0 112.013 179.948 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 92.85 -12.27 70.26 Favored Glycine 0 N--CA 1.447 -0.596 0 C-N-CA 120.79 -0.719 . . . . 0.0 111.881 -179.626 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.648 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 98.9 m -87.55 134.4 33.63 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 121.125 0.488 . . . . 0.0 110.308 179.773 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 12.6 m -107.4 137.55 45.23 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.637 -0.71 . . . . 0.0 109.104 -179.88 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 53.9 t -72.95 115.52 12.35 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-O 121.496 0.665 . . . . 0.0 111.961 -178.739 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 8.7 m -116.29 66.49 0.71 Allowed 'General case' 0 C--N 1.312 -1.03 0 N-CA-C 106.515 -1.661 . . . . 0.0 106.515 177.478 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . 0.432 ' CE3' ' HB3' ' A' ' 20' ' ' PRO . 0.2 OUTLIER -28.82 126.86 0.23 Allowed Pre-proline 0 N--CA 1.464 0.229 0 CA-C-N 114.303 -1.317 . . . . 0.0 112.841 -176.559 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . 0.432 ' HB3' ' CE3' ' A' ' 19' ' ' TRP . 62.6 Cg_endo -97.21 32.79 10.48 Favored 'Cis proline' 0 CA--C 1.532 0.396 0 C-N-CA 123.676 -1.385 . . . . 0.0 114.293 0.93 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 44.2 pt -138.97 133.87 41.41 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-O 121.451 0.643 . . . . 0.0 111.888 -179.239 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.648 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 7.0 t -83.48 142.87 30.62 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-O 121.22 0.533 . . . . 0.0 109.746 179.202 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 14.9 p -145.33 131.99 19.93 Favored 'General case' 0 C--N 1.314 -0.949 0 CA-C-N 115.276 -0.875 . . . . 0.0 111.293 -178.399 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.531 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 0.0 OUTLIER -92.39 128.51 38.26 Favored 'General case' 0 N--CA 1.448 -0.555 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 178.38 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 18.6 m-20 56.57 28.45 13.94 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.191 0.52 . . . . 0.0 109.963 -179.253 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 76.79 13.16 83.87 Favored Glycine 0 C--N 1.333 0.409 0 CA-C-N 115.745 -0.661 . . . . 0.0 112.362 -179.089 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . 0.471 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 87.2 mt -112.49 129.55 24.26 Favored Pre-proline 0 C--O 1.241 0.655 0 CA-C-O 120.887 0.375 . . . . 0.0 110.858 -179.847 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . 0.471 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 2.8 Cg_exo -75.54 54.14 3.8 Favored 'Trans proline' 0 C--N 1.342 0.216 0 C-N-CA 123.718 2.945 . . . . 0.0 112.468 -179.95 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 45.4 t . . . . . 0 C--N 1.323 -0.553 0 CA-C-O 121.331 0.586 . . . . 0.0 110.141 -179.748 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 1' ' ' CYS . . . . . 0.407 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 61.4 m . . . . . 0 N--CA 1.458 -0.043 0 CA-C-O 121.037 0.446 . . . . 0.0 109.806 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 60.26 32.95 78.33 Favored Glycine 0 C--N 1.332 0.347 0 CA-C-N 115.497 -0.774 . . . . 0.0 113.204 179.087 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 3' ' ' GLU . . . . . 0.419 ' HG3' ' HB3' ' A' ' 22' ' ' CYS . 9.3 pt-20 -105.71 145.54 30.96 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 121.045 0.45 . . . . 0.0 111.015 179.901 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 4' ' ' THR . . . . . 0.573 HG22 ' O ' ' A' ' 20' ' ' PRO . 58.3 m -88.83 110.0 20.67 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.89 -0.596 . . . . 0.0 110.399 179.91 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 25.8 p -88.78 59.71 5.2 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 121.429 0.633 . . . . 0.0 110.536 -179.941 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 34.8 t80 -53.64 -43.78 69.02 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.286 -0.87 . . . . 0.0 111.165 -179.75 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -88.23 18.54 40.52 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.743 -0.741 . . . . 0.0 113.004 179.905 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 64.56 37.61 94.63 Favored Glycine 0 N--CA 1.453 -0.233 0 C-N-CA 121.077 -0.582 . . . . 0.0 112.656 179.668 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.6 m -147.38 149.52 32.92 Favored 'General case' 0 C--N 1.324 -0.522 0 N-CA-C 109.665 -0.494 . . . . 0.0 109.665 179.92 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 43.4 m -121.45 146.0 47.35 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.239 -179.899 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 39.1 t30 -88.26 -23.45 23.5 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.154 -179.787 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' THR . . . . . 0.407 ' HB ' ' SG ' ' A' ' 1' ' ' CYS . 2.9 m -101.95 121.11 51.88 Favored Pre-proline 0 C--N 1.323 -0.582 0 CA-C-N 115.999 -0.546 . . . . 0.0 111.413 -178.977 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 22.2 Cg_exo -64.74 141.5 72.5 Favored 'Trans proline' 0 C--N 1.344 0.298 0 C-N-CA 123.021 2.48 . . . . 0.0 111.854 179.76 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 101.62 -28.17 17.16 Favored Glycine 0 N--CA 1.445 -0.747 0 C-N-CA 120.687 -0.768 . . . . 0.0 111.615 -179.331 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.829 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 1.6 m -86.97 136.85 32.78 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 121.136 0.493 . . . . 0.0 110.191 179.446 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 14.2 m -105.26 140.18 38.8 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.596 -0.729 . . . . 0.0 109.314 -179.745 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 53.9 t -72.37 112.33 8.34 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.482 0.658 . . . . 0.0 111.709 -178.887 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 14.1 m -114.54 66.91 0.68 Allowed 'General case' 0 C--N 1.312 -1.052 0 N-CA-C 106.554 -1.647 . . . . 0.0 106.554 177.624 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' TRP . . . . . 0.443 ' CE3' ' HB3' ' A' ' 20' ' ' PRO . 0.2 OUTLIER -28.91 127.01 0.23 Allowed Pre-proline 0 N--CA 1.464 0.266 0 CA-C-N 114.24 -1.345 . . . . 0.0 112.833 -176.631 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' PRO . . . . . 0.573 ' O ' HG22 ' A' ' 4' ' ' THR . 62.2 Cg_endo -97.1 31.85 11.75 Favored 'Cis proline' 0 N--CA 1.46 -0.443 0 C-N-CA 123.627 -1.406 . . . . 0.0 114.213 0.968 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 43.0 pt -138.56 133.61 42.53 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-O 121.663 0.744 . . . . 0.0 112.025 -179.174 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.829 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 8.0 t -83.54 140.1 32.47 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-N 115.927 -0.578 . . . . 0.0 109.547 179.011 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 7.9 p -148.76 135.5 19.76 Favored 'General case' 0 C--N 1.313 -0.982 0 CA-C-N 115.274 -0.875 . . . . 0.0 111.342 -178.104 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' ARG . . . . . 0.496 ' HG3' ' O ' ' A' ' 24' ' ' ARG . 4.8 ptm180 -93.92 126.29 39.04 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 178.576 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 58.52 27.23 15.32 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.36 0.6 . . . . 0.0 109.404 -179.069 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 77.57 9.31 86.94 Favored Glycine 0 C--N 1.333 0.392 0 CA-C-N 115.504 -0.771 . . . . 0.0 112.251 -178.885 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 88.4 mt -108.07 131.12 21.96 Favored Pre-proline 0 C--O 1.24 0.558 0 CA-C-O 121.092 0.472 . . . . 0.0 111.091 -179.724 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -76.14 64.3 7.01 Favored 'Trans proline' 0 C--N 1.341 0.158 0 C-N-CA 123.269 2.646 . . . . 0.0 112.48 179.946 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 55.5 t . . . . . 0 C--N 1.324 -0.532 0 CA-C-O 121.285 0.564 . . . . 0.0 110.163 -179.759 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 5.4 m . . . . . 0 N--CA 1.457 -0.092 0 CA-C-O 121.038 0.447 . . . . 0.0 110.013 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 76.68 -35.45 1.4 Allowed Glycine 0 C--N 1.331 0.259 0 CA-C-N 115.849 -0.614 . . . . 0.0 113.703 179.069 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 7.3 pt-20 -58.13 143.84 42.49 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 121.615 0.721 . . . . 0.0 112.058 -178.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 53.6 m -95.11 121.35 36.65 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.034 -0.985 . . . . 0.0 110.658 179.688 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.77 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 13.7 p -88.08 61.17 6.17 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 121.258 0.552 . . . . 0.0 109.866 179.05 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 29.4 t80 -52.77 -44.5 66.56 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.368 -0.833 . . . . 0.0 110.555 -179.609 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -93.45 25.08 22.52 Favored Glycine 0 N--CA 1.449 -0.462 0 C-N-CA 120.639 -0.791 . . . . 0.0 112.399 179.223 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 75.59 -30.52 1.23 Allowed Glycine 0 CA--C 1.523 0.562 0 C-N-CA 121.485 -0.388 . . . . 0.0 113.789 179.579 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.5 m -89.1 148.95 23.42 Favored 'General case' 0 C--N 1.322 -0.59 0 O-C-N 122.367 -0.49 . . . . 0.0 111.293 -179.483 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 79.7 m -112.15 151.44 29.49 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.859 -0.61 . . . . 0.0 109.684 179.11 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -88.46 -21.64 24.1 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 120.895 0.379 . . . . 0.0 110.53 -179.214 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 4.3 m -100.71 123.38 45.98 Favored Pre-proline 0 C--N 1.323 -0.557 0 CA-C-O 121.148 0.499 . . . . 0.0 111.277 -179.1 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 29.7 Cg_endo -63.75 136.04 51.61 Favored 'Trans proline' 0 C--N 1.344 0.332 0 C-N-CA 122.823 2.348 . . . . 0.0 111.562 179.519 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 98.69 -21.39 46.19 Favored Glycine 0 N--CA 1.443 -0.834 0 C-N-CA 120.509 -0.853 . . . . 0.0 111.744 -179.228 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.534 ' SG ' ' HB3' ' A' ' 24' ' ' ARG . 71.3 m -86.73 126.35 34.52 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 121.212 0.529 . . . . 0.0 110.235 179.597 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 14.8 m -96.85 140.64 31.11 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 115.449 -0.796 . . . . 0.0 109.023 179.634 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 53.7 t -69.76 123.68 22.03 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-O 121.683 0.754 . . . . 0.0 111.92 -178.792 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 7.4 m -130.06 61.68 1.58 Allowed 'General case' 0 C--N 1.313 -0.997 0 N-CA-C 106.031 -1.84 . . . . 0.0 106.031 177.787 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . 0.478 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -27.51 125.71 0.22 Allowed Pre-proline 0 N--CA 1.463 0.198 0 CA-C-N 113.827 -1.533 . . . . 0.0 112.787 -176.576 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.478 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 71.9 Cg_endo -98.03 38.07 5.82 Favored 'Cis proline' 0 N--CA 1.459 -0.533 0 C-N-CA 123.813 -1.328 . . . . 0.0 114.172 0.746 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.443 HD13 HG23 ' A' ' 21' ' ' ILE . 39.9 pt -143.44 136.9 25.21 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 O-C-N 121.6 -0.688 . . . . 0.0 112.026 -179.148 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.77 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 74.0 m -82.37 136.61 34.95 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-O 121.09 0.471 . . . . 0.0 110.236 178.923 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 67.0 p -127.3 123.47 36.47 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.857 -179.615 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.534 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 4.4 ptm180 -92.63 125.69 37.37 Favored 'General case' 0 N--CA 1.445 -0.702 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 178.519 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 58.62 26.75 14.86 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.257 0.551 . . . . 0.0 109.682 -178.941 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 84.11 3.27 89.09 Favored Glycine 0 N--CA 1.45 -0.428 0 CA-C-N 115.723 -0.671 . . . . 0.0 112.668 -179.402 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.451 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 88.8 mt -102.91 121.5 48.97 Favored Pre-proline 0 C--N 1.328 -0.352 0 O-C-N 122.561 -0.376 . . . . 0.0 110.857 -179.947 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.451 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 5.1 Cg_exo -76.98 47.22 2.15 Favored 'Trans proline' 0 C--N 1.343 0.246 0 C-N-CA 123.361 2.707 . . . . 0.0 112.307 179.827 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 10.7 p . . . . . 0 C--N 1.32 -0.692 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.402 -179.856 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.3 m . . . . . 0 CA--C 1.527 0.068 0 CA-C-O 120.962 0.41 . . . . 0.0 110.419 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 77.92 -36.39 1.68 Allowed Glycine 0 C--N 1.331 0.251 0 CA-C-N 115.969 -0.56 . . . . 0.0 113.166 179.415 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 11.8 pt-20 -58.27 137.26 57.26 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 121.5 0.667 . . . . 0.0 112.072 -179.244 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.493 ' HB ' ' CD1' ' A' ' 6' ' ' PHE . 10.6 p -91.15 117.52 29.68 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.37 -0.832 . . . . 0.0 109.804 179.221 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 28.2 p -88.92 57.97 4.37 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.012 0.434 . . . . 0.0 111.764 -178.521 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . 0.493 ' CD1' ' HB ' ' A' ' 4' ' ' THR . 5.3 m-85 -57.64 -38.07 74.4 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.99 179.423 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -89.9 18.06 49.6 Favored Glycine 0 CA--C 1.519 0.315 0 C-N-CA 120.639 -0.791 . . . . 0.0 112.861 179.841 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 62.31 39.48 97.79 Favored Glycine 0 C--N 1.331 0.27 0 C-N-CA 121.092 -0.575 . . . . 0.0 112.916 179.546 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 3.5 m -149.04 152.18 35.8 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 109.724 -0.473 . . . . 0.0 109.724 -179.996 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 56.8 m -129.94 143.4 50.78 Favored 'General case' 0 C--N 1.324 -0.522 0 O-C-N 123.21 0.319 . . . . 0.0 110.225 179.927 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 43.0 t30 -89.13 -18.11 27.86 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.026 -179.229 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.432 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 6.7 m -100.97 125.13 39.34 Favored Pre-proline 0 C--N 1.323 -0.558 0 CA-C-O 121.155 0.503 . . . . 0.0 111.671 -178.649 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_endo -64.41 138.52 60.61 Favored 'Trans proline' 0 C--N 1.346 0.395 0 C-N-CA 122.859 2.372 . . . . 0.0 111.626 179.541 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 93.67 -15.55 62.78 Favored Glycine 0 N--CA 1.447 -0.607 0 C-N-CA 120.726 -0.75 . . . . 0.0 111.557 -179.133 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.746 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 93.7 m -87.45 133.27 33.77 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 121.045 0.45 . . . . 0.0 110.163 179.606 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 14.6 m -110.54 136.58 49.44 Favored 'General case' 0 C--N 1.323 -0.56 0 N-CA-C 109.209 -0.663 . . . . 0.0 109.209 179.934 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.8 t -67.37 126.42 29.2 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-O 121.437 0.637 . . . . 0.0 111.914 -178.604 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 4.9 m -132.35 65.79 1.57 Allowed 'General case' 0 C--N 1.318 -0.79 0 N-CA-C 106.889 -1.523 . . . . 0.0 106.889 178.457 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . 0.45 ' CE3' ' HB3' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -27.71 126.67 0.22 Allowed Pre-proline 0 N--CA 1.465 0.289 0 CA-C-N 114.402 -1.272 . . . . 0.0 112.93 -176.684 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.45 ' HB3' ' CE3' ' A' ' 19' ' ' TRP . 62.8 Cg_endo -97.68 30.72 12.97 Favored 'Cis proline' 0 N--CA 1.461 -0.43 0 C-N-CA 123.802 -1.333 . . . . 0.0 114.424 0.927 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.417 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 43.5 pt -138.65 142.58 34.32 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.36 0 CA-C-O 121.385 0.612 . . . . 0.0 111.448 -179.05 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.746 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 5.8 t -87.97 144.0 26.79 Favored 'General case' 0 C--N 1.314 -0.943 0 CA-C-O 121.137 0.494 . . . . 0.0 110.005 179.393 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 48.7 p -136.58 126.84 26.45 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-N 115.573 -0.74 . . . . 0.0 111.7 -178.58 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.659 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 9.1 ptm180 -91.47 126.9 36.71 Favored 'General case' 0 N--CA 1.445 -0.713 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 177.985 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 29.0 m-20 58.34 26.72 14.38 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 121.209 0.528 . . . . 0.0 109.911 -178.889 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 80.31 10.07 85.82 Favored Glycine 0 N--CA 1.45 -0.432 0 CA-C-N 115.864 -0.607 . . . . 0.0 112.363 -179.395 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 89.7 mt -113.15 128.54 25.52 Favored Pre-proline 0 C--O 1.236 0.379 0 CA-C-O 120.857 0.36 . . . . 0.0 110.755 -180.0 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 6.5 Cg_exo -73.76 52.94 2.65 Favored 'Trans proline' 0 CA--C 1.527 0.166 0 C-N-CA 123.619 2.879 . . . . 0.0 112.54 -179.839 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 39.4 t . . . . . 0 C--N 1.323 -0.57 0 CA-C-O 121.364 0.602 . . . . 0.0 110.206 -179.75 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.5 m . . . . . 0 N--CA 1.458 -0.058 0 CA-C-O 121.081 0.467 . . . . 0.0 110.191 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 77.16 -36.28 1.51 Allowed Glycine 0 C--N 1.332 0.331 0 CA-C-N 115.862 -0.608 . . . . 0.0 113.29 179.256 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 9.1 pt-20 -58.04 138.6 55.85 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 121.585 0.707 . . . . 0.0 112.181 -179.166 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.441 ' HA ' ' HA ' ' A' ' 21' ' ' ILE . 28.9 p -89.77 119.86 30.53 Favored 'General case' 0 N--CA 1.445 -0.675 0 CA-C-N 115.288 -0.869 . . . . 0.0 109.663 179.064 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 25.7 p -87.83 60.6 5.99 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 121.478 0.656 . . . . 0.0 110.507 -179.684 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 36.0 t80 -54.6 -41.5 70.01 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.353 -0.839 . . . . 0.0 110.613 179.942 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -94.33 22.93 34.26 Favored Glycine 0 N--CA 1.449 -0.492 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.733 179.611 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 75.25 -28.85 1.18 Allowed Glycine 0 CA--C 1.523 0.593 0 C-N-CA 121.192 -0.528 . . . . 0.0 113.94 179.382 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.8 m -88.43 151.05 22.82 Favored 'General case' 0 C--N 1.322 -0.616 0 O-C-N 122.522 -0.399 . . . . 0.0 111.445 -179.015 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 61.6 m -120.79 149.77 42.03 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.855 -0.611 . . . . 0.0 109.763 179.266 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 41.3 t30 -88.8 -21.33 23.81 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 121.115 0.483 . . . . 0.0 111.181 -179.227 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 6.4 m -101.08 124.2 42.4 Favored Pre-proline 0 C--N 1.323 -0.575 0 CA-C-O 121.239 0.542 . . . . 0.0 111.793 -178.424 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 33.7 Cg_endo -65.01 138.35 56.66 Favored 'Trans proline' 0 C--N 1.346 0.423 0 C-N-CA 122.897 2.398 . . . . 0.0 111.58 179.461 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 95.22 -16.22 61.75 Favored Glycine 0 N--CA 1.446 -0.655 0 C-N-CA 120.635 -0.793 . . . . 0.0 111.492 -179.224 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.644 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 91.5 m -88.07 133.81 33.89 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 120.991 0.424 . . . . 0.0 109.934 179.368 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 15.1 m -108.62 136.47 48.16 Favored 'General case' 0 C--N 1.322 -0.604 0 N-CA-C 109.201 -0.666 . . . . 0.0 109.201 -179.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.4 t -66.92 126.07 27.95 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-O 121.673 0.749 . . . . 0.0 111.91 -178.49 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 4.6 m -129.93 62.52 1.55 Allowed 'General case' 0 C--N 1.316 -0.87 0 N-CA-C 106.37 -1.715 . . . . 0.0 106.37 178.016 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . 0.434 ' CE3' ' HB3' ' A' ' 20' ' ' PRO . 0.2 OUTLIER -26.11 126.4 0.2 Allowed Pre-proline 0 N--CA 1.465 0.307 0 CA-C-N 114.052 -1.431 . . . . 0.0 113.028 -176.507 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.434 ' HB3' ' CE3' ' A' ' 19' ' ' TRP . 61.0 Cg_endo -97.49 31.55 11.97 Favored 'Cis proline' 0 CA--C 1.533 0.459 0 C-N-CA 123.731 -1.362 . . . . 0.0 114.32 1.02 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.441 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 42.8 pt -138.04 140.29 40.81 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.354 0 CA-C-O 121.272 0.558 . . . . 0.0 111.362 -179.194 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.644 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 4.0 t -87.0 144.07 27.07 Favored 'General case' 0 C--N 1.315 -0.929 0 CA-C-O 121.205 0.526 . . . . 0.0 110.146 179.715 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 60.4 p -136.64 127.82 28.01 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 115.572 -0.74 . . . . 0.0 111.643 -178.553 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.593 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 1.7 ptm180 -89.07 123.42 33.35 Favored 'General case' 0 N--CA 1.446 -0.63 0 N-CA-C 108.528 -0.915 . . . . 0.0 108.528 178.197 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 69.8 m-20 57.44 30.73 19.1 Favored 'General case' 0 N--CA 1.468 0.461 0 O-C-N 123.518 0.511 . . . . 0.0 109.955 -177.627 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 78.54 9.65 86.85 Favored Glycine 0 C--N 1.333 0.415 0 CA-C-N 115.895 -0.593 . . . . 0.0 112.688 -179.656 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 90.4 mt -110.61 127.01 27.67 Favored Pre-proline 0 C--O 1.237 0.4 0 O-C-N 122.682 -0.305 . . . . 0.0 110.686 179.912 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 61.9 Cg_endo -73.57 52.45 2.46 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 123.268 2.645 . . . . 0.0 112.783 -179.837 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 39.7 t . . . . . 0 C--N 1.323 -0.56 0 CA-C-O 121.396 0.617 . . . . 0.0 110.041 -179.948 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.8 m . . . . . 0 CA--C 1.527 0.077 0 CA-C-O 120.967 0.413 . . . . 0.0 110.409 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 77.78 -36.01 1.64 Allowed Glycine 0 C--N 1.33 0.231 0 CA-C-N 115.848 -0.615 . . . . 0.0 113.405 179.278 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 11.1 pt-20 -56.6 136.22 54.61 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.523 0.678 . . . . 0.0 112.085 -179.001 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.524 ' HA ' ' HA ' ' A' ' 21' ' ' ILE . 24.6 p -89.58 114.99 26.65 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.347 -0.842 . . . . 0.0 109.951 179.424 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 28.3 p -88.9 58.34 4.54 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 120.999 0.428 . . . . 0.0 111.673 -179.006 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . 0.478 ' CD1' ' HB ' ' A' ' 4' ' ' THR . 5.1 m-85 -57.17 -38.15 73.17 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.137 179.444 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -89.43 17.52 51.55 Favored Glycine 0 CA--C 1.519 0.314 0 C-N-CA 120.656 -0.783 . . . . 0.0 112.791 179.815 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 62.57 40.23 98.87 Favored Glycine 0 C--N 1.331 0.268 0 C-N-CA 121.141 -0.552 . . . . 0.0 112.88 179.529 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.8 m -148.38 150.57 33.78 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 109.65 -0.5 . . . . 0.0 109.65 179.885 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 56.6 m -128.53 143.65 51.01 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 120.797 0.332 . . . . 0.0 110.413 -179.846 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 42.8 t30 -89.21 -18.98 26.0 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.805 -179.538 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 6.0 m -101.26 124.49 41.12 Favored Pre-proline 0 C--N 1.324 -0.521 0 CA-C-O 121.169 0.509 . . . . 0.0 111.586 -178.593 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 36.0 Cg_endo -65.54 140.43 62.84 Favored 'Trans proline' 0 C--N 1.346 0.404 0 C-N-CA 122.849 2.366 . . . . 0.0 111.72 179.468 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 93.73 -17.09 59.32 Favored Glycine 0 N--CA 1.447 -0.58 0 C-N-CA 120.608 -0.806 . . . . 0.0 111.495 -179.054 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.686 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 94.4 m -87.34 134.6 33.55 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-O 121.067 0.46 . . . . 0.0 110.087 179.714 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 14.5 m -108.71 136.3 48.51 Favored 'General case' 0 C--N 1.323 -0.57 0 N-CA-C 108.997 -0.742 . . . . 0.0 108.997 179.97 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 48.7 t -71.21 121.53 18.55 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-O 121.472 0.654 . . . . 0.0 111.856 -178.644 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 2.0 p -129.64 73.07 1.5 Allowed 'General case' 0 C--N 1.314 -0.956 0 N-CA-C 107.354 -1.35 . . . . 0.0 107.354 177.934 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . 0.482 ' CE3' ' HB3' ' A' ' 20' ' ' PRO . 0.0 OUTLIER -29.57 129.51 0.24 Allowed Pre-proline 0 N--CA 1.465 0.31 0 CA-C-N 114.379 -1.282 . . . . 0.0 112.906 -176.842 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.482 ' HB3' ' CE3' ' A' ' 19' ' ' TRP . 68.2 Cg_endo -97.48 27.56 17.46 Favored 'Cis proline' 0 N--CA 1.46 -0.468 0 C-N-CA 123.696 -1.377 . . . . 0.0 114.682 1.001 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.524 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 0.2 OUTLIER -139.3 148.61 23.45 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.347 0 CA-C-O 121.309 0.576 . . . . 0.0 111.229 -179.297 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.686 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 4.6 t -88.81 144.22 26.37 Favored 'General case' 0 C--N 1.312 -1.057 0 CA-C-O 121.168 0.509 . . . . 0.0 109.783 179.635 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 21.5 p -138.13 126.58 23.32 Favored 'General case' 0 C--N 1.314 -0.954 0 CA-C-N 115.478 -0.783 . . . . 0.0 111.586 -178.486 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.616 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 4.8 ptm180 -90.18 127.52 36.14 Favored 'General case' 0 N--CA 1.446 -0.67 0 N-CA-C 108.803 -0.814 . . . . 0.0 108.803 178.445 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 58.04 27.04 14.3 Favored 'General case' 0 C--N 1.328 -0.37 0 CA-C-O 121.206 0.527 . . . . 0.0 109.873 -179.225 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 78.4 13.52 83.16 Favored Glycine 0 C--N 1.334 0.417 0 CA-C-N 115.821 -0.627 . . . . 0.0 112.201 -179.165 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 89.9 mt -114.94 129.98 24.58 Favored Pre-proline 0 C--O 1.238 0.496 0 CA-C-O 120.914 0.388 . . . . 0.0 110.751 -179.894 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 67.7 Cg_endo -74.24 53.67 3.05 Favored 'Trans proline' 0 C--N 1.344 0.291 0 C-N-CA 123.277 2.651 . . . . 0.0 112.789 -179.807 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 39.9 t . . . . . 0 C--N 1.323 -0.553 0 CA-C-O 121.416 0.627 . . . . 0.0 110.2 -179.896 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.458 -0.031 0 CA-C-O 121.07 0.462 . . . . 0.0 110.253 . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 61.04 38.77 96.09 Favored Glycine 0 C--N 1.332 0.324 0 CA-C-N 115.595 -0.73 . . . . 0.0 112.776 179.33 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -127.55 143.2 51.2 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 121.15 0.5 . . . . 0.0 110.986 -179.812 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.487 ' HB ' ' CD1' ' A' ' 6' ' ' PHE . 21.0 p -89.58 111.67 22.67 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.014 179.487 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 23.8 p -88.85 59.21 4.95 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 121.096 0.474 . . . . 0.0 111.401 -179.24 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . 0.487 ' CD1' ' HB ' ' A' ' 4' ' ' THR . 4.5 m-85 -57.48 -36.41 71.45 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.739 179.382 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -88.53 16.77 52.51 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.788 179.517 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 76.39 -29.6 1.44 Allowed Glycine 0 CA--C 1.523 0.588 0 C-N-CA 121.226 -0.511 . . . . 0.0 113.612 179.536 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.9 m -88.57 150.93 22.82 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 120.844 0.354 . . . . 0.0 111.172 -179.139 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 69.5 m -117.49 148.3 41.96 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.831 -0.622 . . . . 0.0 109.893 179.396 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 66.1 m-80 -88.84 -18.81 26.87 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.819 -179.511 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.522 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 3.2 m -101.87 124.93 38.6 Favored Pre-proline 0 C--N 1.324 -0.527 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.238 -178.984 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -65.77 138.24 52.76 Favored 'Trans proline' 0 C--N 1.344 0.304 0 C-N-CA 122.804 2.336 . . . . 0.0 112.022 179.746 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 91.61 -13.01 67.77 Favored Glycine 0 N--CA 1.449 -0.499 0 C-N-CA 120.761 -0.733 . . . . 0.0 111.876 -179.495 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.684 ' SG ' ' HB3' ' A' ' 24' ' ' ARG . 99.3 m -87.34 136.08 33.07 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.108 0.48 . . . . 0.0 110.401 179.857 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 9.9 m -107.39 135.86 48.16 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 108.99 -0.744 . . . . 0.0 108.99 179.925 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.3 t -72.41 120.73 18.43 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-O 121.596 0.713 . . . . 0.0 112.17 -178.468 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 7.6 m -122.33 65.3 0.94 Allowed 'General case' 0 C--N 1.314 -0.968 0 N-CA-C 106.494 -1.669 . . . . 0.0 106.494 177.705 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . 0.468 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -27.32 126.96 0.21 Allowed Pre-proline 0 N--CA 1.466 0.359 0 CA-C-N 114.222 -1.354 . . . . 0.0 112.955 -176.51 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.468 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 64.9 Cg_endo -97.2 31.07 12.73 Favored 'Cis proline' 0 N--CA 1.461 -0.42 0 C-N-CA 123.704 -1.373 . . . . 0.0 114.324 0.846 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 40.9 pt -137.21 136.02 47.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 121.481 0.658 . . . . 0.0 111.862 -179.112 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.655 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 5.7 t -86.44 144.96 27.03 Favored 'General case' 0 C--N 1.315 -0.905 0 CA-C-O 121.233 0.539 . . . . 0.0 110.064 179.577 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.481 HG23 ' HA ' ' A' ' 28' ' ' PRO . 9.1 p -144.11 128.79 18.21 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-N 115.288 -0.869 . . . . 0.0 111.216 -178.503 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.684 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 5.6 ptm180 -91.33 128.44 37.15 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.095 -0.706 . . . . 0.0 109.095 178.628 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 57.5 27.51 14.13 Favored 'General case' 0 N--CA 1.466 0.37 0 CA-C-O 121.243 0.544 . . . . 0.0 109.654 -179.349 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 76.2 14.53 82.21 Favored Glycine 0 C--N 1.332 0.345 0 CA-C-N 115.725 -0.67 . . . . 0.0 112.106 -178.92 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 88.2 mt -114.99 132.2 23.12 Favored Pre-proline 0 C--O 1.239 0.548 0 CA-C-O 121.071 0.462 . . . . 0.0 110.791 -179.755 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.481 ' HA ' HG23 ' A' ' 23' ' ' THR . 73.2 Cg_endo -76.08 55.16 4.41 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 123.301 2.667 . . . . 0.0 112.548 179.91 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 41.8 t . . . . . 0 C--N 1.324 -0.51 0 CA-C-O 121.272 0.558 . . . . 0.0 110.236 -179.681 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.5 m . . . . . 0 N--CA 1.457 -0.079 0 CA-C-O 121.062 0.458 . . . . 0.0 110.251 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 77.33 -36.59 1.55 Allowed Glycine 0 C--N 1.331 0.287 0 CA-C-N 115.837 -0.619 . . . . 0.0 113.387 179.27 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 7.8 pt-20 -58.17 138.0 56.55 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 121.481 0.657 . . . . 0.0 112.283 -179.109 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.464 ' HA ' ' HA ' ' A' ' 21' ' ' ILE . 26.3 p -89.79 119.34 30.1 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.418 -0.81 . . . . 0.0 109.675 179.056 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 23.0 p -88.1 61.99 6.57 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 121.495 0.664 . . . . 0.0 110.552 -179.691 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 34.2 t80 -54.38 -42.14 70.04 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.281 -0.872 . . . . 0.0 110.819 -179.892 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -93.01 21.3 40.59 Favored Glycine 0 N--CA 1.45 -0.426 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.833 179.712 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 76.52 -29.49 1.47 Allowed Glycine 0 CA--C 1.521 0.433 0 C-N-CA 121.117 -0.563 . . . . 0.0 113.616 179.598 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -88.73 143.22 27.06 Favored 'General case' 0 C--N 1.321 -0.641 0 O-C-N 122.631 -0.334 . . . . 0.0 111.878 -179.127 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 64.5 m -111.03 151.49 27.95 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.895 -0.593 . . . . 0.0 109.893 179.354 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 38.9 t30 -88.6 -24.17 22.9 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 121.132 0.491 . . . . 0.0 110.897 -179.432 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 7.5 m -101.39 123.84 43.17 Favored Pre-proline 0 C--N 1.322 -0.612 0 CA-C-O 121.15 0.5 . . . . 0.0 111.813 -178.573 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -65.95 140.91 62.42 Favored 'Trans proline' 0 C--N 1.345 0.368 0 C-N-CA 122.828 2.352 . . . . 0.0 111.484 179.263 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 96.46 -19.81 53.03 Favored Glycine 0 N--CA 1.446 -0.643 0 C-N-CA 120.539 -0.839 . . . . 0.0 111.457 -179.053 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.652 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 84.7 m -87.41 134.82 33.53 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 120.991 0.424 . . . . 0.0 109.896 179.279 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 11.0 m -106.52 136.2 46.71 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 109.114 -0.699 . . . . 0.0 109.114 -179.872 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 48.2 t -70.91 121.91 18.99 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-O 121.522 0.677 . . . . 0.0 112.23 -178.596 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 18.2 m -125.76 67.63 1.17 Allowed 'General case' 0 C--N 1.314 -0.971 0 N-CA-C 106.308 -1.738 . . . . 0.0 106.308 177.572 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . 0.46 ' CE3' ' HB3' ' A' ' 20' ' ' PRO . 0.2 OUTLIER -28.27 127.84 0.22 Allowed Pre-proline 0 N--CA 1.464 0.25 0 CA-C-N 114.062 -1.427 . . . . 0.0 112.945 -176.446 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.46 ' HB3' ' CE3' ' A' ' 19' ' ' TRP . 60.2 Cg_endo -97.83 31.91 11.38 Favored 'Cis proline' 0 N--CA 1.461 -0.429 0 C-N-CA 123.711 -1.37 . . . . 0.0 114.242 0.872 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.464 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 42.8 pt -138.56 139.22 41.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 121.452 0.644 . . . . 0.0 111.699 -179.019 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.652 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 3.7 t -84.3 144.42 28.89 Favored 'General case' 0 C--N 1.317 -0.839 0 CA-C-O 121.237 0.541 . . . . 0.0 109.55 179.268 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 17.9 p -141.97 130.43 22.49 Favored 'General case' 0 C--N 1.314 -0.944 0 CA-C-N 115.411 -0.813 . . . . 0.0 111.602 -178.143 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.452 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 9.6 ptm180 -93.84 128.17 39.97 Favored 'General case' 0 N--CA 1.448 -0.57 0 N-CA-C 108.729 -0.841 . . . . 0.0 108.729 178.309 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 28.6 m-20 58.4 26.71 14.45 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 121.29 0.567 . . . . 0.0 109.796 -178.876 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 77.75 10.67 86.08 Favored Glycine 0 C--N 1.333 0.411 0 CA-C-N 115.736 -0.666 . . . . 0.0 112.171 -179.118 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.437 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 90.2 mt -110.39 131.04 22.25 Favored Pre-proline 0 C--O 1.24 0.578 0 CA-C-O 120.965 0.412 . . . . 0.0 110.684 -179.75 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.437 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 4.9 Cg_exo -74.85 52.93 3.12 Favored 'Trans proline' 0 C--N 1.344 0.297 0 C-N-CA 123.699 2.933 . . . . 0.0 112.447 -179.832 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 40.5 t . . . . . 0 C--N 1.322 -0.613 0 CA-C-O 121.433 0.635 . . . . 0.0 110.018 -179.881 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.8 m . . . . . 0 C--O 1.23 0.032 0 CA-C-O 121.045 0.45 . . . . 0.0 110.37 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 78.11 -36.02 1.72 Allowed Glycine 0 N--CA 1.453 -0.228 0 CA-C-N 115.781 -0.645 . . . . 0.0 113.496 179.159 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 10.8 pt-20 -60.21 139.22 57.69 Favored 'General case' 0 C--O 1.238 0.471 0 CA-C-O 121.617 0.722 . . . . 0.0 111.831 -178.945 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.49 ' HB ' ' CD1' ' A' ' 6' ' ' PHE . 11.9 p -91.31 118.22 30.32 Favored 'General case' 0 N--CA 1.445 -0.699 0 CA-C-N 115.301 -0.863 . . . . 0.0 109.985 179.347 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 26.5 p -88.93 58.87 4.77 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 121.049 0.452 . . . . 0.0 111.438 -178.992 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . 0.49 ' CD1' ' HB ' ' A' ' 4' ' ' THR . 4.9 m-85 -57.67 -36.43 71.9 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.542 179.306 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -90.13 18.37 48.6 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.649 179.516 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 75.58 -30.28 1.23 Allowed Glycine 0 CA--C 1.522 0.526 0 C-N-CA 121.344 -0.455 . . . . 0.0 113.786 179.531 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.0 m -88.95 151.57 22.23 Favored 'General case' 0 C--N 1.322 -0.591 0 O-C-N 122.53 -0.394 . . . . 0.0 111.237 -179.078 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 82.8 m -118.24 149.34 41.28 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.874 -0.603 . . . . 0.0 109.661 179.29 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 65.5 m-80 -88.92 -26.06 21.76 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 116.059 -0.519 . . . . 0.0 111.659 -178.674 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.446 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 19.3 p -102.06 128.47 28.49 Favored Pre-proline 0 C--N 1.324 -0.53 0 CA-C-O 121.398 0.618 . . . . 0.0 111.841 -178.855 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.446 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 19.6 Cg_exo -66.09 141.36 63.37 Favored 'Trans proline' 0 C--N 1.346 0.402 0 C-N-CA 123.252 2.635 . . . . 0.0 112.164 -179.913 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 96.44 -20.63 49.53 Favored Glycine 0 N--CA 1.447 -0.578 0 C-N-CA 120.761 -0.733 . . . . 0.0 111.545 -179.385 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.678 ' SG ' ' HB3' ' A' ' 24' ' ' ARG . 91.8 m -88.19 135.96 33.2 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-O 121.097 0.475 . . . . 0.0 110.324 179.703 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 15.2 m -109.71 136.65 48.71 Favored 'General case' 0 C--N 1.323 -0.582 0 N-CA-C 109.044 -0.724 . . . . 0.0 109.044 179.889 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 45.4 t -66.41 127.47 32.42 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-O 121.602 0.715 . . . . 0.0 112.062 -178.448 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 5.3 m -132.32 64.61 1.6 Allowed 'General case' 0 C--N 1.316 -0.874 0 N-CA-C 106.583 -1.636 . . . . 0.0 106.583 178.337 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . 0.454 ' CE3' ' HB3' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -27.15 126.73 0.21 Allowed Pre-proline 0 N--CA 1.466 0.343 0 CA-C-N 114.231 -1.349 . . . . 0.0 112.996 -176.592 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.454 ' HB3' ' CE3' ' A' ' 19' ' ' TRP . 66.8 Cg_endo -97.3 31.37 12.28 Favored 'Cis proline' 0 CA--C 1.533 0.433 0 C-N-CA 123.689 -1.38 . . . . 0.0 114.492 1.025 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.427 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 43.4 pt -139.33 141.31 35.87 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.382 0 CA-C-O 121.302 0.573 . . . . 0.0 111.565 -179.212 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.618 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 4.2 t -86.11 144.38 27.55 Favored 'General case' 0 C--N 1.316 -0.854 0 N-CA-C 109.669 -0.493 . . . . 0.0 109.669 179.406 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 61.9 p -137.15 128.24 27.72 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-N 115.661 -0.699 . . . . 0.0 112.007 -178.235 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.678 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 3.3 ptm180 -90.52 125.36 35.58 Favored 'General case' 0 N--CA 1.445 -0.705 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 177.822 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 53.0 m-20 58.59 28.1 16.63 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-O 121.148 0.499 . . . . 0.0 110.007 -178.421 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 79.37 11.27 85.11 Favored Glycine 0 C--N 1.334 0.441 0 CA-C-N 115.933 -0.576 . . . . 0.0 112.541 -179.514 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.44 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 91.7 mt -113.81 127.92 26.31 Favored Pre-proline 0 C--O 1.236 0.382 0 CA-C-O 120.779 0.323 . . . . 0.0 110.777 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.44 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 6.9 Cg_exo -73.29 53.66 2.61 Favored 'Trans proline' 0 C--N 1.344 0.291 0 C-N-CA 123.539 2.826 . . . . 0.0 112.695 -179.776 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 38.8 t . . . . . 0 C--N 1.323 -0.547 0 CA-C-O 121.445 0.641 . . . . 0.0 110.107 -179.926 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 4.1 m . . . . . 0 CA--C 1.527 0.089 0 CA-C-O 121.016 0.436 . . . . 0.0 110.246 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 62.86 45.41 95.75 Favored Glycine 0 C--N 1.333 0.405 0 CA-C-N 115.73 -0.668 . . . . 0.0 112.944 179.068 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 8.2 pt-20 -144.73 140.53 28.61 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 121.323 0.583 . . . . 0.0 111.346 -179.686 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.48 ' HB ' ' CD1' ' A' ' 6' ' ' PHE . 21.6 p -93.39 113.84 26.1 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 115.487 -0.779 . . . . 0.0 109.74 179.148 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 25.4 p -88.65 59.25 5.03 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 121.065 0.46 . . . . 0.0 111.459 -179.019 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . 0.48 ' CD1' ' HB ' ' A' ' 4' ' ' THR . 4.6 m-85 -57.73 -36.46 72.08 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.627 179.33 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -89.75 17.89 50.16 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.665 179.529 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 76.1 -29.57 1.37 Allowed Glycine 0 CA--C 1.524 0.609 0 C-N-CA 121.307 -0.473 . . . . 0.0 113.672 179.531 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.8 m -88.66 150.58 22.94 Favored 'General case' 0 C--N 1.323 -0.55 0 O-C-N 122.582 -0.363 . . . . 0.0 111.149 -179.232 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 67.6 m -117.12 150.87 37.97 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.094 179.517 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 42.3 t30 -88.82 -22.23 23.33 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.789 -179.605 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.423 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 4.5 m -101.42 123.35 44.85 Favored Pre-proline 0 C--N 1.324 -0.519 0 CA-C-O 121.226 0.536 . . . . 0.0 111.556 -178.62 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 22.4 Cg_exo -64.75 136.83 51.14 Favored 'Trans proline' 0 C--N 1.345 0.38 0 C-N-CA 122.96 2.44 . . . . 0.0 111.788 179.656 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 95.02 -15.12 64.09 Favored Glycine 0 N--CA 1.446 -0.648 0 C-N-CA 120.645 -0.788 . . . . 0.0 111.894 -179.436 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.664 ' SG ' ' HB3' ' A' ' 24' ' ' ARG . 88.6 m -87.31 135.5 33.29 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.583 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 13.3 m -105.7 135.25 47.45 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 109.125 -0.695 . . . . 0.0 109.125 -179.844 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.0 t -70.85 120.81 16.98 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-O 121.609 0.719 . . . . 0.0 111.994 -178.445 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 11.2 m -123.62 66.32 1.02 Allowed 'General case' 0 C--N 1.315 -0.933 0 N-CA-C 106.415 -1.698 . . . . 0.0 106.415 177.685 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . 0.458 ' CE3' ' HB3' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -27.76 127.21 0.22 Allowed Pre-proline 0 N--CA 1.466 0.345 0 CA-C-N 114.167 -1.378 . . . . 0.0 112.878 -176.561 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.458 ' HB3' ' CE3' ' A' ' 19' ' ' TRP . 65.0 Cg_endo -97.37 31.29 12.35 Favored 'Cis proline' 0 N--CA 1.46 -0.442 0 C-N-CA 123.765 -1.348 . . . . 0.0 114.34 0.948 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 42.3 pt -138.2 137.34 44.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-O 121.454 0.645 . . . . 0.0 111.722 -179.155 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.594 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 4.5 t -85.05 144.38 28.29 Favored 'General case' 0 C--N 1.316 -0.861 0 CA-C-O 121.177 0.513 . . . . 0.0 109.912 179.447 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 21.5 p -143.52 127.06 16.92 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-N 115.304 -0.862 . . . . 0.0 111.127 -178.266 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.664 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 3.4 ptm180 -93.65 126.28 38.73 Favored 'General case' 0 N--CA 1.447 -0.581 0 N-CA-C 108.859 -0.793 . . . . 0.0 108.859 178.535 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 51.5 m-20 57.75 29.68 17.77 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-O 121.259 0.552 . . . . 0.0 109.657 -178.54 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 78.29 7.99 87.64 Favored Glycine 0 C--N 1.333 0.386 0 CA-C-N 115.587 -0.733 . . . . 0.0 112.67 -179.338 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.463 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 88.2 mt -106.62 124.48 35.45 Favored Pre-proline 0 C--O 1.237 0.442 0 CA-C-O 120.935 0.397 . . . . 0.0 110.867 -179.829 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.463 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 3.8 Cg_exo -79.75 46.35 2.2 Favored 'Trans proline' 0 N--CA 1.462 -0.374 0 C-N-CA 123.574 2.849 . . . . 0.0 112.08 179.868 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 10.5 p . . . . . 0 C--N 1.319 -0.719 0 CA-C-N 115.552 -0.749 . . . . 0.0 110.337 -179.765 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.0 m . . . . . 0 N--CA 1.456 -0.136 0 CA-C-O 121.066 0.46 . . . . 0.0 110.318 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 76.27 -34.05 1.32 Allowed Glycine 0 C--N 1.332 0.325 0 CA-C-N 115.867 -0.606 . . . . 0.0 113.575 179.111 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -55.04 138.44 44.0 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 121.813 0.816 . . . . 0.0 112.315 -178.921 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.553 HG23 ' HD2' ' A' ' 6' ' ' PHE . 81.1 m -89.0 110.86 21.5 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 114.892 -1.049 . . . . 0.0 110.008 179.607 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 28.5 p -89.13 53.42 2.66 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 121.167 0.508 . . . . 0.0 110.9 -179.459 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . 0.553 ' HD2' HG23 ' A' ' 4' ' ' THR . 18.9 p90 -58.15 -30.93 66.75 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.925 -0.58 . . . . 0.0 111.283 -179.988 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -94.32 15.57 62.95 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.687 179.699 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 65.17 40.08 96.57 Favored Glycine 0 CA--C 1.518 0.269 0 C-N-CA 121.049 -0.596 . . . . 0.0 112.79 179.676 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 3.0 m -149.91 150.75 32.35 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 179.91 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 60.1 m -129.26 142.75 50.76 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 120.758 0.313 . . . . 0.0 110.213 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 43.7 t30 -89.23 -17.82 28.29 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.964 -179.367 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.443 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 5.2 m -101.11 123.67 44.21 Favored Pre-proline 0 C--N 1.323 -0.561 0 CA-C-O 121.122 0.487 . . . . 0.0 111.611 -178.546 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.422 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 23.9 Cg_exo -63.61 136.65 55.21 Favored 'Trans proline' 0 C--N 1.345 0.359 0 C-N-CA 122.959 2.44 . . . . 0.0 111.705 179.583 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 94.39 -15.07 64.06 Favored Glycine 0 N--CA 1.447 -0.623 0 C-N-CA 120.638 -0.792 . . . . 0.0 111.594 -179.225 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.707 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 93.1 m -87.88 132.42 34.21 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 121.059 0.457 . . . . 0.0 110.053 179.524 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 15.2 m -108.96 134.78 51.16 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 109.116 -0.698 . . . . 0.0 109.116 179.892 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 41.9 t -67.43 121.98 16.96 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 121.578 0.704 . . . . 0.0 111.873 -178.504 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 4.1 m -125.3 65.96 1.14 Allowed 'General case' 0 C--N 1.317 -0.82 0 N-CA-C 106.765 -1.569 . . . . 0.0 106.765 178.023 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . 0.436 ' CE3' ' HB3' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -27.76 125.77 0.23 Allowed Pre-proline 0 N--CA 1.466 0.331 0 CA-C-N 114.347 -1.297 . . . . 0.0 112.812 -176.74 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.532 ' O ' HG22 ' A' ' 4' ' ' THR . 66.6 Cg_endo -97.51 31.19 12.42 Favored 'Cis proline' 0 N--CA 1.46 -0.452 0 C-N-CA 123.656 -1.393 . . . . 0.0 114.362 0.843 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 41.8 pt -138.54 136.36 43.76 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 O-C-N 121.474 -0.766 . . . . 0.0 111.859 -179.208 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.707 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 5.7 t -83.36 142.77 30.79 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-O 121.201 0.524 . . . . 0.0 109.826 179.367 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 62.0 p -137.05 128.35 28.11 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-N 115.504 -0.771 . . . . 0.0 111.785 -178.276 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.63 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 3.0 ptm180 -89.52 124.71 34.76 Favored 'General case' 0 N--CA 1.446 -0.67 0 N-CA-C 108.483 -0.932 . . . . 0.0 108.483 178.126 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 53.8 m-20 58.11 28.37 16.31 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 121.173 0.511 . . . . 0.0 110.035 -178.434 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 80.14 10.04 85.94 Favored Glycine 0 C--N 1.334 0.426 0 CA-C-N 115.87 -0.604 . . . . 0.0 112.58 -179.423 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 90.1 mt -110.82 127.33 27.11 Favored Pre-proline 0 C--N 1.327 -0.412 0 CA-C-O 120.82 0.343 . . . . 0.0 110.63 179.967 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 62.3 Cg_endo -73.61 52.69 2.53 Favored 'Trans proline' 0 C--N 1.343 0.261 0 C-N-CA 123.202 2.601 . . . . 0.0 112.784 -179.879 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 40.4 t . . . . . 0 C--N 1.322 -0.602 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.094 -179.922 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.7 m . . . . . 0 N--CA 1.457 -0.078 0 CA-C-O 121.03 0.443 . . . . 0.0 110.232 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 75.71 -34.59 1.2 Allowed Glycine 0 C--N 1.33 0.243 0 CA-C-N 115.785 -0.643 . . . . 0.0 113.657 179.114 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 15.3 pt-20 -55.74 141.8 36.89 Favored 'General case' 0 C--O 1.238 0.478 0 CA-C-O 121.639 0.733 . . . . 0.0 112.116 -178.806 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.615 HG22 ' O ' ' A' ' 20' ' ' PRO . 87.8 m -88.68 117.03 27.36 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.157 -0.928 . . . . 0.0 110.308 -179.983 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 26.3 p -88.77 58.51 4.65 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 121.229 0.538 . . . . 0.0 110.209 179.798 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 32.3 t80 -51.76 -46.36 64.08 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 115.438 -0.801 . . . . 0.0 111.243 -179.559 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -94.45 25.41 22.9 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.59 -0.814 . . . . 0.0 112.568 179.749 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.44 38.69 96.18 Favored Glycine 0 CA--C 1.518 0.223 0 C-N-CA 121.184 -0.531 . . . . 0.0 112.742 179.65 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.3 m -139.49 150.66 45.41 Favored 'General case' 0 C--N 1.324 -0.512 0 N-CA-C 110.013 -0.365 . . . . 0.0 110.013 -179.911 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 59.3 m -133.22 140.84 47.75 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 116.404 -0.362 . . . . 0.0 110.057 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 65.0 m-80 -89.56 -13.88 36.33 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.08 -179.047 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.54 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 4.7 m -101.09 124.84 40.15 Favored Pre-proline 0 C--N 1.322 -0.605 0 CA-C-O 121.126 0.489 . . . . 0.0 111.208 -178.751 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.458 ' HD2' HG23 ' A' ' 12' ' ' THR . 28.8 Cg_endo -63.58 135.81 51.1 Favored 'Trans proline' 0 C--N 1.345 0.387 0 C-N-CA 122.88 2.387 . . . . 0.0 112.179 179.957 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 91.83 -11.32 72.43 Favored Glycine 0 N--CA 1.448 -0.556 0 C-N-CA 120.806 -0.711 . . . . 0.0 111.898 -179.508 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.743 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 89.1 m -88.08 132.9 34.12 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.056 0.455 . . . . 0.0 110.344 179.738 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 15.3 m -111.21 138.06 48.13 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 109.158 -0.682 . . . . 0.0 109.158 179.889 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 45.7 t -67.74 123.86 21.69 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-O 121.451 0.643 . . . . 0.0 111.969 -178.766 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 4.6 m -128.35 62.64 1.44 Allowed 'General case' 0 C--N 1.317 -0.815 0 N-CA-C 106.698 -1.593 . . . . 0.0 106.698 178.028 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . 0.429 ' CE3' ' HB3' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -27.48 126.33 0.22 Allowed Pre-proline 0 N--CA 1.464 0.239 0 CA-C-N 114.153 -1.385 . . . . 0.0 112.933 -176.686 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.615 ' O ' HG22 ' A' ' 4' ' ' THR . 67.9 Cg_endo -97.21 33.76 9.47 Favored 'Cis proline' 0 N--CA 1.461 -0.436 0 C-N-CA 123.775 -1.344 . . . . 0.0 114.241 0.848 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 42.0 pt -140.24 137.05 37.55 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 O-C-N 121.654 -0.654 . . . . 0.0 111.582 -179.284 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.743 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 6.6 t -85.36 142.71 29.11 Favored 'General case' 0 C--N 1.316 -0.88 0 CA-C-O 121.062 0.458 . . . . 0.0 109.848 179.346 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 66.2 p -136.88 129.2 29.86 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-N 115.552 -0.749 . . . . 0.0 111.824 -178.47 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.643 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 1.7 ptm180 -90.36 123.04 33.78 Favored 'General case' 0 N--CA 1.445 -0.711 0 N-CA-C 108.634 -0.876 . . . . 0.0 108.634 178.066 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 71.1 m-20 56.85 31.27 19.31 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-O 121.214 0.53 . . . . 0.0 109.987 -177.656 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 79.38 7.31 88.57 Favored Glycine 0 C--N 1.334 0.448 0 CA-C-N 115.879 -0.6 . . . . 0.0 112.856 -179.625 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.462 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 88.0 mt -107.36 126.4 30.12 Favored Pre-proline 0 C--O 1.237 0.41 0 O-C-N 122.624 -0.339 . . . . 0.0 110.697 179.982 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.462 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 7.4 Cg_exo -72.91 52.98 2.29 Favored 'Trans proline' 0 C--N 1.343 0.246 0 C-N-CA 123.587 2.858 . . . . 0.0 112.581 -179.834 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 43.4 t . . . . . 0 C--N 1.323 -0.561 0 CA-C-O 121.307 0.575 . . . . 0.0 110.171 -179.774 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.6 m . . . . . 0 CA--C 1.528 0.104 0 CA-C-O 120.875 0.369 . . . . 0.0 110.763 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.68 42.97 95.08 Favored Glycine 0 N--CA 1.451 -0.321 0 CA-C-N 115.798 -0.637 . . . . 0.0 112.982 179.217 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -142.84 143.44 32.12 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 121.211 0.529 . . . . 0.0 110.864 179.906 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.521 ' HB ' ' CD1' ' A' ' 6' ' ' PHE . 7.3 p -95.97 115.08 26.88 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 115.582 -0.735 . . . . 0.0 110.381 179.506 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 25.5 p -89.11 58.84 4.69 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 121.047 0.451 . . . . 0.0 111.426 -179.248 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . 0.521 ' CD1' ' HB ' ' A' ' 4' ' ' THR . 5.2 m-85 -57.81 -36.36 72.13 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.644 179.416 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -88.36 16.83 51.49 Favored Glycine 0 N--CA 1.448 -0.508 0 C-N-CA 120.833 -0.699 . . . . 0.0 112.703 179.654 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 77.2 -30.62 1.61 Allowed Glycine 0 CA--C 1.523 0.542 0 C-N-CA 121.223 -0.513 . . . . 0.0 113.487 179.635 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.7 m -88.62 149.96 23.28 Favored 'General case' 0 C--N 1.322 -0.626 0 O-C-N 122.655 -0.32 . . . . 0.0 111.035 -179.373 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 77.0 m -113.05 150.6 31.79 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.141 179.52 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 64.8 m-80 -88.65 -27.94 20.95 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 115.818 -0.628 . . . . 0.0 111.244 -179.086 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.425 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 21.3 p -102.46 128.31 28.49 Favored Pre-proline 0 C--N 1.324 -0.509 0 CA-C-O 121.481 0.658 . . . . 0.0 111.746 -179.049 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.425 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 17.3 Cg_exo -67.25 141.09 55.61 Favored 'Trans proline' 0 C--N 1.345 0.375 0 C-N-CA 123.277 2.651 . . . . 0.0 112.172 -179.758 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 96.8 -20.1 52.05 Favored Glycine 0 N--CA 1.448 -0.565 0 C-N-CA 120.739 -0.743 . . . . 0.0 111.7 -179.509 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.723 ' SG ' ' HB3' ' A' ' 24' ' ' ARG . 91.0 m -88.22 138.82 31.1 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-O 121.066 0.46 . . . . 0.0 110.283 179.734 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 16.1 m -108.49 134.52 51.15 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 109.172 -0.677 . . . . 0.0 109.172 179.855 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.4 t -66.31 125.2 24.86 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-O 121.615 0.721 . . . . 0.0 111.893 -178.418 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 3.9 m -129.0 65.6 1.44 Allowed 'General case' 0 C--N 1.315 -0.913 0 N-CA-C 106.708 -1.589 . . . . 0.0 106.708 178.277 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . 0.453 ' CE3' ' HB3' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -27.26 126.42 0.22 Allowed Pre-proline 0 N--CA 1.465 0.312 0 CA-C-N 114.423 -1.262 . . . . 0.0 112.836 -176.571 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.453 ' HB3' ' CE3' ' A' ' 19' ' ' TRP . 63.2 Cg_endo -97.17 31.03 12.79 Favored 'Cis proline' 0 CA--C 1.532 0.407 0 C-N-CA 123.776 -1.343 . . . . 0.0 114.534 0.932 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 42.5 pt -139.42 138.98 39.72 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.333 0 CA-C-O 121.319 0.581 . . . . 0.0 111.719 -179.117 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.54 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 4.4 t -84.93 145.14 27.92 Favored 'General case' 0 C--N 1.316 -0.849 0 N-CA-C 109.622 -0.51 . . . . 0.0 109.622 179.282 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 61.8 p -139.54 128.52 23.6 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-N 115.792 -0.64 . . . . 0.0 112.121 -178.026 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.723 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 3.3 ptm180 -91.68 125.57 36.46 Favored 'General case' 0 N--CA 1.445 -0.697 0 N-CA-C 108.155 -1.054 . . . . 0.0 108.155 177.588 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 54.7 m-20 58.9 28.24 17.28 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-O 121.143 0.497 . . . . 0.0 109.842 -178.319 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 78.87 10.36 86.25 Favored Glycine 0 C--N 1.333 0.374 0 CA-C-N 115.897 -0.592 . . . . 0.0 112.636 -179.413 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 92.1 mt -114.3 126.28 28.18 Favored Pre-proline 0 C--N 1.328 -0.357 0 CA-C-O 120.881 0.372 . . . . 0.0 110.759 -179.961 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -75.28 52.42 3.16 Favored 'Trans proline' 0 CA--C 1.529 0.241 0 C-N-CA 123.159 2.573 . . . . 0.0 112.876 -179.811 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 22.3 t . . . . . 0 C--N 1.323 -0.559 0 CA-C-O 121.389 0.614 . . . . 0.0 110.184 -179.883 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 63.4 m . . . . . 0 N--CA 1.458 -0.061 0 CA-C-O 120.991 0.424 . . . . 0.0 110.104 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 61.45 35.29 90.81 Favored Glycine 0 C--N 1.332 0.348 0 CA-C-N 115.674 -0.694 . . . . 0.0 113.102 179.114 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 9.5 pt-20 -115.9 148.44 40.01 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 120.9 0.381 . . . . 0.0 110.716 179.929 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.41 ' HA ' ' HA ' ' A' ' 21' ' ' ILE . 33.9 p -93.41 118.09 30.88 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.182 -179.933 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.8 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 13.5 p -88.87 61.57 6.0 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.287 0.565 . . . . 0.0 110.52 179.298 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 32.8 t80 -55.14 -41.27 71.54 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.561 -0.745 . . . . 0.0 110.235 179.892 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -92.18 22.94 29.49 Favored Glycine 0 N--CA 1.45 -0.43 0 C-N-CA 120.865 -0.683 . . . . 0.0 112.765 179.338 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 76.66 -35.81 1.4 Allowed Glycine 0 CA--C 1.521 0.446 0 C-N-CA 121.23 -0.51 . . . . 0.0 113.938 179.405 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.5 m -89.2 148.37 23.66 Favored 'General case' 0 C--N 1.322 -0.609 0 O-C-N 122.423 -0.457 . . . . 0.0 111.442 -179.093 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 59.9 m -108.69 153.67 23.11 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.711 -0.677 . . . . 0.0 109.515 179.072 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 39.1 t30 -87.53 -29.42 21.33 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-O 121.255 0.55 . . . . 0.0 110.171 179.956 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.42 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 3.8 m -102.48 118.35 58.92 Favored Pre-proline 0 C--N 1.323 -0.571 0 CA-C-N 115.877 -0.601 . . . . 0.0 111.167 -179.485 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.42 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 13.6 Cg_exo -68.76 136.95 37.19 Favored 'Trans proline' 0 N--CA 1.46 -0.479 0 C-N-CA 122.829 2.352 . . . . 0.0 111.719 179.724 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 117.33 -32.66 5.32 Favored Glycine 0 N--CA 1.439 -1.166 0 N-CA-C 111.134 -0.787 . . . . 0.0 111.134 -179.264 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 32.9 m -89.45 131.43 35.5 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 120.921 0.391 . . . . 0.0 110.36 179.05 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 16.0 m -89.67 136.15 33.2 Favored 'General case' 0 C--N 1.319 -0.724 0 N-CA-C 109.213 -0.662 . . . . 0.0 109.213 179.556 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 43.2 t -67.66 115.45 7.25 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 121.773 0.797 . . . . 0.0 111.031 -179.336 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 2.9 m -118.95 66.96 0.78 Allowed 'General case' 0 C--N 1.309 -1.172 0 N-CA-C 106.332 -1.729 . . . . 0.0 106.332 178.182 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . 0.445 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.3 OUTLIER -27.24 124.6 0.23 Allowed Pre-proline 0 N--CA 1.463 0.196 0 CA-C-N 114.213 -1.358 . . . . 0.0 112.646 -176.314 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.445 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 56.7 Cg_endo -98.77 34.25 8.69 Favored 'Cis proline' 0 N--CA 1.459 -0.52 0 C-N-CA 123.732 -1.362 . . . . 0.0 114.554 1.103 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.437 HD11 HG23 ' A' ' 21' ' ' ILE . 40.8 pt -142.12 136.06 29.09 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.301 0 CA-C-N 118.753 0.706 . . . . 0.0 112.513 -178.939 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.8 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 47.2 m -82.08 131.68 35.24 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.266 178.977 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 65.4 p -142.7 136.7 29.25 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.134 179.785 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.512 ' HG3' ' O ' ' A' ' 24' ' ' ARG . 2.8 ptm180 -94.62 121.86 36.62 Favored 'General case' 0 N--CA 1.443 -0.789 0 N-CA-C 108.153 -1.054 . . . . 0.0 108.153 178.445 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 61.3 m-20 57.36 29.85 17.56 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.134 0.492 . . . . 0.0 109.775 -178.032 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 82.12 1.95 90.46 Favored Glycine 0 CA--C 1.521 0.41 0 CA-C-N 115.801 -0.636 . . . . 0.0 112.667 -179.371 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 88.0 mt -98.87 123.6 48.81 Favored Pre-proline 0 C--O 1.237 0.429 0 CA-C-O 121.074 0.464 . . . . 0.0 111.217 -179.838 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -77.13 69.81 6.93 Favored 'Trans proline' 0 N--CA 1.464 -0.242 0 C-N-CA 123.248 2.632 . . . . 0.0 112.139 179.649 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 47.2 t . . . . . 0 C--N 1.324 -0.504 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.297 -179.396 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 82.0 m . . . . . 0 CA--C 1.524 -0.026 0 CA-C-O 120.92 0.391 . . . . 0.0 110.353 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 76.46 -32.32 1.39 Allowed Glycine 0 CA--C 1.519 0.327 0 CA-C-N 116.117 -0.492 . . . . 0.0 113.85 178.878 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 14.7 pt-20 -53.95 139.31 34.47 Favored 'General case' 0 C--O 1.239 0.509 0 CA-C-O 121.447 0.641 . . . . 0.0 111.889 -178.933 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.473 ' HA ' ' HA ' ' A' ' 21' ' ' ILE . 36.2 p -89.44 120.91 31.18 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 115.276 -0.875 . . . . 0.0 110.801 -179.581 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.76 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 25.0 p -88.98 60.96 5.69 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 121.253 0.549 . . . . 0.0 110.71 179.651 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 34.4 t80 -53.33 -44.36 68.37 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.525 -0.761 . . . . 0.0 110.993 -179.896 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -92.65 22.63 32.39 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.742 179.788 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 62.55 40.68 99.43 Favored Glycine 0 CA--C 1.518 0.27 0 C-N-CA 121.257 -0.497 . . . . 0.0 112.965 179.514 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.5 m -147.99 149.28 31.87 Favored 'General case' 0 C--N 1.324 -0.513 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 179.919 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 47.2 m -124.76 143.42 50.8 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 179.837 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 63.1 m-80 -88.39 -23.24 23.4 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.276 -179.49 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 4.3 m -101.72 119.37 57.35 Favored Pre-proline 0 C--N 1.323 -0.582 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.982 -179.148 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 20.4 Cg_exo -65.55 140.93 64.87 Favored 'Trans proline' 0 N--CA 1.462 -0.324 0 C-N-CA 122.922 2.415 . . . . 0.0 111.939 179.894 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 105.76 -29.9 10.62 Favored Glycine 0 N--CA 1.441 -1.024 0 C-N-CA 120.75 -0.738 . . . . 0.0 111.489 -179.4 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.509 ' HB3' ' HB3' ' A' ' 22' ' ' CYS . 15.7 m -89.04 129.19 35.71 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 121.209 0.528 . . . . 0.0 110.708 179.289 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 19.6 m -94.39 138.51 32.26 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 115.512 -0.767 . . . . 0.0 109.036 179.372 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 43.4 t -66.43 116.16 7.13 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-O 121.593 0.711 . . . . 0.0 111.03 -179.287 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 3.0 m -120.78 68.7 0.87 Allowed 'General case' 0 C--N 1.311 -1.099 0 N-CA-C 106.597 -1.631 . . . . 0.0 106.597 178.422 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . 0.435 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -27.82 125.1 0.23 Allowed Pre-proline 0 N--CA 1.463 0.215 0 O-C-N 124.706 1.253 . . . . 0.0 112.631 -176.52 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.435 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 59.8 Cg_endo -98.54 30.62 12.65 Favored 'Cis proline' 0 CA--C 1.535 0.562 0 C-N-CA 123.613 -1.411 . . . . 0.0 115.061 1.033 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.473 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 0.2 OUTLIER -141.62 141.65 29.68 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.293 0 CA-C-N 118.992 0.815 . . . . 0.0 112.122 -179.422 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.76 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 64.6 m -81.1 133.81 35.54 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.586 179.365 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 64.5 p -134.23 132.4 39.65 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.735 179.856 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.467 ' HG3' ' O ' ' A' ' 24' ' ' ARG . 1.4 ptm180 -91.93 120.25 32.43 Favored 'General case' 0 N--CA 1.443 -0.777 0 N-CA-C 108.185 -1.042 . . . . 0.0 108.185 178.305 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 72.7 m-20 56.6 31.0 18.34 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 121.144 0.497 . . . . 0.0 109.895 -177.437 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 84.0 -0.4 89.45 Favored Glycine 0 CA--C 1.521 0.447 0 CA-C-N 115.885 -0.598 . . . . 0.0 112.907 -179.624 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.472 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 86.9 mt -99.3 122.34 52.31 Favored Pre-proline 0 C--O 1.237 0.41 0 CA-C-O 120.903 0.383 . . . . 0.0 111.155 -179.754 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.472 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 3.4 Cg_exo -74.46 63.78 5.5 Favored 'Trans proline' 0 CA--C 1.528 0.177 0 C-N-CA 123.597 2.865 . . . . 0.0 112.143 179.66 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 48.2 t . . . . . 0 C--N 1.325 -0.479 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.485 -179.233 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 3.0 m . . . . . 0 CA--C 1.527 0.058 0 CA-C-O 120.943 0.402 . . . . 0.0 110.486 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 78.23 -37.16 1.76 Allowed Glycine 0 C--N 1.33 0.226 0 CA-C-N 115.952 -0.567 . . . . 0.0 113.022 179.59 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 8.9 pt-20 -59.77 141.66 54.81 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 121.526 0.679 . . . . 0.0 111.961 -179.331 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.424 ' HA ' ' HA ' ' A' ' 21' ' ' ILE . 14.7 p -94.87 124.73 39.08 Favored 'General case' 0 N--CA 1.444 -0.733 0 CA-C-N 115.316 -0.856 . . . . 0.0 109.695 178.982 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 24.4 p -87.98 58.8 5.01 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 121.479 0.657 . . . . 0.0 110.698 -179.419 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 35.3 t80 -56.27 -39.93 73.42 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.309 -0.859 . . . . 0.0 110.038 179.48 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -91.31 22.68 28.54 Favored Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 120.943 -0.646 . . . . 0.0 112.751 179.375 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 77.25 -36.82 1.53 Allowed Glycine 0 CA--C 1.522 0.482 0 C-N-CA 121.36 -0.448 . . . . 0.0 114.081 179.223 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 10.2 t -89.52 164.46 14.79 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-O 121.229 0.537 . . . . 0.0 111.627 -179.083 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 62.0 m -125.69 151.77 46.15 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 114.983 -1.008 . . . . 0.0 109.514 179.28 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 41.4 t30 -88.88 -22.76 22.99 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-O 121.031 0.444 . . . . 0.0 111.198 -178.983 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.431 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 7.8 m -101.14 124.46 41.42 Favored Pre-proline 0 C--N 1.322 -0.59 0 CA-C-O 121.215 0.531 . . . . 0.0 111.955 -178.375 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.431 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 23.8 Cg_exo -63.81 137.48 58.56 Favored 'Trans proline' 0 C--N 1.346 0.411 0 C-N-CA 123.059 2.506 . . . . 0.0 111.47 179.403 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 96.55 -17.39 59.36 Favored Glycine 0 N--CA 1.446 -0.67 0 C-N-CA 120.596 -0.812 . . . . 0.0 111.447 -179.06 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.681 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 81.6 m -87.61 133.06 33.87 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 109.651 -0.5 . . . . 0.0 109.651 179.39 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 15.4 m -108.87 138.11 45.72 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 -179.577 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.4 t -68.46 127.08 31.69 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 121.752 0.787 . . . . 0.0 111.948 -178.705 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 4.3 m -131.17 60.67 1.65 Allowed 'General case' 0 C--N 1.316 -0.882 0 N-CA-C 106.144 -1.799 . . . . 0.0 106.144 177.891 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . 0.433 ' CE3' ' HB3' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -26.24 126.65 0.2 Allowed Pre-proline 0 N--CA 1.464 0.265 0 CA-C-N 113.951 -1.477 . . . . 0.0 113.002 -176.487 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.433 ' HB3' ' CE3' ' A' ' 19' ' ' TRP . 62.3 Cg_endo -97.01 32.32 11.16 Favored 'Cis proline' 0 CA--C 1.532 0.421 0 C-N-CA 123.684 -1.381 . . . . 0.0 114.41 0.842 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.424 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 43.8 pt -137.53 140.35 41.76 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.39 0 CA-C-O 121.255 0.55 . . . . 0.0 111.346 -179.234 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.681 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 5.4 t -89.4 144.28 26.18 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-O 121.17 0.509 . . . . 0.0 110.233 179.783 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 43.0 p -138.25 127.14 23.89 Favored 'General case' 0 C--N 1.318 -0.784 0 CA-C-N 115.527 -0.761 . . . . 0.0 111.752 -178.673 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.624 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 3.1 ptm180 -89.53 125.07 35.06 Favored 'General case' 0 N--CA 1.447 -0.618 0 N-CA-C 108.601 -0.889 . . . . 0.0 108.601 178.403 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 53.7 m-20 57.98 28.9 16.87 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.216 0.531 . . . . 0.0 109.958 -178.532 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 78.71 12.06 84.6 Favored Glycine 0 C--N 1.334 0.417 0 CA-C-N 115.875 -0.602 . . . . 0.0 112.457 -179.445 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 88.9 mt -113.72 127.71 26.53 Favored Pre-proline 0 C--O 1.237 0.405 0 CA-C-O 120.857 0.36 . . . . 0.0 110.686 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 70.9 Cg_endo -74.57 51.92 2.74 Favored 'Trans proline' 0 C--N 1.343 0.256 0 C-N-CA 123.292 2.662 . . . . 0.0 112.678 -179.949 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 39.4 t . . . . . 0 C--N 1.322 -0.601 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.222 -179.855 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . 0.506 ' HB3' ' HG2' ' A' ' 3' ' ' GLU . 82.5 m . . . . . 0 N--CA 1.458 -0.065 0 CA-C-O 120.897 0.379 . . . . 0.0 110.239 . . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 77.47 -34.73 1.57 Allowed Glycine 0 C--N 1.331 0.285 0 CA-C-N 116.034 -0.53 . . . . 0.0 113.436 179.188 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.506 ' HG2' ' HB3' ' A' ' 1' ' ' CYS . 7.0 pt-20 -53.8 139.88 31.76 Favored 'General case' 0 C--O 1.237 0.429 0 CA-C-O 121.528 0.68 . . . . 0.0 112.423 -179.114 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.486 ' HA ' ' HA ' ' A' ' 21' ' ' ILE . 31.5 p -89.29 121.22 31.36 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 115.271 -0.877 . . . . 0.0 110.01 179.29 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 23.5 p -88.0 61.14 6.19 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 121.382 0.611 . . . . 0.0 110.478 -179.857 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 35.1 t80 -55.11 -41.04 71.17 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.367 -0.833 . . . . 0.0 110.513 179.91 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -91.65 21.58 35.21 Favored Glycine 0 N--CA 1.449 -0.457 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.735 179.51 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 76.7 -33.47 1.41 Allowed Glycine 0 CA--C 1.522 0.51 0 C-N-CA 121.221 -0.514 . . . . 0.0 113.833 179.572 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.7 m -89.11 149.7 23.06 Favored 'General case' 0 C--N 1.321 -0.674 0 O-C-N 122.538 -0.389 . . . . 0.0 111.443 -179.184 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 58.3 m -114.76 152.68 31.66 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.761 -0.654 . . . . 0.0 109.301 179.017 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 36.4 t30 -87.8 -28.52 21.61 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-O 121.215 0.531 . . . . 0.0 110.537 -179.534 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 8.2 m -101.63 120.99 52.82 Favored Pre-proline 0 C--N 1.32 -0.681 0 CA-C-N 115.967 -0.56 . . . . 0.0 111.563 -178.871 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 17.3 Cg_exo -66.62 143.84 69.96 Favored 'Trans proline' 0 N--CA 1.463 -0.316 0 C-N-CA 123.178 2.585 . . . . 0.0 111.888 179.741 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 105.02 -29.59 11.43 Favored Glycine 0 N--CA 1.443 -0.862 0 C-N-CA 120.676 -0.774 . . . . 0.0 111.555 -179.443 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.639 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 9.2 m -87.98 138.87 31.08 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 121.131 0.491 . . . . 0.0 110.158 179.169 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 15.2 m -102.57 141.54 35.22 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 115.645 -0.707 . . . . 0.0 109.099 179.936 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 48.9 t -73.17 114.62 11.56 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-O 121.597 0.713 . . . . 0.0 111.661 -178.908 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 17.0 m -117.42 66.98 0.74 Allowed 'General case' 0 C--N 1.311 -1.103 0 N-CA-C 106.353 -1.721 . . . . 0.0 106.353 177.468 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . 0.44 ' CE3' ' HB3' ' A' ' 20' ' ' PRO . 0.4 OUTLIER -29.08 127.39 0.24 Allowed Pre-proline 0 N--CA 1.463 0.225 0 CA-C-N 114.102 -1.408 . . . . 0.0 112.753 -176.47 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.44 ' HB3' ' CE3' ' A' ' 19' ' ' TRP . 59.5 Cg_endo -97.85 32.77 10.31 Favored 'Cis proline' 0 N--CA 1.46 -0.5 0 C-N-CA 123.68 -1.383 . . . . 0.0 114.304 0.918 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.486 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 42.0 pt -138.3 137.48 43.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 121.443 0.639 . . . . 0.0 111.873 -179.135 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.639 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 3.4 t -85.42 139.74 31.29 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-O 121.309 0.576 . . . . 0.0 109.498 179.284 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 11.7 p -147.85 133.38 18.71 Favored 'General case' 0 C--N 1.313 -1.012 0 CA-C-N 115.279 -0.873 . . . . 0.0 111.297 -178.259 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.508 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 3.1 ptm180 -92.25 124.47 36.34 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 108.81 -0.811 . . . . 0.0 108.81 178.774 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 46.3 m-20 57.53 30.34 18.55 Favored 'General case' 0 N--CA 1.467 0.383 0 N-CA-C 109.384 -0.599 . . . . 0.0 109.384 -178.431 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 76.89 8.53 86.68 Favored Glycine 0 CA--C 1.521 0.423 0 CA-C-N 115.511 -0.768 . . . . 0.0 112.559 -179.116 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 86.8 mt -105.41 129.13 25.23 Favored Pre-proline 0 C--O 1.239 0.545 0 CA-C-O 121.057 0.456 . . . . 0.0 111.059 -179.661 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 74.3 Cg_endo -75.42 62.94 6.3 Favored 'Trans proline' 0 C--N 1.343 0.262 0 C-N-CA 123.372 2.715 . . . . 0.0 112.583 179.84 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 48.5 t . . . . . 0 C--N 1.323 -0.578 0 CA-C-O 121.324 0.583 . . . . 0.0 110.177 -179.661 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 3.8 m . . . . . 0 CA--C 1.528 0.101 0 CA-C-O 121.141 0.496 . . . . 0.0 109.672 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 76.15 -36.38 1.3 Allowed Glycine 0 C--N 1.333 0.366 0 CA-C-N 115.6 -0.727 . . . . 0.0 113.777 178.691 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -60.13 138.54 57.87 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 121.621 0.724 . . . . 0.0 111.953 -178.805 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.465 ' HB ' ' CD1' ' A' ' 6' ' ' PHE . 30.8 p -89.62 118.99 29.65 Favored 'General case' 0 N--CA 1.446 -0.657 0 CA-C-N 115.271 -0.877 . . . . 0.0 109.734 179.245 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 26.2 p -88.62 58.02 4.47 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 121.066 0.46 . . . . 0.0 111.489 -179.034 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . 0.465 ' CD1' ' HB ' ' A' ' 4' ' ' THR . 4.7 m-85 -58.29 -36.56 73.49 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.334 179.049 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -88.99 19.07 40.37 Favored Glycine 0 N--CA 1.45 -0.414 0 C-N-CA 120.86 -0.686 . . . . 0.0 112.611 179.426 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 76.09 -32.77 1.3 Allowed Glycine 0 CA--C 1.524 0.598 0 C-N-CA 121.379 -0.439 . . . . 0.0 113.999 179.353 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 8.9 t -89.24 165.25 14.55 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.238 0.542 . . . . 0.0 111.561 -179.059 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 70.4 m -130.74 147.53 52.41 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.092 -0.958 . . . . 0.0 109.793 179.489 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 64.0 m-80 -89.43 -17.19 29.23 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.925 -0.58 . . . . 0.0 111.212 -178.979 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.414 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 4.6 m -101.22 123.25 45.51 Favored Pre-proline 0 C--N 1.323 -0.568 0 CA-C-O 121.091 0.472 . . . . 0.0 111.335 -178.635 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -63.48 135.03 47.48 Favored 'Trans proline' 0 C--N 1.344 0.299 0 C-N-CA 122.859 2.372 . . . . 0.0 111.941 179.674 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 95.2 -16.35 61.47 Favored Glycine 0 N--CA 1.445 -0.703 0 C-N-CA 120.637 -0.792 . . . . 0.0 111.867 -179.454 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.669 ' SG ' ' HB3' ' A' ' 24' ' ' ARG . 99.6 m -87.31 133.65 33.67 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 121.073 0.463 . . . . 0.0 109.906 179.644 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 15.7 m -109.34 137.83 46.61 Favored 'General case' 0 C--N 1.324 -0.522 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 -179.925 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 44.7 t -66.71 128.2 35.35 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-O 121.718 0.77 . . . . 0.0 112.182 -178.428 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 4.4 m -132.4 61.01 1.67 Allowed 'General case' 0 C--N 1.316 -0.867 0 N-CA-C 106.221 -1.77 . . . . 0.0 106.221 177.953 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . 0.444 ' CE3' ' HB3' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -25.76 126.44 0.19 Allowed Pre-proline 0 N--CA 1.466 0.359 0 CA-C-N 113.931 -1.486 . . . . 0.0 113.037 -176.537 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.444 ' HB3' ' CE3' ' A' ' 19' ' ' TRP . 67.0 Cg_endo -96.85 30.91 13.07 Favored 'Cis proline' 0 CA--C 1.532 0.421 0 C-N-CA 123.757 -1.351 . . . . 0.0 114.515 0.805 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 43.3 pt -137.34 140.92 41.16 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.424 0 CA-C-O 121.273 0.558 . . . . 0.0 111.371 -179.154 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.665 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 4.5 t -88.41 143.99 26.65 Favored 'General case' 0 C--N 1.314 -0.943 0 CA-C-O 121.259 0.552 . . . . 0.0 110.267 179.908 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 68.5 p -138.04 127.61 24.98 Favored 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 115.433 -0.803 . . . . 0.0 111.316 -178.778 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.669 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 3.2 ptm180 -92.73 124.28 36.62 Favored 'General case' 0 N--CA 1.445 -0.687 0 N-CA-C 108.794 -0.817 . . . . 0.0 108.794 178.447 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 53.7 m-20 57.76 28.94 16.64 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.172 0.511 . . . . 0.0 109.744 -178.271 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 82.44 3.65 90.45 Favored Glycine 0 N--CA 1.449 -0.447 0 CA-C-N 115.854 -0.612 . . . . 0.0 112.683 -179.461 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 86.0 mt -101.18 121.06 53.3 Favored Pre-proline 0 C--O 1.236 0.352 0 O-C-N 122.623 -0.339 . . . . 0.0 110.75 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -77.06 47.34 2.19 Favored 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 123.062 2.508 . . . . 0.0 112.601 179.828 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 11.6 p . . . . . 0 C--N 1.321 -0.667 0 CA-C-N 115.537 -0.756 . . . . 0.0 110.239 179.999 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . 0.557 ' SG ' ' HB3' ' A' ' 24' ' ' ARG . 1.8 m . . . . . 0 N--CA 1.458 -0.058 0 CA-C-O 121.007 0.432 . . . . 0.0 110.339 . . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 76.04 -34.37 1.27 Allowed Glycine 0 CA--C 1.519 0.31 0 CA-C-N 115.865 -0.607 . . . . 0.0 113.287 179.515 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.407 ' H ' ' C ' ' A' ' 1' ' ' CYS . 12.1 pt-20 -54.56 140.62 34.22 Favored 'General case' 0 C--O 1.239 0.528 0 CA-C-O 121.658 0.742 . . . . 0.0 112.393 -179.001 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.538 HG23 ' O ' ' A' ' 20' ' ' PRO . 67.8 m -88.89 114.5 25.58 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.059 -0.973 . . . . 0.0 109.984 179.587 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 26.6 p -88.6 58.43 4.66 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 121.324 0.583 . . . . 0.0 110.458 -179.803 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 34.0 t80 -52.69 -44.96 66.62 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.309 -0.859 . . . . 0.0 111.194 -179.726 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -94.06 24.46 26.64 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.582 -0.818 . . . . 0.0 112.781 179.764 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.48 40.38 98.61 Favored Glycine 0 CA--C 1.518 0.264 0 C-N-CA 121.136 -0.554 . . . . 0.0 112.88 179.595 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.3 m -142.45 150.19 40.23 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 179.996 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 57.5 m -132.82 142.02 48.76 Favored 'General case' 0 C--N 1.324 -0.539 0 N-CA-C 110.025 -0.361 . . . . 0.0 110.025 179.869 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 43.6 t30 -89.31 -15.0 34.48 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.842 -0.617 . . . . 0.0 111.229 -179.081 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.624 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 5.7 m -100.67 125.3 39.33 Favored Pre-proline 0 C--N 1.323 -0.549 0 CA-C-O 121.252 0.549 . . . . 0.0 111.509 -178.754 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.469 ' HD2' HG22 ' A' ' 12' ' ' THR . 28.7 Cg_endo -63.58 131.93 33.5 Favored 'Trans proline' 0 C--N 1.347 0.457 0 C-N-CA 122.999 2.466 . . . . 0.0 112.438 -179.819 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 95.08 -8.62 70.08 Favored Glycine 0 N--CA 1.447 -0.587 0 C-N-CA 120.894 -0.67 . . . . 0.0 111.737 -179.472 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.79 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 84.7 m -88.06 131.62 34.6 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-O 121.127 0.489 . . . . 0.0 110.133 179.63 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 13.3 m -109.49 136.45 48.86 Favored 'General case' 0 C--N 1.324 -0.538 0 N-CA-C 108.925 -0.769 . . . . 0.0 108.925 179.906 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 50.2 t -71.89 119.92 16.76 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-O 121.366 0.603 . . . . 0.0 112.106 -178.631 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 18.4 m -123.89 67.21 1.03 Allowed 'General case' 0 C--N 1.315 -0.903 0 N-CA-C 106.624 -1.621 . . . . 0.0 106.624 177.697 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . 0.452 ' CE3' ' HB3' ' A' ' 20' ' ' PRO . 0.2 OUTLIER -29.03 127.51 0.23 Allowed Pre-proline 0 N--CA 1.464 0.234 0 CA-C-N 114.092 -1.413 . . . . 0.0 112.862 -176.721 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.538 ' O ' HG23 ' A' ' 4' ' ' THR . 65.6 Cg_endo -97.71 33.24 9.85 Favored 'Cis proline' 0 N--CA 1.46 -0.484 0 C-N-CA 123.767 -1.347 . . . . 0.0 114.23 0.822 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 41.8 pt -139.59 137.37 40.02 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-O 121.425 0.631 . . . . 0.0 111.632 -179.182 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.79 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 6.2 t -84.27 143.18 29.72 Favored 'General case' 0 C--N 1.316 -0.885 0 CA-C-O 121.311 0.576 . . . . 0.0 109.791 179.222 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' THR . . . . . 0.446 HG22 ' HA ' ' A' ' 28' ' ' PRO . 14.9 p -138.28 125.82 22.04 Favored 'General case' 0 C--N 1.314 -0.943 0 CA-C-N 115.239 -0.892 . . . . 0.0 111.378 -178.497 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.557 ' HB3' ' SG ' ' A' ' 1' ' ' CYS . 0.0 OUTLIER -91.1 129.3 37.11 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 178.864 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.433 ' CG ' ' HD3' ' A' ' 24' ' ' ARG . 54.8 m-20 54.6 30.03 12.48 Favored 'General case' 0 C--N 1.324 -0.529 0 O-C-N 123.85 0.719 . . . . 0.0 110.382 -178.844 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 77.46 13.97 82.98 Favored Glycine 0 C--N 1.335 0.498 0 CA-C-N 115.803 -0.635 . . . . 0.0 112.652 -179.583 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 90.2 mt -117.46 132.23 23.67 Favored Pre-proline 0 C--O 1.236 0.354 0 CA-C-O 120.825 0.345 . . . . 0.0 110.831 -179.888 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.446 ' HA ' HG22 ' A' ' 23' ' ' THR . 70.8 Cg_endo -74.6 53.68 3.22 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 123.116 2.544 . . . . 0.0 112.673 -179.95 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 40.9 t . . . . . 0 C--N 1.323 -0.58 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.404 -179.85 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 67.9 m . . . . . 0 N--CA 1.458 -0.051 0 CA-C-O 120.905 0.383 . . . . 0.0 110.195 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 60.14 38.11 93.9 Favored Glycine 0 C--N 1.333 0.381 0 CA-C-N 115.74 -0.663 . . . . 0.0 112.694 179.299 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -117.87 151.77 36.72 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 120.86 0.362 . . . . 0.0 110.848 -179.789 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.462 HG22 ' O ' ' A' ' 20' ' ' PRO . 28.2 m -96.66 118.67 33.63 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-N 115.893 -0.594 . . . . 0.0 111.051 179.811 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.718 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 7.6 p -88.45 61.2 6.02 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 121.262 0.553 . . . . 0.0 109.699 178.826 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 13.2 t80 -54.26 -41.51 68.91 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.35 -0.841 . . . . 0.0 110.28 -179.548 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -91.94 22.98 28.65 Favored Glycine 0 N--CA 1.449 -0.488 0 C-N-CA 120.926 -0.654 . . . . 0.0 112.611 179.325 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 78.71 -38.28 1.91 Allowed Glycine 0 CA--C 1.522 0.483 0 C-N-CA 121.251 -0.5 . . . . 0.0 113.631 179.447 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.4 m -89.49 147.38 24.02 Favored 'General case' 0 C--N 1.321 -0.65 0 O-C-N 122.498 -0.413 . . . . 0.0 111.49 -179.348 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 62.9 m -104.49 154.82 19.41 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.759 -0.655 . . . . 0.0 109.394 178.834 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 39.7 t30 -87.64 -26.7 22.89 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-O 121.135 0.493 . . . . 0.0 110.496 -179.717 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 3.7 m -102.12 120.42 53.7 Favored Pre-proline 0 C--N 1.324 -0.54 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.283 -179.268 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_exo -65.71 140.62 62.67 Favored 'Trans proline' 0 N--CA 1.461 -0.385 0 C-N-CA 122.943 2.428 . . . . 0.0 111.846 179.693 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 105.1 -28.91 12.74 Favored Glycine 0 N--CA 1.441 -0.976 0 C-N-CA 120.717 -0.754 . . . . 0.0 111.66 -179.356 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.532 ' HB3' ' HB3' ' A' ' 22' ' ' CYS . 2.0 m -87.64 131.55 34.4 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 121.273 0.559 . . . . 0.0 110.546 179.402 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 13.6 m -91.53 140.52 29.67 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.482 -0.781 . . . . 0.0 109.168 179.59 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 39.9 t -75.52 111.14 10.51 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-O 121.645 0.736 . . . . 0.0 111.598 -179.121 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 11.7 m -114.47 65.43 0.67 Allowed 'General case' 0 C--N 1.308 -1.197 0 N-CA-C 106.254 -1.758 . . . . 0.0 106.254 177.385 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . 0.473 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.5 OUTLIER -28.66 125.78 0.24 Allowed Pre-proline 0 N--CA 1.464 0.252 0 CA-C-N 114.072 -1.422 . . . . 0.0 112.574 -176.583 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.473 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 65.0 Cg_endo -98.4 38.03 5.84 Favored 'Cis proline' 0 N--CA 1.459 -0.54 0 C-N-CA 123.963 -1.265 . . . . 0.0 114.109 0.899 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 2.3 pp -143.43 133.02 20.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 121.541 0.686 . . . . 0.0 112.457 -178.938 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.718 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 63.8 m -83.0 134.46 35.05 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.411 179.225 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 5.2 p -138.56 130.56 28.22 Favored 'General case' 0 C--N 1.317 -0.843 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.038 -179.746 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.433 ' HG3' ' O ' ' A' ' 24' ' ' ARG . 9.6 ptm180 -97.5 127.82 43.77 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 178.764 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 27.9 m-20 58.52 27.43 15.61 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.439 0.637 . . . . 0.0 109.504 -178.692 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 77.38 7.86 87.02 Favored Glycine 0 N--CA 1.449 -0.471 0 CA-C-N 115.411 -0.813 . . . . 0.0 112.389 -178.984 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.414 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 91.6 mt -109.59 131.57 21.82 Favored Pre-proline 0 C--O 1.238 0.451 0 CA-C-O 121.158 0.504 . . . . 0.0 111.293 -179.666 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.414 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 5.0 Cg_exo -77.06 65.4 7.81 Favored 'Trans proline' 0 N--CA 1.463 -0.32 0 C-N-CA 123.656 2.904 . . . . 0.0 111.95 179.594 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 47.8 t . . . . . 0 C--N 1.325 -0.465 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.594 -179.166 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 CA--C 1.526 0.035 0 CA-C-O 121.046 0.45 . . . . 0.0 110.299 . . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 60.37 38.63 94.99 Favored Glycine 0 C--N 1.332 0.348 0 CA-C-N 115.535 -0.757 . . . . 0.0 112.796 179.353 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -125.0 143.19 51.03 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 121.187 0.517 . . . . 0.0 111.259 -179.731 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.417 HG21 ' O ' ' A' ' 20' ' ' PRO . 87.9 m -89.18 111.46 22.25 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.376 179.85 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 25.3 p -88.77 58.98 4.87 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 121.287 0.565 . . . . 0.0 110.468 -179.995 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 33.6 t80 -52.92 -46.01 67.88 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.378 -0.828 . . . . 0.0 111.233 -179.688 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -92.56 24.04 25.15 Favored Glycine 0 C--O 1.227 -0.291 0 C-N-CA 120.579 -0.82 . . . . 0.0 112.728 179.73 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.83 36.72 93.2 Favored Glycine 0 C--O 1.228 -0.252 0 C-N-CA 121.2 -0.524 . . . . 0.0 112.666 179.694 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.7 m -136.06 148.95 48.56 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 60.3 m -129.33 141.57 51.05 Favored 'General case' 0 C--N 1.322 -0.628 0 O-C-N 123.218 0.324 . . . . 0.0 110.246 179.9 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 44.0 t30 -89.06 -17.3 29.6 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.804 -0.635 . . . . 0.0 110.614 -179.592 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.512 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 4.3 m -101.31 123.46 44.62 Favored Pre-proline 0 C--N 1.322 -0.596 0 CA-C-O 121.14 0.495 . . . . 0.0 111.33 -178.939 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.416 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 23.4 Cg_exo -64.18 136.65 52.77 Favored 'Trans proline' 0 C--N 1.345 0.349 0 C-N-CA 123.017 2.478 . . . . 0.0 112.013 179.948 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 92.85 -12.27 70.26 Favored Glycine 0 N--CA 1.447 -0.596 0 C-N-CA 120.79 -0.719 . . . . 0.0 111.881 -179.626 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.648 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 98.9 m -87.55 134.4 33.63 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 121.125 0.488 . . . . 0.0 110.308 179.773 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 12.6 m -107.4 137.55 45.23 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.637 -0.71 . . . . 0.0 109.104 -179.88 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 53.9 t -72.95 115.52 12.35 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-O 121.496 0.665 . . . . 0.0 111.961 -178.739 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 8.7 m -116.29 66.49 0.71 Allowed 'General case' 0 C--N 1.312 -1.03 0 N-CA-C 106.515 -1.661 . . . . 0.0 106.515 177.478 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . 0.432 ' CE3' ' HB3' ' A' ' 20' ' ' PRO . 0.2 OUTLIER -28.82 126.86 0.23 Allowed Pre-proline 0 N--CA 1.464 0.229 0 CA-C-N 114.303 -1.317 . . . . 0.0 112.841 -176.559 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.432 ' HB3' ' CE3' ' A' ' 19' ' ' TRP . 62.6 Cg_endo -97.21 32.79 10.48 Favored 'Cis proline' 0 CA--C 1.532 0.396 0 C-N-CA 123.676 -1.385 . . . . 0.0 114.293 0.93 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 44.2 pt -138.97 133.87 41.41 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-O 121.451 0.643 . . . . 0.0 111.888 -179.239 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.648 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 7.0 t -83.48 142.87 30.62 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-O 121.22 0.533 . . . . 0.0 109.746 179.202 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 14.9 p -145.33 131.99 19.93 Favored 'General case' 0 C--N 1.314 -0.949 0 CA-C-N 115.276 -0.875 . . . . 0.0 111.293 -178.399 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.531 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 0.0 OUTLIER -92.39 128.51 38.26 Favored 'General case' 0 N--CA 1.448 -0.555 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 178.38 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 18.6 m-20 56.57 28.45 13.94 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.191 0.52 . . . . 0.0 109.963 -179.253 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 76.79 13.16 83.87 Favored Glycine 0 C--N 1.333 0.409 0 CA-C-N 115.745 -0.661 . . . . 0.0 112.362 -179.089 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.471 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 87.2 mt -112.49 129.55 24.26 Favored Pre-proline 0 C--O 1.241 0.655 0 CA-C-O 120.887 0.375 . . . . 0.0 110.858 -179.847 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.471 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 2.8 Cg_exo -75.54 54.14 3.8 Favored 'Trans proline' 0 C--N 1.342 0.216 0 C-N-CA 123.718 2.945 . . . . 0.0 112.468 -179.95 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 45.4 t . . . . . 0 C--N 1.323 -0.553 0 CA-C-O 121.331 0.586 . . . . 0.0 110.141 -179.748 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' CYS . . . . . 0.407 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 61.4 m . . . . . 0 N--CA 1.458 -0.043 0 CA-C-O 121.037 0.446 . . . . 0.0 109.806 . . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 60.26 32.95 78.33 Favored Glycine 0 C--N 1.332 0.347 0 CA-C-N 115.497 -0.774 . . . . 0.0 113.204 179.087 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.419 ' HG3' ' HB3' ' A' ' 22' ' ' CYS . 9.3 pt-20 -105.71 145.54 30.96 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 121.045 0.45 . . . . 0.0 111.015 179.901 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.573 HG22 ' O ' ' A' ' 20' ' ' PRO . 58.3 m -88.83 110.0 20.67 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.89 -0.596 . . . . 0.0 110.399 179.91 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 25.8 p -88.78 59.71 5.2 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 121.429 0.633 . . . . 0.0 110.536 -179.941 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 34.8 t80 -53.64 -43.78 69.02 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.286 -0.87 . . . . 0.0 111.165 -179.75 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -88.23 18.54 40.52 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.743 -0.741 . . . . 0.0 113.004 179.905 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 64.56 37.61 94.63 Favored Glycine 0 N--CA 1.453 -0.233 0 C-N-CA 121.077 -0.582 . . . . 0.0 112.656 179.668 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.6 m -147.38 149.52 32.92 Favored 'General case' 0 C--N 1.324 -0.522 0 N-CA-C 109.665 -0.494 . . . . 0.0 109.665 179.92 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 43.4 m -121.45 146.0 47.35 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.239 -179.899 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 39.1 t30 -88.26 -23.45 23.5 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.154 -179.787 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' THR . . . . . 0.407 ' HB ' ' SG ' ' A' ' 1' ' ' CYS . 2.9 m -101.95 121.11 51.88 Favored Pre-proline 0 C--N 1.323 -0.582 0 CA-C-N 115.999 -0.546 . . . . 0.0 111.413 -178.977 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 22.2 Cg_exo -64.74 141.5 72.5 Favored 'Trans proline' 0 C--N 1.344 0.298 0 C-N-CA 123.021 2.48 . . . . 0.0 111.854 179.76 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 101.62 -28.17 17.16 Favored Glycine 0 N--CA 1.445 -0.747 0 C-N-CA 120.687 -0.768 . . . . 0.0 111.615 -179.331 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.829 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 1.6 m -86.97 136.85 32.78 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 121.136 0.493 . . . . 0.0 110.191 179.446 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 14.2 m -105.26 140.18 38.8 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.596 -0.729 . . . . 0.0 109.314 -179.745 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 53.9 t -72.37 112.33 8.34 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.482 0.658 . . . . 0.0 111.709 -178.887 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 14.1 m -114.54 66.91 0.68 Allowed 'General case' 0 C--N 1.312 -1.052 0 N-CA-C 106.554 -1.647 . . . . 0.0 106.554 177.624 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' TRP . . . . . 0.443 ' CE3' ' HB3' ' A' ' 20' ' ' PRO . 0.2 OUTLIER -28.91 127.01 0.23 Allowed Pre-proline 0 N--CA 1.464 0.266 0 CA-C-N 114.24 -1.345 . . . . 0.0 112.833 -176.631 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' PRO . . . . . 0.573 ' O ' HG22 ' A' ' 4' ' ' THR . 62.2 Cg_endo -97.1 31.85 11.75 Favored 'Cis proline' 0 N--CA 1.46 -0.443 0 C-N-CA 123.627 -1.406 . . . . 0.0 114.213 0.968 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 43.0 pt -138.56 133.61 42.53 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-O 121.663 0.744 . . . . 0.0 112.025 -179.174 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.829 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 8.0 t -83.54 140.1 32.47 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-N 115.927 -0.578 . . . . 0.0 109.547 179.011 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 7.9 p -148.76 135.5 19.76 Favored 'General case' 0 C--N 1.313 -0.982 0 CA-C-N 115.274 -0.875 . . . . 0.0 111.342 -178.104 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' ARG . . . . . 0.496 ' HG3' ' O ' ' A' ' 24' ' ' ARG . 4.8 ptm180 -93.92 126.29 39.04 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 178.576 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 58.52 27.23 15.32 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.36 0.6 . . . . 0.0 109.404 -179.069 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 77.57 9.31 86.94 Favored Glycine 0 C--N 1.333 0.392 0 CA-C-N 115.504 -0.771 . . . . 0.0 112.251 -178.885 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 88.4 mt -108.07 131.12 21.96 Favored Pre-proline 0 C--O 1.24 0.558 0 CA-C-O 121.092 0.472 . . . . 0.0 111.091 -179.724 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -76.14 64.3 7.01 Favored 'Trans proline' 0 C--N 1.341 0.158 0 C-N-CA 123.269 2.646 . . . . 0.0 112.48 179.946 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 55.5 t . . . . . 0 C--N 1.324 -0.532 0 CA-C-O 121.285 0.564 . . . . 0.0 110.163 -179.759 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 5.4 m . . . . . 0 N--CA 1.457 -0.092 0 CA-C-O 121.038 0.447 . . . . 0.0 110.013 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 76.68 -35.45 1.4 Allowed Glycine 0 C--N 1.331 0.259 0 CA-C-N 115.849 -0.614 . . . . 0.0 113.703 179.069 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 7.3 pt-20 -58.13 143.84 42.49 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 121.615 0.721 . . . . 0.0 112.058 -178.981 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.531 HG23 ' O ' ' A' ' 20' ' ' PRO . 53.6 m -95.11 121.35 36.65 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.034 -0.985 . . . . 0.0 110.658 179.688 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.772 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 13.7 p -88.08 61.17 6.17 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 121.258 0.552 . . . . 0.0 109.866 179.05 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 29.4 t80 -52.77 -44.5 66.56 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.368 -0.833 . . . . 0.0 110.555 -179.609 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -93.45 25.08 22.52 Favored Glycine 0 N--CA 1.449 -0.462 0 C-N-CA 120.639 -0.791 . . . . 0.0 112.399 179.223 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 75.59 -30.52 1.23 Allowed Glycine 0 CA--C 1.523 0.562 0 C-N-CA 121.485 -0.388 . . . . 0.0 113.789 179.579 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.5 m -89.1 148.95 23.42 Favored 'General case' 0 C--N 1.322 -0.59 0 O-C-N 122.367 -0.49 . . . . 0.0 111.293 -179.483 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 79.7 m -112.15 151.44 29.49 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.859 -0.61 . . . . 0.0 109.684 179.11 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 35.7 t-20 -88.46 -21.64 24.1 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 120.895 0.379 . . . . 0.0 110.53 -179.214 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 4.3 m -100.71 123.38 45.98 Favored Pre-proline 0 C--N 1.323 -0.557 0 CA-C-O 121.148 0.499 . . . . 0.0 111.277 -179.1 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 29.7 Cg_endo -63.75 136.04 51.61 Favored 'Trans proline' 0 C--N 1.344 0.332 0 C-N-CA 122.823 2.348 . . . . 0.0 111.562 179.519 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 98.69 -21.39 46.19 Favored Glycine 0 N--CA 1.443 -0.834 0 C-N-CA 120.509 -0.853 . . . . 0.0 111.744 -179.228 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.576 ' HB3' ' HB3' ' A' ' 22' ' ' CYS . 71.3 m -86.73 126.35 34.52 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 121.212 0.529 . . . . 0.0 110.235 179.597 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 14.8 m -96.85 140.64 31.11 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 115.449 -0.796 . . . . 0.0 109.023 179.634 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 53.7 t -69.76 123.68 22.03 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-O 121.683 0.754 . . . . 0.0 111.92 -178.792 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 7.4 m -130.06 61.68 1.58 Allowed 'General case' 0 C--N 1.313 -0.997 0 N-CA-C 106.031 -1.84 . . . . 0.0 106.031 177.787 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.535 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -27.51 125.71 0.22 Allowed Pre-proline 0 N--CA 1.463 0.198 0 CA-C-N 113.827 -1.533 . . . . 0.0 112.787 -176.576 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.535 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 71.9 Cg_endo -98.03 38.07 5.82 Favored 'Cis proline' 0 N--CA 1.459 -0.533 0 C-N-CA 123.813 -1.328 . . . . 0.0 114.172 0.746 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 39.9 pt -143.44 136.9 25.21 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 O-C-N 121.6 -0.688 . . . . 0.0 112.026 -179.148 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.772 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 74.0 m -82.37 136.61 34.95 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-O 121.09 0.471 . . . . 0.0 110.236 178.923 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.41 HG22 ' CA ' ' A' ' 28' ' ' PRO . 67.0 p -127.3 123.47 36.47 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.857 -179.615 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.542 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 4.4 ptm180 -92.63 125.69 37.37 Favored 'General case' 0 N--CA 1.445 -0.702 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 178.519 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 58.62 26.75 14.86 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.257 0.551 . . . . 0.0 109.682 -178.941 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 84.11 3.27 89.09 Favored Glycine 0 N--CA 1.45 -0.428 0 CA-C-N 115.723 -0.671 . . . . 0.0 112.668 -179.402 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.46 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 88.8 mt -102.91 121.5 48.97 Favored Pre-proline 0 C--N 1.328 -0.352 0 O-C-N 122.561 -0.376 . . . . 0.0 110.857 -179.947 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.46 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 5.1 Cg_exo -76.98 47.22 2.15 Favored 'Trans proline' 0 C--N 1.343 0.246 0 C-N-CA 123.361 2.707 . . . . 0.0 112.307 179.827 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 10.7 p . . . . . 0 C--N 1.32 -0.692 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.402 -179.856 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.3 m . . . . . 0 CA--C 1.527 0.068 0 CA-C-O 120.962 0.41 . . . . 0.0 110.419 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 77.92 -36.39 1.68 Allowed Glycine 0 C--N 1.331 0.251 0 CA-C-N 115.969 -0.56 . . . . 0.0 113.166 179.415 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 11.8 pt-20 -58.27 137.26 57.26 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 121.5 0.667 . . . . 0.0 112.072 -179.244 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.498 ' HB ' ' CD1' ' A' ' 6' ' ' PHE . 10.6 p -91.15 117.52 29.68 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.37 -0.832 . . . . 0.0 109.804 179.221 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 28.2 p -88.92 57.97 4.37 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.012 0.434 . . . . 0.0 111.764 -178.521 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 6' ' ' PHE . . . . . 0.498 ' CD1' ' HB ' ' A' ' 4' ' ' THR . 5.3 m-85 -57.64 -38.07 74.4 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.99 179.423 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -89.9 18.06 49.6 Favored Glycine 0 CA--C 1.519 0.315 0 C-N-CA 120.639 -0.791 . . . . 0.0 112.861 179.841 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 62.31 39.48 97.79 Favored Glycine 0 C--N 1.331 0.27 0 C-N-CA 121.092 -0.575 . . . . 0.0 112.916 179.546 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 3.5 m -149.04 152.18 35.8 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 109.724 -0.473 . . . . 0.0 109.724 -179.996 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 56.8 m -129.94 143.4 50.78 Favored 'General case' 0 C--N 1.324 -0.522 0 O-C-N 123.21 0.319 . . . . 0.0 110.225 179.927 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 43.0 t30 -89.13 -18.11 27.86 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.026 -179.229 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.442 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 6.7 m -100.97 125.13 39.34 Favored Pre-proline 0 C--N 1.323 -0.558 0 CA-C-O 121.155 0.503 . . . . 0.0 111.671 -178.649 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_endo -64.41 138.52 60.61 Favored 'Trans proline' 0 C--N 1.346 0.395 0 C-N-CA 122.859 2.372 . . . . 0.0 111.626 179.541 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 93.67 -15.55 62.78 Favored Glycine 0 N--CA 1.447 -0.607 0 C-N-CA 120.726 -0.75 . . . . 0.0 111.557 -179.133 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.769 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 93.7 m -87.45 133.27 33.77 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 121.045 0.45 . . . . 0.0 110.163 179.606 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 14.6 m -110.54 136.58 49.44 Favored 'General case' 0 C--N 1.323 -0.56 0 N-CA-C 109.209 -0.663 . . . . 0.0 109.209 179.934 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.8 t -67.37 126.42 29.2 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-O 121.437 0.637 . . . . 0.0 111.914 -178.604 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 4.9 m -132.35 65.79 1.57 Allowed 'General case' 0 C--N 1.318 -0.79 0 N-CA-C 106.889 -1.523 . . . . 0.0 106.889 178.457 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.506 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -27.71 126.67 0.22 Allowed Pre-proline 0 N--CA 1.465 0.289 0 CA-C-N 114.402 -1.272 . . . . 0.0 112.93 -176.684 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.506 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 62.8 Cg_endo -97.68 30.72 12.97 Favored 'Cis proline' 0 N--CA 1.461 -0.43 0 C-N-CA 123.802 -1.333 . . . . 0.0 114.424 0.927 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.497 HG22 HG22 ' A' ' 4' ' ' THR . 43.5 pt -138.65 142.58 34.32 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.36 0 CA-C-O 121.385 0.612 . . . . 0.0 111.448 -179.05 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.769 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 5.8 t -87.97 144.0 26.79 Favored 'General case' 0 C--N 1.314 -0.943 0 CA-C-O 121.137 0.494 . . . . 0.0 110.005 179.393 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 48.7 p -136.58 126.84 26.45 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-N 115.573 -0.74 . . . . 0.0 111.7 -178.58 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.666 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 9.1 ptm180 -91.47 126.9 36.71 Favored 'General case' 0 N--CA 1.445 -0.713 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 177.985 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 29.0 m-20 58.34 26.72 14.38 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 121.209 0.528 . . . . 0.0 109.911 -178.889 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 80.31 10.07 85.82 Favored Glycine 0 N--CA 1.45 -0.432 0 CA-C-N 115.864 -0.607 . . . . 0.0 112.363 -179.395 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.412 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 89.7 mt -113.15 128.54 25.52 Favored Pre-proline 0 C--O 1.236 0.379 0 CA-C-O 120.857 0.36 . . . . 0.0 110.755 -180.0 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.412 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 6.5 Cg_exo -73.76 52.94 2.65 Favored 'Trans proline' 0 CA--C 1.527 0.166 0 C-N-CA 123.619 2.879 . . . . 0.0 112.54 -179.839 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 39.4 t . . . . . 0 C--N 1.323 -0.57 0 CA-C-O 121.364 0.602 . . . . 0.0 110.206 -179.75 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.5 m . . . . . 0 N--CA 1.458 -0.058 0 CA-C-O 121.081 0.467 . . . . 0.0 110.191 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 77.16 -36.28 1.51 Allowed Glycine 0 C--N 1.332 0.331 0 CA-C-N 115.862 -0.608 . . . . 0.0 113.29 179.256 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 9.1 pt-20 -58.04 138.6 55.85 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 121.585 0.707 . . . . 0.0 112.181 -179.166 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.464 ' HA ' ' HA ' ' A' ' 21' ' ' ILE . 28.9 p -89.77 119.86 30.53 Favored 'General case' 0 N--CA 1.445 -0.675 0 CA-C-N 115.288 -0.869 . . . . 0.0 109.663 179.064 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 25.7 p -87.83 60.6 5.99 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 121.478 0.656 . . . . 0.0 110.507 -179.684 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 36.0 t80 -54.6 -41.5 70.01 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.353 -0.839 . . . . 0.0 110.613 179.942 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -94.33 22.93 34.26 Favored Glycine 0 N--CA 1.449 -0.492 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.733 179.611 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 75.25 -28.85 1.18 Allowed Glycine 0 CA--C 1.523 0.593 0 C-N-CA 121.192 -0.528 . . . . 0.0 113.94 179.382 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.8 m -88.43 151.05 22.82 Favored 'General case' 0 C--N 1.322 -0.616 0 O-C-N 122.522 -0.399 . . . . 0.0 111.445 -179.015 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 61.6 m -120.79 149.77 42.03 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.855 -0.611 . . . . 0.0 109.763 179.266 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 41.3 t30 -88.8 -21.33 23.81 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 121.115 0.483 . . . . 0.0 111.181 -179.227 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 6.4 m -101.08 124.2 42.4 Favored Pre-proline 0 C--N 1.323 -0.575 0 CA-C-O 121.239 0.542 . . . . 0.0 111.793 -178.424 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 33.7 Cg_endo -65.01 138.35 56.66 Favored 'Trans proline' 0 C--N 1.346 0.423 0 C-N-CA 122.897 2.398 . . . . 0.0 111.58 179.461 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 95.22 -16.22 61.75 Favored Glycine 0 N--CA 1.446 -0.655 0 C-N-CA 120.635 -0.793 . . . . 0.0 111.492 -179.224 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.668 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 91.5 m -88.07 133.81 33.89 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 120.991 0.424 . . . . 0.0 109.934 179.368 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 15.1 m -108.62 136.47 48.16 Favored 'General case' 0 C--N 1.322 -0.604 0 N-CA-C 109.201 -0.666 . . . . 0.0 109.201 -179.996 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.4 t -66.92 126.07 27.95 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-O 121.673 0.749 . . . . 0.0 111.91 -178.49 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 4.6 m -129.93 62.52 1.55 Allowed 'General case' 0 C--N 1.316 -0.87 0 N-CA-C 106.37 -1.715 . . . . 0.0 106.37 178.016 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.456 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.2 OUTLIER -26.11 126.4 0.2 Allowed Pre-proline 0 N--CA 1.465 0.307 0 CA-C-N 114.052 -1.431 . . . . 0.0 113.028 -176.507 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.456 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 61.0 Cg_endo -97.49 31.55 11.97 Favored 'Cis proline' 0 CA--C 1.533 0.459 0 C-N-CA 123.731 -1.362 . . . . 0.0 114.32 1.02 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.464 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 42.8 pt -138.04 140.29 40.81 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.354 0 CA-C-O 121.272 0.558 . . . . 0.0 111.362 -179.194 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.668 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 4.0 t -87.0 144.07 27.07 Favored 'General case' 0 C--N 1.315 -0.929 0 CA-C-O 121.205 0.526 . . . . 0.0 110.146 179.715 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 60.4 p -136.64 127.82 28.01 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 115.572 -0.74 . . . . 0.0 111.643 -178.553 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.6 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 1.7 ptm180 -89.07 123.42 33.35 Favored 'General case' 0 N--CA 1.446 -0.63 0 N-CA-C 108.528 -0.915 . . . . 0.0 108.528 178.197 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 69.8 m-20 57.44 30.73 19.1 Favored 'General case' 0 N--CA 1.468 0.461 0 O-C-N 123.518 0.511 . . . . 0.0 109.955 -177.627 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 78.54 9.65 86.85 Favored Glycine 0 C--N 1.333 0.415 0 CA-C-N 115.895 -0.593 . . . . 0.0 112.688 -179.656 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 90.4 mt -110.61 127.01 27.67 Favored Pre-proline 0 C--O 1.237 0.4 0 O-C-N 122.682 -0.305 . . . . 0.0 110.686 179.912 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 61.9 Cg_endo -73.57 52.45 2.46 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 123.268 2.645 . . . . 0.0 112.783 -179.837 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 39.7 t . . . . . 0 C--N 1.323 -0.56 0 CA-C-O 121.396 0.617 . . . . 0.0 110.041 -179.948 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.8 m . . . . . 0 CA--C 1.527 0.077 0 CA-C-O 120.967 0.413 . . . . 0.0 110.409 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 77.78 -36.01 1.64 Allowed Glycine 0 C--N 1.33 0.231 0 CA-C-N 115.848 -0.615 . . . . 0.0 113.405 179.278 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 11.1 pt-20 -56.6 136.22 54.61 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.523 0.678 . . . . 0.0 112.085 -179.001 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.647 HG22 HG22 ' A' ' 21' ' ' ILE . 24.6 p -89.58 114.99 26.65 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.347 -0.842 . . . . 0.0 109.951 179.424 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 28.3 p -88.9 58.34 4.54 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 120.999 0.428 . . . . 0.0 111.673 -179.006 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 6' ' ' PHE . . . . . 0.482 ' CD1' ' HB ' ' A' ' 4' ' ' THR . 5.1 m-85 -57.17 -38.15 73.17 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.137 179.444 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -89.43 17.52 51.55 Favored Glycine 0 CA--C 1.519 0.314 0 C-N-CA 120.656 -0.783 . . . . 0.0 112.791 179.815 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 62.57 40.23 98.87 Favored Glycine 0 C--N 1.331 0.268 0 C-N-CA 121.141 -0.552 . . . . 0.0 112.88 179.529 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.8 m -148.38 150.57 33.78 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 109.65 -0.5 . . . . 0.0 109.65 179.885 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 56.6 m -128.53 143.65 51.01 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 120.797 0.332 . . . . 0.0 110.413 -179.846 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 42.8 t30 -89.21 -18.98 26.0 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.805 -179.538 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 6.0 m -101.26 124.49 41.12 Favored Pre-proline 0 C--N 1.324 -0.521 0 CA-C-O 121.169 0.509 . . . . 0.0 111.586 -178.593 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 36.0 Cg_endo -65.54 140.43 62.84 Favored 'Trans proline' 0 C--N 1.346 0.404 0 C-N-CA 122.849 2.366 . . . . 0.0 111.72 179.468 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 93.73 -17.09 59.32 Favored Glycine 0 N--CA 1.447 -0.58 0 C-N-CA 120.608 -0.806 . . . . 0.0 111.495 -179.054 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.71 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 94.4 m -87.34 134.6 33.55 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-O 121.067 0.46 . . . . 0.0 110.087 179.714 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 14.5 m -108.71 136.3 48.51 Favored 'General case' 0 C--N 1.323 -0.57 0 N-CA-C 108.997 -0.742 . . . . 0.0 108.997 179.97 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 48.7 t -71.21 121.53 18.55 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-O 121.472 0.654 . . . . 0.0 111.856 -178.644 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 2.0 p -129.64 73.07 1.5 Allowed 'General case' 0 C--N 1.314 -0.956 0 N-CA-C 107.354 -1.35 . . . . 0.0 107.354 177.934 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.474 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.0 OUTLIER -29.57 129.51 0.24 Allowed Pre-proline 0 N--CA 1.465 0.31 0 CA-C-N 114.379 -1.282 . . . . 0.0 112.906 -176.842 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.474 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 68.2 Cg_endo -97.48 27.56 17.46 Favored 'Cis proline' 0 N--CA 1.46 -0.468 0 C-N-CA 123.696 -1.377 . . . . 0.0 114.682 1.001 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.647 HG22 HG22 ' A' ' 4' ' ' THR . 0.2 OUTLIER -139.3 148.61 23.45 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.347 0 CA-C-O 121.309 0.576 . . . . 0.0 111.229 -179.297 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.71 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 4.6 t -88.81 144.22 26.37 Favored 'General case' 0 C--N 1.312 -1.057 0 CA-C-O 121.168 0.509 . . . . 0.0 109.783 179.635 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.458 HG22 ' HA ' ' A' ' 28' ' ' PRO . 21.5 p -138.13 126.58 23.32 Favored 'General case' 0 C--N 1.314 -0.954 0 CA-C-N 115.478 -0.783 . . . . 0.0 111.586 -178.486 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.623 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 4.8 ptm180 -90.18 127.52 36.14 Favored 'General case' 0 N--CA 1.446 -0.67 0 N-CA-C 108.803 -0.814 . . . . 0.0 108.803 178.445 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 58.04 27.04 14.3 Favored 'General case' 0 C--N 1.328 -0.37 0 CA-C-O 121.206 0.527 . . . . 0.0 109.873 -179.225 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 78.4 13.52 83.16 Favored Glycine 0 C--N 1.334 0.417 0 CA-C-N 115.821 -0.627 . . . . 0.0 112.201 -179.165 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 89.9 mt -114.94 129.98 24.58 Favored Pre-proline 0 C--O 1.238 0.496 0 CA-C-O 120.914 0.388 . . . . 0.0 110.751 -179.894 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.458 ' HA ' HG22 ' A' ' 23' ' ' THR . 67.7 Cg_endo -74.24 53.67 3.05 Favored 'Trans proline' 0 C--N 1.344 0.291 0 C-N-CA 123.277 2.651 . . . . 0.0 112.789 -179.807 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 39.9 t . . . . . 0 C--N 1.323 -0.553 0 CA-C-O 121.416 0.627 . . . . 0.0 110.2 -179.896 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.458 -0.031 0 CA-C-O 121.07 0.462 . . . . 0.0 110.253 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 61.04 38.77 96.09 Favored Glycine 0 C--N 1.332 0.324 0 CA-C-N 115.595 -0.73 . . . . 0.0 112.776 179.33 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -127.55 143.2 51.2 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 121.15 0.5 . . . . 0.0 110.986 -179.812 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.492 ' HB ' ' CD1' ' A' ' 6' ' ' PHE . 21.0 p -89.58 111.67 22.67 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.014 179.487 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 23.8 p -88.85 59.21 4.95 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 121.096 0.474 . . . . 0.0 111.401 -179.24 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 6' ' ' PHE . . . . . 0.492 ' CD1' ' HB ' ' A' ' 4' ' ' THR . 4.5 m-85 -57.48 -36.41 71.45 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.739 179.382 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -88.53 16.77 52.51 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.788 179.517 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 76.39 -29.6 1.44 Allowed Glycine 0 CA--C 1.523 0.588 0 C-N-CA 121.226 -0.511 . . . . 0.0 113.612 179.536 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.9 m -88.57 150.93 22.82 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 120.844 0.354 . . . . 0.0 111.172 -179.139 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 69.5 m -117.49 148.3 41.96 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.831 -0.622 . . . . 0.0 109.893 179.396 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 66.1 m-80 -88.84 -18.81 26.87 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.819 -179.511 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.529 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 3.2 m -101.87 124.93 38.6 Favored Pre-proline 0 C--N 1.324 -0.527 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.238 -178.984 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -65.77 138.24 52.76 Favored 'Trans proline' 0 C--N 1.344 0.304 0 C-N-CA 122.804 2.336 . . . . 0.0 112.022 179.746 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 91.61 -13.01 67.77 Favored Glycine 0 N--CA 1.449 -0.499 0 C-N-CA 120.761 -0.733 . . . . 0.0 111.876 -179.495 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.689 ' SG ' ' HB3' ' A' ' 24' ' ' ARG . 99.3 m -87.34 136.08 33.07 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.108 0.48 . . . . 0.0 110.401 179.857 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 9.9 m -107.39 135.86 48.16 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 108.99 -0.744 . . . . 0.0 108.99 179.925 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.3 t -72.41 120.73 18.43 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-O 121.596 0.713 . . . . 0.0 112.17 -178.468 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 7.6 m -122.33 65.3 0.94 Allowed 'General case' 0 C--N 1.314 -0.968 0 N-CA-C 106.494 -1.669 . . . . 0.0 106.494 177.705 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.46 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -27.32 126.96 0.21 Allowed Pre-proline 0 N--CA 1.466 0.359 0 CA-C-N 114.222 -1.354 . . . . 0.0 112.955 -176.51 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.46 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 64.9 Cg_endo -97.2 31.07 12.73 Favored 'Cis proline' 0 N--CA 1.461 -0.42 0 C-N-CA 123.704 -1.373 . . . . 0.0 114.324 0.846 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 40.9 pt -137.21 136.02 47.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 121.481 0.658 . . . . 0.0 111.862 -179.112 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.68 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 5.7 t -86.44 144.96 27.03 Favored 'General case' 0 C--N 1.315 -0.905 0 CA-C-O 121.233 0.539 . . . . 0.0 110.064 179.577 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.442 HG22 ' HA ' ' A' ' 28' ' ' PRO . 9.1 p -144.11 128.79 18.21 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-N 115.288 -0.869 . . . . 0.0 111.216 -178.503 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.689 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 5.6 ptm180 -91.33 128.44 37.15 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.095 -0.706 . . . . 0.0 109.095 178.628 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 57.5 27.51 14.13 Favored 'General case' 0 N--CA 1.466 0.37 0 CA-C-O 121.243 0.544 . . . . 0.0 109.654 -179.349 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 76.2 14.53 82.21 Favored Glycine 0 C--N 1.332 0.345 0 CA-C-N 115.725 -0.67 . . . . 0.0 112.106 -178.92 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 88.2 mt -114.99 132.2 23.12 Favored Pre-proline 0 C--O 1.239 0.548 0 CA-C-O 121.071 0.462 . . . . 0.0 110.791 -179.755 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.442 ' HA ' HG22 ' A' ' 23' ' ' THR . 73.2 Cg_endo -76.08 55.16 4.41 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 123.301 2.667 . . . . 0.0 112.548 179.91 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 41.8 t . . . . . 0 C--N 1.324 -0.51 0 CA-C-O 121.272 0.558 . . . . 0.0 110.236 -179.681 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.5 m . . . . . 0 N--CA 1.457 -0.079 0 CA-C-O 121.062 0.458 . . . . 0.0 110.251 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 77.33 -36.59 1.55 Allowed Glycine 0 C--N 1.331 0.287 0 CA-C-N 115.837 -0.619 . . . . 0.0 113.387 179.27 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 7.8 pt-20 -58.17 138.0 56.55 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 121.481 0.657 . . . . 0.0 112.283 -179.109 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.509 HG22 HG22 ' A' ' 21' ' ' ILE . 26.3 p -89.79 119.34 30.1 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.418 -0.81 . . . . 0.0 109.675 179.056 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 23.0 p -88.1 61.99 6.57 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 121.495 0.664 . . . . 0.0 110.552 -179.691 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 34.2 t80 -54.38 -42.14 70.04 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.281 -0.872 . . . . 0.0 110.819 -179.892 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -93.01 21.3 40.59 Favored Glycine 0 N--CA 1.45 -0.426 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.833 179.712 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 76.52 -29.49 1.47 Allowed Glycine 0 CA--C 1.521 0.433 0 C-N-CA 121.117 -0.563 . . . . 0.0 113.616 179.598 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -88.73 143.22 27.06 Favored 'General case' 0 C--N 1.321 -0.641 0 O-C-N 122.631 -0.334 . . . . 0.0 111.878 -179.127 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 64.5 m -111.03 151.49 27.95 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.895 -0.593 . . . . 0.0 109.893 179.354 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 38.9 t30 -88.6 -24.17 22.9 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 121.132 0.491 . . . . 0.0 110.897 -179.432 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 7.5 m -101.39 123.84 43.17 Favored Pre-proline 0 C--N 1.322 -0.612 0 CA-C-O 121.15 0.5 . . . . 0.0 111.813 -178.573 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -65.95 140.91 62.42 Favored 'Trans proline' 0 C--N 1.345 0.368 0 C-N-CA 122.828 2.352 . . . . 0.0 111.484 179.263 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 96.46 -19.81 53.03 Favored Glycine 0 N--CA 1.446 -0.643 0 C-N-CA 120.539 -0.839 . . . . 0.0 111.457 -179.053 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.675 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 84.7 m -87.41 134.82 33.53 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 120.991 0.424 . . . . 0.0 109.896 179.279 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 11.0 m -106.52 136.2 46.71 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 109.114 -0.699 . . . . 0.0 109.114 -179.872 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 48.2 t -70.91 121.91 18.99 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-O 121.522 0.677 . . . . 0.0 112.23 -178.596 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 18.2 m -125.76 67.63 1.17 Allowed 'General case' 0 C--N 1.314 -0.971 0 N-CA-C 106.308 -1.738 . . . . 0.0 106.308 177.572 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.467 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.2 OUTLIER -28.27 127.84 0.22 Allowed Pre-proline 0 N--CA 1.464 0.25 0 CA-C-N 114.062 -1.427 . . . . 0.0 112.945 -176.446 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.467 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 60.2 Cg_endo -97.83 31.91 11.38 Favored 'Cis proline' 0 N--CA 1.461 -0.429 0 C-N-CA 123.711 -1.37 . . . . 0.0 114.242 0.872 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.509 HG22 HG22 ' A' ' 4' ' ' THR . 42.8 pt -138.56 139.22 41.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 121.452 0.644 . . . . 0.0 111.699 -179.019 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.675 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 3.7 t -84.3 144.42 28.89 Favored 'General case' 0 C--N 1.317 -0.839 0 CA-C-O 121.237 0.541 . . . . 0.0 109.55 179.268 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.558 HG22 ' HA ' ' A' ' 28' ' ' PRO . 17.9 p -141.97 130.43 22.49 Favored 'General case' 0 C--N 1.314 -0.944 0 CA-C-N 115.411 -0.813 . . . . 0.0 111.602 -178.143 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.457 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 9.6 ptm180 -93.84 128.17 39.97 Favored 'General case' 0 N--CA 1.448 -0.57 0 N-CA-C 108.729 -0.841 . . . . 0.0 108.729 178.309 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 28.6 m-20 58.4 26.71 14.45 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 121.29 0.567 . . . . 0.0 109.796 -178.876 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 77.75 10.67 86.08 Favored Glycine 0 C--N 1.333 0.411 0 CA-C-N 115.736 -0.666 . . . . 0.0 112.171 -179.118 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.44 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 90.2 mt -110.39 131.04 22.25 Favored Pre-proline 0 C--O 1.24 0.578 0 CA-C-O 120.965 0.412 . . . . 0.0 110.684 -179.75 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.558 ' HA ' HG22 ' A' ' 23' ' ' THR . 4.9 Cg_exo -74.85 52.93 3.12 Favored 'Trans proline' 0 C--N 1.344 0.297 0 C-N-CA 123.699 2.933 . . . . 0.0 112.447 -179.832 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 40.5 t . . . . . 0 C--N 1.322 -0.613 0 CA-C-O 121.433 0.635 . . . . 0.0 110.018 -179.881 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.8 m . . . . . 0 C--O 1.23 0.032 0 CA-C-O 121.045 0.45 . . . . 0.0 110.37 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 78.11 -36.02 1.72 Allowed Glycine 0 N--CA 1.453 -0.228 0 CA-C-N 115.781 -0.645 . . . . 0.0 113.496 179.159 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 10.8 pt-20 -60.21 139.22 57.69 Favored 'General case' 0 C--O 1.238 0.471 0 CA-C-O 121.617 0.722 . . . . 0.0 111.831 -178.945 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.521 HG22 HG22 ' A' ' 21' ' ' ILE . 11.9 p -91.31 118.22 30.32 Favored 'General case' 0 N--CA 1.445 -0.699 0 CA-C-N 115.301 -0.863 . . . . 0.0 109.985 179.347 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 26.5 p -88.93 58.87 4.77 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 121.049 0.452 . . . . 0.0 111.438 -178.992 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 6' ' ' PHE . . . . . 0.494 ' CD1' ' HB ' ' A' ' 4' ' ' THR . 4.9 m-85 -57.67 -36.43 71.9 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.542 179.306 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -90.13 18.37 48.6 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.649 179.516 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 75.58 -30.28 1.23 Allowed Glycine 0 CA--C 1.522 0.526 0 C-N-CA 121.344 -0.455 . . . . 0.0 113.786 179.531 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.0 m -88.95 151.57 22.23 Favored 'General case' 0 C--N 1.322 -0.591 0 O-C-N 122.53 -0.394 . . . . 0.0 111.237 -179.078 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 82.8 m -118.24 149.34 41.28 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.874 -0.603 . . . . 0.0 109.661 179.29 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 65.5 m-80 -88.92 -26.06 21.76 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 116.059 -0.519 . . . . 0.0 111.659 -178.674 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.447 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 19.3 p -102.06 128.47 28.49 Favored Pre-proline 0 C--N 1.324 -0.53 0 CA-C-O 121.398 0.618 . . . . 0.0 111.841 -178.855 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.447 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 19.6 Cg_exo -66.09 141.36 63.37 Favored 'Trans proline' 0 C--N 1.346 0.402 0 C-N-CA 123.252 2.635 . . . . 0.0 112.164 -179.913 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 96.44 -20.63 49.53 Favored Glycine 0 N--CA 1.447 -0.578 0 C-N-CA 120.761 -0.733 . . . . 0.0 111.545 -179.385 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.682 ' SG ' ' HB3' ' A' ' 24' ' ' ARG . 91.8 m -88.19 135.96 33.2 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-O 121.097 0.475 . . . . 0.0 110.324 179.703 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 15.2 m -109.71 136.65 48.71 Favored 'General case' 0 C--N 1.323 -0.582 0 N-CA-C 109.044 -0.724 . . . . 0.0 109.044 179.889 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 45.4 t -66.41 127.47 32.42 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-O 121.602 0.715 . . . . 0.0 112.062 -178.448 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 5.3 m -132.32 64.61 1.6 Allowed 'General case' 0 C--N 1.316 -0.874 0 N-CA-C 106.583 -1.636 . . . . 0.0 106.583 178.337 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.463 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -27.15 126.73 0.21 Allowed Pre-proline 0 N--CA 1.466 0.343 0 CA-C-N 114.231 -1.349 . . . . 0.0 112.996 -176.592 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.463 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 66.8 Cg_endo -97.3 31.37 12.28 Favored 'Cis proline' 0 CA--C 1.533 0.433 0 C-N-CA 123.689 -1.38 . . . . 0.0 114.492 1.025 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.521 HG22 HG22 ' A' ' 4' ' ' THR . 43.4 pt -139.33 141.31 35.87 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.382 0 CA-C-O 121.302 0.573 . . . . 0.0 111.565 -179.212 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.643 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 4.2 t -86.11 144.38 27.55 Favored 'General case' 0 C--N 1.316 -0.854 0 N-CA-C 109.669 -0.493 . . . . 0.0 109.669 179.406 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 61.9 p -137.15 128.24 27.72 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-N 115.661 -0.699 . . . . 0.0 112.007 -178.235 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.682 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 3.3 ptm180 -90.52 125.36 35.58 Favored 'General case' 0 N--CA 1.445 -0.705 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 177.822 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 53.0 m-20 58.59 28.1 16.63 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-O 121.148 0.499 . . . . 0.0 110.007 -178.421 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 79.37 11.27 85.11 Favored Glycine 0 C--N 1.334 0.441 0 CA-C-N 115.933 -0.576 . . . . 0.0 112.541 -179.514 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.463 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 91.7 mt -113.81 127.92 26.31 Favored Pre-proline 0 C--O 1.236 0.382 0 CA-C-O 120.779 0.323 . . . . 0.0 110.777 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.463 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 6.9 Cg_exo -73.29 53.66 2.61 Favored 'Trans proline' 0 C--N 1.344 0.291 0 C-N-CA 123.539 2.826 . . . . 0.0 112.695 -179.776 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 38.8 t . . . . . 0 C--N 1.323 -0.547 0 CA-C-O 121.445 0.641 . . . . 0.0 110.107 -179.926 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 4.1 m . . . . . 0 CA--C 1.527 0.089 0 CA-C-O 121.016 0.436 . . . . 0.0 110.246 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 62.86 45.41 95.75 Favored Glycine 0 C--N 1.333 0.405 0 CA-C-N 115.73 -0.668 . . . . 0.0 112.944 179.068 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 8.2 pt-20 -144.73 140.53 28.61 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 121.323 0.583 . . . . 0.0 111.346 -179.686 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.485 ' HB ' ' CD1' ' A' ' 6' ' ' PHE . 21.6 p -93.39 113.84 26.1 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 115.487 -0.779 . . . . 0.0 109.74 179.148 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 25.4 p -88.65 59.25 5.03 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 121.065 0.46 . . . . 0.0 111.459 -179.019 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 6' ' ' PHE . . . . . 0.485 ' CD1' ' HB ' ' A' ' 4' ' ' THR . 4.6 m-85 -57.73 -36.46 72.08 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.627 179.33 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -89.75 17.89 50.16 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.665 179.529 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 76.1 -29.57 1.37 Allowed Glycine 0 CA--C 1.524 0.609 0 C-N-CA 121.307 -0.473 . . . . 0.0 113.672 179.531 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.8 m -88.66 150.58 22.94 Favored 'General case' 0 C--N 1.323 -0.55 0 O-C-N 122.582 -0.363 . . . . 0.0 111.149 -179.232 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 67.6 m -117.12 150.87 37.97 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.094 179.517 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 42.3 t30 -88.82 -22.23 23.33 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.789 -179.605 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.433 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 4.5 m -101.42 123.35 44.85 Favored Pre-proline 0 C--N 1.324 -0.519 0 CA-C-O 121.226 0.536 . . . . 0.0 111.556 -178.62 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 22.4 Cg_exo -64.75 136.83 51.14 Favored 'Trans proline' 0 C--N 1.345 0.38 0 C-N-CA 122.96 2.44 . . . . 0.0 111.788 179.656 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 95.02 -15.12 64.09 Favored Glycine 0 N--CA 1.446 -0.648 0 C-N-CA 120.645 -0.788 . . . . 0.0 111.894 -179.436 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.669 ' SG ' ' HB3' ' A' ' 24' ' ' ARG . 88.6 m -87.31 135.5 33.29 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.583 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 13.3 m -105.7 135.25 47.45 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 109.125 -0.695 . . . . 0.0 109.125 -179.844 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.0 t -70.85 120.81 16.98 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-O 121.609 0.719 . . . . 0.0 111.994 -178.445 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 11.2 m -123.62 66.32 1.02 Allowed 'General case' 0 C--N 1.315 -0.933 0 N-CA-C 106.415 -1.698 . . . . 0.0 106.415 177.685 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.449 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -27.76 127.21 0.22 Allowed Pre-proline 0 N--CA 1.466 0.345 0 CA-C-N 114.167 -1.378 . . . . 0.0 112.878 -176.561 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.449 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 65.0 Cg_endo -97.37 31.29 12.35 Favored 'Cis proline' 0 N--CA 1.46 -0.442 0 C-N-CA 123.765 -1.348 . . . . 0.0 114.34 0.948 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 42.3 pt -138.2 137.34 44.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-O 121.454 0.645 . . . . 0.0 111.722 -179.155 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.62 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 4.5 t -85.05 144.38 28.29 Favored 'General case' 0 C--N 1.316 -0.861 0 CA-C-O 121.177 0.513 . . . . 0.0 109.912 179.447 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.477 HG22 ' CA ' ' A' ' 28' ' ' PRO . 21.5 p -143.52 127.06 16.92 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-N 115.304 -0.862 . . . . 0.0 111.127 -178.266 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.669 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 3.4 ptm180 -93.65 126.28 38.73 Favored 'General case' 0 N--CA 1.447 -0.581 0 N-CA-C 108.859 -0.793 . . . . 0.0 108.859 178.535 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 51.5 m-20 57.75 29.68 17.77 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-O 121.259 0.552 . . . . 0.0 109.657 -178.54 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 78.29 7.99 87.64 Favored Glycine 0 C--N 1.333 0.386 0 CA-C-N 115.587 -0.733 . . . . 0.0 112.67 -179.338 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.473 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 88.2 mt -106.62 124.48 35.45 Favored Pre-proline 0 C--O 1.237 0.442 0 CA-C-O 120.935 0.397 . . . . 0.0 110.867 -179.829 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.477 ' CA ' HG22 ' A' ' 23' ' ' THR . 3.8 Cg_exo -79.75 46.35 2.2 Favored 'Trans proline' 0 N--CA 1.462 -0.374 0 C-N-CA 123.574 2.849 . . . . 0.0 112.08 179.868 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 10.5 p . . . . . 0 C--N 1.319 -0.719 0 CA-C-N 115.552 -0.749 . . . . 0.0 110.337 -179.765 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.0 m . . . . . 0 N--CA 1.456 -0.136 0 CA-C-O 121.066 0.46 . . . . 0.0 110.318 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 76.27 -34.05 1.32 Allowed Glycine 0 C--N 1.332 0.325 0 CA-C-N 115.867 -0.606 . . . . 0.0 113.575 179.111 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -55.04 138.44 44.0 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 121.813 0.816 . . . . 0.0 112.315 -178.921 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.61 HG23 ' O ' ' A' ' 20' ' ' PRO . 81.1 m -89.0 110.86 21.5 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 114.892 -1.049 . . . . 0.0 110.008 179.607 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 28.5 p -89.13 53.42 2.66 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 121.167 0.508 . . . . 0.0 110.9 -179.459 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 18.9 p90 -58.15 -30.93 66.75 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.925 -0.58 . . . . 0.0 111.283 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -94.32 15.57 62.95 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.687 179.699 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 65.17 40.08 96.57 Favored Glycine 0 CA--C 1.518 0.269 0 C-N-CA 121.049 -0.596 . . . . 0.0 112.79 179.676 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 3.0 m -149.91 150.75 32.35 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 179.91 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 60.1 m -129.26 142.75 50.76 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 120.758 0.313 . . . . 0.0 110.213 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 43.7 t30 -89.23 -17.82 28.29 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.964 -179.367 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.453 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 5.2 m -101.11 123.67 44.21 Favored Pre-proline 0 C--N 1.323 -0.561 0 CA-C-O 121.122 0.487 . . . . 0.0 111.611 -178.546 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.453 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 23.9 Cg_exo -63.61 136.65 55.21 Favored 'Trans proline' 0 C--N 1.345 0.359 0 C-N-CA 122.959 2.44 . . . . 0.0 111.705 179.583 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 94.39 -15.07 64.06 Favored Glycine 0 N--CA 1.447 -0.623 0 C-N-CA 120.638 -0.792 . . . . 0.0 111.594 -179.225 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.73 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 93.1 m -87.88 132.42 34.21 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 121.059 0.457 . . . . 0.0 110.053 179.524 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 15.2 m -108.96 134.78 51.16 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 109.116 -0.698 . . . . 0.0 109.116 179.892 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 41.9 t -67.43 121.98 16.96 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 121.578 0.704 . . . . 0.0 111.873 -178.504 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 4.1 m -125.3 65.96 1.14 Allowed 'General case' 0 C--N 1.317 -0.82 0 N-CA-C 106.765 -1.569 . . . . 0.0 106.765 178.023 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.47 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -27.76 125.77 0.23 Allowed Pre-proline 0 N--CA 1.466 0.331 0 CA-C-N 114.347 -1.297 . . . . 0.0 112.812 -176.74 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.61 ' O ' HG23 ' A' ' 4' ' ' THR . 66.6 Cg_endo -97.51 31.19 12.42 Favored 'Cis proline' 0 N--CA 1.46 -0.452 0 C-N-CA 123.656 -1.393 . . . . 0.0 114.362 0.843 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 41.8 pt -138.54 136.36 43.76 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 O-C-N 121.474 -0.766 . . . . 0.0 111.859 -179.208 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.73 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 5.7 t -83.36 142.77 30.79 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-O 121.201 0.524 . . . . 0.0 109.826 179.367 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 62.0 p -137.05 128.35 28.11 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-N 115.504 -0.771 . . . . 0.0 111.785 -178.276 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.64 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 3.0 ptm180 -89.52 124.71 34.76 Favored 'General case' 0 N--CA 1.446 -0.67 0 N-CA-C 108.483 -0.932 . . . . 0.0 108.483 178.126 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 53.8 m-20 58.11 28.37 16.31 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 121.173 0.511 . . . . 0.0 110.035 -178.434 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 80.14 10.04 85.94 Favored Glycine 0 C--N 1.334 0.426 0 CA-C-N 115.87 -0.604 . . . . 0.0 112.58 -179.423 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 90.1 mt -110.82 127.33 27.11 Favored Pre-proline 0 C--N 1.327 -0.412 0 CA-C-O 120.82 0.343 . . . . 0.0 110.63 179.967 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 62.3 Cg_endo -73.61 52.69 2.53 Favored 'Trans proline' 0 C--N 1.343 0.261 0 C-N-CA 123.202 2.601 . . . . 0.0 112.784 -179.879 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 40.4 t . . . . . 0 C--N 1.322 -0.602 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.094 -179.922 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.7 m . . . . . 0 N--CA 1.457 -0.078 0 CA-C-O 121.03 0.443 . . . . 0.0 110.232 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 75.71 -34.59 1.2 Allowed Glycine 0 C--N 1.33 0.243 0 CA-C-N 115.785 -0.643 . . . . 0.0 113.657 179.114 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 15.3 pt-20 -55.74 141.8 36.89 Favored 'General case' 0 C--O 1.238 0.478 0 CA-C-O 121.639 0.733 . . . . 0.0 112.116 -178.806 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.607 HG23 ' O ' ' A' ' 20' ' ' PRO . 87.8 m -88.68 117.03 27.36 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.157 -0.928 . . . . 0.0 110.308 -179.983 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 26.3 p -88.77 58.51 4.65 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 121.229 0.538 . . . . 0.0 110.209 179.798 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 32.3 t80 -51.76 -46.36 64.08 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 115.438 -0.801 . . . . 0.0 111.243 -179.559 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -94.45 25.41 22.9 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.59 -0.814 . . . . 0.0 112.568 179.749 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.44 38.69 96.18 Favored Glycine 0 CA--C 1.518 0.223 0 C-N-CA 121.184 -0.531 . . . . 0.0 112.742 179.65 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.3 m -139.49 150.66 45.41 Favored 'General case' 0 C--N 1.324 -0.512 0 N-CA-C 110.013 -0.365 . . . . 0.0 110.013 -179.911 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 59.3 m -133.22 140.84 47.75 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 116.404 -0.362 . . . . 0.0 110.057 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 65.0 m-80 -89.56 -13.88 36.33 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.08 -179.047 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.547 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 4.7 m -101.09 124.84 40.15 Favored Pre-proline 0 C--N 1.322 -0.605 0 CA-C-O 121.126 0.489 . . . . 0.0 111.208 -178.751 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 28.8 Cg_endo -63.58 135.81 51.1 Favored 'Trans proline' 0 C--N 1.345 0.387 0 C-N-CA 122.88 2.387 . . . . 0.0 112.179 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 91.83 -11.32 72.43 Favored Glycine 0 N--CA 1.448 -0.556 0 C-N-CA 120.806 -0.711 . . . . 0.0 111.898 -179.508 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.766 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 89.1 m -88.08 132.9 34.12 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.056 0.455 . . . . 0.0 110.344 179.738 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 15.3 m -111.21 138.06 48.13 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 109.158 -0.682 . . . . 0.0 109.158 179.889 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 45.7 t -67.74 123.86 21.69 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-O 121.451 0.643 . . . . 0.0 111.969 -178.766 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 4.6 m -128.35 62.64 1.44 Allowed 'General case' 0 C--N 1.317 -0.815 0 N-CA-C 106.698 -1.593 . . . . 0.0 106.698 178.028 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.448 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -27.48 126.33 0.22 Allowed Pre-proline 0 N--CA 1.464 0.239 0 CA-C-N 114.153 -1.385 . . . . 0.0 112.933 -176.686 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.607 ' O ' HG23 ' A' ' 4' ' ' THR . 67.9 Cg_endo -97.21 33.76 9.47 Favored 'Cis proline' 0 N--CA 1.461 -0.436 0 C-N-CA 123.775 -1.344 . . . . 0.0 114.241 0.848 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 42.0 pt -140.24 137.05 37.55 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 O-C-N 121.654 -0.654 . . . . 0.0 111.582 -179.284 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.766 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 6.6 t -85.36 142.71 29.11 Favored 'General case' 0 C--N 1.316 -0.88 0 CA-C-O 121.062 0.458 . . . . 0.0 109.848 179.346 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 66.2 p -136.88 129.2 29.86 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-N 115.552 -0.749 . . . . 0.0 111.824 -178.47 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.653 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 1.7 ptm180 -90.36 123.04 33.78 Favored 'General case' 0 N--CA 1.445 -0.711 0 N-CA-C 108.634 -0.876 . . . . 0.0 108.634 178.066 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 71.1 m-20 56.85 31.27 19.31 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-O 121.214 0.53 . . . . 0.0 109.987 -177.656 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 79.38 7.31 88.57 Favored Glycine 0 C--N 1.334 0.448 0 CA-C-N 115.879 -0.6 . . . . 0.0 112.856 -179.625 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.47 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 88.0 mt -107.36 126.4 30.12 Favored Pre-proline 0 C--O 1.237 0.41 0 O-C-N 122.624 -0.339 . . . . 0.0 110.697 179.982 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.47 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 7.4 Cg_exo -72.91 52.98 2.29 Favored 'Trans proline' 0 C--N 1.343 0.246 0 C-N-CA 123.587 2.858 . . . . 0.0 112.581 -179.834 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 43.4 t . . . . . 0 C--N 1.323 -0.561 0 CA-C-O 121.307 0.575 . . . . 0.0 110.171 -179.774 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.6 m . . . . . 0 CA--C 1.528 0.104 0 CA-C-O 120.875 0.369 . . . . 0.0 110.763 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.68 42.97 95.08 Favored Glycine 0 N--CA 1.451 -0.321 0 CA-C-N 115.798 -0.637 . . . . 0.0 112.982 179.217 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -142.84 143.44 32.12 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 121.211 0.529 . . . . 0.0 110.864 179.906 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.528 ' HB ' ' CD1' ' A' ' 6' ' ' PHE . 7.3 p -95.97 115.08 26.88 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 115.582 -0.735 . . . . 0.0 110.381 179.506 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 25.5 p -89.11 58.84 4.69 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 121.047 0.451 . . . . 0.0 111.426 -179.248 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 6' ' ' PHE . . . . . 0.528 ' CD1' ' HB ' ' A' ' 4' ' ' THR . 5.2 m-85 -57.81 -36.36 72.13 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.644 179.416 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -88.36 16.83 51.49 Favored Glycine 0 N--CA 1.448 -0.508 0 C-N-CA 120.833 -0.699 . . . . 0.0 112.703 179.654 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 77.2 -30.62 1.61 Allowed Glycine 0 CA--C 1.523 0.542 0 C-N-CA 121.223 -0.513 . . . . 0.0 113.487 179.635 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.7 m -88.62 149.96 23.28 Favored 'General case' 0 C--N 1.322 -0.626 0 O-C-N 122.655 -0.32 . . . . 0.0 111.035 -179.373 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 77.0 m -113.05 150.6 31.79 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.141 179.52 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 64.8 m-80 -88.65 -27.94 20.95 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 115.818 -0.628 . . . . 0.0 111.244 -179.086 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.457 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 21.3 p -102.46 128.31 28.49 Favored Pre-proline 0 C--N 1.324 -0.509 0 CA-C-O 121.481 0.658 . . . . 0.0 111.746 -179.049 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.457 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 17.3 Cg_exo -67.25 141.09 55.61 Favored 'Trans proline' 0 C--N 1.345 0.375 0 C-N-CA 123.277 2.651 . . . . 0.0 112.172 -179.758 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 96.8 -20.1 52.05 Favored Glycine 0 N--CA 1.448 -0.565 0 C-N-CA 120.739 -0.743 . . . . 0.0 111.7 -179.509 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.731 ' SG ' ' HB3' ' A' ' 24' ' ' ARG . 91.0 m -88.22 138.82 31.1 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-O 121.066 0.46 . . . . 0.0 110.283 179.734 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 16.1 m -108.49 134.52 51.15 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 109.172 -0.677 . . . . 0.0 109.172 179.855 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.4 t -66.31 125.2 24.86 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-O 121.615 0.721 . . . . 0.0 111.893 -178.418 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 3.9 m -129.0 65.6 1.44 Allowed 'General case' 0 C--N 1.315 -0.913 0 N-CA-C 106.708 -1.589 . . . . 0.0 106.708 178.277 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.458 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -27.26 126.42 0.22 Allowed Pre-proline 0 N--CA 1.465 0.312 0 CA-C-N 114.423 -1.262 . . . . 0.0 112.836 -176.571 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.458 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 63.2 Cg_endo -97.17 31.03 12.79 Favored 'Cis proline' 0 CA--C 1.532 0.407 0 C-N-CA 123.776 -1.343 . . . . 0.0 114.534 0.932 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.417 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 42.5 pt -139.42 138.98 39.72 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.333 0 CA-C-O 121.319 0.581 . . . . 0.0 111.719 -179.117 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.565 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 4.4 t -84.93 145.14 27.92 Favored 'General case' 0 C--N 1.316 -0.849 0 N-CA-C 109.622 -0.51 . . . . 0.0 109.622 179.282 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 61.8 p -139.54 128.52 23.6 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-N 115.792 -0.64 . . . . 0.0 112.121 -178.026 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.731 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 3.3 ptm180 -91.68 125.57 36.46 Favored 'General case' 0 N--CA 1.445 -0.697 0 N-CA-C 108.155 -1.054 . . . . 0.0 108.155 177.588 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 54.7 m-20 58.9 28.24 17.28 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-O 121.143 0.497 . . . . 0.0 109.842 -178.319 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 78.87 10.36 86.25 Favored Glycine 0 C--N 1.333 0.374 0 CA-C-N 115.897 -0.592 . . . . 0.0 112.636 -179.413 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 92.1 mt -114.3 126.28 28.18 Favored Pre-proline 0 C--N 1.328 -0.357 0 CA-C-O 120.881 0.372 . . . . 0.0 110.759 -179.961 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -75.28 52.42 3.16 Favored 'Trans proline' 0 CA--C 1.529 0.241 0 C-N-CA 123.159 2.573 . . . . 0.0 112.876 -179.811 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 22.3 t . . . . . 0 C--N 1.323 -0.559 0 CA-C-O 121.389 0.614 . . . . 0.0 110.184 -179.883 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 63.4 m . . . . . 0 N--CA 1.458 -0.061 0 CA-C-O 120.991 0.424 . . . . 0.0 110.104 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 61.45 35.29 90.81 Favored Glycine 0 C--N 1.332 0.348 0 CA-C-N 115.674 -0.694 . . . . 0.0 113.102 179.114 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 9.5 pt-20 -115.9 148.44 40.01 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 120.9 0.381 . . . . 0.0 110.716 179.929 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.438 ' HA ' ' HA ' ' A' ' 21' ' ' ILE . 33.9 p -93.41 118.09 30.88 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.182 -179.933 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.798 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 13.5 p -88.87 61.57 6.0 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.287 0.565 . . . . 0.0 110.52 179.298 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 32.8 t80 -55.14 -41.27 71.54 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.561 -0.745 . . . . 0.0 110.235 179.892 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -92.18 22.94 29.49 Favored Glycine 0 N--CA 1.45 -0.43 0 C-N-CA 120.865 -0.683 . . . . 0.0 112.765 179.338 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 76.66 -35.81 1.4 Allowed Glycine 0 CA--C 1.521 0.446 0 C-N-CA 121.23 -0.51 . . . . 0.0 113.938 179.405 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.5 m -89.2 148.37 23.66 Favored 'General case' 0 C--N 1.322 -0.609 0 O-C-N 122.423 -0.457 . . . . 0.0 111.442 -179.093 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 59.9 m -108.69 153.67 23.11 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.711 -0.677 . . . . 0.0 109.515 179.072 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 39.1 t30 -87.53 -29.42 21.33 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-O 121.255 0.55 . . . . 0.0 110.171 179.956 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.443 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 3.8 m -102.48 118.35 58.92 Favored Pre-proline 0 C--N 1.323 -0.571 0 CA-C-N 115.877 -0.601 . . . . 0.0 111.167 -179.485 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.443 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 13.6 Cg_exo -68.76 136.95 37.19 Favored 'Trans proline' 0 N--CA 1.46 -0.479 0 C-N-CA 122.829 2.352 . . . . 0.0 111.719 179.724 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 117.33 -32.66 5.32 Favored Glycine 0 N--CA 1.439 -1.166 0 N-CA-C 111.134 -0.787 . . . . 0.0 111.134 -179.264 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.413 ' HB3' ' HB3' ' A' ' 22' ' ' CYS . 32.9 m -89.45 131.43 35.5 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 120.921 0.391 . . . . 0.0 110.36 179.05 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 16.0 m -89.67 136.15 33.2 Favored 'General case' 0 C--N 1.319 -0.724 0 N-CA-C 109.213 -0.662 . . . . 0.0 109.213 179.556 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 43.2 t -67.66 115.45 7.25 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 121.773 0.797 . . . . 0.0 111.031 -179.336 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 2.9 m -118.95 66.96 0.78 Allowed 'General case' 0 C--N 1.309 -1.172 0 N-CA-C 106.332 -1.729 . . . . 0.0 106.332 178.182 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.475 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.3 OUTLIER -27.24 124.6 0.23 Allowed Pre-proline 0 N--CA 1.463 0.196 0 CA-C-N 114.213 -1.358 . . . . 0.0 112.646 -176.314 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.475 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 56.7 Cg_endo -98.77 34.25 8.69 Favored 'Cis proline' 0 N--CA 1.459 -0.52 0 C-N-CA 123.732 -1.362 . . . . 0.0 114.554 1.103 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.438 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 40.8 pt -142.12 136.06 29.09 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.301 0 CA-C-N 118.753 0.706 . . . . 0.0 112.513 -178.939 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.798 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 47.2 m -82.08 131.68 35.24 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.266 178.977 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 65.4 p -142.7 136.7 29.25 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.134 179.785 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.514 ' O ' ' HG3' ' A' ' 24' ' ' ARG . 2.8 ptm180 -94.62 121.86 36.62 Favored 'General case' 0 N--CA 1.443 -0.789 0 N-CA-C 108.153 -1.054 . . . . 0.0 108.153 178.445 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 61.3 m-20 57.36 29.85 17.56 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.134 0.492 . . . . 0.0 109.775 -178.032 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 82.12 1.95 90.46 Favored Glycine 0 CA--C 1.521 0.41 0 CA-C-N 115.801 -0.636 . . . . 0.0 112.667 -179.371 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 88.0 mt -98.87 123.6 48.81 Favored Pre-proline 0 C--O 1.237 0.429 0 CA-C-O 121.074 0.464 . . . . 0.0 111.217 -179.838 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -77.13 69.81 6.93 Favored 'Trans proline' 0 N--CA 1.464 -0.242 0 C-N-CA 123.248 2.632 . . . . 0.0 112.139 179.649 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 47.2 t . . . . . 0 C--N 1.324 -0.504 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.297 -179.396 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 82.0 m . . . . . 0 CA--C 1.524 -0.026 0 CA-C-O 120.92 0.391 . . . . 0.0 110.353 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 76.46 -32.32 1.39 Allowed Glycine 0 CA--C 1.519 0.327 0 CA-C-N 116.117 -0.492 . . . . 0.0 113.85 178.878 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 14.7 pt-20 -53.95 139.31 34.47 Favored 'General case' 0 C--O 1.239 0.509 0 CA-C-O 121.447 0.641 . . . . 0.0 111.889 -178.933 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.612 HG22 HG22 ' A' ' 21' ' ' ILE . 36.2 p -89.44 120.91 31.18 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 115.276 -0.875 . . . . 0.0 110.801 -179.581 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.761 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 25.0 p -88.98 60.96 5.69 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 121.253 0.549 . . . . 0.0 110.71 179.651 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 34.4 t80 -53.33 -44.36 68.37 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.525 -0.761 . . . . 0.0 110.993 -179.896 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -92.65 22.63 32.39 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.742 179.788 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 62.55 40.68 99.43 Favored Glycine 0 CA--C 1.518 0.27 0 C-N-CA 121.257 -0.497 . . . . 0.0 112.965 179.514 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.5 m -147.99 149.28 31.87 Favored 'General case' 0 C--N 1.324 -0.513 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 179.919 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 47.2 m -124.76 143.42 50.8 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 179.837 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 63.1 m-80 -88.39 -23.24 23.4 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.276 -179.49 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.401 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 4.3 m -101.72 119.37 57.35 Favored Pre-proline 0 C--N 1.323 -0.582 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.982 -179.148 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.401 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 20.4 Cg_exo -65.55 140.93 64.87 Favored 'Trans proline' 0 N--CA 1.462 -0.324 0 C-N-CA 122.922 2.415 . . . . 0.0 111.939 179.894 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 105.76 -29.9 10.62 Favored Glycine 0 N--CA 1.441 -1.024 0 C-N-CA 120.75 -0.738 . . . . 0.0 111.489 -179.4 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.548 ' HB3' ' HB3' ' A' ' 22' ' ' CYS . 15.7 m -89.04 129.19 35.71 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 121.209 0.528 . . . . 0.0 110.708 179.289 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 19.6 m -94.39 138.51 32.26 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 115.512 -0.767 . . . . 0.0 109.036 179.372 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 43.4 t -66.43 116.16 7.13 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-O 121.593 0.711 . . . . 0.0 111.03 -179.287 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 3.0 m -120.78 68.7 0.87 Allowed 'General case' 0 C--N 1.311 -1.099 0 N-CA-C 106.597 -1.631 . . . . 0.0 106.597 178.422 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.478 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -27.82 125.1 0.23 Allowed Pre-proline 0 N--CA 1.463 0.215 0 O-C-N 124.706 1.253 . . . . 0.0 112.631 -176.52 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.478 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 59.8 Cg_endo -98.54 30.62 12.65 Favored 'Cis proline' 0 CA--C 1.535 0.562 0 C-N-CA 123.613 -1.411 . . . . 0.0 115.061 1.033 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.612 HG22 HG22 ' A' ' 4' ' ' THR . 0.2 OUTLIER -141.62 141.65 29.68 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.293 0 CA-C-N 118.992 0.815 . . . . 0.0 112.122 -179.422 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.761 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 64.6 m -81.1 133.81 35.54 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.586 179.365 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 64.5 p -134.23 132.4 39.65 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.735 179.856 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.476 ' O ' ' HG3' ' A' ' 24' ' ' ARG . 1.4 ptm180 -91.93 120.25 32.43 Favored 'General case' 0 N--CA 1.443 -0.777 0 N-CA-C 108.185 -1.042 . . . . 0.0 108.185 178.305 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 72.7 m-20 56.6 31.0 18.34 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 121.144 0.497 . . . . 0.0 109.895 -177.437 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 84.0 -0.4 89.45 Favored Glycine 0 CA--C 1.521 0.447 0 CA-C-N 115.885 -0.598 . . . . 0.0 112.907 -179.624 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.488 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 86.9 mt -99.3 122.34 52.31 Favored Pre-proline 0 C--O 1.237 0.41 0 CA-C-O 120.903 0.383 . . . . 0.0 111.155 -179.754 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.488 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 3.4 Cg_exo -74.46 63.78 5.5 Favored 'Trans proline' 0 CA--C 1.528 0.177 0 C-N-CA 123.597 2.865 . . . . 0.0 112.143 179.66 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 48.2 t . . . . . 0 C--N 1.325 -0.479 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.485 -179.233 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 3.0 m . . . . . 0 CA--C 1.527 0.058 0 CA-C-O 120.943 0.402 . . . . 0.0 110.486 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 78.23 -37.16 1.76 Allowed Glycine 0 C--N 1.33 0.226 0 CA-C-N 115.952 -0.567 . . . . 0.0 113.022 179.59 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 8.9 pt-20 -59.77 141.66 54.81 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 121.526 0.679 . . . . 0.0 111.961 -179.331 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.523 HG22 HG22 ' A' ' 21' ' ' ILE . 14.7 p -94.87 124.73 39.08 Favored 'General case' 0 N--CA 1.444 -0.733 0 CA-C-N 115.316 -0.856 . . . . 0.0 109.695 178.982 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 24.4 p -87.98 58.8 5.01 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 121.479 0.657 . . . . 0.0 110.698 -179.419 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 35.3 t80 -56.27 -39.93 73.42 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.309 -0.859 . . . . 0.0 110.038 179.48 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -91.31 22.68 28.54 Favored Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 120.943 -0.646 . . . . 0.0 112.751 179.375 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 77.25 -36.82 1.53 Allowed Glycine 0 CA--C 1.522 0.482 0 C-N-CA 121.36 -0.448 . . . . 0.0 114.081 179.223 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 10.2 t -89.52 164.46 14.79 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-O 121.229 0.537 . . . . 0.0 111.627 -179.083 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 62.0 m -125.69 151.77 46.15 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 114.983 -1.008 . . . . 0.0 109.514 179.28 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 41.4 t30 -88.88 -22.76 22.99 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-O 121.031 0.444 . . . . 0.0 111.198 -178.983 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.453 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 7.8 m -101.14 124.46 41.42 Favored Pre-proline 0 C--N 1.322 -0.59 0 CA-C-O 121.215 0.531 . . . . 0.0 111.955 -178.375 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.453 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 23.8 Cg_exo -63.81 137.48 58.56 Favored 'Trans proline' 0 C--N 1.346 0.411 0 C-N-CA 123.059 2.506 . . . . 0.0 111.47 179.403 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 96.55 -17.39 59.36 Favored Glycine 0 N--CA 1.446 -0.67 0 C-N-CA 120.596 -0.812 . . . . 0.0 111.447 -179.06 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.706 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 81.6 m -87.61 133.06 33.87 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 109.651 -0.5 . . . . 0.0 109.651 179.39 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 15.4 m -108.87 138.11 45.72 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 -179.577 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.4 t -68.46 127.08 31.69 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 121.752 0.787 . . . . 0.0 111.948 -178.705 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 4.3 m -131.17 60.67 1.65 Allowed 'General case' 0 C--N 1.316 -0.882 0 N-CA-C 106.144 -1.799 . . . . 0.0 106.144 177.891 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.432 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -26.24 126.65 0.2 Allowed Pre-proline 0 N--CA 1.464 0.265 0 CA-C-N 113.951 -1.477 . . . . 0.0 113.002 -176.487 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.432 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 62.3 Cg_endo -97.01 32.32 11.16 Favored 'Cis proline' 0 CA--C 1.532 0.421 0 C-N-CA 123.684 -1.381 . . . . 0.0 114.41 0.842 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.523 HG22 HG22 ' A' ' 4' ' ' THR . 43.8 pt -137.53 140.35 41.76 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.39 0 CA-C-O 121.255 0.55 . . . . 0.0 111.346 -179.234 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.706 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 5.4 t -89.4 144.28 26.18 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-O 121.17 0.509 . . . . 0.0 110.233 179.783 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 43.0 p -138.25 127.14 23.89 Favored 'General case' 0 C--N 1.318 -0.784 0 CA-C-N 115.527 -0.761 . . . . 0.0 111.752 -178.673 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.634 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 3.1 ptm180 -89.53 125.07 35.06 Favored 'General case' 0 N--CA 1.447 -0.618 0 N-CA-C 108.601 -0.889 . . . . 0.0 108.601 178.403 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 53.7 m-20 57.98 28.9 16.87 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.216 0.531 . . . . 0.0 109.958 -178.532 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 78.71 12.06 84.6 Favored Glycine 0 C--N 1.334 0.417 0 CA-C-N 115.875 -0.602 . . . . 0.0 112.457 -179.445 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 88.9 mt -113.72 127.71 26.53 Favored Pre-proline 0 C--O 1.237 0.405 0 CA-C-O 120.857 0.36 . . . . 0.0 110.686 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 70.9 Cg_endo -74.57 51.92 2.74 Favored 'Trans proline' 0 C--N 1.343 0.256 0 C-N-CA 123.292 2.662 . . . . 0.0 112.678 -179.949 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 39.4 t . . . . . 0 C--N 1.322 -0.601 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.222 -179.855 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 1' ' ' CYS . . . . . 0.541 ' HB3' ' HG2' ' A' ' 3' ' ' GLU . 82.5 m . . . . . 0 N--CA 1.458 -0.065 0 CA-C-O 120.897 0.379 . . . . 0.0 110.239 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 77.47 -34.73 1.57 Allowed Glycine 0 C--N 1.331 0.285 0 CA-C-N 116.034 -0.53 . . . . 0.0 113.436 179.188 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.541 ' HG2' ' HB3' ' A' ' 1' ' ' CYS . 7.0 pt-20 -53.8 139.88 31.76 Favored 'General case' 0 C--O 1.237 0.429 0 CA-C-O 121.528 0.68 . . . . 0.0 112.423 -179.114 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.623 HG22 HG22 ' A' ' 21' ' ' ILE . 31.5 p -89.29 121.22 31.36 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 115.271 -0.877 . . . . 0.0 110.01 179.29 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 23.5 p -88.0 61.14 6.19 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 121.382 0.611 . . . . 0.0 110.478 -179.857 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 35.1 t80 -55.11 -41.04 71.17 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.367 -0.833 . . . . 0.0 110.513 179.91 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -91.65 21.58 35.21 Favored Glycine 0 N--CA 1.449 -0.457 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.735 179.51 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 76.7 -33.47 1.41 Allowed Glycine 0 CA--C 1.522 0.51 0 C-N-CA 121.221 -0.514 . . . . 0.0 113.833 179.572 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.7 m -89.11 149.7 23.06 Favored 'General case' 0 C--N 1.321 -0.674 0 O-C-N 122.538 -0.389 . . . . 0.0 111.443 -179.184 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 58.3 m -114.76 152.68 31.66 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.761 -0.654 . . . . 0.0 109.301 179.017 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 36.4 t30 -87.8 -28.52 21.61 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-O 121.215 0.531 . . . . 0.0 110.537 -179.534 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.407 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 8.2 m -101.63 120.99 52.82 Favored Pre-proline 0 C--N 1.32 -0.681 0 CA-C-N 115.967 -0.56 . . . . 0.0 111.563 -178.871 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.407 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 17.3 Cg_exo -66.62 143.84 69.96 Favored 'Trans proline' 0 N--CA 1.463 -0.316 0 C-N-CA 123.178 2.585 . . . . 0.0 111.888 179.741 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 105.02 -29.59 11.43 Favored Glycine 0 N--CA 1.443 -0.862 0 C-N-CA 120.676 -0.774 . . . . 0.0 111.555 -179.443 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.663 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 9.2 m -87.98 138.87 31.08 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 121.131 0.491 . . . . 0.0 110.158 179.169 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 15.2 m -102.57 141.54 35.22 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 115.645 -0.707 . . . . 0.0 109.099 179.936 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 48.9 t -73.17 114.62 11.56 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-O 121.597 0.713 . . . . 0.0 111.661 -178.908 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 17.0 m -117.42 66.98 0.74 Allowed 'General case' 0 C--N 1.311 -1.103 0 N-CA-C 106.353 -1.721 . . . . 0.0 106.353 177.468 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.486 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.4 OUTLIER -29.08 127.39 0.24 Allowed Pre-proline 0 N--CA 1.463 0.225 0 CA-C-N 114.102 -1.408 . . . . 0.0 112.753 -176.47 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.486 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 59.5 Cg_endo -97.85 32.77 10.31 Favored 'Cis proline' 0 N--CA 1.46 -0.5 0 C-N-CA 123.68 -1.383 . . . . 0.0 114.304 0.918 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.623 HG22 HG22 ' A' ' 4' ' ' THR . 42.0 pt -138.3 137.48 43.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 121.443 0.639 . . . . 0.0 111.873 -179.135 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.663 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 3.4 t -85.42 139.74 31.29 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-O 121.309 0.576 . . . . 0.0 109.498 179.284 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.584 HG22 ' HA ' ' A' ' 28' ' ' PRO . 11.7 p -147.85 133.38 18.71 Favored 'General case' 0 C--N 1.313 -1.012 0 CA-C-N 115.279 -0.873 . . . . 0.0 111.297 -178.259 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.509 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 3.1 ptm180 -92.25 124.47 36.34 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 108.81 -0.811 . . . . 0.0 108.81 178.774 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 46.3 m-20 57.53 30.34 18.55 Favored 'General case' 0 N--CA 1.467 0.383 0 N-CA-C 109.384 -0.599 . . . . 0.0 109.384 -178.431 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 76.89 8.53 86.68 Favored Glycine 0 CA--C 1.521 0.423 0 CA-C-N 115.511 -0.768 . . . . 0.0 112.559 -179.116 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 86.8 mt -105.41 129.13 25.23 Favored Pre-proline 0 C--O 1.239 0.545 0 CA-C-O 121.057 0.456 . . . . 0.0 111.059 -179.661 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.584 ' HA ' HG22 ' A' ' 23' ' ' THR . 74.3 Cg_endo -75.42 62.94 6.3 Favored 'Trans proline' 0 C--N 1.343 0.262 0 C-N-CA 123.372 2.715 . . . . 0.0 112.583 179.84 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 48.5 t . . . . . 0 C--N 1.323 -0.578 0 CA-C-O 121.324 0.583 . . . . 0.0 110.177 -179.661 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 3.8 m . . . . . 0 CA--C 1.528 0.101 0 CA-C-O 121.141 0.496 . . . . 0.0 109.672 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 76.15 -36.38 1.3 Allowed Glycine 0 C--N 1.333 0.366 0 CA-C-N 115.6 -0.727 . . . . 0.0 113.777 178.691 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -60.13 138.54 57.87 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 121.621 0.724 . . . . 0.0 111.953 -178.805 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.466 ' HB ' ' CD1' ' A' ' 6' ' ' PHE . 30.8 p -89.62 118.99 29.65 Favored 'General case' 0 N--CA 1.446 -0.657 0 CA-C-N 115.271 -0.877 . . . . 0.0 109.734 179.245 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 26.2 p -88.62 58.02 4.47 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 121.066 0.46 . . . . 0.0 111.489 -179.034 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 6' ' ' PHE . . . . . 0.466 ' CD1' ' HB ' ' A' ' 4' ' ' THR . 4.7 m-85 -58.29 -36.56 73.49 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.334 179.049 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -88.99 19.07 40.37 Favored Glycine 0 N--CA 1.45 -0.414 0 C-N-CA 120.86 -0.686 . . . . 0.0 112.611 179.426 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 76.09 -32.77 1.3 Allowed Glycine 0 CA--C 1.524 0.598 0 C-N-CA 121.379 -0.439 . . . . 0.0 113.999 179.353 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 8.9 t -89.24 165.25 14.55 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.238 0.542 . . . . 0.0 111.561 -179.059 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 70.4 m -130.74 147.53 52.41 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.092 -0.958 . . . . 0.0 109.793 179.489 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 64.0 m-80 -89.43 -17.19 29.23 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.925 -0.58 . . . . 0.0 111.212 -178.979 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.422 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 4.6 m -101.22 123.25 45.51 Favored Pre-proline 0 C--N 1.323 -0.568 0 CA-C-O 121.091 0.472 . . . . 0.0 111.335 -178.635 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -63.48 135.03 47.48 Favored 'Trans proline' 0 C--N 1.344 0.299 0 C-N-CA 122.859 2.372 . . . . 0.0 111.941 179.674 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 95.2 -16.35 61.47 Favored Glycine 0 N--CA 1.445 -0.703 0 C-N-CA 120.637 -0.792 . . . . 0.0 111.867 -179.454 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.687 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 99.6 m -87.31 133.65 33.67 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 121.073 0.463 . . . . 0.0 109.906 179.644 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 15.7 m -109.34 137.83 46.61 Favored 'General case' 0 C--N 1.324 -0.522 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 -179.925 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 44.7 t -66.71 128.2 35.35 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-O 121.718 0.77 . . . . 0.0 112.182 -178.428 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 4.4 m -132.4 61.01 1.67 Allowed 'General case' 0 C--N 1.316 -0.867 0 N-CA-C 106.221 -1.77 . . . . 0.0 106.221 177.953 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.481 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -25.76 126.44 0.19 Allowed Pre-proline 0 N--CA 1.466 0.359 0 CA-C-N 113.931 -1.486 . . . . 0.0 113.037 -176.537 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.481 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 67.0 Cg_endo -96.85 30.91 13.07 Favored 'Cis proline' 0 CA--C 1.532 0.421 0 C-N-CA 123.757 -1.351 . . . . 0.0 114.515 0.805 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 43.3 pt -137.34 140.92 41.16 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.424 0 CA-C-O 121.273 0.558 . . . . 0.0 111.371 -179.154 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.687 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 4.5 t -88.41 143.99 26.65 Favored 'General case' 0 C--N 1.314 -0.943 0 CA-C-O 121.259 0.552 . . . . 0.0 110.267 179.908 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.467 HG22 ' HA ' ' A' ' 28' ' ' PRO . 68.5 p -138.04 127.61 24.98 Favored 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 115.433 -0.803 . . . . 0.0 111.316 -178.778 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.678 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 3.2 ptm180 -92.73 124.28 36.62 Favored 'General case' 0 N--CA 1.445 -0.687 0 N-CA-C 108.794 -0.817 . . . . 0.0 108.794 178.447 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 53.7 m-20 57.76 28.94 16.64 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.172 0.511 . . . . 0.0 109.744 -178.271 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 82.44 3.65 90.45 Favored Glycine 0 N--CA 1.449 -0.447 0 CA-C-N 115.854 -0.612 . . . . 0.0 112.683 -179.461 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 86.0 mt -101.18 121.06 53.3 Favored Pre-proline 0 C--O 1.236 0.352 0 O-C-N 122.623 -0.339 . . . . 0.0 110.75 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.467 ' HA ' HG22 ' A' ' 23' ' ' THR . 72.3 Cg_endo -77.06 47.34 2.19 Favored 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 123.062 2.508 . . . . 0.0 112.601 179.828 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 11.6 p . . . . . 0 C--N 1.321 -0.667 0 CA-C-N 115.537 -0.756 . . . . 0.0 110.239 179.999 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 1' ' ' CYS . . . . . 0.567 ' SG ' ' HB3' ' A' ' 24' ' ' ARG . 1.8 m . . . . . 0 N--CA 1.458 -0.058 0 CA-C-O 121.007 0.432 . . . . 0.0 110.339 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 76.04 -34.37 1.27 Allowed Glycine 0 CA--C 1.519 0.31 0 CA-C-N 115.865 -0.607 . . . . 0.0 113.287 179.515 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -54.56 140.62 34.22 Favored 'General case' 0 C--O 1.239 0.528 0 CA-C-O 121.658 0.742 . . . . 0.0 112.393 -179.001 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.579 HG23 ' O ' ' A' ' 20' ' ' PRO . 67.8 m -88.89 114.5 25.58 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.059 -0.973 . . . . 0.0 109.984 179.587 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 26.6 p -88.6 58.43 4.66 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 121.324 0.583 . . . . 0.0 110.458 -179.803 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 34.0 t80 -52.69 -44.96 66.62 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.309 -0.859 . . . . 0.0 111.194 -179.726 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -94.06 24.46 26.64 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.582 -0.818 . . . . 0.0 112.781 179.764 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.48 40.38 98.61 Favored Glycine 0 CA--C 1.518 0.264 0 C-N-CA 121.136 -0.554 . . . . 0.0 112.88 179.595 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.3 m -142.45 150.19 40.23 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 179.996 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 57.5 m -132.82 142.02 48.76 Favored 'General case' 0 C--N 1.324 -0.539 0 N-CA-C 110.025 -0.361 . . . . 0.0 110.025 179.869 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 43.6 t30 -89.31 -15.0 34.48 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.842 -0.617 . . . . 0.0 111.229 -179.081 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.635 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 5.7 m -100.67 125.3 39.33 Favored Pre-proline 0 C--N 1.323 -0.549 0 CA-C-O 121.252 0.549 . . . . 0.0 111.509 -178.754 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 28.7 Cg_endo -63.58 131.93 33.5 Favored 'Trans proline' 0 C--N 1.347 0.457 0 C-N-CA 122.999 2.466 . . . . 0.0 112.438 -179.819 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 95.08 -8.62 70.08 Favored Glycine 0 N--CA 1.447 -0.587 0 C-N-CA 120.894 -0.67 . . . . 0.0 111.737 -179.472 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.812 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 84.7 m -88.06 131.62 34.6 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-O 121.127 0.489 . . . . 0.0 110.133 179.63 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 13.3 m -109.49 136.45 48.86 Favored 'General case' 0 C--N 1.324 -0.538 0 N-CA-C 108.925 -0.769 . . . . 0.0 108.925 179.906 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 50.2 t -71.89 119.92 16.76 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-O 121.366 0.603 . . . . 0.0 112.106 -178.631 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 18.4 m -123.89 67.21 1.03 Allowed 'General case' 0 C--N 1.315 -0.903 0 N-CA-C 106.624 -1.621 . . . . 0.0 106.624 177.697 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.447 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.2 OUTLIER -29.03 127.51 0.23 Allowed Pre-proline 0 N--CA 1.464 0.234 0 CA-C-N 114.092 -1.413 . . . . 0.0 112.862 -176.721 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.579 ' O ' HG23 ' A' ' 4' ' ' THR . 65.6 Cg_endo -97.71 33.24 9.85 Favored 'Cis proline' 0 N--CA 1.46 -0.484 0 C-N-CA 123.767 -1.347 . . . . 0.0 114.23 0.822 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 41.8 pt -139.59 137.37 40.02 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-O 121.425 0.631 . . . . 0.0 111.632 -179.182 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.812 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 6.2 t -84.27 143.18 29.72 Favored 'General case' 0 C--N 1.316 -0.885 0 CA-C-O 121.311 0.576 . . . . 0.0 109.791 179.222 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.411 HG22 ' HA ' ' A' ' 28' ' ' PRO . 14.9 p -138.28 125.82 22.04 Favored 'General case' 0 C--N 1.314 -0.943 0 CA-C-N 115.239 -0.892 . . . . 0.0 111.378 -178.497 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.567 ' HB3' ' SG ' ' A' ' 1' ' ' CYS . 0.0 OUTLIER -91.1 129.3 37.11 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 178.864 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.453 ' CG ' ' HD3' ' A' ' 24' ' ' ARG . 54.8 m-20 54.6 30.03 12.48 Favored 'General case' 0 C--N 1.324 -0.529 0 O-C-N 123.85 0.719 . . . . 0.0 110.382 -178.844 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 77.46 13.97 82.98 Favored Glycine 0 C--N 1.335 0.498 0 CA-C-N 115.803 -0.635 . . . . 0.0 112.652 -179.583 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 90.2 mt -117.46 132.23 23.67 Favored Pre-proline 0 C--O 1.236 0.354 0 CA-C-O 120.825 0.345 . . . . 0.0 110.831 -179.888 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.411 ' HA ' HG22 ' A' ' 23' ' ' THR . 70.8 Cg_endo -74.6 53.68 3.22 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 123.116 2.544 . . . . 0.0 112.673 -179.95 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 40.9 t . . . . . 0 C--N 1.323 -0.58 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.404 -179.85 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 67.9 m . . . . . 0 N--CA 1.458 -0.051 0 CA-C-O 120.905 0.383 . . . . 0.0 110.195 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 60.14 38.11 93.9 Favored Glycine 0 C--N 1.333 0.381 0 CA-C-N 115.74 -0.663 . . . . 0.0 112.694 179.299 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -117.87 151.77 36.72 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 120.86 0.362 . . . . 0.0 110.848 -179.789 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.491 HG23 ' O ' ' A' ' 20' ' ' PRO . 28.2 m -96.66 118.67 33.63 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-N 115.893 -0.594 . . . . 0.0 111.051 179.811 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.716 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 7.6 p -88.45 61.2 6.02 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 121.262 0.553 . . . . 0.0 109.699 178.826 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 13.2 t80 -54.26 -41.51 68.91 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.35 -0.841 . . . . 0.0 110.28 -179.548 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -91.94 22.98 28.65 Favored Glycine 0 N--CA 1.449 -0.488 0 C-N-CA 120.926 -0.654 . . . . 0.0 112.611 179.325 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 78.71 -38.28 1.91 Allowed Glycine 0 CA--C 1.522 0.483 0 C-N-CA 121.251 -0.5 . . . . 0.0 113.631 179.447 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.4 m -89.49 147.38 24.02 Favored 'General case' 0 C--N 1.321 -0.65 0 O-C-N 122.498 -0.413 . . . . 0.0 111.49 -179.348 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 62.9 m -104.49 154.82 19.41 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.759 -0.655 . . . . 0.0 109.394 178.834 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 39.7 t30 -87.64 -26.7 22.89 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-O 121.135 0.493 . . . . 0.0 110.496 -179.717 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 3.7 m -102.12 120.42 53.7 Favored Pre-proline 0 C--N 1.324 -0.54 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.283 -179.268 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_exo -65.71 140.62 62.67 Favored 'Trans proline' 0 N--CA 1.461 -0.385 0 C-N-CA 122.943 2.428 . . . . 0.0 111.846 179.693 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 105.1 -28.91 12.74 Favored Glycine 0 N--CA 1.441 -0.976 0 C-N-CA 120.717 -0.754 . . . . 0.0 111.66 -179.356 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.578 ' HB3' ' HB3' ' A' ' 22' ' ' CYS . 2.0 m -87.64 131.55 34.4 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 121.273 0.559 . . . . 0.0 110.546 179.402 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 13.6 m -91.53 140.52 29.67 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.482 -0.781 . . . . 0.0 109.168 179.59 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 39.9 t -75.52 111.14 10.51 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-O 121.645 0.736 . . . . 0.0 111.598 -179.121 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 11.7 m -114.47 65.43 0.67 Allowed 'General case' 0 C--N 1.308 -1.197 0 N-CA-C 106.254 -1.758 . . . . 0.0 106.254 177.385 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.527 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.5 OUTLIER -28.66 125.78 0.24 Allowed Pre-proline 0 N--CA 1.464 0.252 0 CA-C-N 114.072 -1.422 . . . . 0.0 112.574 -176.583 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.527 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 65.0 Cg_endo -98.4 38.03 5.84 Favored 'Cis proline' 0 N--CA 1.459 -0.54 0 C-N-CA 123.963 -1.265 . . . . 0.0 114.109 0.899 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 2.3 pp -143.43 133.02 20.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 121.541 0.686 . . . . 0.0 112.457 -178.938 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.716 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 63.8 m -83.0 134.46 35.05 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.411 179.225 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 5.2 p -138.56 130.56 28.22 Favored 'General case' 0 C--N 1.317 -0.843 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.038 -179.746 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.432 ' O ' ' HG3' ' A' ' 24' ' ' ARG . 9.6 ptm180 -97.5 127.82 43.77 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 178.764 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 27.9 m-20 58.52 27.43 15.61 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.439 0.637 . . . . 0.0 109.504 -178.692 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 77.38 7.86 87.02 Favored Glycine 0 N--CA 1.449 -0.471 0 CA-C-N 115.411 -0.813 . . . . 0.0 112.389 -178.984 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.434 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 91.6 mt -109.59 131.57 21.82 Favored Pre-proline 0 C--O 1.238 0.451 0 CA-C-O 121.158 0.504 . . . . 0.0 111.293 -179.666 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.434 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 5.0 Cg_exo -77.06 65.4 7.81 Favored 'Trans proline' 0 N--CA 1.463 -0.32 0 C-N-CA 123.656 2.904 . . . . 0.0 111.95 179.594 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 47.8 t . . . . . 0 C--N 1.325 -0.465 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.594 -179.166 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 CA--C 1.526 0.035 0 CA-C-O 121.046 0.45 . . . . 0.0 110.299 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 60.37 38.63 94.99 Favored Glycine 0 C--N 1.332 0.348 0 CA-C-N 115.535 -0.757 . . . . 0.0 112.796 179.353 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.433 ' HG3' ' HB3' ' A' ' 22' ' ' CYS . 10.9 pt-20 -125.0 143.19 51.03 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 121.187 0.517 . . . . 0.0 111.259 -179.731 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.545 HG23 ' O ' ' A' ' 20' ' ' PRO . 87.9 m -89.18 111.46 22.25 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.376 179.85 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 25.3 p -88.77 58.98 4.87 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 121.287 0.565 . . . . 0.0 110.468 -179.995 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 33.6 t80 -52.92 -46.01 67.88 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.378 -0.828 . . . . 0.0 111.233 -179.688 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -92.56 24.04 25.15 Favored Glycine 0 C--O 1.227 -0.291 0 C-N-CA 120.579 -0.82 . . . . 0.0 112.728 179.73 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.83 36.72 93.2 Favored Glycine 0 C--O 1.228 -0.252 0 C-N-CA 121.2 -0.524 . . . . 0.0 112.666 179.694 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.7 m -136.06 148.95 48.56 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 60.3 m -129.33 141.57 51.05 Favored 'General case' 0 C--N 1.322 -0.628 0 O-C-N 123.218 0.324 . . . . 0.0 110.246 179.9 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 44.0 t30 -89.06 -17.3 29.6 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.804 -0.635 . . . . 0.0 110.614 -179.592 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.522 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 4.3 m -101.31 123.46 44.62 Favored Pre-proline 0 C--N 1.322 -0.596 0 CA-C-O 121.14 0.495 . . . . 0.0 111.33 -178.939 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.447 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 23.4 Cg_exo -64.18 136.65 52.77 Favored 'Trans proline' 0 C--N 1.345 0.349 0 C-N-CA 123.017 2.478 . . . . 0.0 112.013 179.948 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 92.85 -12.27 70.26 Favored Glycine 0 N--CA 1.447 -0.596 0 C-N-CA 120.79 -0.719 . . . . 0.0 111.881 -179.626 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.673 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 98.9 m -87.55 134.4 33.63 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 121.125 0.488 . . . . 0.0 110.308 179.773 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 12.6 m -107.4 137.55 45.23 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.637 -0.71 . . . . 0.0 109.104 -179.88 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 53.9 t -72.95 115.52 12.35 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-O 121.496 0.665 . . . . 0.0 111.961 -178.739 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 8.7 m -116.29 66.49 0.71 Allowed 'General case' 0 C--N 1.312 -1.03 0 N-CA-C 106.515 -1.661 . . . . 0.0 106.515 177.478 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.447 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.2 OUTLIER -28.82 126.86 0.23 Allowed Pre-proline 0 N--CA 1.464 0.229 0 CA-C-N 114.303 -1.317 . . . . 0.0 112.841 -176.559 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.545 ' O ' HG23 ' A' ' 4' ' ' THR . 62.6 Cg_endo -97.21 32.79 10.48 Favored 'Cis proline' 0 CA--C 1.532 0.396 0 C-N-CA 123.676 -1.385 . . . . 0.0 114.293 0.93 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 44.2 pt -138.97 133.87 41.41 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-O 121.451 0.643 . . . . 0.0 111.888 -179.239 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.673 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 7.0 t -83.48 142.87 30.62 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-O 121.22 0.533 . . . . 0.0 109.746 179.202 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.559 HG22 ' HA ' ' A' ' 28' ' ' PRO . 14.9 p -145.33 131.99 19.93 Favored 'General case' 0 C--N 1.314 -0.949 0 CA-C-N 115.276 -0.875 . . . . 0.0 111.293 -178.399 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.535 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 0.0 OUTLIER -92.39 128.51 38.26 Favored 'General case' 0 N--CA 1.448 -0.555 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 178.38 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 18.6 m-20 56.57 28.45 13.94 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.191 0.52 . . . . 0.0 109.963 -179.253 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 76.79 13.16 83.87 Favored Glycine 0 C--N 1.333 0.409 0 CA-C-N 115.745 -0.661 . . . . 0.0 112.362 -179.089 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 27' ' ' LEU . . . . . 0.486 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 87.2 mt -112.49 129.55 24.26 Favored Pre-proline 0 C--O 1.241 0.655 0 CA-C-O 120.887 0.375 . . . . 0.0 110.858 -179.847 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.559 ' HA ' HG22 ' A' ' 23' ' ' THR . 2.8 Cg_exo -75.54 54.14 3.8 Favored 'Trans proline' 0 C--N 1.342 0.216 0 C-N-CA 123.718 2.945 . . . . 0.0 112.468 -179.95 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 45.4 t . . . . . 0 C--N 1.323 -0.553 0 CA-C-O 121.331 0.586 . . . . 0.0 110.141 -179.748 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 1' ' ' CYS . . . . . 0.415 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 61.4 m . . . . . 0 N--CA 1.458 -0.043 0 CA-C-O 121.037 0.446 . . . . 0.0 109.806 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 60.26 32.95 78.33 Favored Glycine 0 C--N 1.332 0.347 0 CA-C-N 115.497 -0.774 . . . . 0.0 113.204 179.087 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 3' ' ' GLU . . . . . 0.463 ' HG3' ' HB3' ' A' ' 22' ' ' CYS . 9.3 pt-20 -105.71 145.54 30.96 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 121.045 0.45 . . . . 0.0 111.015 179.901 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 4' ' ' THR . . . . . 0.511 HG23 ' O ' ' A' ' 20' ' ' PRO . 58.3 m -88.83 110.0 20.67 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.89 -0.596 . . . . 0.0 110.399 179.91 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 25.8 p -88.78 59.71 5.2 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 121.429 0.633 . . . . 0.0 110.536 -179.941 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 34.8 t80 -53.64 -43.78 69.02 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.286 -0.87 . . . . 0.0 111.165 -179.75 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -88.23 18.54 40.52 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.743 -0.741 . . . . 0.0 113.004 179.905 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 64.56 37.61 94.63 Favored Glycine 0 N--CA 1.453 -0.233 0 C-N-CA 121.077 -0.582 . . . . 0.0 112.656 179.668 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.6 m -147.38 149.52 32.92 Favored 'General case' 0 C--N 1.324 -0.522 0 N-CA-C 109.665 -0.494 . . . . 0.0 109.665 179.92 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 43.4 m -121.45 146.0 47.35 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.239 -179.899 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 39.1 t30 -88.26 -23.45 23.5 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.154 -179.787 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 12' ' ' THR . . . . . 0.415 ' HB ' ' SG ' ' A' ' 1' ' ' CYS . 2.9 m -101.95 121.11 51.88 Favored Pre-proline 0 C--N 1.323 -0.582 0 CA-C-N 115.999 -0.546 . . . . 0.0 111.413 -178.977 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 22.2 Cg_exo -64.74 141.5 72.5 Favored 'Trans proline' 0 C--N 1.344 0.298 0 C-N-CA 123.021 2.48 . . . . 0.0 111.854 179.76 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 101.62 -28.17 17.16 Favored Glycine 0 N--CA 1.445 -0.747 0 C-N-CA 120.687 -0.768 . . . . 0.0 111.615 -179.331 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.849 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 1.6 m -86.97 136.85 32.78 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 121.136 0.493 . . . . 0.0 110.191 179.446 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 14.2 m -105.26 140.18 38.8 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.596 -0.729 . . . . 0.0 109.314 -179.745 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 53.9 t -72.37 112.33 8.34 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.482 0.658 . . . . 0.0 111.709 -178.887 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 14.1 m -114.54 66.91 0.68 Allowed 'General case' 0 C--N 1.312 -1.052 0 N-CA-C 106.554 -1.647 . . . . 0.0 106.554 177.624 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 19' ' ' TRP . . . . . 0.472 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.2 OUTLIER -28.91 127.01 0.23 Allowed Pre-proline 0 N--CA 1.464 0.266 0 CA-C-N 114.24 -1.345 . . . . 0.0 112.833 -176.631 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 20' ' ' PRO . . . . . 0.511 ' O ' HG23 ' A' ' 4' ' ' THR . 62.2 Cg_endo -97.1 31.85 11.75 Favored 'Cis proline' 0 N--CA 1.46 -0.443 0 C-N-CA 123.627 -1.406 . . . . 0.0 114.213 0.968 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 43.0 pt -138.56 133.61 42.53 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-O 121.663 0.744 . . . . 0.0 112.025 -179.174 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.849 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 8.0 t -83.54 140.1 32.47 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-N 115.927 -0.578 . . . . 0.0 109.547 179.011 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 23' ' ' THR . . . . . 0.569 HG22 ' HA ' ' A' ' 28' ' ' PRO . 7.9 p -148.76 135.5 19.76 Favored 'General case' 0 C--N 1.313 -0.982 0 CA-C-N 115.274 -0.875 . . . . 0.0 111.342 -178.104 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 24' ' ' ARG . . . . . 0.499 ' O ' ' HG3' ' A' ' 24' ' ' ARG . 4.8 ptm180 -93.92 126.29 39.04 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 178.576 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 58.52 27.23 15.32 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.36 0.6 . . . . 0.0 109.404 -179.069 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 77.57 9.31 86.94 Favored Glycine 0 C--N 1.333 0.392 0 CA-C-N 115.504 -0.771 . . . . 0.0 112.251 -178.885 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 88.4 mt -108.07 131.12 21.96 Favored Pre-proline 0 C--O 1.24 0.558 0 CA-C-O 121.092 0.472 . . . . 0.0 111.091 -179.724 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.569 ' HA ' HG22 ' A' ' 23' ' ' THR . 74.2 Cg_endo -76.14 64.3 7.01 Favored 'Trans proline' 0 C--N 1.341 0.158 0 C-N-CA 123.269 2.646 . . . . 0.0 112.48 179.946 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 55.5 t . . . . . 0 C--N 1.324 -0.532 0 CA-C-O 121.285 0.564 . . . . 0.0 110.163 -179.759 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 5.4 m . . . . . 0 N--CA 1.457 -0.092 0 CA-C-O 121.038 0.447 . . . . 0.0 110.013 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 76.68 -35.45 1.4 Allowed Glycine 0 C--N 1.331 0.259 0 CA-C-N 115.849 -0.614 . . . . 0.0 113.703 179.069 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 7.3 pt-20 -58.13 143.84 42.49 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 121.615 0.721 . . . . 0.0 112.058 -178.981 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.531 HG23 ' O ' ' A' ' 20' ' ' PRO . 53.6 m -95.11 121.35 36.65 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.034 -0.985 . . . . 0.0 110.658 179.688 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.772 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 13.7 p -88.08 61.17 6.17 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 121.258 0.552 . . . . 0.0 109.866 179.05 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 29.4 t80 -52.77 -44.5 66.56 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.368 -0.833 . . . . 0.0 110.555 -179.609 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -93.45 25.08 22.52 Favored Glycine 0 N--CA 1.449 -0.462 0 C-N-CA 120.639 -0.791 . . . . 0.0 112.399 179.223 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 75.59 -30.52 1.23 Allowed Glycine 0 CA--C 1.523 0.562 0 C-N-CA 121.485 -0.388 . . . . 0.0 113.789 179.579 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.5 m -89.1 148.95 23.42 Favored 'General case' 0 C--N 1.322 -0.59 0 O-C-N 122.367 -0.49 . . . . 0.0 111.293 -179.483 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 79.7 m -112.15 151.44 29.49 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.859 -0.61 . . . . 0.0 109.684 179.11 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 35.7 t-20 -88.46 -21.64 24.1 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 120.895 0.379 . . . . 0.0 110.53 -179.214 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 4.3 m -100.71 123.38 45.98 Favored Pre-proline 0 C--N 1.323 -0.557 0 CA-C-O 121.148 0.499 . . . . 0.0 111.277 -179.1 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 29.7 Cg_endo -63.75 136.04 51.61 Favored 'Trans proline' 0 C--N 1.344 0.332 0 C-N-CA 122.823 2.348 . . . . 0.0 111.562 179.519 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 98.69 -21.39 46.19 Favored Glycine 0 N--CA 1.443 -0.834 0 C-N-CA 120.509 -0.853 . . . . 0.0 111.744 -179.228 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.576 ' HB3' ' HB3' ' A' ' 22' ' ' CYS . 71.3 m -86.73 126.35 34.52 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 121.212 0.529 . . . . 0.0 110.235 179.597 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 14.8 m -96.85 140.64 31.11 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 115.449 -0.796 . . . . 0.0 109.023 179.634 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 53.7 t -69.76 123.68 22.03 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-O 121.683 0.754 . . . . 0.0 111.92 -178.792 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 7.4 m -130.06 61.68 1.58 Allowed 'General case' 0 C--N 1.313 -0.997 0 N-CA-C 106.031 -1.84 . . . . 0.0 106.031 177.787 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.535 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -27.51 125.71 0.22 Allowed Pre-proline 0 N--CA 1.463 0.198 0 CA-C-N 113.827 -1.533 . . . . 0.0 112.787 -176.576 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.535 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 71.9 Cg_endo -98.03 38.07 5.82 Favored 'Cis proline' 0 N--CA 1.459 -0.533 0 C-N-CA 123.813 -1.328 . . . . 0.0 114.172 0.746 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 39.9 pt -143.44 136.9 25.21 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 O-C-N 121.6 -0.688 . . . . 0.0 112.026 -179.148 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.772 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 74.0 m -82.37 136.61 34.95 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-O 121.09 0.471 . . . . 0.0 110.236 178.923 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.41 HG22 ' CA ' ' A' ' 28' ' ' PRO . 67.0 p -127.3 123.47 36.47 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.857 -179.615 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.542 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 4.4 ptm180 -92.63 125.69 37.37 Favored 'General case' 0 N--CA 1.445 -0.702 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 178.519 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 58.62 26.75 14.86 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.257 0.551 . . . . 0.0 109.682 -178.941 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 84.11 3.27 89.09 Favored Glycine 0 N--CA 1.45 -0.428 0 CA-C-N 115.723 -0.671 . . . . 0.0 112.668 -179.402 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.46 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 88.8 mt -102.91 121.5 48.97 Favored Pre-proline 0 C--N 1.328 -0.352 0 O-C-N 122.561 -0.376 . . . . 0.0 110.857 -179.947 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.46 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 5.1 Cg_exo -76.98 47.22 2.15 Favored 'Trans proline' 0 C--N 1.343 0.246 0 C-N-CA 123.361 2.707 . . . . 0.0 112.307 179.827 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 10.7 p . . . . . 0 C--N 1.32 -0.692 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.402 -179.856 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.3 m . . . . . 0 CA--C 1.527 0.068 0 CA-C-O 120.962 0.41 . . . . 0.0 110.419 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 77.92 -36.39 1.68 Allowed Glycine 0 C--N 1.331 0.251 0 CA-C-N 115.969 -0.56 . . . . 0.0 113.166 179.415 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 11.8 pt-20 -58.27 137.26 57.26 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 121.5 0.667 . . . . 0.0 112.072 -179.244 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.498 ' HB ' ' CD1' ' A' ' 6' ' ' PHE . 10.6 p -91.15 117.52 29.68 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.37 -0.832 . . . . 0.0 109.804 179.221 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 28.2 p -88.92 57.97 4.37 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.012 0.434 . . . . 0.0 111.764 -178.521 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' PHE . . . . . 0.498 ' CD1' ' HB ' ' A' ' 4' ' ' THR . 5.3 m-85 -57.64 -38.07 74.4 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.99 179.423 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -89.9 18.06 49.6 Favored Glycine 0 CA--C 1.519 0.315 0 C-N-CA 120.639 -0.791 . . . . 0.0 112.861 179.841 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 62.31 39.48 97.79 Favored Glycine 0 C--N 1.331 0.27 0 C-N-CA 121.092 -0.575 . . . . 0.0 112.916 179.546 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 3.5 m -149.04 152.18 35.8 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 109.724 -0.473 . . . . 0.0 109.724 -179.996 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 56.8 m -129.94 143.4 50.78 Favored 'General case' 0 C--N 1.324 -0.522 0 O-C-N 123.21 0.319 . . . . 0.0 110.225 179.927 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 43.0 t30 -89.13 -18.11 27.86 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.026 -179.229 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.442 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 6.7 m -100.97 125.13 39.34 Favored Pre-proline 0 C--N 1.323 -0.558 0 CA-C-O 121.155 0.503 . . . . 0.0 111.671 -178.649 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_endo -64.41 138.52 60.61 Favored 'Trans proline' 0 C--N 1.346 0.395 0 C-N-CA 122.859 2.372 . . . . 0.0 111.626 179.541 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 93.67 -15.55 62.78 Favored Glycine 0 N--CA 1.447 -0.607 0 C-N-CA 120.726 -0.75 . . . . 0.0 111.557 -179.133 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.769 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 93.7 m -87.45 133.27 33.77 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 121.045 0.45 . . . . 0.0 110.163 179.606 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 14.6 m -110.54 136.58 49.44 Favored 'General case' 0 C--N 1.323 -0.56 0 N-CA-C 109.209 -0.663 . . . . 0.0 109.209 179.934 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.8 t -67.37 126.42 29.2 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-O 121.437 0.637 . . . . 0.0 111.914 -178.604 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 4.9 m -132.35 65.79 1.57 Allowed 'General case' 0 C--N 1.318 -0.79 0 N-CA-C 106.889 -1.523 . . . . 0.0 106.889 178.457 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.506 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -27.71 126.67 0.22 Allowed Pre-proline 0 N--CA 1.465 0.289 0 CA-C-N 114.402 -1.272 . . . . 0.0 112.93 -176.684 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.506 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 62.8 Cg_endo -97.68 30.72 12.97 Favored 'Cis proline' 0 N--CA 1.461 -0.43 0 C-N-CA 123.802 -1.333 . . . . 0.0 114.424 0.927 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.497 HG22 HG22 ' A' ' 4' ' ' THR . 43.5 pt -138.65 142.58 34.32 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.36 0 CA-C-O 121.385 0.612 . . . . 0.0 111.448 -179.05 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.769 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 5.8 t -87.97 144.0 26.79 Favored 'General case' 0 C--N 1.314 -0.943 0 CA-C-O 121.137 0.494 . . . . 0.0 110.005 179.393 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 48.7 p -136.58 126.84 26.45 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-N 115.573 -0.74 . . . . 0.0 111.7 -178.58 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.666 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 9.1 ptm180 -91.47 126.9 36.71 Favored 'General case' 0 N--CA 1.445 -0.713 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 177.985 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 29.0 m-20 58.34 26.72 14.38 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 121.209 0.528 . . . . 0.0 109.911 -178.889 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 80.31 10.07 85.82 Favored Glycine 0 N--CA 1.45 -0.432 0 CA-C-N 115.864 -0.607 . . . . 0.0 112.363 -179.395 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.412 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 89.7 mt -113.15 128.54 25.52 Favored Pre-proline 0 C--O 1.236 0.379 0 CA-C-O 120.857 0.36 . . . . 0.0 110.755 -180.0 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.412 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 6.5 Cg_exo -73.76 52.94 2.65 Favored 'Trans proline' 0 CA--C 1.527 0.166 0 C-N-CA 123.619 2.879 . . . . 0.0 112.54 -179.839 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 39.4 t . . . . . 0 C--N 1.323 -0.57 0 CA-C-O 121.364 0.602 . . . . 0.0 110.206 -179.75 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.5 m . . . . . 0 N--CA 1.458 -0.058 0 CA-C-O 121.081 0.467 . . . . 0.0 110.191 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 77.16 -36.28 1.51 Allowed Glycine 0 C--N 1.332 0.331 0 CA-C-N 115.862 -0.608 . . . . 0.0 113.29 179.256 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 9.1 pt-20 -58.04 138.6 55.85 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 121.585 0.707 . . . . 0.0 112.181 -179.166 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.464 ' HA ' ' HA ' ' A' ' 21' ' ' ILE . 28.9 p -89.77 119.86 30.53 Favored 'General case' 0 N--CA 1.445 -0.675 0 CA-C-N 115.288 -0.869 . . . . 0.0 109.663 179.064 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 25.7 p -87.83 60.6 5.99 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 121.478 0.656 . . . . 0.0 110.507 -179.684 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 36.0 t80 -54.6 -41.5 70.01 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.353 -0.839 . . . . 0.0 110.613 179.942 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -94.33 22.93 34.26 Favored Glycine 0 N--CA 1.449 -0.492 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.733 179.611 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 75.25 -28.85 1.18 Allowed Glycine 0 CA--C 1.523 0.593 0 C-N-CA 121.192 -0.528 . . . . 0.0 113.94 179.382 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.8 m -88.43 151.05 22.82 Favored 'General case' 0 C--N 1.322 -0.616 0 O-C-N 122.522 -0.399 . . . . 0.0 111.445 -179.015 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 61.6 m -120.79 149.77 42.03 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.855 -0.611 . . . . 0.0 109.763 179.266 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 41.3 t30 -88.8 -21.33 23.81 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 121.115 0.483 . . . . 0.0 111.181 -179.227 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 6.4 m -101.08 124.2 42.4 Favored Pre-proline 0 C--N 1.323 -0.575 0 CA-C-O 121.239 0.542 . . . . 0.0 111.793 -178.424 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 33.7 Cg_endo -65.01 138.35 56.66 Favored 'Trans proline' 0 C--N 1.346 0.423 0 C-N-CA 122.897 2.398 . . . . 0.0 111.58 179.461 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 95.22 -16.22 61.75 Favored Glycine 0 N--CA 1.446 -0.655 0 C-N-CA 120.635 -0.793 . . . . 0.0 111.492 -179.224 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.668 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 91.5 m -88.07 133.81 33.89 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 120.991 0.424 . . . . 0.0 109.934 179.368 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 15.1 m -108.62 136.47 48.16 Favored 'General case' 0 C--N 1.322 -0.604 0 N-CA-C 109.201 -0.666 . . . . 0.0 109.201 -179.996 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.4 t -66.92 126.07 27.95 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-O 121.673 0.749 . . . . 0.0 111.91 -178.49 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 4.6 m -129.93 62.52 1.55 Allowed 'General case' 0 C--N 1.316 -0.87 0 N-CA-C 106.37 -1.715 . . . . 0.0 106.37 178.016 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.456 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.2 OUTLIER -26.11 126.4 0.2 Allowed Pre-proline 0 N--CA 1.465 0.307 0 CA-C-N 114.052 -1.431 . . . . 0.0 113.028 -176.507 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.456 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 61.0 Cg_endo -97.49 31.55 11.97 Favored 'Cis proline' 0 CA--C 1.533 0.459 0 C-N-CA 123.731 -1.362 . . . . 0.0 114.32 1.02 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.464 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 42.8 pt -138.04 140.29 40.81 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.354 0 CA-C-O 121.272 0.558 . . . . 0.0 111.362 -179.194 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.668 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 4.0 t -87.0 144.07 27.07 Favored 'General case' 0 C--N 1.315 -0.929 0 CA-C-O 121.205 0.526 . . . . 0.0 110.146 179.715 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 60.4 p -136.64 127.82 28.01 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 115.572 -0.74 . . . . 0.0 111.643 -178.553 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.6 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 1.7 ptm180 -89.07 123.42 33.35 Favored 'General case' 0 N--CA 1.446 -0.63 0 N-CA-C 108.528 -0.915 . . . . 0.0 108.528 178.197 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 69.8 m-20 57.44 30.73 19.1 Favored 'General case' 0 N--CA 1.468 0.461 0 O-C-N 123.518 0.511 . . . . 0.0 109.955 -177.627 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 78.54 9.65 86.85 Favored Glycine 0 C--N 1.333 0.415 0 CA-C-N 115.895 -0.593 . . . . 0.0 112.688 -179.656 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 90.4 mt -110.61 127.01 27.67 Favored Pre-proline 0 C--O 1.237 0.4 0 O-C-N 122.682 -0.305 . . . . 0.0 110.686 179.912 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 61.9 Cg_endo -73.57 52.45 2.46 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 123.268 2.645 . . . . 0.0 112.783 -179.837 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 39.7 t . . . . . 0 C--N 1.323 -0.56 0 CA-C-O 121.396 0.617 . . . . 0.0 110.041 -179.948 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.8 m . . . . . 0 CA--C 1.527 0.077 0 CA-C-O 120.967 0.413 . . . . 0.0 110.409 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 77.78 -36.01 1.64 Allowed Glycine 0 C--N 1.33 0.231 0 CA-C-N 115.848 -0.615 . . . . 0.0 113.405 179.278 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 11.1 pt-20 -56.6 136.22 54.61 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.523 0.678 . . . . 0.0 112.085 -179.001 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.647 HG22 HG22 ' A' ' 21' ' ' ILE . 24.6 p -89.58 114.99 26.65 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.347 -0.842 . . . . 0.0 109.951 179.424 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 28.3 p -88.9 58.34 4.54 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 120.999 0.428 . . . . 0.0 111.673 -179.006 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' PHE . . . . . 0.482 ' CD1' ' HB ' ' A' ' 4' ' ' THR . 5.1 m-85 -57.17 -38.15 73.17 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.137 179.444 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -89.43 17.52 51.55 Favored Glycine 0 CA--C 1.519 0.314 0 C-N-CA 120.656 -0.783 . . . . 0.0 112.791 179.815 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 62.57 40.23 98.87 Favored Glycine 0 C--N 1.331 0.268 0 C-N-CA 121.141 -0.552 . . . . 0.0 112.88 179.529 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.8 m -148.38 150.57 33.78 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 109.65 -0.5 . . . . 0.0 109.65 179.885 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 56.6 m -128.53 143.65 51.01 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 120.797 0.332 . . . . 0.0 110.413 -179.846 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 42.8 t30 -89.21 -18.98 26.0 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.805 -179.538 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 6.0 m -101.26 124.49 41.12 Favored Pre-proline 0 C--N 1.324 -0.521 0 CA-C-O 121.169 0.509 . . . . 0.0 111.586 -178.593 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 36.0 Cg_endo -65.54 140.43 62.84 Favored 'Trans proline' 0 C--N 1.346 0.404 0 C-N-CA 122.849 2.366 . . . . 0.0 111.72 179.468 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 93.73 -17.09 59.32 Favored Glycine 0 N--CA 1.447 -0.58 0 C-N-CA 120.608 -0.806 . . . . 0.0 111.495 -179.054 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.71 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 94.4 m -87.34 134.6 33.55 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-O 121.067 0.46 . . . . 0.0 110.087 179.714 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 14.5 m -108.71 136.3 48.51 Favored 'General case' 0 C--N 1.323 -0.57 0 N-CA-C 108.997 -0.742 . . . . 0.0 108.997 179.97 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 48.7 t -71.21 121.53 18.55 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-O 121.472 0.654 . . . . 0.0 111.856 -178.644 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 2.0 p -129.64 73.07 1.5 Allowed 'General case' 0 C--N 1.314 -0.956 0 N-CA-C 107.354 -1.35 . . . . 0.0 107.354 177.934 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.474 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.0 OUTLIER -29.57 129.51 0.24 Allowed Pre-proline 0 N--CA 1.465 0.31 0 CA-C-N 114.379 -1.282 . . . . 0.0 112.906 -176.842 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.474 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 68.2 Cg_endo -97.48 27.56 17.46 Favored 'Cis proline' 0 N--CA 1.46 -0.468 0 C-N-CA 123.696 -1.377 . . . . 0.0 114.682 1.001 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.647 HG22 HG22 ' A' ' 4' ' ' THR . 0.2 OUTLIER -139.3 148.61 23.45 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.347 0 CA-C-O 121.309 0.576 . . . . 0.0 111.229 -179.297 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.71 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 4.6 t -88.81 144.22 26.37 Favored 'General case' 0 C--N 1.312 -1.057 0 CA-C-O 121.168 0.509 . . . . 0.0 109.783 179.635 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.458 HG22 ' HA ' ' A' ' 28' ' ' PRO . 21.5 p -138.13 126.58 23.32 Favored 'General case' 0 C--N 1.314 -0.954 0 CA-C-N 115.478 -0.783 . . . . 0.0 111.586 -178.486 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.623 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 4.8 ptm180 -90.18 127.52 36.14 Favored 'General case' 0 N--CA 1.446 -0.67 0 N-CA-C 108.803 -0.814 . . . . 0.0 108.803 178.445 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 58.04 27.04 14.3 Favored 'General case' 0 C--N 1.328 -0.37 0 CA-C-O 121.206 0.527 . . . . 0.0 109.873 -179.225 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 78.4 13.52 83.16 Favored Glycine 0 C--N 1.334 0.417 0 CA-C-N 115.821 -0.627 . . . . 0.0 112.201 -179.165 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 89.9 mt -114.94 129.98 24.58 Favored Pre-proline 0 C--O 1.238 0.496 0 CA-C-O 120.914 0.388 . . . . 0.0 110.751 -179.894 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.458 ' HA ' HG22 ' A' ' 23' ' ' THR . 67.7 Cg_endo -74.24 53.67 3.05 Favored 'Trans proline' 0 C--N 1.344 0.291 0 C-N-CA 123.277 2.651 . . . . 0.0 112.789 -179.807 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 39.9 t . . . . . 0 C--N 1.323 -0.553 0 CA-C-O 121.416 0.627 . . . . 0.0 110.2 -179.896 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.458 -0.031 0 CA-C-O 121.07 0.462 . . . . 0.0 110.253 . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 61.04 38.77 96.09 Favored Glycine 0 C--N 1.332 0.324 0 CA-C-N 115.595 -0.73 . . . . 0.0 112.776 179.33 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -127.55 143.2 51.2 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 121.15 0.5 . . . . 0.0 110.986 -179.812 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.492 ' HB ' ' CD1' ' A' ' 6' ' ' PHE . 21.0 p -89.58 111.67 22.67 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.014 179.487 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 23.8 p -88.85 59.21 4.95 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 121.096 0.474 . . . . 0.0 111.401 -179.24 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' PHE . . . . . 0.492 ' CD1' ' HB ' ' A' ' 4' ' ' THR . 4.5 m-85 -57.48 -36.41 71.45 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.739 179.382 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -88.53 16.77 52.51 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.788 179.517 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 76.39 -29.6 1.44 Allowed Glycine 0 CA--C 1.523 0.588 0 C-N-CA 121.226 -0.511 . . . . 0.0 113.612 179.536 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.9 m -88.57 150.93 22.82 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 120.844 0.354 . . . . 0.0 111.172 -179.139 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 69.5 m -117.49 148.3 41.96 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.831 -0.622 . . . . 0.0 109.893 179.396 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 66.1 m-80 -88.84 -18.81 26.87 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.819 -179.511 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.529 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 3.2 m -101.87 124.93 38.6 Favored Pre-proline 0 C--N 1.324 -0.527 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.238 -178.984 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -65.77 138.24 52.76 Favored 'Trans proline' 0 C--N 1.344 0.304 0 C-N-CA 122.804 2.336 . . . . 0.0 112.022 179.746 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 91.61 -13.01 67.77 Favored Glycine 0 N--CA 1.449 -0.499 0 C-N-CA 120.761 -0.733 . . . . 0.0 111.876 -179.495 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.689 ' SG ' ' HB3' ' A' ' 24' ' ' ARG . 99.3 m -87.34 136.08 33.07 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.108 0.48 . . . . 0.0 110.401 179.857 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 9.9 m -107.39 135.86 48.16 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 108.99 -0.744 . . . . 0.0 108.99 179.925 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.3 t -72.41 120.73 18.43 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-O 121.596 0.713 . . . . 0.0 112.17 -178.468 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 7.6 m -122.33 65.3 0.94 Allowed 'General case' 0 C--N 1.314 -0.968 0 N-CA-C 106.494 -1.669 . . . . 0.0 106.494 177.705 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.46 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -27.32 126.96 0.21 Allowed Pre-proline 0 N--CA 1.466 0.359 0 CA-C-N 114.222 -1.354 . . . . 0.0 112.955 -176.51 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.46 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 64.9 Cg_endo -97.2 31.07 12.73 Favored 'Cis proline' 0 N--CA 1.461 -0.42 0 C-N-CA 123.704 -1.373 . . . . 0.0 114.324 0.846 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 40.9 pt -137.21 136.02 47.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 121.481 0.658 . . . . 0.0 111.862 -179.112 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.68 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 5.7 t -86.44 144.96 27.03 Favored 'General case' 0 C--N 1.315 -0.905 0 CA-C-O 121.233 0.539 . . . . 0.0 110.064 179.577 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.442 HG22 ' HA ' ' A' ' 28' ' ' PRO . 9.1 p -144.11 128.79 18.21 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-N 115.288 -0.869 . . . . 0.0 111.216 -178.503 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.689 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 5.6 ptm180 -91.33 128.44 37.15 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.095 -0.706 . . . . 0.0 109.095 178.628 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 57.5 27.51 14.13 Favored 'General case' 0 N--CA 1.466 0.37 0 CA-C-O 121.243 0.544 . . . . 0.0 109.654 -179.349 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 76.2 14.53 82.21 Favored Glycine 0 C--N 1.332 0.345 0 CA-C-N 115.725 -0.67 . . . . 0.0 112.106 -178.92 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 88.2 mt -114.99 132.2 23.12 Favored Pre-proline 0 C--O 1.239 0.548 0 CA-C-O 121.071 0.462 . . . . 0.0 110.791 -179.755 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.442 ' HA ' HG22 ' A' ' 23' ' ' THR . 73.2 Cg_endo -76.08 55.16 4.41 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 123.301 2.667 . . . . 0.0 112.548 179.91 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 41.8 t . . . . . 0 C--N 1.324 -0.51 0 CA-C-O 121.272 0.558 . . . . 0.0 110.236 -179.681 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.5 m . . . . . 0 N--CA 1.457 -0.079 0 CA-C-O 121.062 0.458 . . . . 0.0 110.251 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 77.33 -36.59 1.55 Allowed Glycine 0 C--N 1.331 0.287 0 CA-C-N 115.837 -0.619 . . . . 0.0 113.387 179.27 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 7.8 pt-20 -58.17 138.0 56.55 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 121.481 0.657 . . . . 0.0 112.283 -179.109 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.509 HG22 HG22 ' A' ' 21' ' ' ILE . 26.3 p -89.79 119.34 30.1 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.418 -0.81 . . . . 0.0 109.675 179.056 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 23.0 p -88.1 61.99 6.57 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 121.495 0.664 . . . . 0.0 110.552 -179.691 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 34.2 t80 -54.38 -42.14 70.04 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.281 -0.872 . . . . 0.0 110.819 -179.892 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -93.01 21.3 40.59 Favored Glycine 0 N--CA 1.45 -0.426 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.833 179.712 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 76.52 -29.49 1.47 Allowed Glycine 0 CA--C 1.521 0.433 0 C-N-CA 121.117 -0.563 . . . . 0.0 113.616 179.598 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -88.73 143.22 27.06 Favored 'General case' 0 C--N 1.321 -0.641 0 O-C-N 122.631 -0.334 . . . . 0.0 111.878 -179.127 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 64.5 m -111.03 151.49 27.95 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.895 -0.593 . . . . 0.0 109.893 179.354 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 38.9 t30 -88.6 -24.17 22.9 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 121.132 0.491 . . . . 0.0 110.897 -179.432 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 7.5 m -101.39 123.84 43.17 Favored Pre-proline 0 C--N 1.322 -0.612 0 CA-C-O 121.15 0.5 . . . . 0.0 111.813 -178.573 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -65.95 140.91 62.42 Favored 'Trans proline' 0 C--N 1.345 0.368 0 C-N-CA 122.828 2.352 . . . . 0.0 111.484 179.263 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 96.46 -19.81 53.03 Favored Glycine 0 N--CA 1.446 -0.643 0 C-N-CA 120.539 -0.839 . . . . 0.0 111.457 -179.053 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.675 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 84.7 m -87.41 134.82 33.53 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 120.991 0.424 . . . . 0.0 109.896 179.279 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 11.0 m -106.52 136.2 46.71 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 109.114 -0.699 . . . . 0.0 109.114 -179.872 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 48.2 t -70.91 121.91 18.99 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-O 121.522 0.677 . . . . 0.0 112.23 -178.596 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 18.2 m -125.76 67.63 1.17 Allowed 'General case' 0 C--N 1.314 -0.971 0 N-CA-C 106.308 -1.738 . . . . 0.0 106.308 177.572 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.467 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.2 OUTLIER -28.27 127.84 0.22 Allowed Pre-proline 0 N--CA 1.464 0.25 0 CA-C-N 114.062 -1.427 . . . . 0.0 112.945 -176.446 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.467 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 60.2 Cg_endo -97.83 31.91 11.38 Favored 'Cis proline' 0 N--CA 1.461 -0.429 0 C-N-CA 123.711 -1.37 . . . . 0.0 114.242 0.872 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.509 HG22 HG22 ' A' ' 4' ' ' THR . 42.8 pt -138.56 139.22 41.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 121.452 0.644 . . . . 0.0 111.699 -179.019 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.675 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 3.7 t -84.3 144.42 28.89 Favored 'General case' 0 C--N 1.317 -0.839 0 CA-C-O 121.237 0.541 . . . . 0.0 109.55 179.268 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.558 HG22 ' HA ' ' A' ' 28' ' ' PRO . 17.9 p -141.97 130.43 22.49 Favored 'General case' 0 C--N 1.314 -0.944 0 CA-C-N 115.411 -0.813 . . . . 0.0 111.602 -178.143 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.457 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 9.6 ptm180 -93.84 128.17 39.97 Favored 'General case' 0 N--CA 1.448 -0.57 0 N-CA-C 108.729 -0.841 . . . . 0.0 108.729 178.309 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 28.6 m-20 58.4 26.71 14.45 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 121.29 0.567 . . . . 0.0 109.796 -178.876 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 77.75 10.67 86.08 Favored Glycine 0 C--N 1.333 0.411 0 CA-C-N 115.736 -0.666 . . . . 0.0 112.171 -179.118 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.44 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 90.2 mt -110.39 131.04 22.25 Favored Pre-proline 0 C--O 1.24 0.578 0 CA-C-O 120.965 0.412 . . . . 0.0 110.684 -179.75 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.558 ' HA ' HG22 ' A' ' 23' ' ' THR . 4.9 Cg_exo -74.85 52.93 3.12 Favored 'Trans proline' 0 C--N 1.344 0.297 0 C-N-CA 123.699 2.933 . . . . 0.0 112.447 -179.832 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 40.5 t . . . . . 0 C--N 1.322 -0.613 0 CA-C-O 121.433 0.635 . . . . 0.0 110.018 -179.881 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.8 m . . . . . 0 C--O 1.23 0.032 0 CA-C-O 121.045 0.45 . . . . 0.0 110.37 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 78.11 -36.02 1.72 Allowed Glycine 0 N--CA 1.453 -0.228 0 CA-C-N 115.781 -0.645 . . . . 0.0 113.496 179.159 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 10.8 pt-20 -60.21 139.22 57.69 Favored 'General case' 0 C--O 1.238 0.471 0 CA-C-O 121.617 0.722 . . . . 0.0 111.831 -178.945 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.521 HG22 HG22 ' A' ' 21' ' ' ILE . 11.9 p -91.31 118.22 30.32 Favored 'General case' 0 N--CA 1.445 -0.699 0 CA-C-N 115.301 -0.863 . . . . 0.0 109.985 179.347 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 26.5 p -88.93 58.87 4.77 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 121.049 0.452 . . . . 0.0 111.438 -178.992 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' PHE . . . . . 0.494 ' CD1' ' HB ' ' A' ' 4' ' ' THR . 4.9 m-85 -57.67 -36.43 71.9 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.542 179.306 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -90.13 18.37 48.6 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.649 179.516 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 75.58 -30.28 1.23 Allowed Glycine 0 CA--C 1.522 0.526 0 C-N-CA 121.344 -0.455 . . . . 0.0 113.786 179.531 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.0 m -88.95 151.57 22.23 Favored 'General case' 0 C--N 1.322 -0.591 0 O-C-N 122.53 -0.394 . . . . 0.0 111.237 -179.078 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 82.8 m -118.24 149.34 41.28 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.874 -0.603 . . . . 0.0 109.661 179.29 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 65.5 m-80 -88.92 -26.06 21.76 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 116.059 -0.519 . . . . 0.0 111.659 -178.674 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.447 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 19.3 p -102.06 128.47 28.49 Favored Pre-proline 0 C--N 1.324 -0.53 0 CA-C-O 121.398 0.618 . . . . 0.0 111.841 -178.855 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.447 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 19.6 Cg_exo -66.09 141.36 63.37 Favored 'Trans proline' 0 C--N 1.346 0.402 0 C-N-CA 123.252 2.635 . . . . 0.0 112.164 -179.913 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 96.44 -20.63 49.53 Favored Glycine 0 N--CA 1.447 -0.578 0 C-N-CA 120.761 -0.733 . . . . 0.0 111.545 -179.385 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.682 ' SG ' ' HB3' ' A' ' 24' ' ' ARG . 91.8 m -88.19 135.96 33.2 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-O 121.097 0.475 . . . . 0.0 110.324 179.703 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 15.2 m -109.71 136.65 48.71 Favored 'General case' 0 C--N 1.323 -0.582 0 N-CA-C 109.044 -0.724 . . . . 0.0 109.044 179.889 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 45.4 t -66.41 127.47 32.42 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-O 121.602 0.715 . . . . 0.0 112.062 -178.448 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 5.3 m -132.32 64.61 1.6 Allowed 'General case' 0 C--N 1.316 -0.874 0 N-CA-C 106.583 -1.636 . . . . 0.0 106.583 178.337 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.463 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -27.15 126.73 0.21 Allowed Pre-proline 0 N--CA 1.466 0.343 0 CA-C-N 114.231 -1.349 . . . . 0.0 112.996 -176.592 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.463 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 66.8 Cg_endo -97.3 31.37 12.28 Favored 'Cis proline' 0 CA--C 1.533 0.433 0 C-N-CA 123.689 -1.38 . . . . 0.0 114.492 1.025 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.521 HG22 HG22 ' A' ' 4' ' ' THR . 43.4 pt -139.33 141.31 35.87 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.382 0 CA-C-O 121.302 0.573 . . . . 0.0 111.565 -179.212 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.643 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 4.2 t -86.11 144.38 27.55 Favored 'General case' 0 C--N 1.316 -0.854 0 N-CA-C 109.669 -0.493 . . . . 0.0 109.669 179.406 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 61.9 p -137.15 128.24 27.72 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-N 115.661 -0.699 . . . . 0.0 112.007 -178.235 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.682 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 3.3 ptm180 -90.52 125.36 35.58 Favored 'General case' 0 N--CA 1.445 -0.705 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 177.822 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 53.0 m-20 58.59 28.1 16.63 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-O 121.148 0.499 . . . . 0.0 110.007 -178.421 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 79.37 11.27 85.11 Favored Glycine 0 C--N 1.334 0.441 0 CA-C-N 115.933 -0.576 . . . . 0.0 112.541 -179.514 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.463 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 91.7 mt -113.81 127.92 26.31 Favored Pre-proline 0 C--O 1.236 0.382 0 CA-C-O 120.779 0.323 . . . . 0.0 110.777 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.463 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 6.9 Cg_exo -73.29 53.66 2.61 Favored 'Trans proline' 0 C--N 1.344 0.291 0 C-N-CA 123.539 2.826 . . . . 0.0 112.695 -179.776 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 38.8 t . . . . . 0 C--N 1.323 -0.547 0 CA-C-O 121.445 0.641 . . . . 0.0 110.107 -179.926 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 4.1 m . . . . . 0 CA--C 1.527 0.089 0 CA-C-O 121.016 0.436 . . . . 0.0 110.246 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 62.86 45.41 95.75 Favored Glycine 0 C--N 1.333 0.405 0 CA-C-N 115.73 -0.668 . . . . 0.0 112.944 179.068 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 8.2 pt-20 -144.73 140.53 28.61 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 121.323 0.583 . . . . 0.0 111.346 -179.686 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.485 ' HB ' ' CD1' ' A' ' 6' ' ' PHE . 21.6 p -93.39 113.84 26.1 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 115.487 -0.779 . . . . 0.0 109.74 179.148 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 25.4 p -88.65 59.25 5.03 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 121.065 0.46 . . . . 0.0 111.459 -179.019 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' PHE . . . . . 0.485 ' CD1' ' HB ' ' A' ' 4' ' ' THR . 4.6 m-85 -57.73 -36.46 72.08 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.627 179.33 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -89.75 17.89 50.16 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.665 179.529 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 76.1 -29.57 1.37 Allowed Glycine 0 CA--C 1.524 0.609 0 C-N-CA 121.307 -0.473 . . . . 0.0 113.672 179.531 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.8 m -88.66 150.58 22.94 Favored 'General case' 0 C--N 1.323 -0.55 0 O-C-N 122.582 -0.363 . . . . 0.0 111.149 -179.232 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 67.6 m -117.12 150.87 37.97 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.094 179.517 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 42.3 t30 -88.82 -22.23 23.33 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.789 -179.605 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.433 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 4.5 m -101.42 123.35 44.85 Favored Pre-proline 0 C--N 1.324 -0.519 0 CA-C-O 121.226 0.536 . . . . 0.0 111.556 -178.62 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 22.4 Cg_exo -64.75 136.83 51.14 Favored 'Trans proline' 0 C--N 1.345 0.38 0 C-N-CA 122.96 2.44 . . . . 0.0 111.788 179.656 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 95.02 -15.12 64.09 Favored Glycine 0 N--CA 1.446 -0.648 0 C-N-CA 120.645 -0.788 . . . . 0.0 111.894 -179.436 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.669 ' SG ' ' HB3' ' A' ' 24' ' ' ARG . 88.6 m -87.31 135.5 33.29 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.583 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 13.3 m -105.7 135.25 47.45 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 109.125 -0.695 . . . . 0.0 109.125 -179.844 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.0 t -70.85 120.81 16.98 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-O 121.609 0.719 . . . . 0.0 111.994 -178.445 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 11.2 m -123.62 66.32 1.02 Allowed 'General case' 0 C--N 1.315 -0.933 0 N-CA-C 106.415 -1.698 . . . . 0.0 106.415 177.685 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.449 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -27.76 127.21 0.22 Allowed Pre-proline 0 N--CA 1.466 0.345 0 CA-C-N 114.167 -1.378 . . . . 0.0 112.878 -176.561 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.449 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 65.0 Cg_endo -97.37 31.29 12.35 Favored 'Cis proline' 0 N--CA 1.46 -0.442 0 C-N-CA 123.765 -1.348 . . . . 0.0 114.34 0.948 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 42.3 pt -138.2 137.34 44.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-O 121.454 0.645 . . . . 0.0 111.722 -179.155 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.62 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 4.5 t -85.05 144.38 28.29 Favored 'General case' 0 C--N 1.316 -0.861 0 CA-C-O 121.177 0.513 . . . . 0.0 109.912 179.447 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.477 HG22 ' CA ' ' A' ' 28' ' ' PRO . 21.5 p -143.52 127.06 16.92 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-N 115.304 -0.862 . . . . 0.0 111.127 -178.266 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.669 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 3.4 ptm180 -93.65 126.28 38.73 Favored 'General case' 0 N--CA 1.447 -0.581 0 N-CA-C 108.859 -0.793 . . . . 0.0 108.859 178.535 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 51.5 m-20 57.75 29.68 17.77 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-O 121.259 0.552 . . . . 0.0 109.657 -178.54 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 78.29 7.99 87.64 Favored Glycine 0 C--N 1.333 0.386 0 CA-C-N 115.587 -0.733 . . . . 0.0 112.67 -179.338 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.473 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 88.2 mt -106.62 124.48 35.45 Favored Pre-proline 0 C--O 1.237 0.442 0 CA-C-O 120.935 0.397 . . . . 0.0 110.867 -179.829 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.477 ' CA ' HG22 ' A' ' 23' ' ' THR . 3.8 Cg_exo -79.75 46.35 2.2 Favored 'Trans proline' 0 N--CA 1.462 -0.374 0 C-N-CA 123.574 2.849 . . . . 0.0 112.08 179.868 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 10.5 p . . . . . 0 C--N 1.319 -0.719 0 CA-C-N 115.552 -0.749 . . . . 0.0 110.337 -179.765 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.0 m . . . . . 0 N--CA 1.456 -0.136 0 CA-C-O 121.066 0.46 . . . . 0.0 110.318 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 76.27 -34.05 1.32 Allowed Glycine 0 C--N 1.332 0.325 0 CA-C-N 115.867 -0.606 . . . . 0.0 113.575 179.111 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -55.04 138.44 44.0 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 121.813 0.816 . . . . 0.0 112.315 -178.921 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.61 HG23 ' O ' ' A' ' 20' ' ' PRO . 81.1 m -89.0 110.86 21.5 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 114.892 -1.049 . . . . 0.0 110.008 179.607 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 28.5 p -89.13 53.42 2.66 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 121.167 0.508 . . . . 0.0 110.9 -179.459 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 18.9 p90 -58.15 -30.93 66.75 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.925 -0.58 . . . . 0.0 111.283 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -94.32 15.57 62.95 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.687 179.699 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 65.17 40.08 96.57 Favored Glycine 0 CA--C 1.518 0.269 0 C-N-CA 121.049 -0.596 . . . . 0.0 112.79 179.676 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 3.0 m -149.91 150.75 32.35 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 179.91 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 60.1 m -129.26 142.75 50.76 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 120.758 0.313 . . . . 0.0 110.213 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 43.7 t30 -89.23 -17.82 28.29 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.964 -179.367 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.453 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 5.2 m -101.11 123.67 44.21 Favored Pre-proline 0 C--N 1.323 -0.561 0 CA-C-O 121.122 0.487 . . . . 0.0 111.611 -178.546 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.453 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 23.9 Cg_exo -63.61 136.65 55.21 Favored 'Trans proline' 0 C--N 1.345 0.359 0 C-N-CA 122.959 2.44 . . . . 0.0 111.705 179.583 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 94.39 -15.07 64.06 Favored Glycine 0 N--CA 1.447 -0.623 0 C-N-CA 120.638 -0.792 . . . . 0.0 111.594 -179.225 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.73 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 93.1 m -87.88 132.42 34.21 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 121.059 0.457 . . . . 0.0 110.053 179.524 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 15.2 m -108.96 134.78 51.16 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 109.116 -0.698 . . . . 0.0 109.116 179.892 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 41.9 t -67.43 121.98 16.96 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 121.578 0.704 . . . . 0.0 111.873 -178.504 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 4.1 m -125.3 65.96 1.14 Allowed 'General case' 0 C--N 1.317 -0.82 0 N-CA-C 106.765 -1.569 . . . . 0.0 106.765 178.023 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.47 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -27.76 125.77 0.23 Allowed Pre-proline 0 N--CA 1.466 0.331 0 CA-C-N 114.347 -1.297 . . . . 0.0 112.812 -176.74 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.61 ' O ' HG23 ' A' ' 4' ' ' THR . 66.6 Cg_endo -97.51 31.19 12.42 Favored 'Cis proline' 0 N--CA 1.46 -0.452 0 C-N-CA 123.656 -1.393 . . . . 0.0 114.362 0.843 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 41.8 pt -138.54 136.36 43.76 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 O-C-N 121.474 -0.766 . . . . 0.0 111.859 -179.208 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.73 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 5.7 t -83.36 142.77 30.79 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-O 121.201 0.524 . . . . 0.0 109.826 179.367 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 62.0 p -137.05 128.35 28.11 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-N 115.504 -0.771 . . . . 0.0 111.785 -178.276 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.64 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 3.0 ptm180 -89.52 124.71 34.76 Favored 'General case' 0 N--CA 1.446 -0.67 0 N-CA-C 108.483 -0.932 . . . . 0.0 108.483 178.126 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 53.8 m-20 58.11 28.37 16.31 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 121.173 0.511 . . . . 0.0 110.035 -178.434 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 80.14 10.04 85.94 Favored Glycine 0 C--N 1.334 0.426 0 CA-C-N 115.87 -0.604 . . . . 0.0 112.58 -179.423 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 90.1 mt -110.82 127.33 27.11 Favored Pre-proline 0 C--N 1.327 -0.412 0 CA-C-O 120.82 0.343 . . . . 0.0 110.63 179.967 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 62.3 Cg_endo -73.61 52.69 2.53 Favored 'Trans proline' 0 C--N 1.343 0.261 0 C-N-CA 123.202 2.601 . . . . 0.0 112.784 -179.879 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 40.4 t . . . . . 0 C--N 1.322 -0.602 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.094 -179.922 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.7 m . . . . . 0 N--CA 1.457 -0.078 0 CA-C-O 121.03 0.443 . . . . 0.0 110.232 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 75.71 -34.59 1.2 Allowed Glycine 0 C--N 1.33 0.243 0 CA-C-N 115.785 -0.643 . . . . 0.0 113.657 179.114 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 15.3 pt-20 -55.74 141.8 36.89 Favored 'General case' 0 C--O 1.238 0.478 0 CA-C-O 121.639 0.733 . . . . 0.0 112.116 -178.806 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.607 HG23 ' O ' ' A' ' 20' ' ' PRO . 87.8 m -88.68 117.03 27.36 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.157 -0.928 . . . . 0.0 110.308 -179.983 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 26.3 p -88.77 58.51 4.65 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 121.229 0.538 . . . . 0.0 110.209 179.798 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 32.3 t80 -51.76 -46.36 64.08 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 115.438 -0.801 . . . . 0.0 111.243 -179.559 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -94.45 25.41 22.9 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.59 -0.814 . . . . 0.0 112.568 179.749 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.44 38.69 96.18 Favored Glycine 0 CA--C 1.518 0.223 0 C-N-CA 121.184 -0.531 . . . . 0.0 112.742 179.65 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.3 m -139.49 150.66 45.41 Favored 'General case' 0 C--N 1.324 -0.512 0 N-CA-C 110.013 -0.365 . . . . 0.0 110.013 -179.911 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 59.3 m -133.22 140.84 47.75 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 116.404 -0.362 . . . . 0.0 110.057 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 65.0 m-80 -89.56 -13.88 36.33 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.08 -179.047 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.547 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 4.7 m -101.09 124.84 40.15 Favored Pre-proline 0 C--N 1.322 -0.605 0 CA-C-O 121.126 0.489 . . . . 0.0 111.208 -178.751 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 28.8 Cg_endo -63.58 135.81 51.1 Favored 'Trans proline' 0 C--N 1.345 0.387 0 C-N-CA 122.88 2.387 . . . . 0.0 112.179 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 91.83 -11.32 72.43 Favored Glycine 0 N--CA 1.448 -0.556 0 C-N-CA 120.806 -0.711 . . . . 0.0 111.898 -179.508 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.766 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 89.1 m -88.08 132.9 34.12 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.056 0.455 . . . . 0.0 110.344 179.738 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 15.3 m -111.21 138.06 48.13 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 109.158 -0.682 . . . . 0.0 109.158 179.889 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 45.7 t -67.74 123.86 21.69 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-O 121.451 0.643 . . . . 0.0 111.969 -178.766 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 4.6 m -128.35 62.64 1.44 Allowed 'General case' 0 C--N 1.317 -0.815 0 N-CA-C 106.698 -1.593 . . . . 0.0 106.698 178.028 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.448 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -27.48 126.33 0.22 Allowed Pre-proline 0 N--CA 1.464 0.239 0 CA-C-N 114.153 -1.385 . . . . 0.0 112.933 -176.686 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.607 ' O ' HG23 ' A' ' 4' ' ' THR . 67.9 Cg_endo -97.21 33.76 9.47 Favored 'Cis proline' 0 N--CA 1.461 -0.436 0 C-N-CA 123.775 -1.344 . . . . 0.0 114.241 0.848 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 42.0 pt -140.24 137.05 37.55 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 O-C-N 121.654 -0.654 . . . . 0.0 111.582 -179.284 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.766 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 6.6 t -85.36 142.71 29.11 Favored 'General case' 0 C--N 1.316 -0.88 0 CA-C-O 121.062 0.458 . . . . 0.0 109.848 179.346 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 66.2 p -136.88 129.2 29.86 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-N 115.552 -0.749 . . . . 0.0 111.824 -178.47 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.653 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 1.7 ptm180 -90.36 123.04 33.78 Favored 'General case' 0 N--CA 1.445 -0.711 0 N-CA-C 108.634 -0.876 . . . . 0.0 108.634 178.066 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 71.1 m-20 56.85 31.27 19.31 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-O 121.214 0.53 . . . . 0.0 109.987 -177.656 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 79.38 7.31 88.57 Favored Glycine 0 C--N 1.334 0.448 0 CA-C-N 115.879 -0.6 . . . . 0.0 112.856 -179.625 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.47 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 88.0 mt -107.36 126.4 30.12 Favored Pre-proline 0 C--O 1.237 0.41 0 O-C-N 122.624 -0.339 . . . . 0.0 110.697 179.982 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.47 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 7.4 Cg_exo -72.91 52.98 2.29 Favored 'Trans proline' 0 C--N 1.343 0.246 0 C-N-CA 123.587 2.858 . . . . 0.0 112.581 -179.834 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 43.4 t . . . . . 0 C--N 1.323 -0.561 0 CA-C-O 121.307 0.575 . . . . 0.0 110.171 -179.774 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.6 m . . . . . 0 CA--C 1.528 0.104 0 CA-C-O 120.875 0.369 . . . . 0.0 110.763 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.68 42.97 95.08 Favored Glycine 0 N--CA 1.451 -0.321 0 CA-C-N 115.798 -0.637 . . . . 0.0 112.982 179.217 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -142.84 143.44 32.12 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 121.211 0.529 . . . . 0.0 110.864 179.906 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.528 ' HB ' ' CD1' ' A' ' 6' ' ' PHE . 7.3 p -95.97 115.08 26.88 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 115.582 -0.735 . . . . 0.0 110.381 179.506 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 25.5 p -89.11 58.84 4.69 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 121.047 0.451 . . . . 0.0 111.426 -179.248 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' PHE . . . . . 0.528 ' CD1' ' HB ' ' A' ' 4' ' ' THR . 5.2 m-85 -57.81 -36.36 72.13 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.644 179.416 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -88.36 16.83 51.49 Favored Glycine 0 N--CA 1.448 -0.508 0 C-N-CA 120.833 -0.699 . . . . 0.0 112.703 179.654 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 77.2 -30.62 1.61 Allowed Glycine 0 CA--C 1.523 0.542 0 C-N-CA 121.223 -0.513 . . . . 0.0 113.487 179.635 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.7 m -88.62 149.96 23.28 Favored 'General case' 0 C--N 1.322 -0.626 0 O-C-N 122.655 -0.32 . . . . 0.0 111.035 -179.373 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 77.0 m -113.05 150.6 31.79 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.141 179.52 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 64.8 m-80 -88.65 -27.94 20.95 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 115.818 -0.628 . . . . 0.0 111.244 -179.086 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.457 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 21.3 p -102.46 128.31 28.49 Favored Pre-proline 0 C--N 1.324 -0.509 0 CA-C-O 121.481 0.658 . . . . 0.0 111.746 -179.049 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.457 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 17.3 Cg_exo -67.25 141.09 55.61 Favored 'Trans proline' 0 C--N 1.345 0.375 0 C-N-CA 123.277 2.651 . . . . 0.0 112.172 -179.758 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 96.8 -20.1 52.05 Favored Glycine 0 N--CA 1.448 -0.565 0 C-N-CA 120.739 -0.743 . . . . 0.0 111.7 -179.509 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.731 ' SG ' ' HB3' ' A' ' 24' ' ' ARG . 91.0 m -88.22 138.82 31.1 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-O 121.066 0.46 . . . . 0.0 110.283 179.734 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 16.1 m -108.49 134.52 51.15 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 109.172 -0.677 . . . . 0.0 109.172 179.855 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.4 t -66.31 125.2 24.86 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-O 121.615 0.721 . . . . 0.0 111.893 -178.418 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 3.9 m -129.0 65.6 1.44 Allowed 'General case' 0 C--N 1.315 -0.913 0 N-CA-C 106.708 -1.589 . . . . 0.0 106.708 178.277 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.458 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -27.26 126.42 0.22 Allowed Pre-proline 0 N--CA 1.465 0.312 0 CA-C-N 114.423 -1.262 . . . . 0.0 112.836 -176.571 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.458 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 63.2 Cg_endo -97.17 31.03 12.79 Favored 'Cis proline' 0 CA--C 1.532 0.407 0 C-N-CA 123.776 -1.343 . . . . 0.0 114.534 0.932 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.417 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 42.5 pt -139.42 138.98 39.72 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.333 0 CA-C-O 121.319 0.581 . . . . 0.0 111.719 -179.117 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.565 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 4.4 t -84.93 145.14 27.92 Favored 'General case' 0 C--N 1.316 -0.849 0 N-CA-C 109.622 -0.51 . . . . 0.0 109.622 179.282 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 61.8 p -139.54 128.52 23.6 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-N 115.792 -0.64 . . . . 0.0 112.121 -178.026 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.731 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 3.3 ptm180 -91.68 125.57 36.46 Favored 'General case' 0 N--CA 1.445 -0.697 0 N-CA-C 108.155 -1.054 . . . . 0.0 108.155 177.588 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 54.7 m-20 58.9 28.24 17.28 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-O 121.143 0.497 . . . . 0.0 109.842 -178.319 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 78.87 10.36 86.25 Favored Glycine 0 C--N 1.333 0.374 0 CA-C-N 115.897 -0.592 . . . . 0.0 112.636 -179.413 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 92.1 mt -114.3 126.28 28.18 Favored Pre-proline 0 C--N 1.328 -0.357 0 CA-C-O 120.881 0.372 . . . . 0.0 110.759 -179.961 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -75.28 52.42 3.16 Favored 'Trans proline' 0 CA--C 1.529 0.241 0 C-N-CA 123.159 2.573 . . . . 0.0 112.876 -179.811 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 22.3 t . . . . . 0 C--N 1.323 -0.559 0 CA-C-O 121.389 0.614 . . . . 0.0 110.184 -179.883 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 63.4 m . . . . . 0 N--CA 1.458 -0.061 0 CA-C-O 120.991 0.424 . . . . 0.0 110.104 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 61.45 35.29 90.81 Favored Glycine 0 C--N 1.332 0.348 0 CA-C-N 115.674 -0.694 . . . . 0.0 113.102 179.114 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 9.5 pt-20 -115.9 148.44 40.01 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 120.9 0.381 . . . . 0.0 110.716 179.929 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.438 ' HA ' ' HA ' ' A' ' 21' ' ' ILE . 33.9 p -93.41 118.09 30.88 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.182 -179.933 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.798 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 13.5 p -88.87 61.57 6.0 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.287 0.565 . . . . 0.0 110.52 179.298 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 32.8 t80 -55.14 -41.27 71.54 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.561 -0.745 . . . . 0.0 110.235 179.892 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -92.18 22.94 29.49 Favored Glycine 0 N--CA 1.45 -0.43 0 C-N-CA 120.865 -0.683 . . . . 0.0 112.765 179.338 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 76.66 -35.81 1.4 Allowed Glycine 0 CA--C 1.521 0.446 0 C-N-CA 121.23 -0.51 . . . . 0.0 113.938 179.405 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.5 m -89.2 148.37 23.66 Favored 'General case' 0 C--N 1.322 -0.609 0 O-C-N 122.423 -0.457 . . . . 0.0 111.442 -179.093 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 59.9 m -108.69 153.67 23.11 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.711 -0.677 . . . . 0.0 109.515 179.072 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 39.1 t30 -87.53 -29.42 21.33 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-O 121.255 0.55 . . . . 0.0 110.171 179.956 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.443 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 3.8 m -102.48 118.35 58.92 Favored Pre-proline 0 C--N 1.323 -0.571 0 CA-C-N 115.877 -0.601 . . . . 0.0 111.167 -179.485 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.443 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 13.6 Cg_exo -68.76 136.95 37.19 Favored 'Trans proline' 0 N--CA 1.46 -0.479 0 C-N-CA 122.829 2.352 . . . . 0.0 111.719 179.724 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 117.33 -32.66 5.32 Favored Glycine 0 N--CA 1.439 -1.166 0 N-CA-C 111.134 -0.787 . . . . 0.0 111.134 -179.264 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.413 ' HB3' ' HB3' ' A' ' 22' ' ' CYS . 32.9 m -89.45 131.43 35.5 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 120.921 0.391 . . . . 0.0 110.36 179.05 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 16.0 m -89.67 136.15 33.2 Favored 'General case' 0 C--N 1.319 -0.724 0 N-CA-C 109.213 -0.662 . . . . 0.0 109.213 179.556 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 43.2 t -67.66 115.45 7.25 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 121.773 0.797 . . . . 0.0 111.031 -179.336 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 2.9 m -118.95 66.96 0.78 Allowed 'General case' 0 C--N 1.309 -1.172 0 N-CA-C 106.332 -1.729 . . . . 0.0 106.332 178.182 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.475 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.3 OUTLIER -27.24 124.6 0.23 Allowed Pre-proline 0 N--CA 1.463 0.196 0 CA-C-N 114.213 -1.358 . . . . 0.0 112.646 -176.314 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.475 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 56.7 Cg_endo -98.77 34.25 8.69 Favored 'Cis proline' 0 N--CA 1.459 -0.52 0 C-N-CA 123.732 -1.362 . . . . 0.0 114.554 1.103 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.438 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 40.8 pt -142.12 136.06 29.09 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.301 0 CA-C-N 118.753 0.706 . . . . 0.0 112.513 -178.939 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.798 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 47.2 m -82.08 131.68 35.24 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.266 178.977 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 65.4 p -142.7 136.7 29.25 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.134 179.785 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.514 ' O ' ' HG3' ' A' ' 24' ' ' ARG . 2.8 ptm180 -94.62 121.86 36.62 Favored 'General case' 0 N--CA 1.443 -0.789 0 N-CA-C 108.153 -1.054 . . . . 0.0 108.153 178.445 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 61.3 m-20 57.36 29.85 17.56 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.134 0.492 . . . . 0.0 109.775 -178.032 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 82.12 1.95 90.46 Favored Glycine 0 CA--C 1.521 0.41 0 CA-C-N 115.801 -0.636 . . . . 0.0 112.667 -179.371 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 88.0 mt -98.87 123.6 48.81 Favored Pre-proline 0 C--O 1.237 0.429 0 CA-C-O 121.074 0.464 . . . . 0.0 111.217 -179.838 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -77.13 69.81 6.93 Favored 'Trans proline' 0 N--CA 1.464 -0.242 0 C-N-CA 123.248 2.632 . . . . 0.0 112.139 179.649 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 47.2 t . . . . . 0 C--N 1.324 -0.504 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.297 -179.396 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 82.0 m . . . . . 0 CA--C 1.524 -0.026 0 CA-C-O 120.92 0.391 . . . . 0.0 110.353 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 76.46 -32.32 1.39 Allowed Glycine 0 CA--C 1.519 0.327 0 CA-C-N 116.117 -0.492 . . . . 0.0 113.85 178.878 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 14.7 pt-20 -53.95 139.31 34.47 Favored 'General case' 0 C--O 1.239 0.509 0 CA-C-O 121.447 0.641 . . . . 0.0 111.889 -178.933 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.612 HG22 HG22 ' A' ' 21' ' ' ILE . 36.2 p -89.44 120.91 31.18 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 115.276 -0.875 . . . . 0.0 110.801 -179.581 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.761 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 25.0 p -88.98 60.96 5.69 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 121.253 0.549 . . . . 0.0 110.71 179.651 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 34.4 t80 -53.33 -44.36 68.37 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.525 -0.761 . . . . 0.0 110.993 -179.896 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -92.65 22.63 32.39 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.742 179.788 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 62.55 40.68 99.43 Favored Glycine 0 CA--C 1.518 0.27 0 C-N-CA 121.257 -0.497 . . . . 0.0 112.965 179.514 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.5 m -147.99 149.28 31.87 Favored 'General case' 0 C--N 1.324 -0.513 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 179.919 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 47.2 m -124.76 143.42 50.8 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 179.837 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 63.1 m-80 -88.39 -23.24 23.4 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.276 -179.49 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.401 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 4.3 m -101.72 119.37 57.35 Favored Pre-proline 0 C--N 1.323 -0.582 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.982 -179.148 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.401 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 20.4 Cg_exo -65.55 140.93 64.87 Favored 'Trans proline' 0 N--CA 1.462 -0.324 0 C-N-CA 122.922 2.415 . . . . 0.0 111.939 179.894 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 105.76 -29.9 10.62 Favored Glycine 0 N--CA 1.441 -1.024 0 C-N-CA 120.75 -0.738 . . . . 0.0 111.489 -179.4 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.548 ' HB3' ' HB3' ' A' ' 22' ' ' CYS . 15.7 m -89.04 129.19 35.71 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 121.209 0.528 . . . . 0.0 110.708 179.289 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 19.6 m -94.39 138.51 32.26 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 115.512 -0.767 . . . . 0.0 109.036 179.372 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 43.4 t -66.43 116.16 7.13 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-O 121.593 0.711 . . . . 0.0 111.03 -179.287 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 3.0 m -120.78 68.7 0.87 Allowed 'General case' 0 C--N 1.311 -1.099 0 N-CA-C 106.597 -1.631 . . . . 0.0 106.597 178.422 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.478 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -27.82 125.1 0.23 Allowed Pre-proline 0 N--CA 1.463 0.215 0 O-C-N 124.706 1.253 . . . . 0.0 112.631 -176.52 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.478 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 59.8 Cg_endo -98.54 30.62 12.65 Favored 'Cis proline' 0 CA--C 1.535 0.562 0 C-N-CA 123.613 -1.411 . . . . 0.0 115.061 1.033 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.612 HG22 HG22 ' A' ' 4' ' ' THR . 0.2 OUTLIER -141.62 141.65 29.68 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.293 0 CA-C-N 118.992 0.815 . . . . 0.0 112.122 -179.422 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.761 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 64.6 m -81.1 133.81 35.54 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.586 179.365 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 64.5 p -134.23 132.4 39.65 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.735 179.856 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.476 ' O ' ' HG3' ' A' ' 24' ' ' ARG . 1.4 ptm180 -91.93 120.25 32.43 Favored 'General case' 0 N--CA 1.443 -0.777 0 N-CA-C 108.185 -1.042 . . . . 0.0 108.185 178.305 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 72.7 m-20 56.6 31.0 18.34 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 121.144 0.497 . . . . 0.0 109.895 -177.437 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 84.0 -0.4 89.45 Favored Glycine 0 CA--C 1.521 0.447 0 CA-C-N 115.885 -0.598 . . . . 0.0 112.907 -179.624 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.488 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 86.9 mt -99.3 122.34 52.31 Favored Pre-proline 0 C--O 1.237 0.41 0 CA-C-O 120.903 0.383 . . . . 0.0 111.155 -179.754 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.488 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 3.4 Cg_exo -74.46 63.78 5.5 Favored 'Trans proline' 0 CA--C 1.528 0.177 0 C-N-CA 123.597 2.865 . . . . 0.0 112.143 179.66 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 48.2 t . . . . . 0 C--N 1.325 -0.479 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.485 -179.233 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 3.0 m . . . . . 0 CA--C 1.527 0.058 0 CA-C-O 120.943 0.402 . . . . 0.0 110.486 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 78.23 -37.16 1.76 Allowed Glycine 0 C--N 1.33 0.226 0 CA-C-N 115.952 -0.567 . . . . 0.0 113.022 179.59 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 8.9 pt-20 -59.77 141.66 54.81 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 121.526 0.679 . . . . 0.0 111.961 -179.331 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.523 HG22 HG22 ' A' ' 21' ' ' ILE . 14.7 p -94.87 124.73 39.08 Favored 'General case' 0 N--CA 1.444 -0.733 0 CA-C-N 115.316 -0.856 . . . . 0.0 109.695 178.982 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 24.4 p -87.98 58.8 5.01 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 121.479 0.657 . . . . 0.0 110.698 -179.419 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 35.3 t80 -56.27 -39.93 73.42 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.309 -0.859 . . . . 0.0 110.038 179.48 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -91.31 22.68 28.54 Favored Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 120.943 -0.646 . . . . 0.0 112.751 179.375 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 77.25 -36.82 1.53 Allowed Glycine 0 CA--C 1.522 0.482 0 C-N-CA 121.36 -0.448 . . . . 0.0 114.081 179.223 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 10.2 t -89.52 164.46 14.79 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-O 121.229 0.537 . . . . 0.0 111.627 -179.083 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 62.0 m -125.69 151.77 46.15 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 114.983 -1.008 . . . . 0.0 109.514 179.28 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 41.4 t30 -88.88 -22.76 22.99 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-O 121.031 0.444 . . . . 0.0 111.198 -178.983 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.453 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 7.8 m -101.14 124.46 41.42 Favored Pre-proline 0 C--N 1.322 -0.59 0 CA-C-O 121.215 0.531 . . . . 0.0 111.955 -178.375 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.453 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 23.8 Cg_exo -63.81 137.48 58.56 Favored 'Trans proline' 0 C--N 1.346 0.411 0 C-N-CA 123.059 2.506 . . . . 0.0 111.47 179.403 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 96.55 -17.39 59.36 Favored Glycine 0 N--CA 1.446 -0.67 0 C-N-CA 120.596 -0.812 . . . . 0.0 111.447 -179.06 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.706 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 81.6 m -87.61 133.06 33.87 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 109.651 -0.5 . . . . 0.0 109.651 179.39 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 15.4 m -108.87 138.11 45.72 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 -179.577 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.4 t -68.46 127.08 31.69 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 121.752 0.787 . . . . 0.0 111.948 -178.705 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 4.3 m -131.17 60.67 1.65 Allowed 'General case' 0 C--N 1.316 -0.882 0 N-CA-C 106.144 -1.799 . . . . 0.0 106.144 177.891 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.432 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -26.24 126.65 0.2 Allowed Pre-proline 0 N--CA 1.464 0.265 0 CA-C-N 113.951 -1.477 . . . . 0.0 113.002 -176.487 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.432 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 62.3 Cg_endo -97.01 32.32 11.16 Favored 'Cis proline' 0 CA--C 1.532 0.421 0 C-N-CA 123.684 -1.381 . . . . 0.0 114.41 0.842 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.523 HG22 HG22 ' A' ' 4' ' ' THR . 43.8 pt -137.53 140.35 41.76 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.39 0 CA-C-O 121.255 0.55 . . . . 0.0 111.346 -179.234 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.706 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 5.4 t -89.4 144.28 26.18 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-O 121.17 0.509 . . . . 0.0 110.233 179.783 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 43.0 p -138.25 127.14 23.89 Favored 'General case' 0 C--N 1.318 -0.784 0 CA-C-N 115.527 -0.761 . . . . 0.0 111.752 -178.673 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.634 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 3.1 ptm180 -89.53 125.07 35.06 Favored 'General case' 0 N--CA 1.447 -0.618 0 N-CA-C 108.601 -0.889 . . . . 0.0 108.601 178.403 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 53.7 m-20 57.98 28.9 16.87 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.216 0.531 . . . . 0.0 109.958 -178.532 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 78.71 12.06 84.6 Favored Glycine 0 C--N 1.334 0.417 0 CA-C-N 115.875 -0.602 . . . . 0.0 112.457 -179.445 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 88.9 mt -113.72 127.71 26.53 Favored Pre-proline 0 C--O 1.237 0.405 0 CA-C-O 120.857 0.36 . . . . 0.0 110.686 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 70.9 Cg_endo -74.57 51.92 2.74 Favored 'Trans proline' 0 C--N 1.343 0.256 0 C-N-CA 123.292 2.662 . . . . 0.0 112.678 -179.949 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 39.4 t . . . . . 0 C--N 1.322 -0.601 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.222 -179.855 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' CYS . . . . . 0.541 ' HB3' ' HG2' ' A' ' 3' ' ' GLU . 82.5 m . . . . . 0 N--CA 1.458 -0.065 0 CA-C-O 120.897 0.379 . . . . 0.0 110.239 . . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 77.47 -34.73 1.57 Allowed Glycine 0 C--N 1.331 0.285 0 CA-C-N 116.034 -0.53 . . . . 0.0 113.436 179.188 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.541 ' HG2' ' HB3' ' A' ' 1' ' ' CYS . 7.0 pt-20 -53.8 139.88 31.76 Favored 'General case' 0 C--O 1.237 0.429 0 CA-C-O 121.528 0.68 . . . . 0.0 112.423 -179.114 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.623 HG22 HG22 ' A' ' 21' ' ' ILE . 31.5 p -89.29 121.22 31.36 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 115.271 -0.877 . . . . 0.0 110.01 179.29 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 23.5 p -88.0 61.14 6.19 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 121.382 0.611 . . . . 0.0 110.478 -179.857 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 35.1 t80 -55.11 -41.04 71.17 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.367 -0.833 . . . . 0.0 110.513 179.91 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -91.65 21.58 35.21 Favored Glycine 0 N--CA 1.449 -0.457 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.735 179.51 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 76.7 -33.47 1.41 Allowed Glycine 0 CA--C 1.522 0.51 0 C-N-CA 121.221 -0.514 . . . . 0.0 113.833 179.572 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.7 m -89.11 149.7 23.06 Favored 'General case' 0 C--N 1.321 -0.674 0 O-C-N 122.538 -0.389 . . . . 0.0 111.443 -179.184 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 58.3 m -114.76 152.68 31.66 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.761 -0.654 . . . . 0.0 109.301 179.017 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 36.4 t30 -87.8 -28.52 21.61 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-O 121.215 0.531 . . . . 0.0 110.537 -179.534 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.407 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 8.2 m -101.63 120.99 52.82 Favored Pre-proline 0 C--N 1.32 -0.681 0 CA-C-N 115.967 -0.56 . . . . 0.0 111.563 -178.871 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.407 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 17.3 Cg_exo -66.62 143.84 69.96 Favored 'Trans proline' 0 N--CA 1.463 -0.316 0 C-N-CA 123.178 2.585 . . . . 0.0 111.888 179.741 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 105.02 -29.59 11.43 Favored Glycine 0 N--CA 1.443 -0.862 0 C-N-CA 120.676 -0.774 . . . . 0.0 111.555 -179.443 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.663 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 9.2 m -87.98 138.87 31.08 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 121.131 0.491 . . . . 0.0 110.158 179.169 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 15.2 m -102.57 141.54 35.22 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 115.645 -0.707 . . . . 0.0 109.099 179.936 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 48.9 t -73.17 114.62 11.56 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-O 121.597 0.713 . . . . 0.0 111.661 -178.908 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 17.0 m -117.42 66.98 0.74 Allowed 'General case' 0 C--N 1.311 -1.103 0 N-CA-C 106.353 -1.721 . . . . 0.0 106.353 177.468 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.486 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.4 OUTLIER -29.08 127.39 0.24 Allowed Pre-proline 0 N--CA 1.463 0.225 0 CA-C-N 114.102 -1.408 . . . . 0.0 112.753 -176.47 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.486 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 59.5 Cg_endo -97.85 32.77 10.31 Favored 'Cis proline' 0 N--CA 1.46 -0.5 0 C-N-CA 123.68 -1.383 . . . . 0.0 114.304 0.918 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.623 HG22 HG22 ' A' ' 4' ' ' THR . 42.0 pt -138.3 137.48 43.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 121.443 0.639 . . . . 0.0 111.873 -179.135 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.663 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 3.4 t -85.42 139.74 31.29 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-O 121.309 0.576 . . . . 0.0 109.498 179.284 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.584 HG22 ' HA ' ' A' ' 28' ' ' PRO . 11.7 p -147.85 133.38 18.71 Favored 'General case' 0 C--N 1.313 -1.012 0 CA-C-N 115.279 -0.873 . . . . 0.0 111.297 -178.259 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.509 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 3.1 ptm180 -92.25 124.47 36.34 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 108.81 -0.811 . . . . 0.0 108.81 178.774 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 46.3 m-20 57.53 30.34 18.55 Favored 'General case' 0 N--CA 1.467 0.383 0 N-CA-C 109.384 -0.599 . . . . 0.0 109.384 -178.431 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 76.89 8.53 86.68 Favored Glycine 0 CA--C 1.521 0.423 0 CA-C-N 115.511 -0.768 . . . . 0.0 112.559 -179.116 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 86.8 mt -105.41 129.13 25.23 Favored Pre-proline 0 C--O 1.239 0.545 0 CA-C-O 121.057 0.456 . . . . 0.0 111.059 -179.661 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.584 ' HA ' HG22 ' A' ' 23' ' ' THR . 74.3 Cg_endo -75.42 62.94 6.3 Favored 'Trans proline' 0 C--N 1.343 0.262 0 C-N-CA 123.372 2.715 . . . . 0.0 112.583 179.84 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 48.5 t . . . . . 0 C--N 1.323 -0.578 0 CA-C-O 121.324 0.583 . . . . 0.0 110.177 -179.661 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 3.8 m . . . . . 0 CA--C 1.528 0.101 0 CA-C-O 121.141 0.496 . . . . 0.0 109.672 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 76.15 -36.38 1.3 Allowed Glycine 0 C--N 1.333 0.366 0 CA-C-N 115.6 -0.727 . . . . 0.0 113.777 178.691 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -60.13 138.54 57.87 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 121.621 0.724 . . . . 0.0 111.953 -178.805 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.466 ' HB ' ' CD1' ' A' ' 6' ' ' PHE . 30.8 p -89.62 118.99 29.65 Favored 'General case' 0 N--CA 1.446 -0.657 0 CA-C-N 115.271 -0.877 . . . . 0.0 109.734 179.245 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 26.2 p -88.62 58.02 4.47 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 121.066 0.46 . . . . 0.0 111.489 -179.034 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' PHE . . . . . 0.466 ' CD1' ' HB ' ' A' ' 4' ' ' THR . 4.7 m-85 -58.29 -36.56 73.49 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.334 179.049 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -88.99 19.07 40.37 Favored Glycine 0 N--CA 1.45 -0.414 0 C-N-CA 120.86 -0.686 . . . . 0.0 112.611 179.426 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 76.09 -32.77 1.3 Allowed Glycine 0 CA--C 1.524 0.598 0 C-N-CA 121.379 -0.439 . . . . 0.0 113.999 179.353 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 8.9 t -89.24 165.25 14.55 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.238 0.542 . . . . 0.0 111.561 -179.059 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 70.4 m -130.74 147.53 52.41 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.092 -0.958 . . . . 0.0 109.793 179.489 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 64.0 m-80 -89.43 -17.19 29.23 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.925 -0.58 . . . . 0.0 111.212 -178.979 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.422 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 4.6 m -101.22 123.25 45.51 Favored Pre-proline 0 C--N 1.323 -0.568 0 CA-C-O 121.091 0.472 . . . . 0.0 111.335 -178.635 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -63.48 135.03 47.48 Favored 'Trans proline' 0 C--N 1.344 0.299 0 C-N-CA 122.859 2.372 . . . . 0.0 111.941 179.674 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 95.2 -16.35 61.47 Favored Glycine 0 N--CA 1.445 -0.703 0 C-N-CA 120.637 -0.792 . . . . 0.0 111.867 -179.454 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.687 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 99.6 m -87.31 133.65 33.67 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 121.073 0.463 . . . . 0.0 109.906 179.644 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 15.7 m -109.34 137.83 46.61 Favored 'General case' 0 C--N 1.324 -0.522 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 -179.925 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 44.7 t -66.71 128.2 35.35 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-O 121.718 0.77 . . . . 0.0 112.182 -178.428 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 4.4 m -132.4 61.01 1.67 Allowed 'General case' 0 C--N 1.316 -0.867 0 N-CA-C 106.221 -1.77 . . . . 0.0 106.221 177.953 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.481 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -25.76 126.44 0.19 Allowed Pre-proline 0 N--CA 1.466 0.359 0 CA-C-N 113.931 -1.486 . . . . 0.0 113.037 -176.537 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.481 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 67.0 Cg_endo -96.85 30.91 13.07 Favored 'Cis proline' 0 CA--C 1.532 0.421 0 C-N-CA 123.757 -1.351 . . . . 0.0 114.515 0.805 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 43.3 pt -137.34 140.92 41.16 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.424 0 CA-C-O 121.273 0.558 . . . . 0.0 111.371 -179.154 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.687 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 4.5 t -88.41 143.99 26.65 Favored 'General case' 0 C--N 1.314 -0.943 0 CA-C-O 121.259 0.552 . . . . 0.0 110.267 179.908 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.467 HG22 ' HA ' ' A' ' 28' ' ' PRO . 68.5 p -138.04 127.61 24.98 Favored 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 115.433 -0.803 . . . . 0.0 111.316 -178.778 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.678 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 3.2 ptm180 -92.73 124.28 36.62 Favored 'General case' 0 N--CA 1.445 -0.687 0 N-CA-C 108.794 -0.817 . . . . 0.0 108.794 178.447 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 53.7 m-20 57.76 28.94 16.64 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.172 0.511 . . . . 0.0 109.744 -178.271 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 82.44 3.65 90.45 Favored Glycine 0 N--CA 1.449 -0.447 0 CA-C-N 115.854 -0.612 . . . . 0.0 112.683 -179.461 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 86.0 mt -101.18 121.06 53.3 Favored Pre-proline 0 C--O 1.236 0.352 0 O-C-N 122.623 -0.339 . . . . 0.0 110.75 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.467 ' HA ' HG22 ' A' ' 23' ' ' THR . 72.3 Cg_endo -77.06 47.34 2.19 Favored 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 123.062 2.508 . . . . 0.0 112.601 179.828 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 11.6 p . . . . . 0 C--N 1.321 -0.667 0 CA-C-N 115.537 -0.756 . . . . 0.0 110.239 179.999 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' CYS . . . . . 0.567 ' SG ' ' HB3' ' A' ' 24' ' ' ARG . 1.8 m . . . . . 0 N--CA 1.458 -0.058 0 CA-C-O 121.007 0.432 . . . . 0.0 110.339 . . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 76.04 -34.37 1.27 Allowed Glycine 0 CA--C 1.519 0.31 0 CA-C-N 115.865 -0.607 . . . . 0.0 113.287 179.515 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -54.56 140.62 34.22 Favored 'General case' 0 C--O 1.239 0.528 0 CA-C-O 121.658 0.742 . . . . 0.0 112.393 -179.001 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.579 HG23 ' O ' ' A' ' 20' ' ' PRO . 67.8 m -88.89 114.5 25.58 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.059 -0.973 . . . . 0.0 109.984 179.587 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 26.6 p -88.6 58.43 4.66 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 121.324 0.583 . . . . 0.0 110.458 -179.803 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 34.0 t80 -52.69 -44.96 66.62 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.309 -0.859 . . . . 0.0 111.194 -179.726 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -94.06 24.46 26.64 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.582 -0.818 . . . . 0.0 112.781 179.764 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.48 40.38 98.61 Favored Glycine 0 CA--C 1.518 0.264 0 C-N-CA 121.136 -0.554 . . . . 0.0 112.88 179.595 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.3 m -142.45 150.19 40.23 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 179.996 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 57.5 m -132.82 142.02 48.76 Favored 'General case' 0 C--N 1.324 -0.539 0 N-CA-C 110.025 -0.361 . . . . 0.0 110.025 179.869 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 43.6 t30 -89.31 -15.0 34.48 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.842 -0.617 . . . . 0.0 111.229 -179.081 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.635 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 5.7 m -100.67 125.3 39.33 Favored Pre-proline 0 C--N 1.323 -0.549 0 CA-C-O 121.252 0.549 . . . . 0.0 111.509 -178.754 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 28.7 Cg_endo -63.58 131.93 33.5 Favored 'Trans proline' 0 C--N 1.347 0.457 0 C-N-CA 122.999 2.466 . . . . 0.0 112.438 -179.819 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 95.08 -8.62 70.08 Favored Glycine 0 N--CA 1.447 -0.587 0 C-N-CA 120.894 -0.67 . . . . 0.0 111.737 -179.472 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.812 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 84.7 m -88.06 131.62 34.6 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-O 121.127 0.489 . . . . 0.0 110.133 179.63 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 13.3 m -109.49 136.45 48.86 Favored 'General case' 0 C--N 1.324 -0.538 0 N-CA-C 108.925 -0.769 . . . . 0.0 108.925 179.906 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 50.2 t -71.89 119.92 16.76 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-O 121.366 0.603 . . . . 0.0 112.106 -178.631 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 18.4 m -123.89 67.21 1.03 Allowed 'General case' 0 C--N 1.315 -0.903 0 N-CA-C 106.624 -1.621 . . . . 0.0 106.624 177.697 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.447 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.2 OUTLIER -29.03 127.51 0.23 Allowed Pre-proline 0 N--CA 1.464 0.234 0 CA-C-N 114.092 -1.413 . . . . 0.0 112.862 -176.721 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.579 ' O ' HG23 ' A' ' 4' ' ' THR . 65.6 Cg_endo -97.71 33.24 9.85 Favored 'Cis proline' 0 N--CA 1.46 -0.484 0 C-N-CA 123.767 -1.347 . . . . 0.0 114.23 0.822 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 41.8 pt -139.59 137.37 40.02 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-O 121.425 0.631 . . . . 0.0 111.632 -179.182 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.812 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 6.2 t -84.27 143.18 29.72 Favored 'General case' 0 C--N 1.316 -0.885 0 CA-C-O 121.311 0.576 . . . . 0.0 109.791 179.222 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.411 HG22 ' HA ' ' A' ' 28' ' ' PRO . 14.9 p -138.28 125.82 22.04 Favored 'General case' 0 C--N 1.314 -0.943 0 CA-C-N 115.239 -0.892 . . . . 0.0 111.378 -178.497 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.567 ' HB3' ' SG ' ' A' ' 1' ' ' CYS . 0.0 OUTLIER -91.1 129.3 37.11 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 178.864 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.453 ' CG ' ' HD3' ' A' ' 24' ' ' ARG . 54.8 m-20 54.6 30.03 12.48 Favored 'General case' 0 C--N 1.324 -0.529 0 O-C-N 123.85 0.719 . . . . 0.0 110.382 -178.844 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 77.46 13.97 82.98 Favored Glycine 0 C--N 1.335 0.498 0 CA-C-N 115.803 -0.635 . . . . 0.0 112.652 -179.583 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 90.2 mt -117.46 132.23 23.67 Favored Pre-proline 0 C--O 1.236 0.354 0 CA-C-O 120.825 0.345 . . . . 0.0 110.831 -179.888 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.411 ' HA ' HG22 ' A' ' 23' ' ' THR . 70.8 Cg_endo -74.6 53.68 3.22 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 123.116 2.544 . . . . 0.0 112.673 -179.95 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 40.9 t . . . . . 0 C--N 1.323 -0.58 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.404 -179.85 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 67.9 m . . . . . 0 N--CA 1.458 -0.051 0 CA-C-O 120.905 0.383 . . . . 0.0 110.195 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 60.14 38.11 93.9 Favored Glycine 0 C--N 1.333 0.381 0 CA-C-N 115.74 -0.663 . . . . 0.0 112.694 179.299 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -117.87 151.77 36.72 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 120.86 0.362 . . . . 0.0 110.848 -179.789 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.491 HG23 ' O ' ' A' ' 20' ' ' PRO . 28.2 m -96.66 118.67 33.63 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-N 115.893 -0.594 . . . . 0.0 111.051 179.811 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.716 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 7.6 p -88.45 61.2 6.02 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 121.262 0.553 . . . . 0.0 109.699 178.826 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 13.2 t80 -54.26 -41.51 68.91 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.35 -0.841 . . . . 0.0 110.28 -179.548 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -91.94 22.98 28.65 Favored Glycine 0 N--CA 1.449 -0.488 0 C-N-CA 120.926 -0.654 . . . . 0.0 112.611 179.325 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 78.71 -38.28 1.91 Allowed Glycine 0 CA--C 1.522 0.483 0 C-N-CA 121.251 -0.5 . . . . 0.0 113.631 179.447 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.4 m -89.49 147.38 24.02 Favored 'General case' 0 C--N 1.321 -0.65 0 O-C-N 122.498 -0.413 . . . . 0.0 111.49 -179.348 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 62.9 m -104.49 154.82 19.41 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.759 -0.655 . . . . 0.0 109.394 178.834 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 39.7 t30 -87.64 -26.7 22.89 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-O 121.135 0.493 . . . . 0.0 110.496 -179.717 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 3.7 m -102.12 120.42 53.7 Favored Pre-proline 0 C--N 1.324 -0.54 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.283 -179.268 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_exo -65.71 140.62 62.67 Favored 'Trans proline' 0 N--CA 1.461 -0.385 0 C-N-CA 122.943 2.428 . . . . 0.0 111.846 179.693 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 105.1 -28.91 12.74 Favored Glycine 0 N--CA 1.441 -0.976 0 C-N-CA 120.717 -0.754 . . . . 0.0 111.66 -179.356 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.578 ' HB3' ' HB3' ' A' ' 22' ' ' CYS . 2.0 m -87.64 131.55 34.4 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 121.273 0.559 . . . . 0.0 110.546 179.402 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 13.6 m -91.53 140.52 29.67 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.482 -0.781 . . . . 0.0 109.168 179.59 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 39.9 t -75.52 111.14 10.51 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-O 121.645 0.736 . . . . 0.0 111.598 -179.121 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 11.7 m -114.47 65.43 0.67 Allowed 'General case' 0 C--N 1.308 -1.197 0 N-CA-C 106.254 -1.758 . . . . 0.0 106.254 177.385 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.527 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.5 OUTLIER -28.66 125.78 0.24 Allowed Pre-proline 0 N--CA 1.464 0.252 0 CA-C-N 114.072 -1.422 . . . . 0.0 112.574 -176.583 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.527 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 65.0 Cg_endo -98.4 38.03 5.84 Favored 'Cis proline' 0 N--CA 1.459 -0.54 0 C-N-CA 123.963 -1.265 . . . . 0.0 114.109 0.899 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 2.3 pp -143.43 133.02 20.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 121.541 0.686 . . . . 0.0 112.457 -178.938 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.716 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 63.8 m -83.0 134.46 35.05 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.411 179.225 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 5.2 p -138.56 130.56 28.22 Favored 'General case' 0 C--N 1.317 -0.843 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.038 -179.746 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.432 ' O ' ' HG3' ' A' ' 24' ' ' ARG . 9.6 ptm180 -97.5 127.82 43.77 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 178.764 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 27.9 m-20 58.52 27.43 15.61 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.439 0.637 . . . . 0.0 109.504 -178.692 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 77.38 7.86 87.02 Favored Glycine 0 N--CA 1.449 -0.471 0 CA-C-N 115.411 -0.813 . . . . 0.0 112.389 -178.984 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.434 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 91.6 mt -109.59 131.57 21.82 Favored Pre-proline 0 C--O 1.238 0.451 0 CA-C-O 121.158 0.504 . . . . 0.0 111.293 -179.666 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.434 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 5.0 Cg_exo -77.06 65.4 7.81 Favored 'Trans proline' 0 N--CA 1.463 -0.32 0 C-N-CA 123.656 2.904 . . . . 0.0 111.95 179.594 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 47.8 t . . . . . 0 C--N 1.325 -0.465 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.594 -179.166 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 CA--C 1.526 0.035 0 CA-C-O 121.046 0.45 . . . . 0.0 110.299 . . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 60.37 38.63 94.99 Favored Glycine 0 C--N 1.332 0.348 0 CA-C-N 115.535 -0.757 . . . . 0.0 112.796 179.353 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.433 ' HG3' ' HB3' ' A' ' 22' ' ' CYS . 10.9 pt-20 -125.0 143.19 51.03 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 121.187 0.517 . . . . 0.0 111.259 -179.731 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.545 HG23 ' O ' ' A' ' 20' ' ' PRO . 87.9 m -89.18 111.46 22.25 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.376 179.85 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 25.3 p -88.77 58.98 4.87 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 121.287 0.565 . . . . 0.0 110.468 -179.995 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 33.6 t80 -52.92 -46.01 67.88 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.378 -0.828 . . . . 0.0 111.233 -179.688 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -92.56 24.04 25.15 Favored Glycine 0 C--O 1.227 -0.291 0 C-N-CA 120.579 -0.82 . . . . 0.0 112.728 179.73 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.83 36.72 93.2 Favored Glycine 0 C--O 1.228 -0.252 0 C-N-CA 121.2 -0.524 . . . . 0.0 112.666 179.694 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.7 m -136.06 148.95 48.56 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 60.3 m -129.33 141.57 51.05 Favored 'General case' 0 C--N 1.322 -0.628 0 O-C-N 123.218 0.324 . . . . 0.0 110.246 179.9 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 44.0 t30 -89.06 -17.3 29.6 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.804 -0.635 . . . . 0.0 110.614 -179.592 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.522 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 4.3 m -101.31 123.46 44.62 Favored Pre-proline 0 C--N 1.322 -0.596 0 CA-C-O 121.14 0.495 . . . . 0.0 111.33 -178.939 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.447 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 23.4 Cg_exo -64.18 136.65 52.77 Favored 'Trans proline' 0 C--N 1.345 0.349 0 C-N-CA 123.017 2.478 . . . . 0.0 112.013 179.948 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 92.85 -12.27 70.26 Favored Glycine 0 N--CA 1.447 -0.596 0 C-N-CA 120.79 -0.719 . . . . 0.0 111.881 -179.626 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.673 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 98.9 m -87.55 134.4 33.63 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 121.125 0.488 . . . . 0.0 110.308 179.773 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 12.6 m -107.4 137.55 45.23 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.637 -0.71 . . . . 0.0 109.104 -179.88 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 53.9 t -72.95 115.52 12.35 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-O 121.496 0.665 . . . . 0.0 111.961 -178.739 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 8.7 m -116.29 66.49 0.71 Allowed 'General case' 0 C--N 1.312 -1.03 0 N-CA-C 106.515 -1.661 . . . . 0.0 106.515 177.478 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.447 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.2 OUTLIER -28.82 126.86 0.23 Allowed Pre-proline 0 N--CA 1.464 0.229 0 CA-C-N 114.303 -1.317 . . . . 0.0 112.841 -176.559 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.545 ' O ' HG23 ' A' ' 4' ' ' THR . 62.6 Cg_endo -97.21 32.79 10.48 Favored 'Cis proline' 0 CA--C 1.532 0.396 0 C-N-CA 123.676 -1.385 . . . . 0.0 114.293 0.93 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 44.2 pt -138.97 133.87 41.41 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-O 121.451 0.643 . . . . 0.0 111.888 -179.239 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.673 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 7.0 t -83.48 142.87 30.62 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-O 121.22 0.533 . . . . 0.0 109.746 179.202 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.559 HG22 ' HA ' ' A' ' 28' ' ' PRO . 14.9 p -145.33 131.99 19.93 Favored 'General case' 0 C--N 1.314 -0.949 0 CA-C-N 115.276 -0.875 . . . . 0.0 111.293 -178.399 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.535 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 0.0 OUTLIER -92.39 128.51 38.26 Favored 'General case' 0 N--CA 1.448 -0.555 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 178.38 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 18.6 m-20 56.57 28.45 13.94 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.191 0.52 . . . . 0.0 109.963 -179.253 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 76.79 13.16 83.87 Favored Glycine 0 C--N 1.333 0.409 0 CA-C-N 115.745 -0.661 . . . . 0.0 112.362 -179.089 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 27' ' ' LEU . . . . . 0.486 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 87.2 mt -112.49 129.55 24.26 Favored Pre-proline 0 C--O 1.241 0.655 0 CA-C-O 120.887 0.375 . . . . 0.0 110.858 -179.847 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.559 ' HA ' HG22 ' A' ' 23' ' ' THR . 2.8 Cg_exo -75.54 54.14 3.8 Favored 'Trans proline' 0 C--N 1.342 0.216 0 C-N-CA 123.718 2.945 . . . . 0.0 112.468 -179.95 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 45.4 t . . . . . 0 C--N 1.323 -0.553 0 CA-C-O 121.331 0.586 . . . . 0.0 110.141 -179.748 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' CYS . . . . . 0.415 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 61.4 m . . . . . 0 N--CA 1.458 -0.043 0 CA-C-O 121.037 0.446 . . . . 0.0 109.806 . . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 60.26 32.95 78.33 Favored Glycine 0 C--N 1.332 0.347 0 CA-C-N 115.497 -0.774 . . . . 0.0 113.204 179.087 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.463 ' HG3' ' HB3' ' A' ' 22' ' ' CYS . 9.3 pt-20 -105.71 145.54 30.96 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 121.045 0.45 . . . . 0.0 111.015 179.901 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.511 HG23 ' O ' ' A' ' 20' ' ' PRO . 58.3 m -88.83 110.0 20.67 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.89 -0.596 . . . . 0.0 110.399 179.91 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 25.8 p -88.78 59.71 5.2 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 121.429 0.633 . . . . 0.0 110.536 -179.941 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 34.8 t80 -53.64 -43.78 69.02 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.286 -0.87 . . . . 0.0 111.165 -179.75 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -88.23 18.54 40.52 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.743 -0.741 . . . . 0.0 113.004 179.905 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 64.56 37.61 94.63 Favored Glycine 0 N--CA 1.453 -0.233 0 C-N-CA 121.077 -0.582 . . . . 0.0 112.656 179.668 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.6 m -147.38 149.52 32.92 Favored 'General case' 0 C--N 1.324 -0.522 0 N-CA-C 109.665 -0.494 . . . . 0.0 109.665 179.92 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 43.4 m -121.45 146.0 47.35 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.239 -179.899 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 39.1 t30 -88.26 -23.45 23.5 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.154 -179.787 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' THR . . . . . 0.415 ' HB ' ' SG ' ' A' ' 1' ' ' CYS . 2.9 m -101.95 121.11 51.88 Favored Pre-proline 0 C--N 1.323 -0.582 0 CA-C-N 115.999 -0.546 . . . . 0.0 111.413 -178.977 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 22.2 Cg_exo -64.74 141.5 72.5 Favored 'Trans proline' 0 C--N 1.344 0.298 0 C-N-CA 123.021 2.48 . . . . 0.0 111.854 179.76 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 101.62 -28.17 17.16 Favored Glycine 0 N--CA 1.445 -0.747 0 C-N-CA 120.687 -0.768 . . . . 0.0 111.615 -179.331 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.849 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 1.6 m -86.97 136.85 32.78 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 121.136 0.493 . . . . 0.0 110.191 179.446 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 14.2 m -105.26 140.18 38.8 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.596 -0.729 . . . . 0.0 109.314 -179.745 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 53.9 t -72.37 112.33 8.34 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.482 0.658 . . . . 0.0 111.709 -178.887 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 14.1 m -114.54 66.91 0.68 Allowed 'General case' 0 C--N 1.312 -1.052 0 N-CA-C 106.554 -1.647 . . . . 0.0 106.554 177.624 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 19' ' ' TRP . . . . . 0.472 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.2 OUTLIER -28.91 127.01 0.23 Allowed Pre-proline 0 N--CA 1.464 0.266 0 CA-C-N 114.24 -1.345 . . . . 0.0 112.833 -176.631 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 20' ' ' PRO . . . . . 0.511 ' O ' HG23 ' A' ' 4' ' ' THR . 62.2 Cg_endo -97.1 31.85 11.75 Favored 'Cis proline' 0 N--CA 1.46 -0.443 0 C-N-CA 123.627 -1.406 . . . . 0.0 114.213 0.968 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 43.0 pt -138.56 133.61 42.53 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-O 121.663 0.744 . . . . 0.0 112.025 -179.174 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.849 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 8.0 t -83.54 140.1 32.47 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-N 115.927 -0.578 . . . . 0.0 109.547 179.011 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 23' ' ' THR . . . . . 0.569 HG22 ' HA ' ' A' ' 28' ' ' PRO . 7.9 p -148.76 135.5 19.76 Favored 'General case' 0 C--N 1.313 -0.982 0 CA-C-N 115.274 -0.875 . . . . 0.0 111.342 -178.104 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 24' ' ' ARG . . . . . 0.499 ' O ' ' HG3' ' A' ' 24' ' ' ARG . 4.8 ptm180 -93.92 126.29 39.04 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 178.576 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 58.52 27.23 15.32 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.36 0.6 . . . . 0.0 109.404 -179.069 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 77.57 9.31 86.94 Favored Glycine 0 C--N 1.333 0.392 0 CA-C-N 115.504 -0.771 . . . . 0.0 112.251 -178.885 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 88.4 mt -108.07 131.12 21.96 Favored Pre-proline 0 C--O 1.24 0.558 0 CA-C-O 121.092 0.472 . . . . 0.0 111.091 -179.724 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.569 ' HA ' HG22 ' A' ' 23' ' ' THR . 74.2 Cg_endo -76.14 64.3 7.01 Favored 'Trans proline' 0 C--N 1.341 0.158 0 C-N-CA 123.269 2.646 . . . . 0.0 112.48 179.946 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 55.5 t . . . . . 0 C--N 1.324 -0.532 0 CA-C-O 121.285 0.564 . . . . 0.0 110.163 -179.759 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 5.4 m . . . . . 0 N--CA 1.457 -0.092 0 CA-C-O 121.038 0.447 . . . . 0.0 110.013 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 76.68 -35.45 1.4 Allowed Glycine 0 C--N 1.331 0.259 0 CA-C-N 115.849 -0.614 . . . . 0.0 113.703 179.069 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 7.3 pt-20 -58.13 143.84 42.49 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 121.615 0.721 . . . . 0.0 112.058 -178.981 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.531 HG23 ' O ' ' A' ' 20' ' ' PRO . 53.6 m -95.11 121.35 36.65 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.034 -0.985 . . . . 0.0 110.658 179.688 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.772 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 13.7 p -88.08 61.17 6.17 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 121.258 0.552 . . . . 0.0 109.866 179.05 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 29.4 t80 -52.77 -44.5 66.56 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.368 -0.833 . . . . 0.0 110.555 -179.609 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -93.45 25.08 22.52 Favored Glycine 0 N--CA 1.449 -0.462 0 C-N-CA 120.639 -0.791 . . . . 0.0 112.399 179.223 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 75.59 -30.52 1.23 Allowed Glycine 0 CA--C 1.523 0.562 0 C-N-CA 121.485 -0.388 . . . . 0.0 113.789 179.579 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.5 m -89.1 148.95 23.42 Favored 'General case' 0 C--N 1.322 -0.59 0 O-C-N 122.367 -0.49 . . . . 0.0 111.293 -179.483 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 79.7 m -112.15 151.44 29.49 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.859 -0.61 . . . . 0.0 109.684 179.11 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -88.46 -21.64 24.1 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 120.895 0.379 . . . . 0.0 110.53 -179.214 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 4.3 m -100.71 123.38 45.98 Favored Pre-proline 0 C--N 1.323 -0.557 0 CA-C-O 121.148 0.499 . . . . 0.0 111.277 -179.1 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 29.7 Cg_endo -63.75 136.04 51.61 Favored 'Trans proline' 0 C--N 1.344 0.332 0 C-N-CA 122.823 2.348 . . . . 0.0 111.562 179.519 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 98.69 -21.39 46.19 Favored Glycine 0 N--CA 1.443 -0.834 0 C-N-CA 120.509 -0.853 . . . . 0.0 111.744 -179.228 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.576 ' HB3' ' HB3' ' A' ' 22' ' ' CYS . 71.3 m -86.73 126.35 34.52 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 121.212 0.529 . . . . 0.0 110.235 179.597 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 14.8 m -96.85 140.64 31.11 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 115.449 -0.796 . . . . 0.0 109.023 179.634 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 53.7 t -69.76 123.68 22.03 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-O 121.683 0.754 . . . . 0.0 111.92 -178.792 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 7.4 m -130.06 61.68 1.58 Allowed 'General case' 0 C--N 1.313 -0.997 0 N-CA-C 106.031 -1.84 . . . . 0.0 106.031 177.787 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.535 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -27.51 125.71 0.22 Allowed Pre-proline 0 N--CA 1.463 0.198 0 CA-C-N 113.827 -1.533 . . . . 0.0 112.787 -176.576 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.535 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 71.9 Cg_endo -98.03 38.07 5.82 Favored 'Cis proline' 0 N--CA 1.459 -0.533 0 C-N-CA 123.813 -1.328 . . . . 0.0 114.172 0.746 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 39.9 pt -143.44 136.9 25.21 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 O-C-N 121.6 -0.688 . . . . 0.0 112.026 -179.148 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.772 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 74.0 m -82.37 136.61 34.95 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-O 121.09 0.471 . . . . 0.0 110.236 178.923 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.41 HG22 ' CA ' ' A' ' 28' ' ' PRO . 67.0 p -127.3 123.47 36.47 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.857 -179.615 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.542 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 4.4 ptm180 -92.63 125.69 37.37 Favored 'General case' 0 N--CA 1.445 -0.702 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 178.519 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 58.62 26.75 14.86 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.257 0.551 . . . . 0.0 109.682 -178.941 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 84.11 3.27 89.09 Favored Glycine 0 N--CA 1.45 -0.428 0 CA-C-N 115.723 -0.671 . . . . 0.0 112.668 -179.402 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.46 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 88.8 mt -102.91 121.5 48.97 Favored Pre-proline 0 C--N 1.328 -0.352 0 O-C-N 122.561 -0.376 . . . . 0.0 110.857 -179.947 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.46 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 5.1 Cg_exo -76.98 47.22 2.15 Favored 'Trans proline' 0 C--N 1.343 0.246 0 C-N-CA 123.361 2.707 . . . . 0.0 112.307 179.827 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 10.7 p . . . . . 0 C--N 1.32 -0.692 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.402 -179.856 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.3 m . . . . . 0 CA--C 1.527 0.068 0 CA-C-O 120.962 0.41 . . . . 0.0 110.419 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 77.92 -36.39 1.68 Allowed Glycine 0 C--N 1.331 0.251 0 CA-C-N 115.969 -0.56 . . . . 0.0 113.166 179.415 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 11.8 pt-20 -58.27 137.26 57.26 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 121.5 0.667 . . . . 0.0 112.072 -179.244 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.498 ' HB ' ' CD1' ' A' ' 6' ' ' PHE . 10.6 p -91.15 117.52 29.68 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.37 -0.832 . . . . 0.0 109.804 179.221 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 28.2 p -88.92 57.97 4.37 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.012 0.434 . . . . 0.0 111.764 -178.521 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . 0.498 ' CD1' ' HB ' ' A' ' 4' ' ' THR . 5.3 m-85 -57.64 -38.07 74.4 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.99 179.423 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -89.9 18.06 49.6 Favored Glycine 0 CA--C 1.519 0.315 0 C-N-CA 120.639 -0.791 . . . . 0.0 112.861 179.841 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 62.31 39.48 97.79 Favored Glycine 0 C--N 1.331 0.27 0 C-N-CA 121.092 -0.575 . . . . 0.0 112.916 179.546 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 3.5 m -149.04 152.18 35.8 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 109.724 -0.473 . . . . 0.0 109.724 -179.996 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 56.8 m -129.94 143.4 50.78 Favored 'General case' 0 C--N 1.324 -0.522 0 O-C-N 123.21 0.319 . . . . 0.0 110.225 179.927 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 43.0 t30 -89.13 -18.11 27.86 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.026 -179.229 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.442 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 6.7 m -100.97 125.13 39.34 Favored Pre-proline 0 C--N 1.323 -0.558 0 CA-C-O 121.155 0.503 . . . . 0.0 111.671 -178.649 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_endo -64.41 138.52 60.61 Favored 'Trans proline' 0 C--N 1.346 0.395 0 C-N-CA 122.859 2.372 . . . . 0.0 111.626 179.541 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 93.67 -15.55 62.78 Favored Glycine 0 N--CA 1.447 -0.607 0 C-N-CA 120.726 -0.75 . . . . 0.0 111.557 -179.133 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.769 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 93.7 m -87.45 133.27 33.77 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 121.045 0.45 . . . . 0.0 110.163 179.606 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 14.6 m -110.54 136.58 49.44 Favored 'General case' 0 C--N 1.323 -0.56 0 N-CA-C 109.209 -0.663 . . . . 0.0 109.209 179.934 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.8 t -67.37 126.42 29.2 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-O 121.437 0.637 . . . . 0.0 111.914 -178.604 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 4.9 m -132.35 65.79 1.57 Allowed 'General case' 0 C--N 1.318 -0.79 0 N-CA-C 106.889 -1.523 . . . . 0.0 106.889 178.457 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.506 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -27.71 126.67 0.22 Allowed Pre-proline 0 N--CA 1.465 0.289 0 CA-C-N 114.402 -1.272 . . . . 0.0 112.93 -176.684 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.506 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 62.8 Cg_endo -97.68 30.72 12.97 Favored 'Cis proline' 0 N--CA 1.461 -0.43 0 C-N-CA 123.802 -1.333 . . . . 0.0 114.424 0.927 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.497 HG22 HG22 ' A' ' 4' ' ' THR . 43.5 pt -138.65 142.58 34.32 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.36 0 CA-C-O 121.385 0.612 . . . . 0.0 111.448 -179.05 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.769 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 5.8 t -87.97 144.0 26.79 Favored 'General case' 0 C--N 1.314 -0.943 0 CA-C-O 121.137 0.494 . . . . 0.0 110.005 179.393 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 48.7 p -136.58 126.84 26.45 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-N 115.573 -0.74 . . . . 0.0 111.7 -178.58 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.666 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 9.1 ptm180 -91.47 126.9 36.71 Favored 'General case' 0 N--CA 1.445 -0.713 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 177.985 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 29.0 m-20 58.34 26.72 14.38 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 121.209 0.528 . . . . 0.0 109.911 -178.889 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 80.31 10.07 85.82 Favored Glycine 0 N--CA 1.45 -0.432 0 CA-C-N 115.864 -0.607 . . . . 0.0 112.363 -179.395 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.412 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 89.7 mt -113.15 128.54 25.52 Favored Pre-proline 0 C--O 1.236 0.379 0 CA-C-O 120.857 0.36 . . . . 0.0 110.755 -180.0 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.412 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 6.5 Cg_exo -73.76 52.94 2.65 Favored 'Trans proline' 0 CA--C 1.527 0.166 0 C-N-CA 123.619 2.879 . . . . 0.0 112.54 -179.839 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 39.4 t . . . . . 0 C--N 1.323 -0.57 0 CA-C-O 121.364 0.602 . . . . 0.0 110.206 -179.75 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.5 m . . . . . 0 N--CA 1.458 -0.058 0 CA-C-O 121.081 0.467 . . . . 0.0 110.191 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 77.16 -36.28 1.51 Allowed Glycine 0 C--N 1.332 0.331 0 CA-C-N 115.862 -0.608 . . . . 0.0 113.29 179.256 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 9.1 pt-20 -58.04 138.6 55.85 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 121.585 0.707 . . . . 0.0 112.181 -179.166 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.464 ' HA ' ' HA ' ' A' ' 21' ' ' ILE . 28.9 p -89.77 119.86 30.53 Favored 'General case' 0 N--CA 1.445 -0.675 0 CA-C-N 115.288 -0.869 . . . . 0.0 109.663 179.064 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 25.7 p -87.83 60.6 5.99 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 121.478 0.656 . . . . 0.0 110.507 -179.684 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 36.0 t80 -54.6 -41.5 70.01 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.353 -0.839 . . . . 0.0 110.613 179.942 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -94.33 22.93 34.26 Favored Glycine 0 N--CA 1.449 -0.492 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.733 179.611 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 75.25 -28.85 1.18 Allowed Glycine 0 CA--C 1.523 0.593 0 C-N-CA 121.192 -0.528 . . . . 0.0 113.94 179.382 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.8 m -88.43 151.05 22.82 Favored 'General case' 0 C--N 1.322 -0.616 0 O-C-N 122.522 -0.399 . . . . 0.0 111.445 -179.015 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 61.6 m -120.79 149.77 42.03 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.855 -0.611 . . . . 0.0 109.763 179.266 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 41.3 t30 -88.8 -21.33 23.81 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 121.115 0.483 . . . . 0.0 111.181 -179.227 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 6.4 m -101.08 124.2 42.4 Favored Pre-proline 0 C--N 1.323 -0.575 0 CA-C-O 121.239 0.542 . . . . 0.0 111.793 -178.424 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 33.7 Cg_endo -65.01 138.35 56.66 Favored 'Trans proline' 0 C--N 1.346 0.423 0 C-N-CA 122.897 2.398 . . . . 0.0 111.58 179.461 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 95.22 -16.22 61.75 Favored Glycine 0 N--CA 1.446 -0.655 0 C-N-CA 120.635 -0.793 . . . . 0.0 111.492 -179.224 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.668 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 91.5 m -88.07 133.81 33.89 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 120.991 0.424 . . . . 0.0 109.934 179.368 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 15.1 m -108.62 136.47 48.16 Favored 'General case' 0 C--N 1.322 -0.604 0 N-CA-C 109.201 -0.666 . . . . 0.0 109.201 -179.996 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.4 t -66.92 126.07 27.95 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-O 121.673 0.749 . . . . 0.0 111.91 -178.49 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 4.6 m -129.93 62.52 1.55 Allowed 'General case' 0 C--N 1.316 -0.87 0 N-CA-C 106.37 -1.715 . . . . 0.0 106.37 178.016 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.456 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.2 OUTLIER -26.11 126.4 0.2 Allowed Pre-proline 0 N--CA 1.465 0.307 0 CA-C-N 114.052 -1.431 . . . . 0.0 113.028 -176.507 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.456 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 61.0 Cg_endo -97.49 31.55 11.97 Favored 'Cis proline' 0 CA--C 1.533 0.459 0 C-N-CA 123.731 -1.362 . . . . 0.0 114.32 1.02 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.464 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 42.8 pt -138.04 140.29 40.81 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.354 0 CA-C-O 121.272 0.558 . . . . 0.0 111.362 -179.194 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.668 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 4.0 t -87.0 144.07 27.07 Favored 'General case' 0 C--N 1.315 -0.929 0 CA-C-O 121.205 0.526 . . . . 0.0 110.146 179.715 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 60.4 p -136.64 127.82 28.01 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 115.572 -0.74 . . . . 0.0 111.643 -178.553 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.6 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 1.7 ptm180 -89.07 123.42 33.35 Favored 'General case' 0 N--CA 1.446 -0.63 0 N-CA-C 108.528 -0.915 . . . . 0.0 108.528 178.197 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 69.8 m-20 57.44 30.73 19.1 Favored 'General case' 0 N--CA 1.468 0.461 0 O-C-N 123.518 0.511 . . . . 0.0 109.955 -177.627 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 78.54 9.65 86.85 Favored Glycine 0 C--N 1.333 0.415 0 CA-C-N 115.895 -0.593 . . . . 0.0 112.688 -179.656 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 90.4 mt -110.61 127.01 27.67 Favored Pre-proline 0 C--O 1.237 0.4 0 O-C-N 122.682 -0.305 . . . . 0.0 110.686 179.912 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 61.9 Cg_endo -73.57 52.45 2.46 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 123.268 2.645 . . . . 0.0 112.783 -179.837 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 39.7 t . . . . . 0 C--N 1.323 -0.56 0 CA-C-O 121.396 0.617 . . . . 0.0 110.041 -179.948 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.8 m . . . . . 0 CA--C 1.527 0.077 0 CA-C-O 120.967 0.413 . . . . 0.0 110.409 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 77.78 -36.01 1.64 Allowed Glycine 0 C--N 1.33 0.231 0 CA-C-N 115.848 -0.615 . . . . 0.0 113.405 179.278 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 11.1 pt-20 -56.6 136.22 54.61 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.523 0.678 . . . . 0.0 112.085 -179.001 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.647 HG22 HG22 ' A' ' 21' ' ' ILE . 24.6 p -89.58 114.99 26.65 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.347 -0.842 . . . . 0.0 109.951 179.424 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 28.3 p -88.9 58.34 4.54 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 120.999 0.428 . . . . 0.0 111.673 -179.006 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . 0.482 ' CD1' ' HB ' ' A' ' 4' ' ' THR . 5.1 m-85 -57.17 -38.15 73.17 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.137 179.444 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -89.43 17.52 51.55 Favored Glycine 0 CA--C 1.519 0.314 0 C-N-CA 120.656 -0.783 . . . . 0.0 112.791 179.815 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 62.57 40.23 98.87 Favored Glycine 0 C--N 1.331 0.268 0 C-N-CA 121.141 -0.552 . . . . 0.0 112.88 179.529 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.8 m -148.38 150.57 33.78 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 109.65 -0.5 . . . . 0.0 109.65 179.885 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 56.6 m -128.53 143.65 51.01 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 120.797 0.332 . . . . 0.0 110.413 -179.846 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 42.8 t30 -89.21 -18.98 26.0 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.805 -179.538 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 6.0 m -101.26 124.49 41.12 Favored Pre-proline 0 C--N 1.324 -0.521 0 CA-C-O 121.169 0.509 . . . . 0.0 111.586 -178.593 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 36.0 Cg_endo -65.54 140.43 62.84 Favored 'Trans proline' 0 C--N 1.346 0.404 0 C-N-CA 122.849 2.366 . . . . 0.0 111.72 179.468 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 93.73 -17.09 59.32 Favored Glycine 0 N--CA 1.447 -0.58 0 C-N-CA 120.608 -0.806 . . . . 0.0 111.495 -179.054 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.71 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 94.4 m -87.34 134.6 33.55 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-O 121.067 0.46 . . . . 0.0 110.087 179.714 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 14.5 m -108.71 136.3 48.51 Favored 'General case' 0 C--N 1.323 -0.57 0 N-CA-C 108.997 -0.742 . . . . 0.0 108.997 179.97 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 48.7 t -71.21 121.53 18.55 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-O 121.472 0.654 . . . . 0.0 111.856 -178.644 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 2.0 p -129.64 73.07 1.5 Allowed 'General case' 0 C--N 1.314 -0.956 0 N-CA-C 107.354 -1.35 . . . . 0.0 107.354 177.934 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.474 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.0 OUTLIER -29.57 129.51 0.24 Allowed Pre-proline 0 N--CA 1.465 0.31 0 CA-C-N 114.379 -1.282 . . . . 0.0 112.906 -176.842 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.474 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 68.2 Cg_endo -97.48 27.56 17.46 Favored 'Cis proline' 0 N--CA 1.46 -0.468 0 C-N-CA 123.696 -1.377 . . . . 0.0 114.682 1.001 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.647 HG22 HG22 ' A' ' 4' ' ' THR . 0.2 OUTLIER -139.3 148.61 23.45 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.347 0 CA-C-O 121.309 0.576 . . . . 0.0 111.229 -179.297 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.71 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 4.6 t -88.81 144.22 26.37 Favored 'General case' 0 C--N 1.312 -1.057 0 CA-C-O 121.168 0.509 . . . . 0.0 109.783 179.635 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.458 HG22 ' HA ' ' A' ' 28' ' ' PRO . 21.5 p -138.13 126.58 23.32 Favored 'General case' 0 C--N 1.314 -0.954 0 CA-C-N 115.478 -0.783 . . . . 0.0 111.586 -178.486 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.623 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 4.8 ptm180 -90.18 127.52 36.14 Favored 'General case' 0 N--CA 1.446 -0.67 0 N-CA-C 108.803 -0.814 . . . . 0.0 108.803 178.445 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 58.04 27.04 14.3 Favored 'General case' 0 C--N 1.328 -0.37 0 CA-C-O 121.206 0.527 . . . . 0.0 109.873 -179.225 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 78.4 13.52 83.16 Favored Glycine 0 C--N 1.334 0.417 0 CA-C-N 115.821 -0.627 . . . . 0.0 112.201 -179.165 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 89.9 mt -114.94 129.98 24.58 Favored Pre-proline 0 C--O 1.238 0.496 0 CA-C-O 120.914 0.388 . . . . 0.0 110.751 -179.894 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.458 ' HA ' HG22 ' A' ' 23' ' ' THR . 67.7 Cg_endo -74.24 53.67 3.05 Favored 'Trans proline' 0 C--N 1.344 0.291 0 C-N-CA 123.277 2.651 . . . . 0.0 112.789 -179.807 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 39.9 t . . . . . 0 C--N 1.323 -0.553 0 CA-C-O 121.416 0.627 . . . . 0.0 110.2 -179.896 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.458 -0.031 0 CA-C-O 121.07 0.462 . . . . 0.0 110.253 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 61.04 38.77 96.09 Favored Glycine 0 C--N 1.332 0.324 0 CA-C-N 115.595 -0.73 . . . . 0.0 112.776 179.33 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -127.55 143.2 51.2 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 121.15 0.5 . . . . 0.0 110.986 -179.812 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.492 ' HB ' ' CD1' ' A' ' 6' ' ' PHE . 21.0 p -89.58 111.67 22.67 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.014 179.487 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 23.8 p -88.85 59.21 4.95 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 121.096 0.474 . . . . 0.0 111.401 -179.24 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . 0.492 ' CD1' ' HB ' ' A' ' 4' ' ' THR . 4.5 m-85 -57.48 -36.41 71.45 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.739 179.382 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -88.53 16.77 52.51 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.788 179.517 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 76.39 -29.6 1.44 Allowed Glycine 0 CA--C 1.523 0.588 0 C-N-CA 121.226 -0.511 . . . . 0.0 113.612 179.536 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.9 m -88.57 150.93 22.82 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 120.844 0.354 . . . . 0.0 111.172 -179.139 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 69.5 m -117.49 148.3 41.96 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.831 -0.622 . . . . 0.0 109.893 179.396 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 66.1 m-80 -88.84 -18.81 26.87 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.819 -179.511 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.529 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 3.2 m -101.87 124.93 38.6 Favored Pre-proline 0 C--N 1.324 -0.527 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.238 -178.984 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -65.77 138.24 52.76 Favored 'Trans proline' 0 C--N 1.344 0.304 0 C-N-CA 122.804 2.336 . . . . 0.0 112.022 179.746 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 91.61 -13.01 67.77 Favored Glycine 0 N--CA 1.449 -0.499 0 C-N-CA 120.761 -0.733 . . . . 0.0 111.876 -179.495 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.689 ' SG ' ' HB3' ' A' ' 24' ' ' ARG . 99.3 m -87.34 136.08 33.07 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.108 0.48 . . . . 0.0 110.401 179.857 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 9.9 m -107.39 135.86 48.16 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 108.99 -0.744 . . . . 0.0 108.99 179.925 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.3 t -72.41 120.73 18.43 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-O 121.596 0.713 . . . . 0.0 112.17 -178.468 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 7.6 m -122.33 65.3 0.94 Allowed 'General case' 0 C--N 1.314 -0.968 0 N-CA-C 106.494 -1.669 . . . . 0.0 106.494 177.705 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.46 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -27.32 126.96 0.21 Allowed Pre-proline 0 N--CA 1.466 0.359 0 CA-C-N 114.222 -1.354 . . . . 0.0 112.955 -176.51 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.46 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 64.9 Cg_endo -97.2 31.07 12.73 Favored 'Cis proline' 0 N--CA 1.461 -0.42 0 C-N-CA 123.704 -1.373 . . . . 0.0 114.324 0.846 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 40.9 pt -137.21 136.02 47.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 121.481 0.658 . . . . 0.0 111.862 -179.112 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.68 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 5.7 t -86.44 144.96 27.03 Favored 'General case' 0 C--N 1.315 -0.905 0 CA-C-O 121.233 0.539 . . . . 0.0 110.064 179.577 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.442 HG22 ' HA ' ' A' ' 28' ' ' PRO . 9.1 p -144.11 128.79 18.21 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-N 115.288 -0.869 . . . . 0.0 111.216 -178.503 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.689 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 5.6 ptm180 -91.33 128.44 37.15 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.095 -0.706 . . . . 0.0 109.095 178.628 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 57.5 27.51 14.13 Favored 'General case' 0 N--CA 1.466 0.37 0 CA-C-O 121.243 0.544 . . . . 0.0 109.654 -179.349 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 76.2 14.53 82.21 Favored Glycine 0 C--N 1.332 0.345 0 CA-C-N 115.725 -0.67 . . . . 0.0 112.106 -178.92 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 88.2 mt -114.99 132.2 23.12 Favored Pre-proline 0 C--O 1.239 0.548 0 CA-C-O 121.071 0.462 . . . . 0.0 110.791 -179.755 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.442 ' HA ' HG22 ' A' ' 23' ' ' THR . 73.2 Cg_endo -76.08 55.16 4.41 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 123.301 2.667 . . . . 0.0 112.548 179.91 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 41.8 t . . . . . 0 C--N 1.324 -0.51 0 CA-C-O 121.272 0.558 . . . . 0.0 110.236 -179.681 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.5 m . . . . . 0 N--CA 1.457 -0.079 0 CA-C-O 121.062 0.458 . . . . 0.0 110.251 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 77.33 -36.59 1.55 Allowed Glycine 0 C--N 1.331 0.287 0 CA-C-N 115.837 -0.619 . . . . 0.0 113.387 179.27 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 7.8 pt-20 -58.17 138.0 56.55 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 121.481 0.657 . . . . 0.0 112.283 -179.109 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.509 HG22 HG22 ' A' ' 21' ' ' ILE . 26.3 p -89.79 119.34 30.1 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.418 -0.81 . . . . 0.0 109.675 179.056 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 23.0 p -88.1 61.99 6.57 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 121.495 0.664 . . . . 0.0 110.552 -179.691 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 34.2 t80 -54.38 -42.14 70.04 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.281 -0.872 . . . . 0.0 110.819 -179.892 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -93.01 21.3 40.59 Favored Glycine 0 N--CA 1.45 -0.426 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.833 179.712 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 76.52 -29.49 1.47 Allowed Glycine 0 CA--C 1.521 0.433 0 C-N-CA 121.117 -0.563 . . . . 0.0 113.616 179.598 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -88.73 143.22 27.06 Favored 'General case' 0 C--N 1.321 -0.641 0 O-C-N 122.631 -0.334 . . . . 0.0 111.878 -179.127 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 64.5 m -111.03 151.49 27.95 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.895 -0.593 . . . . 0.0 109.893 179.354 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 38.9 t30 -88.6 -24.17 22.9 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 121.132 0.491 . . . . 0.0 110.897 -179.432 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 7.5 m -101.39 123.84 43.17 Favored Pre-proline 0 C--N 1.322 -0.612 0 CA-C-O 121.15 0.5 . . . . 0.0 111.813 -178.573 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -65.95 140.91 62.42 Favored 'Trans proline' 0 C--N 1.345 0.368 0 C-N-CA 122.828 2.352 . . . . 0.0 111.484 179.263 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 96.46 -19.81 53.03 Favored Glycine 0 N--CA 1.446 -0.643 0 C-N-CA 120.539 -0.839 . . . . 0.0 111.457 -179.053 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.675 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 84.7 m -87.41 134.82 33.53 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 120.991 0.424 . . . . 0.0 109.896 179.279 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 11.0 m -106.52 136.2 46.71 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 109.114 -0.699 . . . . 0.0 109.114 -179.872 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 48.2 t -70.91 121.91 18.99 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-O 121.522 0.677 . . . . 0.0 112.23 -178.596 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 18.2 m -125.76 67.63 1.17 Allowed 'General case' 0 C--N 1.314 -0.971 0 N-CA-C 106.308 -1.738 . . . . 0.0 106.308 177.572 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.467 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.2 OUTLIER -28.27 127.84 0.22 Allowed Pre-proline 0 N--CA 1.464 0.25 0 CA-C-N 114.062 -1.427 . . . . 0.0 112.945 -176.446 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.467 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 60.2 Cg_endo -97.83 31.91 11.38 Favored 'Cis proline' 0 N--CA 1.461 -0.429 0 C-N-CA 123.711 -1.37 . . . . 0.0 114.242 0.872 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.509 HG22 HG22 ' A' ' 4' ' ' THR . 42.8 pt -138.56 139.22 41.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 121.452 0.644 . . . . 0.0 111.699 -179.019 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.675 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 3.7 t -84.3 144.42 28.89 Favored 'General case' 0 C--N 1.317 -0.839 0 CA-C-O 121.237 0.541 . . . . 0.0 109.55 179.268 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.558 HG22 ' HA ' ' A' ' 28' ' ' PRO . 17.9 p -141.97 130.43 22.49 Favored 'General case' 0 C--N 1.314 -0.944 0 CA-C-N 115.411 -0.813 . . . . 0.0 111.602 -178.143 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.457 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 9.6 ptm180 -93.84 128.17 39.97 Favored 'General case' 0 N--CA 1.448 -0.57 0 N-CA-C 108.729 -0.841 . . . . 0.0 108.729 178.309 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 28.6 m-20 58.4 26.71 14.45 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 121.29 0.567 . . . . 0.0 109.796 -178.876 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 77.75 10.67 86.08 Favored Glycine 0 C--N 1.333 0.411 0 CA-C-N 115.736 -0.666 . . . . 0.0 112.171 -179.118 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.44 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 90.2 mt -110.39 131.04 22.25 Favored Pre-proline 0 C--O 1.24 0.578 0 CA-C-O 120.965 0.412 . . . . 0.0 110.684 -179.75 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.558 ' HA ' HG22 ' A' ' 23' ' ' THR . 4.9 Cg_exo -74.85 52.93 3.12 Favored 'Trans proline' 0 C--N 1.344 0.297 0 C-N-CA 123.699 2.933 . . . . 0.0 112.447 -179.832 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 40.5 t . . . . . 0 C--N 1.322 -0.613 0 CA-C-O 121.433 0.635 . . . . 0.0 110.018 -179.881 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.8 m . . . . . 0 C--O 1.23 0.032 0 CA-C-O 121.045 0.45 . . . . 0.0 110.37 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 78.11 -36.02 1.72 Allowed Glycine 0 N--CA 1.453 -0.228 0 CA-C-N 115.781 -0.645 . . . . 0.0 113.496 179.159 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 10.8 pt-20 -60.21 139.22 57.69 Favored 'General case' 0 C--O 1.238 0.471 0 CA-C-O 121.617 0.722 . . . . 0.0 111.831 -178.945 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.521 HG22 HG22 ' A' ' 21' ' ' ILE . 11.9 p -91.31 118.22 30.32 Favored 'General case' 0 N--CA 1.445 -0.699 0 CA-C-N 115.301 -0.863 . . . . 0.0 109.985 179.347 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 26.5 p -88.93 58.87 4.77 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 121.049 0.452 . . . . 0.0 111.438 -178.992 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . 0.494 ' CD1' ' HB ' ' A' ' 4' ' ' THR . 4.9 m-85 -57.67 -36.43 71.9 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.542 179.306 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -90.13 18.37 48.6 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.649 179.516 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 75.58 -30.28 1.23 Allowed Glycine 0 CA--C 1.522 0.526 0 C-N-CA 121.344 -0.455 . . . . 0.0 113.786 179.531 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.0 m -88.95 151.57 22.23 Favored 'General case' 0 C--N 1.322 -0.591 0 O-C-N 122.53 -0.394 . . . . 0.0 111.237 -179.078 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 82.8 m -118.24 149.34 41.28 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.874 -0.603 . . . . 0.0 109.661 179.29 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 65.5 m-80 -88.92 -26.06 21.76 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 116.059 -0.519 . . . . 0.0 111.659 -178.674 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.447 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 19.3 p -102.06 128.47 28.49 Favored Pre-proline 0 C--N 1.324 -0.53 0 CA-C-O 121.398 0.618 . . . . 0.0 111.841 -178.855 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.447 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 19.6 Cg_exo -66.09 141.36 63.37 Favored 'Trans proline' 0 C--N 1.346 0.402 0 C-N-CA 123.252 2.635 . . . . 0.0 112.164 -179.913 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 96.44 -20.63 49.53 Favored Glycine 0 N--CA 1.447 -0.578 0 C-N-CA 120.761 -0.733 . . . . 0.0 111.545 -179.385 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.682 ' SG ' ' HB3' ' A' ' 24' ' ' ARG . 91.8 m -88.19 135.96 33.2 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-O 121.097 0.475 . . . . 0.0 110.324 179.703 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 15.2 m -109.71 136.65 48.71 Favored 'General case' 0 C--N 1.323 -0.582 0 N-CA-C 109.044 -0.724 . . . . 0.0 109.044 179.889 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 45.4 t -66.41 127.47 32.42 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-O 121.602 0.715 . . . . 0.0 112.062 -178.448 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 5.3 m -132.32 64.61 1.6 Allowed 'General case' 0 C--N 1.316 -0.874 0 N-CA-C 106.583 -1.636 . . . . 0.0 106.583 178.337 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.463 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -27.15 126.73 0.21 Allowed Pre-proline 0 N--CA 1.466 0.343 0 CA-C-N 114.231 -1.349 . . . . 0.0 112.996 -176.592 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.463 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 66.8 Cg_endo -97.3 31.37 12.28 Favored 'Cis proline' 0 CA--C 1.533 0.433 0 C-N-CA 123.689 -1.38 . . . . 0.0 114.492 1.025 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.521 HG22 HG22 ' A' ' 4' ' ' THR . 43.4 pt -139.33 141.31 35.87 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.382 0 CA-C-O 121.302 0.573 . . . . 0.0 111.565 -179.212 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.643 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 4.2 t -86.11 144.38 27.55 Favored 'General case' 0 C--N 1.316 -0.854 0 N-CA-C 109.669 -0.493 . . . . 0.0 109.669 179.406 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 61.9 p -137.15 128.24 27.72 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-N 115.661 -0.699 . . . . 0.0 112.007 -178.235 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.682 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 3.3 ptm180 -90.52 125.36 35.58 Favored 'General case' 0 N--CA 1.445 -0.705 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 177.822 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 53.0 m-20 58.59 28.1 16.63 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-O 121.148 0.499 . . . . 0.0 110.007 -178.421 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 79.37 11.27 85.11 Favored Glycine 0 C--N 1.334 0.441 0 CA-C-N 115.933 -0.576 . . . . 0.0 112.541 -179.514 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.463 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 91.7 mt -113.81 127.92 26.31 Favored Pre-proline 0 C--O 1.236 0.382 0 CA-C-O 120.779 0.323 . . . . 0.0 110.777 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.463 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 6.9 Cg_exo -73.29 53.66 2.61 Favored 'Trans proline' 0 C--N 1.344 0.291 0 C-N-CA 123.539 2.826 . . . . 0.0 112.695 -179.776 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 38.8 t . . . . . 0 C--N 1.323 -0.547 0 CA-C-O 121.445 0.641 . . . . 0.0 110.107 -179.926 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 4.1 m . . . . . 0 CA--C 1.527 0.089 0 CA-C-O 121.016 0.436 . . . . 0.0 110.246 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 62.86 45.41 95.75 Favored Glycine 0 C--N 1.333 0.405 0 CA-C-N 115.73 -0.668 . . . . 0.0 112.944 179.068 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 8.2 pt-20 -144.73 140.53 28.61 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 121.323 0.583 . . . . 0.0 111.346 -179.686 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.485 ' HB ' ' CD1' ' A' ' 6' ' ' PHE . 21.6 p -93.39 113.84 26.1 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 115.487 -0.779 . . . . 0.0 109.74 179.148 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 25.4 p -88.65 59.25 5.03 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 121.065 0.46 . . . . 0.0 111.459 -179.019 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . 0.485 ' CD1' ' HB ' ' A' ' 4' ' ' THR . 4.6 m-85 -57.73 -36.46 72.08 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.627 179.33 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -89.75 17.89 50.16 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.665 179.529 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 76.1 -29.57 1.37 Allowed Glycine 0 CA--C 1.524 0.609 0 C-N-CA 121.307 -0.473 . . . . 0.0 113.672 179.531 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.8 m -88.66 150.58 22.94 Favored 'General case' 0 C--N 1.323 -0.55 0 O-C-N 122.582 -0.363 . . . . 0.0 111.149 -179.232 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 67.6 m -117.12 150.87 37.97 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.094 179.517 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 42.3 t30 -88.82 -22.23 23.33 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.789 -179.605 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.433 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 4.5 m -101.42 123.35 44.85 Favored Pre-proline 0 C--N 1.324 -0.519 0 CA-C-O 121.226 0.536 . . . . 0.0 111.556 -178.62 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 22.4 Cg_exo -64.75 136.83 51.14 Favored 'Trans proline' 0 C--N 1.345 0.38 0 C-N-CA 122.96 2.44 . . . . 0.0 111.788 179.656 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 95.02 -15.12 64.09 Favored Glycine 0 N--CA 1.446 -0.648 0 C-N-CA 120.645 -0.788 . . . . 0.0 111.894 -179.436 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.669 ' SG ' ' HB3' ' A' ' 24' ' ' ARG . 88.6 m -87.31 135.5 33.29 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.583 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 13.3 m -105.7 135.25 47.45 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 109.125 -0.695 . . . . 0.0 109.125 -179.844 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.0 t -70.85 120.81 16.98 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-O 121.609 0.719 . . . . 0.0 111.994 -178.445 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 11.2 m -123.62 66.32 1.02 Allowed 'General case' 0 C--N 1.315 -0.933 0 N-CA-C 106.415 -1.698 . . . . 0.0 106.415 177.685 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.449 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -27.76 127.21 0.22 Allowed Pre-proline 0 N--CA 1.466 0.345 0 CA-C-N 114.167 -1.378 . . . . 0.0 112.878 -176.561 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.449 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 65.0 Cg_endo -97.37 31.29 12.35 Favored 'Cis proline' 0 N--CA 1.46 -0.442 0 C-N-CA 123.765 -1.348 . . . . 0.0 114.34 0.948 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 42.3 pt -138.2 137.34 44.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-O 121.454 0.645 . . . . 0.0 111.722 -179.155 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.62 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 4.5 t -85.05 144.38 28.29 Favored 'General case' 0 C--N 1.316 -0.861 0 CA-C-O 121.177 0.513 . . . . 0.0 109.912 179.447 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.477 HG22 ' CA ' ' A' ' 28' ' ' PRO . 21.5 p -143.52 127.06 16.92 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-N 115.304 -0.862 . . . . 0.0 111.127 -178.266 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.669 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 3.4 ptm180 -93.65 126.28 38.73 Favored 'General case' 0 N--CA 1.447 -0.581 0 N-CA-C 108.859 -0.793 . . . . 0.0 108.859 178.535 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 51.5 m-20 57.75 29.68 17.77 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-O 121.259 0.552 . . . . 0.0 109.657 -178.54 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 78.29 7.99 87.64 Favored Glycine 0 C--N 1.333 0.386 0 CA-C-N 115.587 -0.733 . . . . 0.0 112.67 -179.338 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.473 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 88.2 mt -106.62 124.48 35.45 Favored Pre-proline 0 C--O 1.237 0.442 0 CA-C-O 120.935 0.397 . . . . 0.0 110.867 -179.829 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.477 ' CA ' HG22 ' A' ' 23' ' ' THR . 3.8 Cg_exo -79.75 46.35 2.2 Favored 'Trans proline' 0 N--CA 1.462 -0.374 0 C-N-CA 123.574 2.849 . . . . 0.0 112.08 179.868 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 10.5 p . . . . . 0 C--N 1.319 -0.719 0 CA-C-N 115.552 -0.749 . . . . 0.0 110.337 -179.765 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.0 m . . . . . 0 N--CA 1.456 -0.136 0 CA-C-O 121.066 0.46 . . . . 0.0 110.318 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 76.27 -34.05 1.32 Allowed Glycine 0 C--N 1.332 0.325 0 CA-C-N 115.867 -0.606 . . . . 0.0 113.575 179.111 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -55.04 138.44 44.0 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 121.813 0.816 . . . . 0.0 112.315 -178.921 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.61 HG23 ' O ' ' A' ' 20' ' ' PRO . 81.1 m -89.0 110.86 21.5 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 114.892 -1.049 . . . . 0.0 110.008 179.607 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 28.5 p -89.13 53.42 2.66 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 121.167 0.508 . . . . 0.0 110.9 -179.459 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 18.9 p90 -58.15 -30.93 66.75 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.925 -0.58 . . . . 0.0 111.283 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -94.32 15.57 62.95 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.687 179.699 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 65.17 40.08 96.57 Favored Glycine 0 CA--C 1.518 0.269 0 C-N-CA 121.049 -0.596 . . . . 0.0 112.79 179.676 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 3.0 m -149.91 150.75 32.35 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 179.91 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 60.1 m -129.26 142.75 50.76 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 120.758 0.313 . . . . 0.0 110.213 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 43.7 t30 -89.23 -17.82 28.29 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.964 -179.367 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.453 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 5.2 m -101.11 123.67 44.21 Favored Pre-proline 0 C--N 1.323 -0.561 0 CA-C-O 121.122 0.487 . . . . 0.0 111.611 -178.546 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.453 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 23.9 Cg_exo -63.61 136.65 55.21 Favored 'Trans proline' 0 C--N 1.345 0.359 0 C-N-CA 122.959 2.44 . . . . 0.0 111.705 179.583 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 94.39 -15.07 64.06 Favored Glycine 0 N--CA 1.447 -0.623 0 C-N-CA 120.638 -0.792 . . . . 0.0 111.594 -179.225 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.73 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 93.1 m -87.88 132.42 34.21 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 121.059 0.457 . . . . 0.0 110.053 179.524 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 15.2 m -108.96 134.78 51.16 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 109.116 -0.698 . . . . 0.0 109.116 179.892 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 41.9 t -67.43 121.98 16.96 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 121.578 0.704 . . . . 0.0 111.873 -178.504 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 4.1 m -125.3 65.96 1.14 Allowed 'General case' 0 C--N 1.317 -0.82 0 N-CA-C 106.765 -1.569 . . . . 0.0 106.765 178.023 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.47 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -27.76 125.77 0.23 Allowed Pre-proline 0 N--CA 1.466 0.331 0 CA-C-N 114.347 -1.297 . . . . 0.0 112.812 -176.74 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.61 ' O ' HG23 ' A' ' 4' ' ' THR . 66.6 Cg_endo -97.51 31.19 12.42 Favored 'Cis proline' 0 N--CA 1.46 -0.452 0 C-N-CA 123.656 -1.393 . . . . 0.0 114.362 0.843 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 41.8 pt -138.54 136.36 43.76 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 O-C-N 121.474 -0.766 . . . . 0.0 111.859 -179.208 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.73 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 5.7 t -83.36 142.77 30.79 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-O 121.201 0.524 . . . . 0.0 109.826 179.367 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 62.0 p -137.05 128.35 28.11 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-N 115.504 -0.771 . . . . 0.0 111.785 -178.276 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.64 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 3.0 ptm180 -89.52 124.71 34.76 Favored 'General case' 0 N--CA 1.446 -0.67 0 N-CA-C 108.483 -0.932 . . . . 0.0 108.483 178.126 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 53.8 m-20 58.11 28.37 16.31 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 121.173 0.511 . . . . 0.0 110.035 -178.434 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 80.14 10.04 85.94 Favored Glycine 0 C--N 1.334 0.426 0 CA-C-N 115.87 -0.604 . . . . 0.0 112.58 -179.423 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 90.1 mt -110.82 127.33 27.11 Favored Pre-proline 0 C--N 1.327 -0.412 0 CA-C-O 120.82 0.343 . . . . 0.0 110.63 179.967 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 62.3 Cg_endo -73.61 52.69 2.53 Favored 'Trans proline' 0 C--N 1.343 0.261 0 C-N-CA 123.202 2.601 . . . . 0.0 112.784 -179.879 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 40.4 t . . . . . 0 C--N 1.322 -0.602 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.094 -179.922 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.7 m . . . . . 0 N--CA 1.457 -0.078 0 CA-C-O 121.03 0.443 . . . . 0.0 110.232 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 75.71 -34.59 1.2 Allowed Glycine 0 C--N 1.33 0.243 0 CA-C-N 115.785 -0.643 . . . . 0.0 113.657 179.114 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 15.3 pt-20 -55.74 141.8 36.89 Favored 'General case' 0 C--O 1.238 0.478 0 CA-C-O 121.639 0.733 . . . . 0.0 112.116 -178.806 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.607 HG23 ' O ' ' A' ' 20' ' ' PRO . 87.8 m -88.68 117.03 27.36 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.157 -0.928 . . . . 0.0 110.308 -179.983 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 26.3 p -88.77 58.51 4.65 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 121.229 0.538 . . . . 0.0 110.209 179.798 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 32.3 t80 -51.76 -46.36 64.08 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 115.438 -0.801 . . . . 0.0 111.243 -179.559 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -94.45 25.41 22.9 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.59 -0.814 . . . . 0.0 112.568 179.749 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.44 38.69 96.18 Favored Glycine 0 CA--C 1.518 0.223 0 C-N-CA 121.184 -0.531 . . . . 0.0 112.742 179.65 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.3 m -139.49 150.66 45.41 Favored 'General case' 0 C--N 1.324 -0.512 0 N-CA-C 110.013 -0.365 . . . . 0.0 110.013 -179.911 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 59.3 m -133.22 140.84 47.75 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 116.404 -0.362 . . . . 0.0 110.057 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 65.0 m-80 -89.56 -13.88 36.33 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.08 -179.047 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.547 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 4.7 m -101.09 124.84 40.15 Favored Pre-proline 0 C--N 1.322 -0.605 0 CA-C-O 121.126 0.489 . . . . 0.0 111.208 -178.751 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 28.8 Cg_endo -63.58 135.81 51.1 Favored 'Trans proline' 0 C--N 1.345 0.387 0 C-N-CA 122.88 2.387 . . . . 0.0 112.179 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 91.83 -11.32 72.43 Favored Glycine 0 N--CA 1.448 -0.556 0 C-N-CA 120.806 -0.711 . . . . 0.0 111.898 -179.508 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.766 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 89.1 m -88.08 132.9 34.12 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.056 0.455 . . . . 0.0 110.344 179.738 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 15.3 m -111.21 138.06 48.13 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 109.158 -0.682 . . . . 0.0 109.158 179.889 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 45.7 t -67.74 123.86 21.69 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-O 121.451 0.643 . . . . 0.0 111.969 -178.766 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 4.6 m -128.35 62.64 1.44 Allowed 'General case' 0 C--N 1.317 -0.815 0 N-CA-C 106.698 -1.593 . . . . 0.0 106.698 178.028 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.448 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -27.48 126.33 0.22 Allowed Pre-proline 0 N--CA 1.464 0.239 0 CA-C-N 114.153 -1.385 . . . . 0.0 112.933 -176.686 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.607 ' O ' HG23 ' A' ' 4' ' ' THR . 67.9 Cg_endo -97.21 33.76 9.47 Favored 'Cis proline' 0 N--CA 1.461 -0.436 0 C-N-CA 123.775 -1.344 . . . . 0.0 114.241 0.848 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 42.0 pt -140.24 137.05 37.55 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 O-C-N 121.654 -0.654 . . . . 0.0 111.582 -179.284 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.766 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 6.6 t -85.36 142.71 29.11 Favored 'General case' 0 C--N 1.316 -0.88 0 CA-C-O 121.062 0.458 . . . . 0.0 109.848 179.346 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 66.2 p -136.88 129.2 29.86 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-N 115.552 -0.749 . . . . 0.0 111.824 -178.47 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.653 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 1.7 ptm180 -90.36 123.04 33.78 Favored 'General case' 0 N--CA 1.445 -0.711 0 N-CA-C 108.634 -0.876 . . . . 0.0 108.634 178.066 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 71.1 m-20 56.85 31.27 19.31 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-O 121.214 0.53 . . . . 0.0 109.987 -177.656 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 79.38 7.31 88.57 Favored Glycine 0 C--N 1.334 0.448 0 CA-C-N 115.879 -0.6 . . . . 0.0 112.856 -179.625 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.47 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 88.0 mt -107.36 126.4 30.12 Favored Pre-proline 0 C--O 1.237 0.41 0 O-C-N 122.624 -0.339 . . . . 0.0 110.697 179.982 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.47 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 7.4 Cg_exo -72.91 52.98 2.29 Favored 'Trans proline' 0 C--N 1.343 0.246 0 C-N-CA 123.587 2.858 . . . . 0.0 112.581 -179.834 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 43.4 t . . . . . 0 C--N 1.323 -0.561 0 CA-C-O 121.307 0.575 . . . . 0.0 110.171 -179.774 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.6 m . . . . . 0 CA--C 1.528 0.104 0 CA-C-O 120.875 0.369 . . . . 0.0 110.763 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.68 42.97 95.08 Favored Glycine 0 N--CA 1.451 -0.321 0 CA-C-N 115.798 -0.637 . . . . 0.0 112.982 179.217 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -142.84 143.44 32.12 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 121.211 0.529 . . . . 0.0 110.864 179.906 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.528 ' HB ' ' CD1' ' A' ' 6' ' ' PHE . 7.3 p -95.97 115.08 26.88 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 115.582 -0.735 . . . . 0.0 110.381 179.506 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 25.5 p -89.11 58.84 4.69 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 121.047 0.451 . . . . 0.0 111.426 -179.248 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . 0.528 ' CD1' ' HB ' ' A' ' 4' ' ' THR . 5.2 m-85 -57.81 -36.36 72.13 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.644 179.416 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -88.36 16.83 51.49 Favored Glycine 0 N--CA 1.448 -0.508 0 C-N-CA 120.833 -0.699 . . . . 0.0 112.703 179.654 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 77.2 -30.62 1.61 Allowed Glycine 0 CA--C 1.523 0.542 0 C-N-CA 121.223 -0.513 . . . . 0.0 113.487 179.635 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.7 m -88.62 149.96 23.28 Favored 'General case' 0 C--N 1.322 -0.626 0 O-C-N 122.655 -0.32 . . . . 0.0 111.035 -179.373 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 77.0 m -113.05 150.6 31.79 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.141 179.52 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 64.8 m-80 -88.65 -27.94 20.95 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 115.818 -0.628 . . . . 0.0 111.244 -179.086 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.457 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 21.3 p -102.46 128.31 28.49 Favored Pre-proline 0 C--N 1.324 -0.509 0 CA-C-O 121.481 0.658 . . . . 0.0 111.746 -179.049 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.457 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 17.3 Cg_exo -67.25 141.09 55.61 Favored 'Trans proline' 0 C--N 1.345 0.375 0 C-N-CA 123.277 2.651 . . . . 0.0 112.172 -179.758 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 96.8 -20.1 52.05 Favored Glycine 0 N--CA 1.448 -0.565 0 C-N-CA 120.739 -0.743 . . . . 0.0 111.7 -179.509 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.731 ' SG ' ' HB3' ' A' ' 24' ' ' ARG . 91.0 m -88.22 138.82 31.1 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-O 121.066 0.46 . . . . 0.0 110.283 179.734 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 16.1 m -108.49 134.52 51.15 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 109.172 -0.677 . . . . 0.0 109.172 179.855 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.4 t -66.31 125.2 24.86 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-O 121.615 0.721 . . . . 0.0 111.893 -178.418 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 3.9 m -129.0 65.6 1.44 Allowed 'General case' 0 C--N 1.315 -0.913 0 N-CA-C 106.708 -1.589 . . . . 0.0 106.708 178.277 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.458 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -27.26 126.42 0.22 Allowed Pre-proline 0 N--CA 1.465 0.312 0 CA-C-N 114.423 -1.262 . . . . 0.0 112.836 -176.571 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.458 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 63.2 Cg_endo -97.17 31.03 12.79 Favored 'Cis proline' 0 CA--C 1.532 0.407 0 C-N-CA 123.776 -1.343 . . . . 0.0 114.534 0.932 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.417 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 42.5 pt -139.42 138.98 39.72 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.333 0 CA-C-O 121.319 0.581 . . . . 0.0 111.719 -179.117 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.565 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 4.4 t -84.93 145.14 27.92 Favored 'General case' 0 C--N 1.316 -0.849 0 N-CA-C 109.622 -0.51 . . . . 0.0 109.622 179.282 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 61.8 p -139.54 128.52 23.6 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-N 115.792 -0.64 . . . . 0.0 112.121 -178.026 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.731 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 3.3 ptm180 -91.68 125.57 36.46 Favored 'General case' 0 N--CA 1.445 -0.697 0 N-CA-C 108.155 -1.054 . . . . 0.0 108.155 177.588 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 54.7 m-20 58.9 28.24 17.28 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-O 121.143 0.497 . . . . 0.0 109.842 -178.319 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 78.87 10.36 86.25 Favored Glycine 0 C--N 1.333 0.374 0 CA-C-N 115.897 -0.592 . . . . 0.0 112.636 -179.413 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 92.1 mt -114.3 126.28 28.18 Favored Pre-proline 0 C--N 1.328 -0.357 0 CA-C-O 120.881 0.372 . . . . 0.0 110.759 -179.961 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -75.28 52.42 3.16 Favored 'Trans proline' 0 CA--C 1.529 0.241 0 C-N-CA 123.159 2.573 . . . . 0.0 112.876 -179.811 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 22.3 t . . . . . 0 C--N 1.323 -0.559 0 CA-C-O 121.389 0.614 . . . . 0.0 110.184 -179.883 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 63.4 m . . . . . 0 N--CA 1.458 -0.061 0 CA-C-O 120.991 0.424 . . . . 0.0 110.104 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 61.45 35.29 90.81 Favored Glycine 0 C--N 1.332 0.348 0 CA-C-N 115.674 -0.694 . . . . 0.0 113.102 179.114 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 9.5 pt-20 -115.9 148.44 40.01 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 120.9 0.381 . . . . 0.0 110.716 179.929 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.438 ' HA ' ' HA ' ' A' ' 21' ' ' ILE . 33.9 p -93.41 118.09 30.88 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.182 -179.933 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.798 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 13.5 p -88.87 61.57 6.0 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.287 0.565 . . . . 0.0 110.52 179.298 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 32.8 t80 -55.14 -41.27 71.54 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.561 -0.745 . . . . 0.0 110.235 179.892 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -92.18 22.94 29.49 Favored Glycine 0 N--CA 1.45 -0.43 0 C-N-CA 120.865 -0.683 . . . . 0.0 112.765 179.338 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 76.66 -35.81 1.4 Allowed Glycine 0 CA--C 1.521 0.446 0 C-N-CA 121.23 -0.51 . . . . 0.0 113.938 179.405 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.5 m -89.2 148.37 23.66 Favored 'General case' 0 C--N 1.322 -0.609 0 O-C-N 122.423 -0.457 . . . . 0.0 111.442 -179.093 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 59.9 m -108.69 153.67 23.11 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.711 -0.677 . . . . 0.0 109.515 179.072 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 39.1 t30 -87.53 -29.42 21.33 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-O 121.255 0.55 . . . . 0.0 110.171 179.956 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.443 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 3.8 m -102.48 118.35 58.92 Favored Pre-proline 0 C--N 1.323 -0.571 0 CA-C-N 115.877 -0.601 . . . . 0.0 111.167 -179.485 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.443 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 13.6 Cg_exo -68.76 136.95 37.19 Favored 'Trans proline' 0 N--CA 1.46 -0.479 0 C-N-CA 122.829 2.352 . . . . 0.0 111.719 179.724 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 117.33 -32.66 5.32 Favored Glycine 0 N--CA 1.439 -1.166 0 N-CA-C 111.134 -0.787 . . . . 0.0 111.134 -179.264 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.413 ' HB3' ' HB3' ' A' ' 22' ' ' CYS . 32.9 m -89.45 131.43 35.5 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 120.921 0.391 . . . . 0.0 110.36 179.05 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 16.0 m -89.67 136.15 33.2 Favored 'General case' 0 C--N 1.319 -0.724 0 N-CA-C 109.213 -0.662 . . . . 0.0 109.213 179.556 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 43.2 t -67.66 115.45 7.25 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 121.773 0.797 . . . . 0.0 111.031 -179.336 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 2.9 m -118.95 66.96 0.78 Allowed 'General case' 0 C--N 1.309 -1.172 0 N-CA-C 106.332 -1.729 . . . . 0.0 106.332 178.182 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.475 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.3 OUTLIER -27.24 124.6 0.23 Allowed Pre-proline 0 N--CA 1.463 0.196 0 CA-C-N 114.213 -1.358 . . . . 0.0 112.646 -176.314 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.475 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 56.7 Cg_endo -98.77 34.25 8.69 Favored 'Cis proline' 0 N--CA 1.459 -0.52 0 C-N-CA 123.732 -1.362 . . . . 0.0 114.554 1.103 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.438 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 40.8 pt -142.12 136.06 29.09 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.301 0 CA-C-N 118.753 0.706 . . . . 0.0 112.513 -178.939 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.798 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 47.2 m -82.08 131.68 35.24 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.266 178.977 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 65.4 p -142.7 136.7 29.25 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.134 179.785 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.514 ' HG3' ' O ' ' A' ' 24' ' ' ARG . 2.8 ptm180 -94.62 121.86 36.62 Favored 'General case' 0 N--CA 1.443 -0.789 0 N-CA-C 108.153 -1.054 . . . . 0.0 108.153 178.445 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 61.3 m-20 57.36 29.85 17.56 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.134 0.492 . . . . 0.0 109.775 -178.032 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 82.12 1.95 90.46 Favored Glycine 0 CA--C 1.521 0.41 0 CA-C-N 115.801 -0.636 . . . . 0.0 112.667 -179.371 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 88.0 mt -98.87 123.6 48.81 Favored Pre-proline 0 C--O 1.237 0.429 0 CA-C-O 121.074 0.464 . . . . 0.0 111.217 -179.838 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -77.13 69.81 6.93 Favored 'Trans proline' 0 N--CA 1.464 -0.242 0 C-N-CA 123.248 2.632 . . . . 0.0 112.139 179.649 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 47.2 t . . . . . 0 C--N 1.324 -0.504 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.297 -179.396 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 82.0 m . . . . . 0 CA--C 1.524 -0.026 0 CA-C-O 120.92 0.391 . . . . 0.0 110.353 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 76.46 -32.32 1.39 Allowed Glycine 0 CA--C 1.519 0.327 0 CA-C-N 116.117 -0.492 . . . . 0.0 113.85 178.878 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 14.7 pt-20 -53.95 139.31 34.47 Favored 'General case' 0 C--O 1.239 0.509 0 CA-C-O 121.447 0.641 . . . . 0.0 111.889 -178.933 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.612 HG22 HG22 ' A' ' 21' ' ' ILE . 36.2 p -89.44 120.91 31.18 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 115.276 -0.875 . . . . 0.0 110.801 -179.581 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.761 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 25.0 p -88.98 60.96 5.69 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 121.253 0.549 . . . . 0.0 110.71 179.651 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 34.4 t80 -53.33 -44.36 68.37 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.525 -0.761 . . . . 0.0 110.993 -179.896 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -92.65 22.63 32.39 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.742 179.788 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 62.55 40.68 99.43 Favored Glycine 0 CA--C 1.518 0.27 0 C-N-CA 121.257 -0.497 . . . . 0.0 112.965 179.514 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.5 m -147.99 149.28 31.87 Favored 'General case' 0 C--N 1.324 -0.513 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 179.919 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 47.2 m -124.76 143.42 50.8 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 179.837 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 63.1 m-80 -88.39 -23.24 23.4 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.276 -179.49 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.401 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 4.3 m -101.72 119.37 57.35 Favored Pre-proline 0 C--N 1.323 -0.582 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.982 -179.148 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.401 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 20.4 Cg_exo -65.55 140.93 64.87 Favored 'Trans proline' 0 N--CA 1.462 -0.324 0 C-N-CA 122.922 2.415 . . . . 0.0 111.939 179.894 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 105.76 -29.9 10.62 Favored Glycine 0 N--CA 1.441 -1.024 0 C-N-CA 120.75 -0.738 . . . . 0.0 111.489 -179.4 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.548 ' HB3' ' HB3' ' A' ' 22' ' ' CYS . 15.7 m -89.04 129.19 35.71 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 121.209 0.528 . . . . 0.0 110.708 179.289 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 19.6 m -94.39 138.51 32.26 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 115.512 -0.767 . . . . 0.0 109.036 179.372 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 43.4 t -66.43 116.16 7.13 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-O 121.593 0.711 . . . . 0.0 111.03 -179.287 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 3.0 m -120.78 68.7 0.87 Allowed 'General case' 0 C--N 1.311 -1.099 0 N-CA-C 106.597 -1.631 . . . . 0.0 106.597 178.422 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.478 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -27.82 125.1 0.23 Allowed Pre-proline 0 N--CA 1.463 0.215 0 O-C-N 124.706 1.253 . . . . 0.0 112.631 -176.52 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.478 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 59.8 Cg_endo -98.54 30.62 12.65 Favored 'Cis proline' 0 CA--C 1.535 0.562 0 C-N-CA 123.613 -1.411 . . . . 0.0 115.061 1.033 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.612 HG22 HG22 ' A' ' 4' ' ' THR . 0.2 OUTLIER -141.62 141.65 29.68 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.293 0 CA-C-N 118.992 0.815 . . . . 0.0 112.122 -179.422 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.761 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 64.6 m -81.1 133.81 35.54 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.586 179.365 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 64.5 p -134.23 132.4 39.65 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.735 179.856 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.476 ' HG3' ' O ' ' A' ' 24' ' ' ARG . 1.4 ptm180 -91.93 120.25 32.43 Favored 'General case' 0 N--CA 1.443 -0.777 0 N-CA-C 108.185 -1.042 . . . . 0.0 108.185 178.305 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 72.7 m-20 56.6 31.0 18.34 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 121.144 0.497 . . . . 0.0 109.895 -177.437 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 84.0 -0.4 89.45 Favored Glycine 0 CA--C 1.521 0.447 0 CA-C-N 115.885 -0.598 . . . . 0.0 112.907 -179.624 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.488 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 86.9 mt -99.3 122.34 52.31 Favored Pre-proline 0 C--O 1.237 0.41 0 CA-C-O 120.903 0.383 . . . . 0.0 111.155 -179.754 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.488 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 3.4 Cg_exo -74.46 63.78 5.5 Favored 'Trans proline' 0 CA--C 1.528 0.177 0 C-N-CA 123.597 2.865 . . . . 0.0 112.143 179.66 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 48.2 t . . . . . 0 C--N 1.325 -0.479 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.485 -179.233 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 3.0 m . . . . . 0 CA--C 1.527 0.058 0 CA-C-O 120.943 0.402 . . . . 0.0 110.486 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 78.23 -37.16 1.76 Allowed Glycine 0 C--N 1.33 0.226 0 CA-C-N 115.952 -0.567 . . . . 0.0 113.022 179.59 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 8.9 pt-20 -59.77 141.66 54.81 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 121.526 0.679 . . . . 0.0 111.961 -179.331 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.523 HG22 HG22 ' A' ' 21' ' ' ILE . 14.7 p -94.87 124.73 39.08 Favored 'General case' 0 N--CA 1.444 -0.733 0 CA-C-N 115.316 -0.856 . . . . 0.0 109.695 178.982 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 24.4 p -87.98 58.8 5.01 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 121.479 0.657 . . . . 0.0 110.698 -179.419 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 35.3 t80 -56.27 -39.93 73.42 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.309 -0.859 . . . . 0.0 110.038 179.48 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -91.31 22.68 28.54 Favored Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 120.943 -0.646 . . . . 0.0 112.751 179.375 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 77.25 -36.82 1.53 Allowed Glycine 0 CA--C 1.522 0.482 0 C-N-CA 121.36 -0.448 . . . . 0.0 114.081 179.223 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 10.2 t -89.52 164.46 14.79 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-O 121.229 0.537 . . . . 0.0 111.627 -179.083 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 62.0 m -125.69 151.77 46.15 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 114.983 -1.008 . . . . 0.0 109.514 179.28 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 41.4 t30 -88.88 -22.76 22.99 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-O 121.031 0.444 . . . . 0.0 111.198 -178.983 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.453 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 7.8 m -101.14 124.46 41.42 Favored Pre-proline 0 C--N 1.322 -0.59 0 CA-C-O 121.215 0.531 . . . . 0.0 111.955 -178.375 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.453 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 23.8 Cg_exo -63.81 137.48 58.56 Favored 'Trans proline' 0 C--N 1.346 0.411 0 C-N-CA 123.059 2.506 . . . . 0.0 111.47 179.403 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 96.55 -17.39 59.36 Favored Glycine 0 N--CA 1.446 -0.67 0 C-N-CA 120.596 -0.812 . . . . 0.0 111.447 -179.06 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.706 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 81.6 m -87.61 133.06 33.87 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 109.651 -0.5 . . . . 0.0 109.651 179.39 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 15.4 m -108.87 138.11 45.72 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 -179.577 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.4 t -68.46 127.08 31.69 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 121.752 0.787 . . . . 0.0 111.948 -178.705 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 4.3 m -131.17 60.67 1.65 Allowed 'General case' 0 C--N 1.316 -0.882 0 N-CA-C 106.144 -1.799 . . . . 0.0 106.144 177.891 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.432 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -26.24 126.65 0.2 Allowed Pre-proline 0 N--CA 1.464 0.265 0 CA-C-N 113.951 -1.477 . . . . 0.0 113.002 -176.487 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.432 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 62.3 Cg_endo -97.01 32.32 11.16 Favored 'Cis proline' 0 CA--C 1.532 0.421 0 C-N-CA 123.684 -1.381 . . . . 0.0 114.41 0.842 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.523 HG22 HG22 ' A' ' 4' ' ' THR . 43.8 pt -137.53 140.35 41.76 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.39 0 CA-C-O 121.255 0.55 . . . . 0.0 111.346 -179.234 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.706 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 5.4 t -89.4 144.28 26.18 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-O 121.17 0.509 . . . . 0.0 110.233 179.783 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 43.0 p -138.25 127.14 23.89 Favored 'General case' 0 C--N 1.318 -0.784 0 CA-C-N 115.527 -0.761 . . . . 0.0 111.752 -178.673 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.634 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 3.1 ptm180 -89.53 125.07 35.06 Favored 'General case' 0 N--CA 1.447 -0.618 0 N-CA-C 108.601 -0.889 . . . . 0.0 108.601 178.403 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 53.7 m-20 57.98 28.9 16.87 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.216 0.531 . . . . 0.0 109.958 -178.532 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 78.71 12.06 84.6 Favored Glycine 0 C--N 1.334 0.417 0 CA-C-N 115.875 -0.602 . . . . 0.0 112.457 -179.445 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 88.9 mt -113.72 127.71 26.53 Favored Pre-proline 0 C--O 1.237 0.405 0 CA-C-O 120.857 0.36 . . . . 0.0 110.686 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 70.9 Cg_endo -74.57 51.92 2.74 Favored 'Trans proline' 0 C--N 1.343 0.256 0 C-N-CA 123.292 2.662 . . . . 0.0 112.678 -179.949 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 39.4 t . . . . . 0 C--N 1.322 -0.601 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.222 -179.855 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . 0.541 ' HB3' ' HG2' ' A' ' 3' ' ' GLU . 82.5 m . . . . . 0 N--CA 1.458 -0.065 0 CA-C-O 120.897 0.379 . . . . 0.0 110.239 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 77.47 -34.73 1.57 Allowed Glycine 0 C--N 1.331 0.285 0 CA-C-N 116.034 -0.53 . . . . 0.0 113.436 179.188 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.541 ' HG2' ' HB3' ' A' ' 1' ' ' CYS . 7.0 pt-20 -53.8 139.88 31.76 Favored 'General case' 0 C--O 1.237 0.429 0 CA-C-O 121.528 0.68 . . . . 0.0 112.423 -179.114 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.623 HG22 HG22 ' A' ' 21' ' ' ILE . 31.5 p -89.29 121.22 31.36 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 115.271 -0.877 . . . . 0.0 110.01 179.29 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 23.5 p -88.0 61.14 6.19 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 121.382 0.611 . . . . 0.0 110.478 -179.857 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 35.1 t80 -55.11 -41.04 71.17 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.367 -0.833 . . . . 0.0 110.513 179.91 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -91.65 21.58 35.21 Favored Glycine 0 N--CA 1.449 -0.457 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.735 179.51 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 76.7 -33.47 1.41 Allowed Glycine 0 CA--C 1.522 0.51 0 C-N-CA 121.221 -0.514 . . . . 0.0 113.833 179.572 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.7 m -89.11 149.7 23.06 Favored 'General case' 0 C--N 1.321 -0.674 0 O-C-N 122.538 -0.389 . . . . 0.0 111.443 -179.184 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 58.3 m -114.76 152.68 31.66 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.761 -0.654 . . . . 0.0 109.301 179.017 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 36.4 t30 -87.8 -28.52 21.61 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-O 121.215 0.531 . . . . 0.0 110.537 -179.534 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.407 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 8.2 m -101.63 120.99 52.82 Favored Pre-proline 0 C--N 1.32 -0.681 0 CA-C-N 115.967 -0.56 . . . . 0.0 111.563 -178.871 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.407 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 17.3 Cg_exo -66.62 143.84 69.96 Favored 'Trans proline' 0 N--CA 1.463 -0.316 0 C-N-CA 123.178 2.585 . . . . 0.0 111.888 179.741 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 105.02 -29.59 11.43 Favored Glycine 0 N--CA 1.443 -0.862 0 C-N-CA 120.676 -0.774 . . . . 0.0 111.555 -179.443 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.663 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 9.2 m -87.98 138.87 31.08 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 121.131 0.491 . . . . 0.0 110.158 179.169 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 15.2 m -102.57 141.54 35.22 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 115.645 -0.707 . . . . 0.0 109.099 179.936 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 48.9 t -73.17 114.62 11.56 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-O 121.597 0.713 . . . . 0.0 111.661 -178.908 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 17.0 m -117.42 66.98 0.74 Allowed 'General case' 0 C--N 1.311 -1.103 0 N-CA-C 106.353 -1.721 . . . . 0.0 106.353 177.468 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.486 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.4 OUTLIER -29.08 127.39 0.24 Allowed Pre-proline 0 N--CA 1.463 0.225 0 CA-C-N 114.102 -1.408 . . . . 0.0 112.753 -176.47 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.486 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 59.5 Cg_endo -97.85 32.77 10.31 Favored 'Cis proline' 0 N--CA 1.46 -0.5 0 C-N-CA 123.68 -1.383 . . . . 0.0 114.304 0.918 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.623 HG22 HG22 ' A' ' 4' ' ' THR . 42.0 pt -138.3 137.48 43.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 121.443 0.639 . . . . 0.0 111.873 -179.135 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.663 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 3.4 t -85.42 139.74 31.29 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-O 121.309 0.576 . . . . 0.0 109.498 179.284 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.584 HG22 ' HA ' ' A' ' 28' ' ' PRO . 11.7 p -147.85 133.38 18.71 Favored 'General case' 0 C--N 1.313 -1.012 0 CA-C-N 115.279 -0.873 . . . . 0.0 111.297 -178.259 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.509 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 3.1 ptm180 -92.25 124.47 36.34 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 108.81 -0.811 . . . . 0.0 108.81 178.774 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 46.3 m-20 57.53 30.34 18.55 Favored 'General case' 0 N--CA 1.467 0.383 0 N-CA-C 109.384 -0.599 . . . . 0.0 109.384 -178.431 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 76.89 8.53 86.68 Favored Glycine 0 CA--C 1.521 0.423 0 CA-C-N 115.511 -0.768 . . . . 0.0 112.559 -179.116 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 86.8 mt -105.41 129.13 25.23 Favored Pre-proline 0 C--O 1.239 0.545 0 CA-C-O 121.057 0.456 . . . . 0.0 111.059 -179.661 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.584 ' HA ' HG22 ' A' ' 23' ' ' THR . 74.3 Cg_endo -75.42 62.94 6.3 Favored 'Trans proline' 0 C--N 1.343 0.262 0 C-N-CA 123.372 2.715 . . . . 0.0 112.583 179.84 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 48.5 t . . . . . 0 C--N 1.323 -0.578 0 CA-C-O 121.324 0.583 . . . . 0.0 110.177 -179.661 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 3.8 m . . . . . 0 CA--C 1.528 0.101 0 CA-C-O 121.141 0.496 . . . . 0.0 109.672 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 76.15 -36.38 1.3 Allowed Glycine 0 C--N 1.333 0.366 0 CA-C-N 115.6 -0.727 . . . . 0.0 113.777 178.691 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -60.13 138.54 57.87 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 121.621 0.724 . . . . 0.0 111.953 -178.805 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.466 ' HB ' ' CD1' ' A' ' 6' ' ' PHE . 30.8 p -89.62 118.99 29.65 Favored 'General case' 0 N--CA 1.446 -0.657 0 CA-C-N 115.271 -0.877 . . . . 0.0 109.734 179.245 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 26.2 p -88.62 58.02 4.47 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 121.066 0.46 . . . . 0.0 111.489 -179.034 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . 0.466 ' CD1' ' HB ' ' A' ' 4' ' ' THR . 4.7 m-85 -58.29 -36.56 73.49 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.334 179.049 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -88.99 19.07 40.37 Favored Glycine 0 N--CA 1.45 -0.414 0 C-N-CA 120.86 -0.686 . . . . 0.0 112.611 179.426 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 76.09 -32.77 1.3 Allowed Glycine 0 CA--C 1.524 0.598 0 C-N-CA 121.379 -0.439 . . . . 0.0 113.999 179.353 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 8.9 t -89.24 165.25 14.55 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.238 0.542 . . . . 0.0 111.561 -179.059 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 70.4 m -130.74 147.53 52.41 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.092 -0.958 . . . . 0.0 109.793 179.489 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 64.0 m-80 -89.43 -17.19 29.23 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.925 -0.58 . . . . 0.0 111.212 -178.979 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.422 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 4.6 m -101.22 123.25 45.51 Favored Pre-proline 0 C--N 1.323 -0.568 0 CA-C-O 121.091 0.472 . . . . 0.0 111.335 -178.635 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -63.48 135.03 47.48 Favored 'Trans proline' 0 C--N 1.344 0.299 0 C-N-CA 122.859 2.372 . . . . 0.0 111.941 179.674 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 95.2 -16.35 61.47 Favored Glycine 0 N--CA 1.445 -0.703 0 C-N-CA 120.637 -0.792 . . . . 0.0 111.867 -179.454 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.687 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 99.6 m -87.31 133.65 33.67 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 121.073 0.463 . . . . 0.0 109.906 179.644 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 15.7 m -109.34 137.83 46.61 Favored 'General case' 0 C--N 1.324 -0.522 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 -179.925 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 44.7 t -66.71 128.2 35.35 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-O 121.718 0.77 . . . . 0.0 112.182 -178.428 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 4.4 m -132.4 61.01 1.67 Allowed 'General case' 0 C--N 1.316 -0.867 0 N-CA-C 106.221 -1.77 . . . . 0.0 106.221 177.953 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.481 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -25.76 126.44 0.19 Allowed Pre-proline 0 N--CA 1.466 0.359 0 CA-C-N 113.931 -1.486 . . . . 0.0 113.037 -176.537 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.481 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 67.0 Cg_endo -96.85 30.91 13.07 Favored 'Cis proline' 0 CA--C 1.532 0.421 0 C-N-CA 123.757 -1.351 . . . . 0.0 114.515 0.805 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 43.3 pt -137.34 140.92 41.16 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.424 0 CA-C-O 121.273 0.558 . . . . 0.0 111.371 -179.154 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.687 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 4.5 t -88.41 143.99 26.65 Favored 'General case' 0 C--N 1.314 -0.943 0 CA-C-O 121.259 0.552 . . . . 0.0 110.267 179.908 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.467 HG22 ' HA ' ' A' ' 28' ' ' PRO . 68.5 p -138.04 127.61 24.98 Favored 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 115.433 -0.803 . . . . 0.0 111.316 -178.778 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.678 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 3.2 ptm180 -92.73 124.28 36.62 Favored 'General case' 0 N--CA 1.445 -0.687 0 N-CA-C 108.794 -0.817 . . . . 0.0 108.794 178.447 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 53.7 m-20 57.76 28.94 16.64 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.172 0.511 . . . . 0.0 109.744 -178.271 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 82.44 3.65 90.45 Favored Glycine 0 N--CA 1.449 -0.447 0 CA-C-N 115.854 -0.612 . . . . 0.0 112.683 -179.461 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 86.0 mt -101.18 121.06 53.3 Favored Pre-proline 0 C--O 1.236 0.352 0 O-C-N 122.623 -0.339 . . . . 0.0 110.75 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.467 ' HA ' HG22 ' A' ' 23' ' ' THR . 72.3 Cg_endo -77.06 47.34 2.19 Favored 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 123.062 2.508 . . . . 0.0 112.601 179.828 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 11.6 p . . . . . 0 C--N 1.321 -0.667 0 CA-C-N 115.537 -0.756 . . . . 0.0 110.239 179.999 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . 0.567 ' SG ' ' HB3' ' A' ' 24' ' ' ARG . 1.8 m . . . . . 0 N--CA 1.458 -0.058 0 CA-C-O 121.007 0.432 . . . . 0.0 110.339 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 76.04 -34.37 1.27 Allowed Glycine 0 CA--C 1.519 0.31 0 CA-C-N 115.865 -0.607 . . . . 0.0 113.287 179.515 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -54.56 140.62 34.22 Favored 'General case' 0 C--O 1.239 0.528 0 CA-C-O 121.658 0.742 . . . . 0.0 112.393 -179.001 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.579 HG23 ' O ' ' A' ' 20' ' ' PRO . 67.8 m -88.89 114.5 25.58 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.059 -0.973 . . . . 0.0 109.984 179.587 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 26.6 p -88.6 58.43 4.66 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 121.324 0.583 . . . . 0.0 110.458 -179.803 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 34.0 t80 -52.69 -44.96 66.62 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.309 -0.859 . . . . 0.0 111.194 -179.726 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -94.06 24.46 26.64 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.582 -0.818 . . . . 0.0 112.781 179.764 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.48 40.38 98.61 Favored Glycine 0 CA--C 1.518 0.264 0 C-N-CA 121.136 -0.554 . . . . 0.0 112.88 179.595 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.3 m -142.45 150.19 40.23 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 179.996 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 57.5 m -132.82 142.02 48.76 Favored 'General case' 0 C--N 1.324 -0.539 0 N-CA-C 110.025 -0.361 . . . . 0.0 110.025 179.869 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 43.6 t30 -89.31 -15.0 34.48 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.842 -0.617 . . . . 0.0 111.229 -179.081 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.635 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 5.7 m -100.67 125.3 39.33 Favored Pre-proline 0 C--N 1.323 -0.549 0 CA-C-O 121.252 0.549 . . . . 0.0 111.509 -178.754 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 28.7 Cg_endo -63.58 131.93 33.5 Favored 'Trans proline' 0 C--N 1.347 0.457 0 C-N-CA 122.999 2.466 . . . . 0.0 112.438 -179.819 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 95.08 -8.62 70.08 Favored Glycine 0 N--CA 1.447 -0.587 0 C-N-CA 120.894 -0.67 . . . . 0.0 111.737 -179.472 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.812 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 84.7 m -88.06 131.62 34.6 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-O 121.127 0.489 . . . . 0.0 110.133 179.63 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 13.3 m -109.49 136.45 48.86 Favored 'General case' 0 C--N 1.324 -0.538 0 N-CA-C 108.925 -0.769 . . . . 0.0 108.925 179.906 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 50.2 t -71.89 119.92 16.76 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-O 121.366 0.603 . . . . 0.0 112.106 -178.631 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 18.4 m -123.89 67.21 1.03 Allowed 'General case' 0 C--N 1.315 -0.903 0 N-CA-C 106.624 -1.621 . . . . 0.0 106.624 177.697 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.447 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.2 OUTLIER -29.03 127.51 0.23 Allowed Pre-proline 0 N--CA 1.464 0.234 0 CA-C-N 114.092 -1.413 . . . . 0.0 112.862 -176.721 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.579 ' O ' HG23 ' A' ' 4' ' ' THR . 65.6 Cg_endo -97.71 33.24 9.85 Favored 'Cis proline' 0 N--CA 1.46 -0.484 0 C-N-CA 123.767 -1.347 . . . . 0.0 114.23 0.822 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 41.8 pt -139.59 137.37 40.02 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-O 121.425 0.631 . . . . 0.0 111.632 -179.182 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.812 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 6.2 t -84.27 143.18 29.72 Favored 'General case' 0 C--N 1.316 -0.885 0 CA-C-O 121.311 0.576 . . . . 0.0 109.791 179.222 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.411 HG22 ' HA ' ' A' ' 28' ' ' PRO . 14.9 p -138.28 125.82 22.04 Favored 'General case' 0 C--N 1.314 -0.943 0 CA-C-N 115.239 -0.892 . . . . 0.0 111.378 -178.497 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.567 ' HB3' ' SG ' ' A' ' 1' ' ' CYS . 0.0 OUTLIER -91.1 129.3 37.11 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 178.864 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.453 ' CG ' ' HD3' ' A' ' 24' ' ' ARG . 54.8 m-20 54.6 30.03 12.48 Favored 'General case' 0 C--N 1.324 -0.529 0 O-C-N 123.85 0.719 . . . . 0.0 110.382 -178.844 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 77.46 13.97 82.98 Favored Glycine 0 C--N 1.335 0.498 0 CA-C-N 115.803 -0.635 . . . . 0.0 112.652 -179.583 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 90.2 mt -117.46 132.23 23.67 Favored Pre-proline 0 C--O 1.236 0.354 0 CA-C-O 120.825 0.345 . . . . 0.0 110.831 -179.888 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.411 ' HA ' HG22 ' A' ' 23' ' ' THR . 70.8 Cg_endo -74.6 53.68 3.22 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 123.116 2.544 . . . . 0.0 112.673 -179.95 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 40.9 t . . . . . 0 C--N 1.323 -0.58 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.404 -179.85 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 67.9 m . . . . . 0 N--CA 1.458 -0.051 0 CA-C-O 120.905 0.383 . . . . 0.0 110.195 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 60.14 38.11 93.9 Favored Glycine 0 C--N 1.333 0.381 0 CA-C-N 115.74 -0.663 . . . . 0.0 112.694 179.299 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -117.87 151.77 36.72 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 120.86 0.362 . . . . 0.0 110.848 -179.789 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.491 HG23 ' O ' ' A' ' 20' ' ' PRO . 28.2 m -96.66 118.67 33.63 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-N 115.893 -0.594 . . . . 0.0 111.051 179.811 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.716 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 7.6 p -88.45 61.2 6.02 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 121.262 0.553 . . . . 0.0 109.699 178.826 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 13.2 t80 -54.26 -41.51 68.91 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.35 -0.841 . . . . 0.0 110.28 -179.548 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -91.94 22.98 28.65 Favored Glycine 0 N--CA 1.449 -0.488 0 C-N-CA 120.926 -0.654 . . . . 0.0 112.611 179.325 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 78.71 -38.28 1.91 Allowed Glycine 0 CA--C 1.522 0.483 0 C-N-CA 121.251 -0.5 . . . . 0.0 113.631 179.447 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.4 m -89.49 147.38 24.02 Favored 'General case' 0 C--N 1.321 -0.65 0 O-C-N 122.498 -0.413 . . . . 0.0 111.49 -179.348 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 62.9 m -104.49 154.82 19.41 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.759 -0.655 . . . . 0.0 109.394 178.834 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 39.7 t30 -87.64 -26.7 22.89 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-O 121.135 0.493 . . . . 0.0 110.496 -179.717 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 3.7 m -102.12 120.42 53.7 Favored Pre-proline 0 C--N 1.324 -0.54 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.283 -179.268 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_exo -65.71 140.62 62.67 Favored 'Trans proline' 0 N--CA 1.461 -0.385 0 C-N-CA 122.943 2.428 . . . . 0.0 111.846 179.693 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 105.1 -28.91 12.74 Favored Glycine 0 N--CA 1.441 -0.976 0 C-N-CA 120.717 -0.754 . . . . 0.0 111.66 -179.356 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.578 ' HB3' ' HB3' ' A' ' 22' ' ' CYS . 2.0 m -87.64 131.55 34.4 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 121.273 0.559 . . . . 0.0 110.546 179.402 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 13.6 m -91.53 140.52 29.67 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.482 -0.781 . . . . 0.0 109.168 179.59 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 39.9 t -75.52 111.14 10.51 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-O 121.645 0.736 . . . . 0.0 111.598 -179.121 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 11.7 m -114.47 65.43 0.67 Allowed 'General case' 0 C--N 1.308 -1.197 0 N-CA-C 106.254 -1.758 . . . . 0.0 106.254 177.385 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.527 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.5 OUTLIER -28.66 125.78 0.24 Allowed Pre-proline 0 N--CA 1.464 0.252 0 CA-C-N 114.072 -1.422 . . . . 0.0 112.574 -176.583 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.527 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 65.0 Cg_endo -98.4 38.03 5.84 Favored 'Cis proline' 0 N--CA 1.459 -0.54 0 C-N-CA 123.963 -1.265 . . . . 0.0 114.109 0.899 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 2.3 pp -143.43 133.02 20.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 121.541 0.686 . . . . 0.0 112.457 -178.938 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.716 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 63.8 m -83.0 134.46 35.05 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.411 179.225 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 5.2 p -138.56 130.56 28.22 Favored 'General case' 0 C--N 1.317 -0.843 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.038 -179.746 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.432 ' HG3' ' O ' ' A' ' 24' ' ' ARG . 9.6 ptm180 -97.5 127.82 43.77 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 178.764 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 27.9 m-20 58.52 27.43 15.61 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.439 0.637 . . . . 0.0 109.504 -178.692 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 77.38 7.86 87.02 Favored Glycine 0 N--CA 1.449 -0.471 0 CA-C-N 115.411 -0.813 . . . . 0.0 112.389 -178.984 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.434 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 91.6 mt -109.59 131.57 21.82 Favored Pre-proline 0 C--O 1.238 0.451 0 CA-C-O 121.158 0.504 . . . . 0.0 111.293 -179.666 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.434 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 5.0 Cg_exo -77.06 65.4 7.81 Favored 'Trans proline' 0 N--CA 1.463 -0.32 0 C-N-CA 123.656 2.904 . . . . 0.0 111.95 179.594 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 47.8 t . . . . . 0 C--N 1.325 -0.465 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.594 -179.166 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 CA--C 1.526 0.035 0 CA-C-O 121.046 0.45 . . . . 0.0 110.299 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 60.37 38.63 94.99 Favored Glycine 0 C--N 1.332 0.348 0 CA-C-N 115.535 -0.757 . . . . 0.0 112.796 179.353 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.433 ' HG3' ' HB3' ' A' ' 22' ' ' CYS . 10.9 pt-20 -125.0 143.19 51.03 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 121.187 0.517 . . . . 0.0 111.259 -179.731 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.545 HG23 ' O ' ' A' ' 20' ' ' PRO . 87.9 m -89.18 111.46 22.25 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.376 179.85 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 25.3 p -88.77 58.98 4.87 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 121.287 0.565 . . . . 0.0 110.468 -179.995 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 33.6 t80 -52.92 -46.01 67.88 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.378 -0.828 . . . . 0.0 111.233 -179.688 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -92.56 24.04 25.15 Favored Glycine 0 C--O 1.227 -0.291 0 C-N-CA 120.579 -0.82 . . . . 0.0 112.728 179.73 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.83 36.72 93.2 Favored Glycine 0 C--O 1.228 -0.252 0 C-N-CA 121.2 -0.524 . . . . 0.0 112.666 179.694 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.7 m -136.06 148.95 48.56 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 60.3 m -129.33 141.57 51.05 Favored 'General case' 0 C--N 1.322 -0.628 0 O-C-N 123.218 0.324 . . . . 0.0 110.246 179.9 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 44.0 t30 -89.06 -17.3 29.6 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.804 -0.635 . . . . 0.0 110.614 -179.592 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.522 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 4.3 m -101.31 123.46 44.62 Favored Pre-proline 0 C--N 1.322 -0.596 0 CA-C-O 121.14 0.495 . . . . 0.0 111.33 -178.939 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.447 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 23.4 Cg_exo -64.18 136.65 52.77 Favored 'Trans proline' 0 C--N 1.345 0.349 0 C-N-CA 123.017 2.478 . . . . 0.0 112.013 179.948 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 92.85 -12.27 70.26 Favored Glycine 0 N--CA 1.447 -0.596 0 C-N-CA 120.79 -0.719 . . . . 0.0 111.881 -179.626 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.673 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 98.9 m -87.55 134.4 33.63 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 121.125 0.488 . . . . 0.0 110.308 179.773 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 12.6 m -107.4 137.55 45.23 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.637 -0.71 . . . . 0.0 109.104 -179.88 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 53.9 t -72.95 115.52 12.35 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-O 121.496 0.665 . . . . 0.0 111.961 -178.739 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 8.7 m -116.29 66.49 0.71 Allowed 'General case' 0 C--N 1.312 -1.03 0 N-CA-C 106.515 -1.661 . . . . 0.0 106.515 177.478 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.447 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.2 OUTLIER -28.82 126.86 0.23 Allowed Pre-proline 0 N--CA 1.464 0.229 0 CA-C-N 114.303 -1.317 . . . . 0.0 112.841 -176.559 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.545 ' O ' HG23 ' A' ' 4' ' ' THR . 62.6 Cg_endo -97.21 32.79 10.48 Favored 'Cis proline' 0 CA--C 1.532 0.396 0 C-N-CA 123.676 -1.385 . . . . 0.0 114.293 0.93 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 44.2 pt -138.97 133.87 41.41 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-O 121.451 0.643 . . . . 0.0 111.888 -179.239 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.673 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 7.0 t -83.48 142.87 30.62 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-O 121.22 0.533 . . . . 0.0 109.746 179.202 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.559 HG22 ' HA ' ' A' ' 28' ' ' PRO . 14.9 p -145.33 131.99 19.93 Favored 'General case' 0 C--N 1.314 -0.949 0 CA-C-N 115.276 -0.875 . . . . 0.0 111.293 -178.399 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.535 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 0.0 OUTLIER -92.39 128.51 38.26 Favored 'General case' 0 N--CA 1.448 -0.555 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 178.38 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 18.6 m-20 56.57 28.45 13.94 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.191 0.52 . . . . 0.0 109.963 -179.253 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 76.79 13.16 83.87 Favored Glycine 0 C--N 1.333 0.409 0 CA-C-N 115.745 -0.661 . . . . 0.0 112.362 -179.089 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . 0.486 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 87.2 mt -112.49 129.55 24.26 Favored Pre-proline 0 C--O 1.241 0.655 0 CA-C-O 120.887 0.375 . . . . 0.0 110.858 -179.847 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.559 ' HA ' HG22 ' A' ' 23' ' ' THR . 2.8 Cg_exo -75.54 54.14 3.8 Favored 'Trans proline' 0 C--N 1.342 0.216 0 C-N-CA 123.718 2.945 . . . . 0.0 112.468 -179.95 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 45.4 t . . . . . 0 C--N 1.323 -0.553 0 CA-C-O 121.331 0.586 . . . . 0.0 110.141 -179.748 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 1' ' ' CYS . . . . . 0.415 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 61.4 m . . . . . 0 N--CA 1.458 -0.043 0 CA-C-O 121.037 0.446 . . . . 0.0 109.806 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 60.26 32.95 78.33 Favored Glycine 0 C--N 1.332 0.347 0 CA-C-N 115.497 -0.774 . . . . 0.0 113.204 179.087 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 3' ' ' GLU . . . . . 0.463 ' HG3' ' HB3' ' A' ' 22' ' ' CYS . 9.3 pt-20 -105.71 145.54 30.96 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 121.045 0.45 . . . . 0.0 111.015 179.901 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 4' ' ' THR . . . . . 0.511 HG23 ' O ' ' A' ' 20' ' ' PRO . 58.3 m -88.83 110.0 20.67 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.89 -0.596 . . . . 0.0 110.399 179.91 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 25.8 p -88.78 59.71 5.2 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 121.429 0.633 . . . . 0.0 110.536 -179.941 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 34.8 t80 -53.64 -43.78 69.02 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.286 -0.87 . . . . 0.0 111.165 -179.75 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -88.23 18.54 40.52 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.743 -0.741 . . . . 0.0 113.004 179.905 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 64.56 37.61 94.63 Favored Glycine 0 N--CA 1.453 -0.233 0 C-N-CA 121.077 -0.582 . . . . 0.0 112.656 179.668 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.6 m -147.38 149.52 32.92 Favored 'General case' 0 C--N 1.324 -0.522 0 N-CA-C 109.665 -0.494 . . . . 0.0 109.665 179.92 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 43.4 m -121.45 146.0 47.35 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.239 -179.899 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 39.1 t30 -88.26 -23.45 23.5 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.154 -179.787 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' THR . . . . . 0.415 ' HB ' ' SG ' ' A' ' 1' ' ' CYS . 2.9 m -101.95 121.11 51.88 Favored Pre-proline 0 C--N 1.323 -0.582 0 CA-C-N 115.999 -0.546 . . . . 0.0 111.413 -178.977 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 22.2 Cg_exo -64.74 141.5 72.5 Favored 'Trans proline' 0 C--N 1.344 0.298 0 C-N-CA 123.021 2.48 . . . . 0.0 111.854 179.76 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 101.62 -28.17 17.16 Favored Glycine 0 N--CA 1.445 -0.747 0 C-N-CA 120.687 -0.768 . . . . 0.0 111.615 -179.331 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.849 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 1.6 m -86.97 136.85 32.78 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 121.136 0.493 . . . . 0.0 110.191 179.446 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 14.2 m -105.26 140.18 38.8 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.596 -0.729 . . . . 0.0 109.314 -179.745 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 53.9 t -72.37 112.33 8.34 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.482 0.658 . . . . 0.0 111.709 -178.887 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 14.1 m -114.54 66.91 0.68 Allowed 'General case' 0 C--N 1.312 -1.052 0 N-CA-C 106.554 -1.647 . . . . 0.0 106.554 177.624 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' TRP . . . . . 0.472 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.2 OUTLIER -28.91 127.01 0.23 Allowed Pre-proline 0 N--CA 1.464 0.266 0 CA-C-N 114.24 -1.345 . . . . 0.0 112.833 -176.631 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' PRO . . . . . 0.511 ' O ' HG23 ' A' ' 4' ' ' THR . 62.2 Cg_endo -97.1 31.85 11.75 Favored 'Cis proline' 0 N--CA 1.46 -0.443 0 C-N-CA 123.627 -1.406 . . . . 0.0 114.213 0.968 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 43.0 pt -138.56 133.61 42.53 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-O 121.663 0.744 . . . . 0.0 112.025 -179.174 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.849 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 8.0 t -83.54 140.1 32.47 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-N 115.927 -0.578 . . . . 0.0 109.547 179.011 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' THR . . . . . 0.569 HG22 ' HA ' ' A' ' 28' ' ' PRO . 7.9 p -148.76 135.5 19.76 Favored 'General case' 0 C--N 1.313 -0.982 0 CA-C-N 115.274 -0.875 . . . . 0.0 111.342 -178.104 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' ARG . . . . . 0.499 ' HG3' ' O ' ' A' ' 24' ' ' ARG . 4.8 ptm180 -93.92 126.29 39.04 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 178.576 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 58.52 27.23 15.32 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.36 0.6 . . . . 0.0 109.404 -179.069 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 77.57 9.31 86.94 Favored Glycine 0 C--N 1.333 0.392 0 CA-C-N 115.504 -0.771 . . . . 0.0 112.251 -178.885 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 88.4 mt -108.07 131.12 21.96 Favored Pre-proline 0 C--O 1.24 0.558 0 CA-C-O 121.092 0.472 . . . . 0.0 111.091 -179.724 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.569 ' HA ' HG22 ' A' ' 23' ' ' THR . 74.2 Cg_endo -76.14 64.3 7.01 Favored 'Trans proline' 0 C--N 1.341 0.158 0 C-N-CA 123.269 2.646 . . . . 0.0 112.48 179.946 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 55.5 t . . . . . 0 C--N 1.324 -0.532 0 CA-C-O 121.285 0.564 . . . . 0.0 110.163 -179.759 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 5.4 m . . . . . 0 N--CA 1.457 -0.092 0 CA-C-O 121.038 0.447 . . . . 0.0 110.013 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 76.68 -35.45 1.4 Allowed Glycine 0 C--N 1.331 0.259 0 CA-C-N 115.849 -0.614 . . . . 0.0 113.703 179.069 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 7.3 pt-20 -58.13 143.84 42.49 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-O 121.615 0.721 . . . . 0.0 112.058 -178.981 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.531 HG23 ' O ' ' A' ' 20' ' ' PRO . 53.6 m -95.11 121.35 36.65 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.034 -0.985 . . . . 0.0 110.658 179.688 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.772 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 13.7 p -88.08 61.17 6.17 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 121.258 0.552 . . . . 0.0 109.866 179.05 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 29.4 t80 -52.77 -44.5 66.56 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.368 -0.833 . . . . 0.0 110.555 -179.609 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -93.45 25.08 22.52 Favored Glycine 0 N--CA 1.449 -0.462 0 C-N-CA 120.639 -0.791 . . . . 0.0 112.399 179.223 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 75.59 -30.52 1.23 Allowed Glycine 0 CA--C 1.523 0.562 0 C-N-CA 121.485 -0.388 . . . . 0.0 113.789 179.579 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.5 m -89.1 148.95 23.42 Favored 'General case' 0 C--N 1.322 -0.59 0 O-C-N 122.367 -0.49 . . . . 0.0 111.293 -179.483 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 79.7 m -112.15 151.44 29.49 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.859 -0.61 . . . . 0.0 109.684 179.11 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -88.46 -21.64 24.1 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 120.895 0.379 . . . . 0.0 110.53 -179.214 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 4.3 m -100.71 123.38 45.98 Favored Pre-proline 0 C--N 1.323 -0.557 0 CA-C-O 121.148 0.499 . . . . 0.0 111.277 -179.1 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 29.7 Cg_endo -63.75 136.04 51.61 Favored 'Trans proline' 0 C--N 1.344 0.332 0 C-N-CA 122.823 2.348 . . . . 0.0 111.562 179.519 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 98.69 -21.39 46.19 Favored Glycine 0 N--CA 1.443 -0.834 0 C-N-CA 120.509 -0.853 . . . . 0.0 111.744 -179.228 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.576 ' HB3' ' HB3' ' A' ' 22' ' ' CYS . 71.3 m -86.73 126.35 34.52 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 121.212 0.529 . . . . 0.0 110.235 179.597 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 14.8 m -96.85 140.64 31.11 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 115.449 -0.796 . . . . 0.0 109.023 179.634 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 53.7 t -69.76 123.68 22.03 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-O 121.683 0.754 . . . . 0.0 111.92 -178.792 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 7.4 m -130.06 61.68 1.58 Allowed 'General case' 0 C--N 1.313 -0.997 0 N-CA-C 106.031 -1.84 . . . . 0.0 106.031 177.787 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.535 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -27.51 125.71 0.22 Allowed Pre-proline 0 N--CA 1.463 0.198 0 CA-C-N 113.827 -1.533 . . . . 0.0 112.787 -176.576 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.535 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 71.9 Cg_endo -98.03 38.07 5.82 Favored 'Cis proline' 0 N--CA 1.459 -0.533 0 C-N-CA 123.813 -1.328 . . . . 0.0 114.172 0.746 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 39.9 pt -143.44 136.9 25.21 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 O-C-N 121.6 -0.688 . . . . 0.0 112.026 -179.148 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.772 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 74.0 m -82.37 136.61 34.95 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-O 121.09 0.471 . . . . 0.0 110.236 178.923 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.41 HG22 ' CA ' ' A' ' 28' ' ' PRO . 67.0 p -127.3 123.47 36.47 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 115.759 -0.655 . . . . 0.0 110.857 -179.615 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.542 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 4.4 ptm180 -92.63 125.69 37.37 Favored 'General case' 0 N--CA 1.445 -0.702 0 N-CA-C 108.506 -0.924 . . . . 0.0 108.506 178.519 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 58.62 26.75 14.86 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 121.257 0.551 . . . . 0.0 109.682 -178.941 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 84.11 3.27 89.09 Favored Glycine 0 N--CA 1.45 -0.428 0 CA-C-N 115.723 -0.671 . . . . 0.0 112.668 -179.402 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.46 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 88.8 mt -102.91 121.5 48.97 Favored Pre-proline 0 C--N 1.328 -0.352 0 O-C-N 122.561 -0.376 . . . . 0.0 110.857 -179.947 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.46 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 5.1 Cg_exo -76.98 47.22 2.15 Favored 'Trans proline' 0 C--N 1.343 0.246 0 C-N-CA 123.361 2.707 . . . . 0.0 112.307 179.827 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 10.7 p . . . . . 0 C--N 1.32 -0.692 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.402 -179.856 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.3 m . . . . . 0 CA--C 1.527 0.068 0 CA-C-O 120.962 0.41 . . . . 0.0 110.419 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 77.92 -36.39 1.68 Allowed Glycine 0 C--N 1.331 0.251 0 CA-C-N 115.969 -0.56 . . . . 0.0 113.166 179.415 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 11.8 pt-20 -58.27 137.26 57.26 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 121.5 0.667 . . . . 0.0 112.072 -179.244 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.498 ' HB ' ' CD1' ' A' ' 6' ' ' PHE . 10.6 p -91.15 117.52 29.68 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.37 -0.832 . . . . 0.0 109.804 179.221 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 28.2 p -88.92 57.97 4.37 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.012 0.434 . . . . 0.0 111.764 -178.521 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . 0.498 ' CD1' ' HB ' ' A' ' 4' ' ' THR . 5.3 m-85 -57.64 -38.07 74.4 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.99 179.423 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -89.9 18.06 49.6 Favored Glycine 0 CA--C 1.519 0.315 0 C-N-CA 120.639 -0.791 . . . . 0.0 112.861 179.841 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 62.31 39.48 97.79 Favored Glycine 0 C--N 1.331 0.27 0 C-N-CA 121.092 -0.575 . . . . 0.0 112.916 179.546 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 3.5 m -149.04 152.18 35.8 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 109.724 -0.473 . . . . 0.0 109.724 -179.996 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 56.8 m -129.94 143.4 50.78 Favored 'General case' 0 C--N 1.324 -0.522 0 O-C-N 123.21 0.319 . . . . 0.0 110.225 179.927 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 43.0 t30 -89.13 -18.11 27.86 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.026 -179.229 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.442 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 6.7 m -100.97 125.13 39.34 Favored Pre-proline 0 C--N 1.323 -0.558 0 CA-C-O 121.155 0.503 . . . . 0.0 111.671 -178.649 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_endo -64.41 138.52 60.61 Favored 'Trans proline' 0 C--N 1.346 0.395 0 C-N-CA 122.859 2.372 . . . . 0.0 111.626 179.541 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 93.67 -15.55 62.78 Favored Glycine 0 N--CA 1.447 -0.607 0 C-N-CA 120.726 -0.75 . . . . 0.0 111.557 -179.133 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.769 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 93.7 m -87.45 133.27 33.77 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 121.045 0.45 . . . . 0.0 110.163 179.606 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 14.6 m -110.54 136.58 49.44 Favored 'General case' 0 C--N 1.323 -0.56 0 N-CA-C 109.209 -0.663 . . . . 0.0 109.209 179.934 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.8 t -67.37 126.42 29.2 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-O 121.437 0.637 . . . . 0.0 111.914 -178.604 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 4.9 m -132.35 65.79 1.57 Allowed 'General case' 0 C--N 1.318 -0.79 0 N-CA-C 106.889 -1.523 . . . . 0.0 106.889 178.457 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.506 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -27.71 126.67 0.22 Allowed Pre-proline 0 N--CA 1.465 0.289 0 CA-C-N 114.402 -1.272 . . . . 0.0 112.93 -176.684 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.506 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 62.8 Cg_endo -97.68 30.72 12.97 Favored 'Cis proline' 0 N--CA 1.461 -0.43 0 C-N-CA 123.802 -1.333 . . . . 0.0 114.424 0.927 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.497 HG22 HG22 ' A' ' 4' ' ' THR . 43.5 pt -138.65 142.58 34.32 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.36 0 CA-C-O 121.385 0.612 . . . . 0.0 111.448 -179.05 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.769 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 5.8 t -87.97 144.0 26.79 Favored 'General case' 0 C--N 1.314 -0.943 0 CA-C-O 121.137 0.494 . . . . 0.0 110.005 179.393 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 48.7 p -136.58 126.84 26.45 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-N 115.573 -0.74 . . . . 0.0 111.7 -178.58 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.666 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 9.1 ptm180 -91.47 126.9 36.71 Favored 'General case' 0 N--CA 1.445 -0.713 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 177.985 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 29.0 m-20 58.34 26.72 14.38 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 121.209 0.528 . . . . 0.0 109.911 -178.889 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 80.31 10.07 85.82 Favored Glycine 0 N--CA 1.45 -0.432 0 CA-C-N 115.864 -0.607 . . . . 0.0 112.363 -179.395 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.412 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 89.7 mt -113.15 128.54 25.52 Favored Pre-proline 0 C--O 1.236 0.379 0 CA-C-O 120.857 0.36 . . . . 0.0 110.755 -180.0 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.412 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 6.5 Cg_exo -73.76 52.94 2.65 Favored 'Trans proline' 0 CA--C 1.527 0.166 0 C-N-CA 123.619 2.879 . . . . 0.0 112.54 -179.839 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 39.4 t . . . . . 0 C--N 1.323 -0.57 0 CA-C-O 121.364 0.602 . . . . 0.0 110.206 -179.75 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.5 m . . . . . 0 N--CA 1.458 -0.058 0 CA-C-O 121.081 0.467 . . . . 0.0 110.191 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 77.16 -36.28 1.51 Allowed Glycine 0 C--N 1.332 0.331 0 CA-C-N 115.862 -0.608 . . . . 0.0 113.29 179.256 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 9.1 pt-20 -58.04 138.6 55.85 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 121.585 0.707 . . . . 0.0 112.181 -179.166 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.464 ' HA ' ' HA ' ' A' ' 21' ' ' ILE . 28.9 p -89.77 119.86 30.53 Favored 'General case' 0 N--CA 1.445 -0.675 0 CA-C-N 115.288 -0.869 . . . . 0.0 109.663 179.064 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 25.7 p -87.83 60.6 5.99 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 121.478 0.656 . . . . 0.0 110.507 -179.684 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 36.0 t80 -54.6 -41.5 70.01 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.353 -0.839 . . . . 0.0 110.613 179.942 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -94.33 22.93 34.26 Favored Glycine 0 N--CA 1.449 -0.492 0 C-N-CA 120.694 -0.765 . . . . 0.0 112.733 179.611 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 75.25 -28.85 1.18 Allowed Glycine 0 CA--C 1.523 0.593 0 C-N-CA 121.192 -0.528 . . . . 0.0 113.94 179.382 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.8 m -88.43 151.05 22.82 Favored 'General case' 0 C--N 1.322 -0.616 0 O-C-N 122.522 -0.399 . . . . 0.0 111.445 -179.015 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 61.6 m -120.79 149.77 42.03 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.855 -0.611 . . . . 0.0 109.763 179.266 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 41.3 t30 -88.8 -21.33 23.81 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-O 121.115 0.483 . . . . 0.0 111.181 -179.227 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 6.4 m -101.08 124.2 42.4 Favored Pre-proline 0 C--N 1.323 -0.575 0 CA-C-O 121.239 0.542 . . . . 0.0 111.793 -178.424 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 33.7 Cg_endo -65.01 138.35 56.66 Favored 'Trans proline' 0 C--N 1.346 0.423 0 C-N-CA 122.897 2.398 . . . . 0.0 111.58 179.461 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 95.22 -16.22 61.75 Favored Glycine 0 N--CA 1.446 -0.655 0 C-N-CA 120.635 -0.793 . . . . 0.0 111.492 -179.224 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.668 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 91.5 m -88.07 133.81 33.89 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 120.991 0.424 . . . . 0.0 109.934 179.368 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 15.1 m -108.62 136.47 48.16 Favored 'General case' 0 C--N 1.322 -0.604 0 N-CA-C 109.201 -0.666 . . . . 0.0 109.201 -179.996 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.4 t -66.92 126.07 27.95 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-O 121.673 0.749 . . . . 0.0 111.91 -178.49 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 4.6 m -129.93 62.52 1.55 Allowed 'General case' 0 C--N 1.316 -0.87 0 N-CA-C 106.37 -1.715 . . . . 0.0 106.37 178.016 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.456 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.2 OUTLIER -26.11 126.4 0.2 Allowed Pre-proline 0 N--CA 1.465 0.307 0 CA-C-N 114.052 -1.431 . . . . 0.0 113.028 -176.507 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.456 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 61.0 Cg_endo -97.49 31.55 11.97 Favored 'Cis proline' 0 CA--C 1.533 0.459 0 C-N-CA 123.731 -1.362 . . . . 0.0 114.32 1.02 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.464 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 42.8 pt -138.04 140.29 40.81 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.354 0 CA-C-O 121.272 0.558 . . . . 0.0 111.362 -179.194 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.668 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 4.0 t -87.0 144.07 27.07 Favored 'General case' 0 C--N 1.315 -0.929 0 CA-C-O 121.205 0.526 . . . . 0.0 110.146 179.715 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 60.4 p -136.64 127.82 28.01 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-N 115.572 -0.74 . . . . 0.0 111.643 -178.553 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.6 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 1.7 ptm180 -89.07 123.42 33.35 Favored 'General case' 0 N--CA 1.446 -0.63 0 N-CA-C 108.528 -0.915 . . . . 0.0 108.528 178.197 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 69.8 m-20 57.44 30.73 19.1 Favored 'General case' 0 N--CA 1.468 0.461 0 O-C-N 123.518 0.511 . . . . 0.0 109.955 -177.627 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 78.54 9.65 86.85 Favored Glycine 0 C--N 1.333 0.415 0 CA-C-N 115.895 -0.593 . . . . 0.0 112.688 -179.656 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 90.4 mt -110.61 127.01 27.67 Favored Pre-proline 0 C--O 1.237 0.4 0 O-C-N 122.682 -0.305 . . . . 0.0 110.686 179.912 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 61.9 Cg_endo -73.57 52.45 2.46 Favored 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 123.268 2.645 . . . . 0.0 112.783 -179.837 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 39.7 t . . . . . 0 C--N 1.323 -0.56 0 CA-C-O 121.396 0.617 . . . . 0.0 110.041 -179.948 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.8 m . . . . . 0 CA--C 1.527 0.077 0 CA-C-O 120.967 0.413 . . . . 0.0 110.409 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 77.78 -36.01 1.64 Allowed Glycine 0 C--N 1.33 0.231 0 CA-C-N 115.848 -0.615 . . . . 0.0 113.405 179.278 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 11.1 pt-20 -56.6 136.22 54.61 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.523 0.678 . . . . 0.0 112.085 -179.001 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.647 HG22 HG22 ' A' ' 21' ' ' ILE . 24.6 p -89.58 114.99 26.65 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.347 -0.842 . . . . 0.0 109.951 179.424 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 28.3 p -88.9 58.34 4.54 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 120.999 0.428 . . . . 0.0 111.673 -179.006 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . 0.482 ' CD1' ' HB ' ' A' ' 4' ' ' THR . 5.1 m-85 -57.17 -38.15 73.17 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.259 -0.428 . . . . 0.0 111.137 179.444 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -89.43 17.52 51.55 Favored Glycine 0 CA--C 1.519 0.314 0 C-N-CA 120.656 -0.783 . . . . 0.0 112.791 179.815 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 62.57 40.23 98.87 Favored Glycine 0 C--N 1.331 0.268 0 C-N-CA 121.141 -0.552 . . . . 0.0 112.88 179.529 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.8 m -148.38 150.57 33.78 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 109.65 -0.5 . . . . 0.0 109.65 179.885 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 56.6 m -128.53 143.65 51.01 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 120.797 0.332 . . . . 0.0 110.413 -179.846 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 42.8 t30 -89.21 -18.98 26.0 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.805 -179.538 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 6.0 m -101.26 124.49 41.12 Favored Pre-proline 0 C--N 1.324 -0.521 0 CA-C-O 121.169 0.509 . . . . 0.0 111.586 -178.593 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 36.0 Cg_endo -65.54 140.43 62.84 Favored 'Trans proline' 0 C--N 1.346 0.404 0 C-N-CA 122.849 2.366 . . . . 0.0 111.72 179.468 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 93.73 -17.09 59.32 Favored Glycine 0 N--CA 1.447 -0.58 0 C-N-CA 120.608 -0.806 . . . . 0.0 111.495 -179.054 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.71 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 94.4 m -87.34 134.6 33.55 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-O 121.067 0.46 . . . . 0.0 110.087 179.714 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 14.5 m -108.71 136.3 48.51 Favored 'General case' 0 C--N 1.323 -0.57 0 N-CA-C 108.997 -0.742 . . . . 0.0 108.997 179.97 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 48.7 t -71.21 121.53 18.55 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-O 121.472 0.654 . . . . 0.0 111.856 -178.644 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 2.0 p -129.64 73.07 1.5 Allowed 'General case' 0 C--N 1.314 -0.956 0 N-CA-C 107.354 -1.35 . . . . 0.0 107.354 177.934 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.474 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.0 OUTLIER -29.57 129.51 0.24 Allowed Pre-proline 0 N--CA 1.465 0.31 0 CA-C-N 114.379 -1.282 . . . . 0.0 112.906 -176.842 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.474 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 68.2 Cg_endo -97.48 27.56 17.46 Favored 'Cis proline' 0 N--CA 1.46 -0.468 0 C-N-CA 123.696 -1.377 . . . . 0.0 114.682 1.001 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.647 HG22 HG22 ' A' ' 4' ' ' THR . 0.2 OUTLIER -139.3 148.61 23.45 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.347 0 CA-C-O 121.309 0.576 . . . . 0.0 111.229 -179.297 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.71 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 4.6 t -88.81 144.22 26.37 Favored 'General case' 0 C--N 1.312 -1.057 0 CA-C-O 121.168 0.509 . . . . 0.0 109.783 179.635 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.458 HG22 ' HA ' ' A' ' 28' ' ' PRO . 21.5 p -138.13 126.58 23.32 Favored 'General case' 0 C--N 1.314 -0.954 0 CA-C-N 115.478 -0.783 . . . . 0.0 111.586 -178.486 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.623 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 4.8 ptm180 -90.18 127.52 36.14 Favored 'General case' 0 N--CA 1.446 -0.67 0 N-CA-C 108.803 -0.814 . . . . 0.0 108.803 178.445 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 58.04 27.04 14.3 Favored 'General case' 0 C--N 1.328 -0.37 0 CA-C-O 121.206 0.527 . . . . 0.0 109.873 -179.225 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 78.4 13.52 83.16 Favored Glycine 0 C--N 1.334 0.417 0 CA-C-N 115.821 -0.627 . . . . 0.0 112.201 -179.165 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 89.9 mt -114.94 129.98 24.58 Favored Pre-proline 0 C--O 1.238 0.496 0 CA-C-O 120.914 0.388 . . . . 0.0 110.751 -179.894 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.458 ' HA ' HG22 ' A' ' 23' ' ' THR . 67.7 Cg_endo -74.24 53.67 3.05 Favored 'Trans proline' 0 C--N 1.344 0.291 0 C-N-CA 123.277 2.651 . . . . 0.0 112.789 -179.807 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 39.9 t . . . . . 0 C--N 1.323 -0.553 0 CA-C-O 121.416 0.627 . . . . 0.0 110.2 -179.896 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.458 -0.031 0 CA-C-O 121.07 0.462 . . . . 0.0 110.253 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 61.04 38.77 96.09 Favored Glycine 0 C--N 1.332 0.324 0 CA-C-N 115.595 -0.73 . . . . 0.0 112.776 179.33 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 12.7 pt-20 -127.55 143.2 51.2 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 121.15 0.5 . . . . 0.0 110.986 -179.812 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.492 ' HB ' ' CD1' ' A' ' 6' ' ' PHE . 21.0 p -89.58 111.67 22.67 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.014 179.487 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 23.8 p -88.85 59.21 4.95 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 121.096 0.474 . . . . 0.0 111.401 -179.24 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . 0.492 ' CD1' ' HB ' ' A' ' 4' ' ' THR . 4.5 m-85 -57.48 -36.41 71.45 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.739 179.382 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -88.53 16.77 52.51 Favored Glycine 0 N--CA 1.449 -0.489 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.788 179.517 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 76.39 -29.6 1.44 Allowed Glycine 0 CA--C 1.523 0.588 0 C-N-CA 121.226 -0.511 . . . . 0.0 113.612 179.536 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.9 m -88.57 150.93 22.82 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 120.844 0.354 . . . . 0.0 111.172 -179.139 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 69.5 m -117.49 148.3 41.96 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.831 -0.622 . . . . 0.0 109.893 179.396 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 66.1 m-80 -88.84 -18.81 26.87 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.819 -179.511 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.529 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 3.2 m -101.87 124.93 38.6 Favored Pre-proline 0 C--N 1.324 -0.527 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.238 -178.984 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -65.77 138.24 52.76 Favored 'Trans proline' 0 C--N 1.344 0.304 0 C-N-CA 122.804 2.336 . . . . 0.0 112.022 179.746 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 91.61 -13.01 67.77 Favored Glycine 0 N--CA 1.449 -0.499 0 C-N-CA 120.761 -0.733 . . . . 0.0 111.876 -179.495 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.689 ' SG ' ' HB3' ' A' ' 24' ' ' ARG . 99.3 m -87.34 136.08 33.07 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.108 0.48 . . . . 0.0 110.401 179.857 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 9.9 m -107.39 135.86 48.16 Favored 'General case' 0 C--N 1.323 -0.55 0 N-CA-C 108.99 -0.744 . . . . 0.0 108.99 179.925 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.3 t -72.41 120.73 18.43 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-O 121.596 0.713 . . . . 0.0 112.17 -178.468 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 7.6 m -122.33 65.3 0.94 Allowed 'General case' 0 C--N 1.314 -0.968 0 N-CA-C 106.494 -1.669 . . . . 0.0 106.494 177.705 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.46 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -27.32 126.96 0.21 Allowed Pre-proline 0 N--CA 1.466 0.359 0 CA-C-N 114.222 -1.354 . . . . 0.0 112.955 -176.51 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.46 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 64.9 Cg_endo -97.2 31.07 12.73 Favored 'Cis proline' 0 N--CA 1.461 -0.42 0 C-N-CA 123.704 -1.373 . . . . 0.0 114.324 0.846 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 40.9 pt -137.21 136.02 47.19 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 121.481 0.658 . . . . 0.0 111.862 -179.112 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.68 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 5.7 t -86.44 144.96 27.03 Favored 'General case' 0 C--N 1.315 -0.905 0 CA-C-O 121.233 0.539 . . . . 0.0 110.064 179.577 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.442 HG22 ' HA ' ' A' ' 28' ' ' PRO . 9.1 p -144.11 128.79 18.21 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-N 115.288 -0.869 . . . . 0.0 111.216 -178.503 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.689 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 5.6 ptm180 -91.33 128.44 37.15 Favored 'General case' 0 N--CA 1.449 -0.508 0 N-CA-C 109.095 -0.706 . . . . 0.0 109.095 178.628 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 57.5 27.51 14.13 Favored 'General case' 0 N--CA 1.466 0.37 0 CA-C-O 121.243 0.544 . . . . 0.0 109.654 -179.349 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 76.2 14.53 82.21 Favored Glycine 0 C--N 1.332 0.345 0 CA-C-N 115.725 -0.67 . . . . 0.0 112.106 -178.92 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 88.2 mt -114.99 132.2 23.12 Favored Pre-proline 0 C--O 1.239 0.548 0 CA-C-O 121.071 0.462 . . . . 0.0 110.791 -179.755 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.442 ' HA ' HG22 ' A' ' 23' ' ' THR . 73.2 Cg_endo -76.08 55.16 4.41 Favored 'Trans proline' 0 C--N 1.342 0.188 0 C-N-CA 123.301 2.667 . . . . 0.0 112.548 179.91 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 41.8 t . . . . . 0 C--N 1.324 -0.51 0 CA-C-O 121.272 0.558 . . . . 0.0 110.236 -179.681 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.5 m . . . . . 0 N--CA 1.457 -0.079 0 CA-C-O 121.062 0.458 . . . . 0.0 110.251 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 77.33 -36.59 1.55 Allowed Glycine 0 C--N 1.331 0.287 0 CA-C-N 115.837 -0.619 . . . . 0.0 113.387 179.27 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 7.8 pt-20 -58.17 138.0 56.55 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 121.481 0.657 . . . . 0.0 112.283 -179.109 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.509 HG22 HG22 ' A' ' 21' ' ' ILE . 26.3 p -89.79 119.34 30.1 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.418 -0.81 . . . . 0.0 109.675 179.056 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 23.0 p -88.1 61.99 6.57 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 121.495 0.664 . . . . 0.0 110.552 -179.691 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 34.2 t80 -54.38 -42.14 70.04 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.281 -0.872 . . . . 0.0 110.819 -179.892 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -93.01 21.3 40.59 Favored Glycine 0 N--CA 1.45 -0.426 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.833 179.712 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 76.52 -29.49 1.47 Allowed Glycine 0 CA--C 1.521 0.433 0 C-N-CA 121.117 -0.563 . . . . 0.0 113.616 179.598 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -88.73 143.22 27.06 Favored 'General case' 0 C--N 1.321 -0.641 0 O-C-N 122.631 -0.334 . . . . 0.0 111.878 -179.127 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 64.5 m -111.03 151.49 27.95 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 115.895 -0.593 . . . . 0.0 109.893 179.354 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 38.9 t30 -88.6 -24.17 22.9 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 121.132 0.491 . . . . 0.0 110.897 -179.432 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 7.5 m -101.39 123.84 43.17 Favored Pre-proline 0 C--N 1.322 -0.612 0 CA-C-O 121.15 0.5 . . . . 0.0 111.813 -178.573 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -65.95 140.91 62.42 Favored 'Trans proline' 0 C--N 1.345 0.368 0 C-N-CA 122.828 2.352 . . . . 0.0 111.484 179.263 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 96.46 -19.81 53.03 Favored Glycine 0 N--CA 1.446 -0.643 0 C-N-CA 120.539 -0.839 . . . . 0.0 111.457 -179.053 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.675 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 84.7 m -87.41 134.82 33.53 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 120.991 0.424 . . . . 0.0 109.896 179.279 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 11.0 m -106.52 136.2 46.71 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 109.114 -0.699 . . . . 0.0 109.114 -179.872 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 48.2 t -70.91 121.91 18.99 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-O 121.522 0.677 . . . . 0.0 112.23 -178.596 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 18.2 m -125.76 67.63 1.17 Allowed 'General case' 0 C--N 1.314 -0.971 0 N-CA-C 106.308 -1.738 . . . . 0.0 106.308 177.572 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.467 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.2 OUTLIER -28.27 127.84 0.22 Allowed Pre-proline 0 N--CA 1.464 0.25 0 CA-C-N 114.062 -1.427 . . . . 0.0 112.945 -176.446 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.467 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 60.2 Cg_endo -97.83 31.91 11.38 Favored 'Cis proline' 0 N--CA 1.461 -0.429 0 C-N-CA 123.711 -1.37 . . . . 0.0 114.242 0.872 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.509 HG22 HG22 ' A' ' 4' ' ' THR . 42.8 pt -138.56 139.22 41.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 121.452 0.644 . . . . 0.0 111.699 -179.019 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.675 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 3.7 t -84.3 144.42 28.89 Favored 'General case' 0 C--N 1.317 -0.839 0 CA-C-O 121.237 0.541 . . . . 0.0 109.55 179.268 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.558 HG22 ' HA ' ' A' ' 28' ' ' PRO . 17.9 p -141.97 130.43 22.49 Favored 'General case' 0 C--N 1.314 -0.944 0 CA-C-N 115.411 -0.813 . . . . 0.0 111.602 -178.143 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.457 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 9.6 ptm180 -93.84 128.17 39.97 Favored 'General case' 0 N--CA 1.448 -0.57 0 N-CA-C 108.729 -0.841 . . . . 0.0 108.729 178.309 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 28.6 m-20 58.4 26.71 14.45 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 121.29 0.567 . . . . 0.0 109.796 -178.876 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 77.75 10.67 86.08 Favored Glycine 0 C--N 1.333 0.411 0 CA-C-N 115.736 -0.666 . . . . 0.0 112.171 -179.118 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.44 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 90.2 mt -110.39 131.04 22.25 Favored Pre-proline 0 C--O 1.24 0.578 0 CA-C-O 120.965 0.412 . . . . 0.0 110.684 -179.75 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.558 ' HA ' HG22 ' A' ' 23' ' ' THR . 4.9 Cg_exo -74.85 52.93 3.12 Favored 'Trans proline' 0 C--N 1.344 0.297 0 C-N-CA 123.699 2.933 . . . . 0.0 112.447 -179.832 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 40.5 t . . . . . 0 C--N 1.322 -0.613 0 CA-C-O 121.433 0.635 . . . . 0.0 110.018 -179.881 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.8 m . . . . . 0 C--O 1.23 0.032 0 CA-C-O 121.045 0.45 . . . . 0.0 110.37 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 78.11 -36.02 1.72 Allowed Glycine 0 N--CA 1.453 -0.228 0 CA-C-N 115.781 -0.645 . . . . 0.0 113.496 179.159 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 10.8 pt-20 -60.21 139.22 57.69 Favored 'General case' 0 C--O 1.238 0.471 0 CA-C-O 121.617 0.722 . . . . 0.0 111.831 -178.945 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.521 HG22 HG22 ' A' ' 21' ' ' ILE . 11.9 p -91.31 118.22 30.32 Favored 'General case' 0 N--CA 1.445 -0.699 0 CA-C-N 115.301 -0.863 . . . . 0.0 109.985 179.347 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 26.5 p -88.93 58.87 4.77 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 121.049 0.452 . . . . 0.0 111.438 -178.992 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . 0.494 ' CD1' ' HB ' ' A' ' 4' ' ' THR . 4.9 m-85 -57.67 -36.43 71.9 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.542 179.306 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -90.13 18.37 48.6 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.649 179.516 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 75.58 -30.28 1.23 Allowed Glycine 0 CA--C 1.522 0.526 0 C-N-CA 121.344 -0.455 . . . . 0.0 113.786 179.531 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.0 m -88.95 151.57 22.23 Favored 'General case' 0 C--N 1.322 -0.591 0 O-C-N 122.53 -0.394 . . . . 0.0 111.237 -179.078 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 82.8 m -118.24 149.34 41.28 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 115.874 -0.603 . . . . 0.0 109.661 179.29 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 65.5 m-80 -88.92 -26.06 21.76 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 116.059 -0.519 . . . . 0.0 111.659 -178.674 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.447 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 19.3 p -102.06 128.47 28.49 Favored Pre-proline 0 C--N 1.324 -0.53 0 CA-C-O 121.398 0.618 . . . . 0.0 111.841 -178.855 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.447 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 19.6 Cg_exo -66.09 141.36 63.37 Favored 'Trans proline' 0 C--N 1.346 0.402 0 C-N-CA 123.252 2.635 . . . . 0.0 112.164 -179.913 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 96.44 -20.63 49.53 Favored Glycine 0 N--CA 1.447 -0.578 0 C-N-CA 120.761 -0.733 . . . . 0.0 111.545 -179.385 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.682 ' SG ' ' HB3' ' A' ' 24' ' ' ARG . 91.8 m -88.19 135.96 33.2 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-O 121.097 0.475 . . . . 0.0 110.324 179.703 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 15.2 m -109.71 136.65 48.71 Favored 'General case' 0 C--N 1.323 -0.582 0 N-CA-C 109.044 -0.724 . . . . 0.0 109.044 179.889 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 45.4 t -66.41 127.47 32.42 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-O 121.602 0.715 . . . . 0.0 112.062 -178.448 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 5.3 m -132.32 64.61 1.6 Allowed 'General case' 0 C--N 1.316 -0.874 0 N-CA-C 106.583 -1.636 . . . . 0.0 106.583 178.337 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.463 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -27.15 126.73 0.21 Allowed Pre-proline 0 N--CA 1.466 0.343 0 CA-C-N 114.231 -1.349 . . . . 0.0 112.996 -176.592 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.463 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 66.8 Cg_endo -97.3 31.37 12.28 Favored 'Cis proline' 0 CA--C 1.533 0.433 0 C-N-CA 123.689 -1.38 . . . . 0.0 114.492 1.025 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.521 HG22 HG22 ' A' ' 4' ' ' THR . 43.4 pt -139.33 141.31 35.87 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.382 0 CA-C-O 121.302 0.573 . . . . 0.0 111.565 -179.212 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.643 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 4.2 t -86.11 144.38 27.55 Favored 'General case' 0 C--N 1.316 -0.854 0 N-CA-C 109.669 -0.493 . . . . 0.0 109.669 179.406 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 61.9 p -137.15 128.24 27.72 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-N 115.661 -0.699 . . . . 0.0 112.007 -178.235 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.682 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 3.3 ptm180 -90.52 125.36 35.58 Favored 'General case' 0 N--CA 1.445 -0.705 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 177.822 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 53.0 m-20 58.59 28.1 16.63 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-O 121.148 0.499 . . . . 0.0 110.007 -178.421 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 79.37 11.27 85.11 Favored Glycine 0 C--N 1.334 0.441 0 CA-C-N 115.933 -0.576 . . . . 0.0 112.541 -179.514 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.463 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 91.7 mt -113.81 127.92 26.31 Favored Pre-proline 0 C--O 1.236 0.382 0 CA-C-O 120.779 0.323 . . . . 0.0 110.777 -179.998 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.463 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 6.9 Cg_exo -73.29 53.66 2.61 Favored 'Trans proline' 0 C--N 1.344 0.291 0 C-N-CA 123.539 2.826 . . . . 0.0 112.695 -179.776 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 38.8 t . . . . . 0 C--N 1.323 -0.547 0 CA-C-O 121.445 0.641 . . . . 0.0 110.107 -179.926 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 4.1 m . . . . . 0 CA--C 1.527 0.089 0 CA-C-O 121.016 0.436 . . . . 0.0 110.246 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 62.86 45.41 95.75 Favored Glycine 0 C--N 1.333 0.405 0 CA-C-N 115.73 -0.668 . . . . 0.0 112.944 179.068 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 8.2 pt-20 -144.73 140.53 28.61 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 121.323 0.583 . . . . 0.0 111.346 -179.686 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.485 ' HB ' ' CD1' ' A' ' 6' ' ' PHE . 21.6 p -93.39 113.84 26.1 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 115.487 -0.779 . . . . 0.0 109.74 179.148 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 25.4 p -88.65 59.25 5.03 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 121.065 0.46 . . . . 0.0 111.459 -179.019 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . 0.485 ' CD1' ' HB ' ' A' ' 4' ' ' THR . 4.6 m-85 -57.73 -36.46 72.08 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.627 179.33 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -89.75 17.89 50.16 Favored Glycine 0 N--CA 1.45 -0.374 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.665 179.529 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 76.1 -29.57 1.37 Allowed Glycine 0 CA--C 1.524 0.609 0 C-N-CA 121.307 -0.473 . . . . 0.0 113.672 179.531 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.8 m -88.66 150.58 22.94 Favored 'General case' 0 C--N 1.323 -0.55 0 O-C-N 122.582 -0.363 . . . . 0.0 111.149 -179.232 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 67.6 m -117.12 150.87 37.97 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.094 179.517 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 42.3 t30 -88.82 -22.23 23.33 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.789 -179.605 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.433 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 4.5 m -101.42 123.35 44.85 Favored Pre-proline 0 C--N 1.324 -0.519 0 CA-C-O 121.226 0.536 . . . . 0.0 111.556 -178.62 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 22.4 Cg_exo -64.75 136.83 51.14 Favored 'Trans proline' 0 C--N 1.345 0.38 0 C-N-CA 122.96 2.44 . . . . 0.0 111.788 179.656 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 95.02 -15.12 64.09 Favored Glycine 0 N--CA 1.446 -0.648 0 C-N-CA 120.645 -0.788 . . . . 0.0 111.894 -179.436 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.669 ' SG ' ' HB3' ' A' ' 24' ' ' ARG . 88.6 m -87.31 135.5 33.29 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 109.828 -0.434 . . . . 0.0 109.828 179.583 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 13.3 m -105.7 135.25 47.45 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 109.125 -0.695 . . . . 0.0 109.125 -179.844 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.0 t -70.85 120.81 16.98 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-O 121.609 0.719 . . . . 0.0 111.994 -178.445 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 11.2 m -123.62 66.32 1.02 Allowed 'General case' 0 C--N 1.315 -0.933 0 N-CA-C 106.415 -1.698 . . . . 0.0 106.415 177.685 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.449 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -27.76 127.21 0.22 Allowed Pre-proline 0 N--CA 1.466 0.345 0 CA-C-N 114.167 -1.378 . . . . 0.0 112.878 -176.561 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.449 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 65.0 Cg_endo -97.37 31.29 12.35 Favored 'Cis proline' 0 N--CA 1.46 -0.442 0 C-N-CA 123.765 -1.348 . . . . 0.0 114.34 0.948 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 42.3 pt -138.2 137.34 44.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-O 121.454 0.645 . . . . 0.0 111.722 -179.155 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.62 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 4.5 t -85.05 144.38 28.29 Favored 'General case' 0 C--N 1.316 -0.861 0 CA-C-O 121.177 0.513 . . . . 0.0 109.912 179.447 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.477 HG22 ' CA ' ' A' ' 28' ' ' PRO . 21.5 p -143.52 127.06 16.92 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-N 115.304 -0.862 . . . . 0.0 111.127 -178.266 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.669 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 3.4 ptm180 -93.65 126.28 38.73 Favored 'General case' 0 N--CA 1.447 -0.581 0 N-CA-C 108.859 -0.793 . . . . 0.0 108.859 178.535 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 51.5 m-20 57.75 29.68 17.77 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-O 121.259 0.552 . . . . 0.0 109.657 -178.54 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 78.29 7.99 87.64 Favored Glycine 0 C--N 1.333 0.386 0 CA-C-N 115.587 -0.733 . . . . 0.0 112.67 -179.338 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.473 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 88.2 mt -106.62 124.48 35.45 Favored Pre-proline 0 C--O 1.237 0.442 0 CA-C-O 120.935 0.397 . . . . 0.0 110.867 -179.829 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.477 ' CA ' HG22 ' A' ' 23' ' ' THR . 3.8 Cg_exo -79.75 46.35 2.2 Favored 'Trans proline' 0 N--CA 1.462 -0.374 0 C-N-CA 123.574 2.849 . . . . 0.0 112.08 179.868 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 10.5 p . . . . . 0 C--N 1.319 -0.719 0 CA-C-N 115.552 -0.749 . . . . 0.0 110.337 -179.765 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.0 m . . . . . 0 N--CA 1.456 -0.136 0 CA-C-O 121.066 0.46 . . . . 0.0 110.318 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 76.27 -34.05 1.32 Allowed Glycine 0 C--N 1.332 0.325 0 CA-C-N 115.867 -0.606 . . . . 0.0 113.575 179.111 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -55.04 138.44 44.0 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 121.813 0.816 . . . . 0.0 112.315 -178.921 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.61 HG23 ' O ' ' A' ' 20' ' ' PRO . 81.1 m -89.0 110.86 21.5 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 114.892 -1.049 . . . . 0.0 110.008 179.607 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 28.5 p -89.13 53.42 2.66 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 121.167 0.508 . . . . 0.0 110.9 -179.459 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 18.9 p90 -58.15 -30.93 66.75 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.925 -0.58 . . . . 0.0 111.283 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -94.32 15.57 62.95 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.687 179.699 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 65.17 40.08 96.57 Favored Glycine 0 CA--C 1.518 0.269 0 C-N-CA 121.049 -0.596 . . . . 0.0 112.79 179.676 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 3.0 m -149.91 150.75 32.35 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 179.91 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 60.1 m -129.26 142.75 50.76 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 120.758 0.313 . . . . 0.0 110.213 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 43.7 t30 -89.23 -17.82 28.29 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.964 -179.367 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.453 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 5.2 m -101.11 123.67 44.21 Favored Pre-proline 0 C--N 1.323 -0.561 0 CA-C-O 121.122 0.487 . . . . 0.0 111.611 -178.546 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.453 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 23.9 Cg_exo -63.61 136.65 55.21 Favored 'Trans proline' 0 C--N 1.345 0.359 0 C-N-CA 122.959 2.44 . . . . 0.0 111.705 179.583 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 94.39 -15.07 64.06 Favored Glycine 0 N--CA 1.447 -0.623 0 C-N-CA 120.638 -0.792 . . . . 0.0 111.594 -179.225 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.73 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 93.1 m -87.88 132.42 34.21 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-O 121.059 0.457 . . . . 0.0 110.053 179.524 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 15.2 m -108.96 134.78 51.16 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 109.116 -0.698 . . . . 0.0 109.116 179.892 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 41.9 t -67.43 121.98 16.96 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 121.578 0.704 . . . . 0.0 111.873 -178.504 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 4.1 m -125.3 65.96 1.14 Allowed 'General case' 0 C--N 1.317 -0.82 0 N-CA-C 106.765 -1.569 . . . . 0.0 106.765 178.023 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.47 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -27.76 125.77 0.23 Allowed Pre-proline 0 N--CA 1.466 0.331 0 CA-C-N 114.347 -1.297 . . . . 0.0 112.812 -176.74 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.61 ' O ' HG23 ' A' ' 4' ' ' THR . 66.6 Cg_endo -97.51 31.19 12.42 Favored 'Cis proline' 0 N--CA 1.46 -0.452 0 C-N-CA 123.656 -1.393 . . . . 0.0 114.362 0.843 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 41.8 pt -138.54 136.36 43.76 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 O-C-N 121.474 -0.766 . . . . 0.0 111.859 -179.208 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.73 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 5.7 t -83.36 142.77 30.79 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-O 121.201 0.524 . . . . 0.0 109.826 179.367 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 62.0 p -137.05 128.35 28.11 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-N 115.504 -0.771 . . . . 0.0 111.785 -178.276 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.64 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 3.0 ptm180 -89.52 124.71 34.76 Favored 'General case' 0 N--CA 1.446 -0.67 0 N-CA-C 108.483 -0.932 . . . . 0.0 108.483 178.126 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 53.8 m-20 58.11 28.37 16.31 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 121.173 0.511 . . . . 0.0 110.035 -178.434 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 80.14 10.04 85.94 Favored Glycine 0 C--N 1.334 0.426 0 CA-C-N 115.87 -0.604 . . . . 0.0 112.58 -179.423 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 90.1 mt -110.82 127.33 27.11 Favored Pre-proline 0 C--N 1.327 -0.412 0 CA-C-O 120.82 0.343 . . . . 0.0 110.63 179.967 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 62.3 Cg_endo -73.61 52.69 2.53 Favored 'Trans proline' 0 C--N 1.343 0.261 0 C-N-CA 123.202 2.601 . . . . 0.0 112.784 -179.879 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 40.4 t . . . . . 0 C--N 1.322 -0.602 0 CA-C-N 115.876 -0.602 . . . . 0.0 110.094 -179.922 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 1.7 m . . . . . 0 N--CA 1.457 -0.078 0 CA-C-O 121.03 0.443 . . . . 0.0 110.232 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 75.71 -34.59 1.2 Allowed Glycine 0 C--N 1.33 0.243 0 CA-C-N 115.785 -0.643 . . . . 0.0 113.657 179.114 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 15.3 pt-20 -55.74 141.8 36.89 Favored 'General case' 0 C--O 1.238 0.478 0 CA-C-O 121.639 0.733 . . . . 0.0 112.116 -178.806 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.607 HG23 ' O ' ' A' ' 20' ' ' PRO . 87.8 m -88.68 117.03 27.36 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 115.157 -0.928 . . . . 0.0 110.308 -179.983 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 26.3 p -88.77 58.51 4.65 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 121.229 0.538 . . . . 0.0 110.209 179.798 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 32.3 t80 -51.76 -46.36 64.08 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 115.438 -0.801 . . . . 0.0 111.243 -179.559 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -94.45 25.41 22.9 Favored Glycine 0 N--CA 1.45 -0.369 0 C-N-CA 120.59 -0.814 . . . . 0.0 112.568 179.749 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.44 38.69 96.18 Favored Glycine 0 CA--C 1.518 0.223 0 C-N-CA 121.184 -0.531 . . . . 0.0 112.742 179.65 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.3 m -139.49 150.66 45.41 Favored 'General case' 0 C--N 1.324 -0.512 0 N-CA-C 110.013 -0.365 . . . . 0.0 110.013 -179.911 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 59.3 m -133.22 140.84 47.75 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 116.404 -0.362 . . . . 0.0 110.057 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 65.0 m-80 -89.56 -13.88 36.33 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.08 -179.047 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.547 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 4.7 m -101.09 124.84 40.15 Favored Pre-proline 0 C--N 1.322 -0.605 0 CA-C-O 121.126 0.489 . . . . 0.0 111.208 -178.751 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 28.8 Cg_endo -63.58 135.81 51.1 Favored 'Trans proline' 0 C--N 1.345 0.387 0 C-N-CA 122.88 2.387 . . . . 0.0 112.179 179.957 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 91.83 -11.32 72.43 Favored Glycine 0 N--CA 1.448 -0.556 0 C-N-CA 120.806 -0.711 . . . . 0.0 111.898 -179.508 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.766 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 89.1 m -88.08 132.9 34.12 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.056 0.455 . . . . 0.0 110.344 179.738 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 15.3 m -111.21 138.06 48.13 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 109.158 -0.682 . . . . 0.0 109.158 179.889 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 45.7 t -67.74 123.86 21.69 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-O 121.451 0.643 . . . . 0.0 111.969 -178.766 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 4.6 m -128.35 62.64 1.44 Allowed 'General case' 0 C--N 1.317 -0.815 0 N-CA-C 106.698 -1.593 . . . . 0.0 106.698 178.028 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.448 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -27.48 126.33 0.22 Allowed Pre-proline 0 N--CA 1.464 0.239 0 CA-C-N 114.153 -1.385 . . . . 0.0 112.933 -176.686 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.607 ' O ' HG23 ' A' ' 4' ' ' THR . 67.9 Cg_endo -97.21 33.76 9.47 Favored 'Cis proline' 0 N--CA 1.461 -0.436 0 C-N-CA 123.775 -1.344 . . . . 0.0 114.241 0.848 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 42.0 pt -140.24 137.05 37.55 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 O-C-N 121.654 -0.654 . . . . 0.0 111.582 -179.284 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.766 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 6.6 t -85.36 142.71 29.11 Favored 'General case' 0 C--N 1.316 -0.88 0 CA-C-O 121.062 0.458 . . . . 0.0 109.848 179.346 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 66.2 p -136.88 129.2 29.86 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-N 115.552 -0.749 . . . . 0.0 111.824 -178.47 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.653 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 1.7 ptm180 -90.36 123.04 33.78 Favored 'General case' 0 N--CA 1.445 -0.711 0 N-CA-C 108.634 -0.876 . . . . 0.0 108.634 178.066 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 71.1 m-20 56.85 31.27 19.31 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-O 121.214 0.53 . . . . 0.0 109.987 -177.656 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 79.38 7.31 88.57 Favored Glycine 0 C--N 1.334 0.448 0 CA-C-N 115.879 -0.6 . . . . 0.0 112.856 -179.625 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.47 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 88.0 mt -107.36 126.4 30.12 Favored Pre-proline 0 C--O 1.237 0.41 0 O-C-N 122.624 -0.339 . . . . 0.0 110.697 179.982 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.47 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 7.4 Cg_exo -72.91 52.98 2.29 Favored 'Trans proline' 0 C--N 1.343 0.246 0 C-N-CA 123.587 2.858 . . . . 0.0 112.581 -179.834 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 43.4 t . . . . . 0 C--N 1.323 -0.561 0 CA-C-O 121.307 0.575 . . . . 0.0 110.171 -179.774 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 2.6 m . . . . . 0 CA--C 1.528 0.104 0 CA-C-O 120.875 0.369 . . . . 0.0 110.763 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 65.68 42.97 95.08 Favored Glycine 0 N--CA 1.451 -0.321 0 CA-C-N 115.798 -0.637 . . . . 0.0 112.982 179.217 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -142.84 143.44 32.12 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 121.211 0.529 . . . . 0.0 110.864 179.906 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.528 ' HB ' ' CD1' ' A' ' 6' ' ' PHE . 7.3 p -95.97 115.08 26.88 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 115.582 -0.735 . . . . 0.0 110.381 179.506 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 25.5 p -89.11 58.84 4.69 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 121.047 0.451 . . . . 0.0 111.426 -179.248 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . 0.528 ' CD1' ' HB ' ' A' ' 4' ' ' THR . 5.2 m-85 -57.81 -36.36 72.13 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.644 179.416 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -88.36 16.83 51.49 Favored Glycine 0 N--CA 1.448 -0.508 0 C-N-CA 120.833 -0.699 . . . . 0.0 112.703 179.654 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 77.2 -30.62 1.61 Allowed Glycine 0 CA--C 1.523 0.542 0 C-N-CA 121.223 -0.513 . . . . 0.0 113.487 179.635 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.7 m -88.62 149.96 23.28 Favored 'General case' 0 C--N 1.322 -0.626 0 O-C-N 122.655 -0.32 . . . . 0.0 111.035 -179.373 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 77.0 m -113.05 150.6 31.79 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.141 179.52 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 64.8 m-80 -88.65 -27.94 20.95 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 115.818 -0.628 . . . . 0.0 111.244 -179.086 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.457 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 21.3 p -102.46 128.31 28.49 Favored Pre-proline 0 C--N 1.324 -0.509 0 CA-C-O 121.481 0.658 . . . . 0.0 111.746 -179.049 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.457 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 17.3 Cg_exo -67.25 141.09 55.61 Favored 'Trans proline' 0 C--N 1.345 0.375 0 C-N-CA 123.277 2.651 . . . . 0.0 112.172 -179.758 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 96.8 -20.1 52.05 Favored Glycine 0 N--CA 1.448 -0.565 0 C-N-CA 120.739 -0.743 . . . . 0.0 111.7 -179.509 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.731 ' SG ' ' HB3' ' A' ' 24' ' ' ARG . 91.0 m -88.22 138.82 31.1 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-O 121.066 0.46 . . . . 0.0 110.283 179.734 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 16.1 m -108.49 134.52 51.15 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 109.172 -0.677 . . . . 0.0 109.172 179.855 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.4 t -66.31 125.2 24.86 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-O 121.615 0.721 . . . . 0.0 111.893 -178.418 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 3.9 m -129.0 65.6 1.44 Allowed 'General case' 0 C--N 1.315 -0.913 0 N-CA-C 106.708 -1.589 . . . . 0.0 106.708 178.277 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.458 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -27.26 126.42 0.22 Allowed Pre-proline 0 N--CA 1.465 0.312 0 CA-C-N 114.423 -1.262 . . . . 0.0 112.836 -176.571 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.458 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 63.2 Cg_endo -97.17 31.03 12.79 Favored 'Cis proline' 0 CA--C 1.532 0.407 0 C-N-CA 123.776 -1.343 . . . . 0.0 114.534 0.932 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.417 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 42.5 pt -139.42 138.98 39.72 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.333 0 CA-C-O 121.319 0.581 . . . . 0.0 111.719 -179.117 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.565 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 4.4 t -84.93 145.14 27.92 Favored 'General case' 0 C--N 1.316 -0.849 0 N-CA-C 109.622 -0.51 . . . . 0.0 109.622 179.282 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 61.8 p -139.54 128.52 23.6 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-N 115.792 -0.64 . . . . 0.0 112.121 -178.026 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.731 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 3.3 ptm180 -91.68 125.57 36.46 Favored 'General case' 0 N--CA 1.445 -0.697 0 N-CA-C 108.155 -1.054 . . . . 0.0 108.155 177.588 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 54.7 m-20 58.9 28.24 17.28 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-O 121.143 0.497 . . . . 0.0 109.842 -178.319 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 78.87 10.36 86.25 Favored Glycine 0 C--N 1.333 0.374 0 CA-C-N 115.897 -0.592 . . . . 0.0 112.636 -179.413 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 92.1 mt -114.3 126.28 28.18 Favored Pre-proline 0 C--N 1.328 -0.357 0 CA-C-O 120.881 0.372 . . . . 0.0 110.759 -179.961 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_endo -75.28 52.42 3.16 Favored 'Trans proline' 0 CA--C 1.529 0.241 0 C-N-CA 123.159 2.573 . . . . 0.0 112.876 -179.811 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 22.3 t . . . . . 0 C--N 1.323 -0.559 0 CA-C-O 121.389 0.614 . . . . 0.0 110.184 -179.883 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 63.4 m . . . . . 0 N--CA 1.458 -0.061 0 CA-C-O 120.991 0.424 . . . . 0.0 110.104 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 61.45 35.29 90.81 Favored Glycine 0 C--N 1.332 0.348 0 CA-C-N 115.674 -0.694 . . . . 0.0 113.102 179.114 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 9.5 pt-20 -115.9 148.44 40.01 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 120.9 0.381 . . . . 0.0 110.716 179.929 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.438 ' HA ' ' HA ' ' A' ' 21' ' ' ILE . 33.9 p -93.41 118.09 30.88 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 115.965 -0.561 . . . . 0.0 111.182 -179.933 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.798 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 13.5 p -88.87 61.57 6.0 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.287 0.565 . . . . 0.0 110.52 179.298 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 32.8 t80 -55.14 -41.27 71.54 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.561 -0.745 . . . . 0.0 110.235 179.892 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -92.18 22.94 29.49 Favored Glycine 0 N--CA 1.45 -0.43 0 C-N-CA 120.865 -0.683 . . . . 0.0 112.765 179.338 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 76.66 -35.81 1.4 Allowed Glycine 0 CA--C 1.521 0.446 0 C-N-CA 121.23 -0.51 . . . . 0.0 113.938 179.405 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.5 m -89.2 148.37 23.66 Favored 'General case' 0 C--N 1.322 -0.609 0 O-C-N 122.423 -0.457 . . . . 0.0 111.442 -179.093 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 59.9 m -108.69 153.67 23.11 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.711 -0.677 . . . . 0.0 109.515 179.072 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 39.1 t30 -87.53 -29.42 21.33 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-O 121.255 0.55 . . . . 0.0 110.171 179.956 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.443 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 3.8 m -102.48 118.35 58.92 Favored Pre-proline 0 C--N 1.323 -0.571 0 CA-C-N 115.877 -0.601 . . . . 0.0 111.167 -179.485 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.443 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 13.6 Cg_exo -68.76 136.95 37.19 Favored 'Trans proline' 0 N--CA 1.46 -0.479 0 C-N-CA 122.829 2.352 . . . . 0.0 111.719 179.724 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 117.33 -32.66 5.32 Favored Glycine 0 N--CA 1.439 -1.166 0 N-CA-C 111.134 -0.787 . . . . 0.0 111.134 -179.264 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.413 ' HB3' ' HB3' ' A' ' 22' ' ' CYS . 32.9 m -89.45 131.43 35.5 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 120.921 0.391 . . . . 0.0 110.36 179.05 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 16.0 m -89.67 136.15 33.2 Favored 'General case' 0 C--N 1.319 -0.724 0 N-CA-C 109.213 -0.662 . . . . 0.0 109.213 179.556 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 43.2 t -67.66 115.45 7.25 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-O 121.773 0.797 . . . . 0.0 111.031 -179.336 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 2.9 m -118.95 66.96 0.78 Allowed 'General case' 0 C--N 1.309 -1.172 0 N-CA-C 106.332 -1.729 . . . . 0.0 106.332 178.182 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.475 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.3 OUTLIER -27.24 124.6 0.23 Allowed Pre-proline 0 N--CA 1.463 0.196 0 CA-C-N 114.213 -1.358 . . . . 0.0 112.646 -176.314 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.475 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 56.7 Cg_endo -98.77 34.25 8.69 Favored 'Cis proline' 0 N--CA 1.459 -0.52 0 C-N-CA 123.732 -1.362 . . . . 0.0 114.554 1.103 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.438 ' HA ' ' HA ' ' A' ' 4' ' ' THR . 40.8 pt -142.12 136.06 29.09 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.301 0 CA-C-N 118.753 0.706 . . . . 0.0 112.513 -178.939 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.798 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 47.2 m -82.08 131.68 35.24 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.266 178.977 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 65.4 p -142.7 136.7 29.25 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.134 179.785 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.514 ' HG3' ' O ' ' A' ' 24' ' ' ARG . 2.8 ptm180 -94.62 121.86 36.62 Favored 'General case' 0 N--CA 1.443 -0.789 0 N-CA-C 108.153 -1.054 . . . . 0.0 108.153 178.445 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 61.3 m-20 57.36 29.85 17.56 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.134 0.492 . . . . 0.0 109.775 -178.032 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 82.12 1.95 90.46 Favored Glycine 0 CA--C 1.521 0.41 0 CA-C-N 115.801 -0.636 . . . . 0.0 112.667 -179.371 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 88.0 mt -98.87 123.6 48.81 Favored Pre-proline 0 C--O 1.237 0.429 0 CA-C-O 121.074 0.464 . . . . 0.0 111.217 -179.838 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -77.13 69.81 6.93 Favored 'Trans proline' 0 N--CA 1.464 -0.242 0 C-N-CA 123.248 2.632 . . . . 0.0 112.139 179.649 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 47.2 t . . . . . 0 C--N 1.324 -0.504 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.297 -179.396 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 82.0 m . . . . . 0 CA--C 1.524 -0.026 0 CA-C-O 120.92 0.391 . . . . 0.0 110.353 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 76.46 -32.32 1.39 Allowed Glycine 0 CA--C 1.519 0.327 0 CA-C-N 116.117 -0.492 . . . . 0.0 113.85 178.878 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 14.7 pt-20 -53.95 139.31 34.47 Favored 'General case' 0 C--O 1.239 0.509 0 CA-C-O 121.447 0.641 . . . . 0.0 111.889 -178.933 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.612 HG22 HG22 ' A' ' 21' ' ' ILE . 36.2 p -89.44 120.91 31.18 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 115.276 -0.875 . . . . 0.0 110.801 -179.581 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.761 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 25.0 p -88.98 60.96 5.69 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-O 121.253 0.549 . . . . 0.0 110.71 179.651 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 34.4 t80 -53.33 -44.36 68.37 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.525 -0.761 . . . . 0.0 110.993 -179.896 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -92.65 22.63 32.39 Favored Glycine 0 N--CA 1.452 -0.295 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.742 179.788 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 62.55 40.68 99.43 Favored Glycine 0 CA--C 1.518 0.27 0 C-N-CA 121.257 -0.497 . . . . 0.0 112.965 179.514 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.5 m -147.99 149.28 31.87 Favored 'General case' 0 C--N 1.324 -0.513 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 179.919 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 47.2 m -124.76 143.42 50.8 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 179.837 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 63.1 m-80 -88.39 -23.24 23.4 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.276 -179.49 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.401 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 4.3 m -101.72 119.37 57.35 Favored Pre-proline 0 C--N 1.323 -0.582 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.982 -179.148 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.401 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 20.4 Cg_exo -65.55 140.93 64.87 Favored 'Trans proline' 0 N--CA 1.462 -0.324 0 C-N-CA 122.922 2.415 . . . . 0.0 111.939 179.894 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 105.76 -29.9 10.62 Favored Glycine 0 N--CA 1.441 -1.024 0 C-N-CA 120.75 -0.738 . . . . 0.0 111.489 -179.4 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.548 ' HB3' ' HB3' ' A' ' 22' ' ' CYS . 15.7 m -89.04 129.19 35.71 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 121.209 0.528 . . . . 0.0 110.708 179.289 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 19.6 m -94.39 138.51 32.26 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 115.512 -0.767 . . . . 0.0 109.036 179.372 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 43.4 t -66.43 116.16 7.13 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-O 121.593 0.711 . . . . 0.0 111.03 -179.287 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 3.0 m -120.78 68.7 0.87 Allowed 'General case' 0 C--N 1.311 -1.099 0 N-CA-C 106.597 -1.631 . . . . 0.0 106.597 178.422 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.478 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -27.82 125.1 0.23 Allowed Pre-proline 0 N--CA 1.463 0.215 0 O-C-N 124.706 1.253 . . . . 0.0 112.631 -176.52 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.478 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 59.8 Cg_endo -98.54 30.62 12.65 Favored 'Cis proline' 0 CA--C 1.535 0.562 0 C-N-CA 123.613 -1.411 . . . . 0.0 115.061 1.033 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.612 HG22 HG22 ' A' ' 4' ' ' THR . 0.2 OUTLIER -141.62 141.65 29.68 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.293 0 CA-C-N 118.992 0.815 . . . . 0.0 112.122 -179.422 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.761 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 64.6 m -81.1 133.81 35.54 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.586 179.365 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 64.5 p -134.23 132.4 39.65 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-N 115.954 -0.566 . . . . 0.0 110.735 179.856 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.476 ' HG3' ' O ' ' A' ' 24' ' ' ARG . 1.4 ptm180 -91.93 120.25 32.43 Favored 'General case' 0 N--CA 1.443 -0.777 0 N-CA-C 108.185 -1.042 . . . . 0.0 108.185 178.305 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 72.7 m-20 56.6 31.0 18.34 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 121.144 0.497 . . . . 0.0 109.895 -177.437 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 84.0 -0.4 89.45 Favored Glycine 0 CA--C 1.521 0.447 0 CA-C-N 115.885 -0.598 . . . . 0.0 112.907 -179.624 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.488 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 86.9 mt -99.3 122.34 52.31 Favored Pre-proline 0 C--O 1.237 0.41 0 CA-C-O 120.903 0.383 . . . . 0.0 111.155 -179.754 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.488 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 3.4 Cg_exo -74.46 63.78 5.5 Favored 'Trans proline' 0 CA--C 1.528 0.177 0 C-N-CA 123.597 2.865 . . . . 0.0 112.143 179.66 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 48.2 t . . . . . 0 C--N 1.325 -0.479 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.485 -179.233 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 3.0 m . . . . . 0 CA--C 1.527 0.058 0 CA-C-O 120.943 0.402 . . . . 0.0 110.486 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 78.23 -37.16 1.76 Allowed Glycine 0 C--N 1.33 0.226 0 CA-C-N 115.952 -0.567 . . . . 0.0 113.022 179.59 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 8.9 pt-20 -59.77 141.66 54.81 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 121.526 0.679 . . . . 0.0 111.961 -179.331 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.523 HG22 HG22 ' A' ' 21' ' ' ILE . 14.7 p -94.87 124.73 39.08 Favored 'General case' 0 N--CA 1.444 -0.733 0 CA-C-N 115.316 -0.856 . . . . 0.0 109.695 178.982 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 24.4 p -87.98 58.8 5.01 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 121.479 0.657 . . . . 0.0 110.698 -179.419 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 35.3 t80 -56.27 -39.93 73.42 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.309 -0.859 . . . . 0.0 110.038 179.48 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -91.31 22.68 28.54 Favored Glycine 0 N--CA 1.449 -0.486 0 C-N-CA 120.943 -0.646 . . . . 0.0 112.751 179.375 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 77.25 -36.82 1.53 Allowed Glycine 0 CA--C 1.522 0.482 0 C-N-CA 121.36 -0.448 . . . . 0.0 114.081 179.223 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 10.2 t -89.52 164.46 14.79 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-O 121.229 0.537 . . . . 0.0 111.627 -179.083 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 62.0 m -125.69 151.77 46.15 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 114.983 -1.008 . . . . 0.0 109.514 179.28 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 41.4 t30 -88.88 -22.76 22.99 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-O 121.031 0.444 . . . . 0.0 111.198 -178.983 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.453 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 7.8 m -101.14 124.46 41.42 Favored Pre-proline 0 C--N 1.322 -0.59 0 CA-C-O 121.215 0.531 . . . . 0.0 111.955 -178.375 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.453 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 23.8 Cg_exo -63.81 137.48 58.56 Favored 'Trans proline' 0 C--N 1.346 0.411 0 C-N-CA 123.059 2.506 . . . . 0.0 111.47 179.403 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 96.55 -17.39 59.36 Favored Glycine 0 N--CA 1.446 -0.67 0 C-N-CA 120.596 -0.812 . . . . 0.0 111.447 -179.06 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.706 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 81.6 m -87.61 133.06 33.87 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 109.651 -0.5 . . . . 0.0 109.651 179.39 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 15.4 m -108.87 138.11 45.72 Favored 'General case' 0 C--N 1.324 -0.515 0 N-CA-C 109.48 -0.563 . . . . 0.0 109.48 -179.577 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 42.4 t -68.46 127.08 31.69 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 121.752 0.787 . . . . 0.0 111.948 -178.705 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 4.3 m -131.17 60.67 1.65 Allowed 'General case' 0 C--N 1.316 -0.882 0 N-CA-C 106.144 -1.799 . . . . 0.0 106.144 177.891 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.432 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -26.24 126.65 0.2 Allowed Pre-proline 0 N--CA 1.464 0.265 0 CA-C-N 113.951 -1.477 . . . . 0.0 113.002 -176.487 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.432 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 62.3 Cg_endo -97.01 32.32 11.16 Favored 'Cis proline' 0 CA--C 1.532 0.421 0 C-N-CA 123.684 -1.381 . . . . 0.0 114.41 0.842 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.523 HG22 HG22 ' A' ' 4' ' ' THR . 43.8 pt -137.53 140.35 41.76 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.39 0 CA-C-O 121.255 0.55 . . . . 0.0 111.346 -179.234 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.706 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 5.4 t -89.4 144.28 26.18 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-O 121.17 0.509 . . . . 0.0 110.233 179.783 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 43.0 p -138.25 127.14 23.89 Favored 'General case' 0 C--N 1.318 -0.784 0 CA-C-N 115.527 -0.761 . . . . 0.0 111.752 -178.673 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.634 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 3.1 ptm180 -89.53 125.07 35.06 Favored 'General case' 0 N--CA 1.447 -0.618 0 N-CA-C 108.601 -0.889 . . . . 0.0 108.601 178.403 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 53.7 m-20 57.98 28.9 16.87 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.216 0.531 . . . . 0.0 109.958 -178.532 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 78.71 12.06 84.6 Favored Glycine 0 C--N 1.334 0.417 0 CA-C-N 115.875 -0.602 . . . . 0.0 112.457 -179.445 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 88.9 mt -113.72 127.71 26.53 Favored Pre-proline 0 C--O 1.237 0.405 0 CA-C-O 120.857 0.36 . . . . 0.0 110.686 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 70.9 Cg_endo -74.57 51.92 2.74 Favored 'Trans proline' 0 C--N 1.343 0.256 0 C-N-CA 123.292 2.662 . . . . 0.0 112.678 -179.949 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 39.4 t . . . . . 0 C--N 1.322 -0.601 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.222 -179.855 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . 0.541 ' HB3' ' HG2' ' A' ' 3' ' ' GLU . 82.5 m . . . . . 0 N--CA 1.458 -0.065 0 CA-C-O 120.897 0.379 . . . . 0.0 110.239 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 77.47 -34.73 1.57 Allowed Glycine 0 C--N 1.331 0.285 0 CA-C-N 116.034 -0.53 . . . . 0.0 113.436 179.188 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.541 ' HG2' ' HB3' ' A' ' 1' ' ' CYS . 7.0 pt-20 -53.8 139.88 31.76 Favored 'General case' 0 C--O 1.237 0.429 0 CA-C-O 121.528 0.68 . . . . 0.0 112.423 -179.114 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.623 HG22 HG22 ' A' ' 21' ' ' ILE . 31.5 p -89.29 121.22 31.36 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 115.271 -0.877 . . . . 0.0 110.01 179.29 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 23.5 p -88.0 61.14 6.19 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-O 121.382 0.611 . . . . 0.0 110.478 -179.857 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 35.1 t80 -55.11 -41.04 71.17 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.367 -0.833 . . . . 0.0 110.513 179.91 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -91.65 21.58 35.21 Favored Glycine 0 N--CA 1.449 -0.457 0 C-N-CA 120.78 -0.724 . . . . 0.0 112.735 179.51 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 76.7 -33.47 1.41 Allowed Glycine 0 CA--C 1.522 0.51 0 C-N-CA 121.221 -0.514 . . . . 0.0 113.833 179.572 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.7 m -89.11 149.7 23.06 Favored 'General case' 0 C--N 1.321 -0.674 0 O-C-N 122.538 -0.389 . . . . 0.0 111.443 -179.184 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 58.3 m -114.76 152.68 31.66 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.761 -0.654 . . . . 0.0 109.301 179.017 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 36.4 t30 -87.8 -28.52 21.61 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-O 121.215 0.531 . . . . 0.0 110.537 -179.534 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.407 ' HA ' ' HD3' ' A' ' 13' ' ' PRO . 8.2 m -101.63 120.99 52.82 Favored Pre-proline 0 C--N 1.32 -0.681 0 CA-C-N 115.967 -0.56 . . . . 0.0 111.563 -178.871 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.407 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 17.3 Cg_exo -66.62 143.84 69.96 Favored 'Trans proline' 0 N--CA 1.463 -0.316 0 C-N-CA 123.178 2.585 . . . . 0.0 111.888 179.741 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 105.02 -29.59 11.43 Favored Glycine 0 N--CA 1.443 -0.862 0 C-N-CA 120.676 -0.774 . . . . 0.0 111.555 -179.443 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.663 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 9.2 m -87.98 138.87 31.08 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 121.131 0.491 . . . . 0.0 110.158 179.169 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 15.2 m -102.57 141.54 35.22 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 115.645 -0.707 . . . . 0.0 109.099 179.936 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 48.9 t -73.17 114.62 11.56 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-O 121.597 0.713 . . . . 0.0 111.661 -178.908 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 17.0 m -117.42 66.98 0.74 Allowed 'General case' 0 C--N 1.311 -1.103 0 N-CA-C 106.353 -1.721 . . . . 0.0 106.353 177.468 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.486 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.4 OUTLIER -29.08 127.39 0.24 Allowed Pre-proline 0 N--CA 1.463 0.225 0 CA-C-N 114.102 -1.408 . . . . 0.0 112.753 -176.47 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.486 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 59.5 Cg_endo -97.85 32.77 10.31 Favored 'Cis proline' 0 N--CA 1.46 -0.5 0 C-N-CA 123.68 -1.383 . . . . 0.0 114.304 0.918 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.623 HG22 HG22 ' A' ' 4' ' ' THR . 42.0 pt -138.3 137.48 43.9 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 121.443 0.639 . . . . 0.0 111.873 -179.135 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.663 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 3.4 t -85.42 139.74 31.29 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-O 121.309 0.576 . . . . 0.0 109.498 179.284 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.584 HG22 ' HA ' ' A' ' 28' ' ' PRO . 11.7 p -147.85 133.38 18.71 Favored 'General case' 0 C--N 1.313 -1.012 0 CA-C-N 115.279 -0.873 . . . . 0.0 111.297 -178.259 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.509 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 3.1 ptm180 -92.25 124.47 36.34 Favored 'General case' 0 N--CA 1.449 -0.507 0 N-CA-C 108.81 -0.811 . . . . 0.0 108.81 178.774 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 46.3 m-20 57.53 30.34 18.55 Favored 'General case' 0 N--CA 1.467 0.383 0 N-CA-C 109.384 -0.599 . . . . 0.0 109.384 -178.431 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 76.89 8.53 86.68 Favored Glycine 0 CA--C 1.521 0.423 0 CA-C-N 115.511 -0.768 . . . . 0.0 112.559 -179.116 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 86.8 mt -105.41 129.13 25.23 Favored Pre-proline 0 C--O 1.239 0.545 0 CA-C-O 121.057 0.456 . . . . 0.0 111.059 -179.661 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.584 ' HA ' HG22 ' A' ' 23' ' ' THR . 74.3 Cg_endo -75.42 62.94 6.3 Favored 'Trans proline' 0 C--N 1.343 0.262 0 C-N-CA 123.372 2.715 . . . . 0.0 112.583 179.84 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 48.5 t . . . . . 0 C--N 1.323 -0.578 0 CA-C-O 121.324 0.583 . . . . 0.0 110.177 -179.661 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 3.8 m . . . . . 0 CA--C 1.528 0.101 0 CA-C-O 121.141 0.496 . . . . 0.0 109.672 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 76.15 -36.38 1.3 Allowed Glycine 0 C--N 1.333 0.366 0 CA-C-N 115.6 -0.727 . . . . 0.0 113.777 178.691 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -60.13 138.54 57.87 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 121.621 0.724 . . . . 0.0 111.953 -178.805 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.466 ' HB ' ' CD1' ' A' ' 6' ' ' PHE . 30.8 p -89.62 118.99 29.65 Favored 'General case' 0 N--CA 1.446 -0.657 0 CA-C-N 115.271 -0.877 . . . . 0.0 109.734 179.245 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 26.2 p -88.62 58.02 4.47 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 121.066 0.46 . . . . 0.0 111.489 -179.034 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . 0.466 ' CD1' ' HB ' ' A' ' 4' ' ' THR . 4.7 m-85 -58.29 -36.56 73.49 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.334 179.049 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -88.99 19.07 40.37 Favored Glycine 0 N--CA 1.45 -0.414 0 C-N-CA 120.86 -0.686 . . . . 0.0 112.611 179.426 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 76.09 -32.77 1.3 Allowed Glycine 0 CA--C 1.524 0.598 0 C-N-CA 121.379 -0.439 . . . . 0.0 113.999 179.353 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 8.9 t -89.24 165.25 14.55 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.238 0.542 . . . . 0.0 111.561 -179.059 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 70.4 m -130.74 147.53 52.41 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.092 -0.958 . . . . 0.0 109.793 179.489 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 64.0 m-80 -89.43 -17.19 29.23 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.925 -0.58 . . . . 0.0 111.212 -178.979 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.422 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 4.6 m -101.22 123.25 45.51 Favored Pre-proline 0 C--N 1.323 -0.568 0 CA-C-O 121.091 0.472 . . . . 0.0 111.335 -178.635 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 29.4 Cg_endo -63.48 135.03 47.48 Favored 'Trans proline' 0 C--N 1.344 0.299 0 C-N-CA 122.859 2.372 . . . . 0.0 111.941 179.674 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 95.2 -16.35 61.47 Favored Glycine 0 N--CA 1.445 -0.703 0 C-N-CA 120.637 -0.792 . . . . 0.0 111.867 -179.454 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.687 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 99.6 m -87.31 133.65 33.67 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 121.073 0.463 . . . . 0.0 109.906 179.644 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 15.7 m -109.34 137.83 46.61 Favored 'General case' 0 C--N 1.324 -0.522 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 -179.925 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 44.7 t -66.71 128.2 35.35 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-O 121.718 0.77 . . . . 0.0 112.182 -178.428 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 4.4 m -132.4 61.01 1.67 Allowed 'General case' 0 C--N 1.316 -0.867 0 N-CA-C 106.221 -1.77 . . . . 0.0 106.221 177.953 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.481 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.1 OUTLIER -25.76 126.44 0.19 Allowed Pre-proline 0 N--CA 1.466 0.359 0 CA-C-N 113.931 -1.486 . . . . 0.0 113.037 -176.537 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.481 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 67.0 Cg_endo -96.85 30.91 13.07 Favored 'Cis proline' 0 CA--C 1.532 0.421 0 C-N-CA 123.757 -1.351 . . . . 0.0 114.515 0.805 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 43.3 pt -137.34 140.92 41.16 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.424 0 CA-C-O 121.273 0.558 . . . . 0.0 111.371 -179.154 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.687 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 4.5 t -88.41 143.99 26.65 Favored 'General case' 0 C--N 1.314 -0.943 0 CA-C-O 121.259 0.552 . . . . 0.0 110.267 179.908 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.467 HG22 ' HA ' ' A' ' 28' ' ' PRO . 68.5 p -138.04 127.61 24.98 Favored 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 115.433 -0.803 . . . . 0.0 111.316 -178.778 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.678 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 3.2 ptm180 -92.73 124.28 36.62 Favored 'General case' 0 N--CA 1.445 -0.687 0 N-CA-C 108.794 -0.817 . . . . 0.0 108.794 178.447 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 53.7 m-20 57.76 28.94 16.64 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.172 0.511 . . . . 0.0 109.744 -178.271 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 82.44 3.65 90.45 Favored Glycine 0 N--CA 1.449 -0.447 0 CA-C-N 115.854 -0.612 . . . . 0.0 112.683 -179.461 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 86.0 mt -101.18 121.06 53.3 Favored Pre-proline 0 C--O 1.236 0.352 0 O-C-N 122.623 -0.339 . . . . 0.0 110.75 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.467 ' HA ' HG22 ' A' ' 23' ' ' THR . 72.3 Cg_endo -77.06 47.34 2.19 Favored 'Trans proline' 0 C--N 1.342 0.217 0 C-N-CA 123.062 2.508 . . . . 0.0 112.601 179.828 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 11.6 p . . . . . 0 C--N 1.321 -0.667 0 CA-C-N 115.537 -0.756 . . . . 0.0 110.239 179.999 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . 0.567 ' SG ' ' HB3' ' A' ' 24' ' ' ARG . 1.8 m . . . . . 0 N--CA 1.458 -0.058 0 CA-C-O 121.007 0.432 . . . . 0.0 110.339 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 76.04 -34.37 1.27 Allowed Glycine 0 CA--C 1.519 0.31 0 CA-C-N 115.865 -0.607 . . . . 0.0 113.287 179.515 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -54.56 140.62 34.22 Favored 'General case' 0 C--O 1.239 0.528 0 CA-C-O 121.658 0.742 . . . . 0.0 112.393 -179.001 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.579 HG23 ' O ' ' A' ' 20' ' ' PRO . 67.8 m -88.89 114.5 25.58 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.059 -0.973 . . . . 0.0 109.984 179.587 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 26.6 p -88.6 58.43 4.66 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 121.324 0.583 . . . . 0.0 110.458 -179.803 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 34.0 t80 -52.69 -44.96 66.62 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.309 -0.859 . . . . 0.0 111.194 -179.726 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -94.06 24.46 26.64 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.582 -0.818 . . . . 0.0 112.781 179.764 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.48 40.38 98.61 Favored Glycine 0 CA--C 1.518 0.264 0 C-N-CA 121.136 -0.554 . . . . 0.0 112.88 179.595 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.3 m -142.45 150.19 40.23 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 109.968 -0.382 . . . . 0.0 109.968 179.996 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 57.5 m -132.82 142.02 48.76 Favored 'General case' 0 C--N 1.324 -0.539 0 N-CA-C 110.025 -0.361 . . . . 0.0 110.025 179.869 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 43.6 t30 -89.31 -15.0 34.48 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.842 -0.617 . . . . 0.0 111.229 -179.081 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.635 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 5.7 m -100.67 125.3 39.33 Favored Pre-proline 0 C--N 1.323 -0.549 0 CA-C-O 121.252 0.549 . . . . 0.0 111.509 -178.754 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 28.7 Cg_endo -63.58 131.93 33.5 Favored 'Trans proline' 0 C--N 1.347 0.457 0 C-N-CA 122.999 2.466 . . . . 0.0 112.438 -179.819 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 95.08 -8.62 70.08 Favored Glycine 0 N--CA 1.447 -0.587 0 C-N-CA 120.894 -0.67 . . . . 0.0 111.737 -179.472 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.812 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 84.7 m -88.06 131.62 34.6 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-O 121.127 0.489 . . . . 0.0 110.133 179.63 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 13.3 m -109.49 136.45 48.86 Favored 'General case' 0 C--N 1.324 -0.538 0 N-CA-C 108.925 -0.769 . . . . 0.0 108.925 179.906 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 50.2 t -71.89 119.92 16.76 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-O 121.366 0.603 . . . . 0.0 112.106 -178.631 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 18.4 m -123.89 67.21 1.03 Allowed 'General case' 0 C--N 1.315 -0.903 0 N-CA-C 106.624 -1.621 . . . . 0.0 106.624 177.697 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.447 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.2 OUTLIER -29.03 127.51 0.23 Allowed Pre-proline 0 N--CA 1.464 0.234 0 CA-C-N 114.092 -1.413 . . . . 0.0 112.862 -176.721 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.579 ' O ' HG23 ' A' ' 4' ' ' THR . 65.6 Cg_endo -97.71 33.24 9.85 Favored 'Cis proline' 0 N--CA 1.46 -0.484 0 C-N-CA 123.767 -1.347 . . . . 0.0 114.23 0.822 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 41.8 pt -139.59 137.37 40.02 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-O 121.425 0.631 . . . . 0.0 111.632 -179.182 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.812 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 6.2 t -84.27 143.18 29.72 Favored 'General case' 0 C--N 1.316 -0.885 0 CA-C-O 121.311 0.576 . . . . 0.0 109.791 179.222 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.411 HG22 ' HA ' ' A' ' 28' ' ' PRO . 14.9 p -138.28 125.82 22.04 Favored 'General case' 0 C--N 1.314 -0.943 0 CA-C-N 115.239 -0.892 . . . . 0.0 111.378 -178.497 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.567 ' HB3' ' SG ' ' A' ' 1' ' ' CYS . 0.0 OUTLIER -91.1 129.3 37.11 Favored 'General case' 0 C--N 1.324 -0.537 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 178.864 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.453 ' CG ' ' HD3' ' A' ' 24' ' ' ARG . 54.8 m-20 54.6 30.03 12.48 Favored 'General case' 0 C--N 1.324 -0.529 0 O-C-N 123.85 0.719 . . . . 0.0 110.382 -178.844 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 77.46 13.97 82.98 Favored Glycine 0 C--N 1.335 0.498 0 CA-C-N 115.803 -0.635 . . . . 0.0 112.652 -179.583 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 90.2 mt -117.46 132.23 23.67 Favored Pre-proline 0 C--O 1.236 0.354 0 CA-C-O 120.825 0.345 . . . . 0.0 110.831 -179.888 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.411 ' HA ' HG22 ' A' ' 23' ' ' THR . 70.8 Cg_endo -74.6 53.68 3.22 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 123.116 2.544 . . . . 0.0 112.673 -179.95 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 40.9 t . . . . . 0 C--N 1.323 -0.58 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.404 -179.85 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 67.9 m . . . . . 0 N--CA 1.458 -0.051 0 CA-C-O 120.905 0.383 . . . . 0.0 110.195 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 60.14 38.11 93.9 Favored Glycine 0 C--N 1.333 0.381 0 CA-C-N 115.74 -0.663 . . . . 0.0 112.694 179.299 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -117.87 151.77 36.72 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 120.86 0.362 . . . . 0.0 110.848 -179.789 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.491 HG23 ' O ' ' A' ' 20' ' ' PRO . 28.2 m -96.66 118.67 33.63 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-N 115.893 -0.594 . . . . 0.0 111.051 179.811 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.716 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 7.6 p -88.45 61.2 6.02 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-O 121.262 0.553 . . . . 0.0 109.699 178.826 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 13.2 t80 -54.26 -41.51 68.91 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.35 -0.841 . . . . 0.0 110.28 -179.548 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -91.94 22.98 28.65 Favored Glycine 0 N--CA 1.449 -0.488 0 C-N-CA 120.926 -0.654 . . . . 0.0 112.611 179.325 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 78.71 -38.28 1.91 Allowed Glycine 0 CA--C 1.522 0.483 0 C-N-CA 121.251 -0.5 . . . . 0.0 113.631 179.447 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.4 m -89.49 147.38 24.02 Favored 'General case' 0 C--N 1.321 -0.65 0 O-C-N 122.498 -0.413 . . . . 0.0 111.49 -179.348 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 62.9 m -104.49 154.82 19.41 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.759 -0.655 . . . . 0.0 109.394 178.834 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 39.7 t30 -87.64 -26.7 22.89 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-O 121.135 0.493 . . . . 0.0 110.496 -179.717 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . . . . . . . . . 3.7 m -102.12 120.42 53.7 Favored Pre-proline 0 C--N 1.324 -0.54 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.283 -179.268 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_exo -65.71 140.62 62.67 Favored 'Trans proline' 0 N--CA 1.461 -0.385 0 C-N-CA 122.943 2.428 . . . . 0.0 111.846 179.693 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 105.1 -28.91 12.74 Favored Glycine 0 N--CA 1.441 -0.976 0 C-N-CA 120.717 -0.754 . . . . 0.0 111.66 -179.356 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.578 ' HB3' ' HB3' ' A' ' 22' ' ' CYS . 2.0 m -87.64 131.55 34.4 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 121.273 0.559 . . . . 0.0 110.546 179.402 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 13.6 m -91.53 140.52 29.67 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.482 -0.781 . . . . 0.0 109.168 179.59 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 39.9 t -75.52 111.14 10.51 Favored 'General case' 0 C--N 1.32 -0.714 0 CA-C-O 121.645 0.736 . . . . 0.0 111.598 -179.121 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 11.7 m -114.47 65.43 0.67 Allowed 'General case' 0 C--N 1.308 -1.197 0 N-CA-C 106.254 -1.758 . . . . 0.0 106.254 177.385 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.527 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.5 OUTLIER -28.66 125.78 0.24 Allowed Pre-proline 0 N--CA 1.464 0.252 0 CA-C-N 114.072 -1.422 . . . . 0.0 112.574 -176.583 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.527 ' HA ' ' HA ' ' A' ' 19' ' ' TRP . 65.0 Cg_endo -98.4 38.03 5.84 Favored 'Cis proline' 0 N--CA 1.459 -0.54 0 C-N-CA 123.963 -1.265 . . . . 0.0 114.109 0.899 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 2.3 pp -143.43 133.02 20.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 121.541 0.686 . . . . 0.0 112.457 -178.938 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.716 ' SG ' ' HB3' ' A' ' 5' ' ' CYS . 63.8 m -83.0 134.46 35.05 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.411 179.225 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . . . . . . . . . 5.2 p -138.56 130.56 28.22 Favored 'General case' 0 C--N 1.317 -0.843 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.038 -179.746 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.432 ' HG3' ' O ' ' A' ' 24' ' ' ARG . 9.6 ptm180 -97.5 127.82 43.77 Favored 'General case' 0 N--CA 1.448 -0.541 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 178.764 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 27.9 m-20 58.52 27.43 15.61 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.439 0.637 . . . . 0.0 109.504 -178.692 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 77.38 7.86 87.02 Favored Glycine 0 N--CA 1.449 -0.471 0 CA-C-N 115.411 -0.813 . . . . 0.0 112.389 -178.984 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.434 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 91.6 mt -109.59 131.57 21.82 Favored Pre-proline 0 C--O 1.238 0.451 0 CA-C-O 121.158 0.504 . . . . 0.0 111.293 -179.666 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.434 ' HD3' ' HA ' ' A' ' 27' ' ' LEU . 5.0 Cg_exo -77.06 65.4 7.81 Favored 'Trans proline' 0 N--CA 1.463 -0.32 0 C-N-CA 123.656 2.904 . . . . 0.0 111.95 179.594 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 47.8 t . . . . . 0 C--N 1.325 -0.465 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.594 -179.166 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 CA--C 1.526 0.035 0 CA-C-O 121.046 0.45 . . . . 0.0 110.299 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 60.37 38.63 94.99 Favored Glycine 0 C--N 1.332 0.348 0 CA-C-N 115.535 -0.757 . . . . 0.0 112.796 179.353 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.433 ' HG3' ' HB3' ' A' ' 22' ' ' CYS . 10.9 pt-20 -125.0 143.19 51.03 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 121.187 0.517 . . . . 0.0 111.259 -179.731 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.545 HG23 ' O ' ' A' ' 20' ' ' PRO . 87.9 m -89.18 111.46 22.25 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.643 -0.708 . . . . 0.0 110.376 179.85 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 25.3 p -88.77 58.98 4.87 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 121.287 0.565 . . . . 0.0 110.468 -179.995 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 33.6 t80 -52.92 -46.01 67.88 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 115.378 -0.828 . . . . 0.0 111.233 -179.688 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -92.56 24.04 25.15 Favored Glycine 0 C--O 1.227 -0.291 0 C-N-CA 120.579 -0.82 . . . . 0.0 112.728 179.73 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 61.83 36.72 93.2 Favored Glycine 0 C--O 1.228 -0.252 0 C-N-CA 121.2 -0.524 . . . . 0.0 112.666 179.694 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 1.7 m -136.06 148.95 48.56 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 -179.958 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 60.3 m -129.33 141.57 51.05 Favored 'General case' 0 C--N 1.322 -0.628 0 O-C-N 123.218 0.324 . . . . 0.0 110.246 179.9 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 44.0 t30 -89.06 -17.3 29.6 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 115.804 -0.635 . . . . 0.0 110.614 -179.592 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.522 ' HB ' ' SG ' ' A' ' 15' ' ' CYS . 4.3 m -101.31 123.46 44.62 Favored Pre-proline 0 C--N 1.322 -0.596 0 CA-C-O 121.14 0.495 . . . . 0.0 111.33 -178.939 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.447 ' HD3' ' HA ' ' A' ' 12' ' ' THR . 23.4 Cg_exo -64.18 136.65 52.77 Favored 'Trans proline' 0 C--N 1.345 0.349 0 C-N-CA 123.017 2.478 . . . . 0.0 112.013 179.948 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 92.85 -12.27 70.26 Favored Glycine 0 N--CA 1.447 -0.596 0 C-N-CA 120.79 -0.719 . . . . 0.0 111.881 -179.626 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.673 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 98.9 m -87.55 134.4 33.63 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 121.125 0.488 . . . . 0.0 110.308 179.773 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 12.6 m -107.4 137.55 45.23 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.637 -0.71 . . . . 0.0 109.104 -179.88 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 53.9 t -72.95 115.52 12.35 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-O 121.496 0.665 . . . . 0.0 111.961 -178.739 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 8.7 m -116.29 66.49 0.71 Allowed 'General case' 0 C--N 1.312 -1.03 0 N-CA-C 106.515 -1.661 . . . . 0.0 106.515 177.478 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.447 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.2 OUTLIER -28.82 126.86 0.23 Allowed Pre-proline 0 N--CA 1.464 0.229 0 CA-C-N 114.303 -1.317 . . . . 0.0 112.841 -176.559 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.545 ' O ' HG23 ' A' ' 4' ' ' THR . 62.6 Cg_endo -97.21 32.79 10.48 Favored 'Cis proline' 0 CA--C 1.532 0.396 0 C-N-CA 123.676 -1.385 . . . . 0.0 114.293 0.93 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 44.2 pt -138.97 133.87 41.41 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.423 0 CA-C-O 121.451 0.643 . . . . 0.0 111.888 -179.239 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.673 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 7.0 t -83.48 142.87 30.62 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-O 121.22 0.533 . . . . 0.0 109.746 179.202 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.559 HG22 ' HA ' ' A' ' 28' ' ' PRO . 14.9 p -145.33 131.99 19.93 Favored 'General case' 0 C--N 1.314 -0.949 0 CA-C-N 115.276 -0.875 . . . . 0.0 111.293 -178.399 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.535 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 0.0 OUTLIER -92.39 128.51 38.26 Favored 'General case' 0 N--CA 1.448 -0.555 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 178.38 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 18.6 m-20 56.57 28.45 13.94 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.191 0.52 . . . . 0.0 109.963 -179.253 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 76.79 13.16 83.87 Favored Glycine 0 C--N 1.333 0.409 0 CA-C-N 115.745 -0.661 . . . . 0.0 112.362 -179.089 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . 0.486 ' HA ' ' HD3' ' A' ' 28' ' ' PRO . 87.2 mt -112.49 129.55 24.26 Favored Pre-proline 0 C--O 1.241 0.655 0 CA-C-O 120.887 0.375 . . . . 0.0 110.858 -179.847 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.559 ' HA ' HG22 ' A' ' 23' ' ' THR . 2.8 Cg_exo -75.54 54.14 3.8 Favored 'Trans proline' 0 C--N 1.342 0.216 0 C-N-CA 123.718 2.945 . . . . 0.0 112.468 -179.95 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 45.4 t . . . . . 0 C--N 1.323 -0.553 0 CA-C-O 121.331 0.586 . . . . 0.0 110.141 -179.748 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' CYS . . . . . 0.415 ' SG ' ' HB ' ' A' ' 12' ' ' THR . 61.4 m . . . . . 0 N--CA 1.458 -0.043 0 CA-C-O 121.037 0.446 . . . . 0.0 109.806 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 60.26 32.95 78.33 Favored Glycine 0 C--N 1.332 0.347 0 CA-C-N 115.497 -0.774 . . . . 0.0 113.204 179.087 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.463 ' HG3' ' HB3' ' A' ' 22' ' ' CYS . 9.3 pt-20 -105.71 145.54 30.96 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 121.045 0.45 . . . . 0.0 111.015 179.901 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.511 HG23 ' O ' ' A' ' 20' ' ' PRO . 58.3 m -88.83 110.0 20.67 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.89 -0.596 . . . . 0.0 110.399 179.91 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 25.8 p -88.78 59.71 5.2 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 121.429 0.633 . . . . 0.0 110.536 -179.941 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' PHE . . . . . . . . . . . . . 34.8 t80 -53.64 -43.78 69.02 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.286 -0.87 . . . . 0.0 111.165 -179.75 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' GLY . . . . . . . . . . . . . . . -88.23 18.54 40.52 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.743 -0.741 . . . . 0.0 113.004 179.905 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' GLY . . . . . . . . . . . . . . . 64.56 37.61 94.63 Favored Glycine 0 N--CA 1.453 -0.233 0 C-N-CA 121.077 -0.582 . . . . 0.0 112.656 179.668 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' THR . . . . . . . . . . . . . 2.6 m -147.38 149.52 32.92 Favored 'General case' 0 C--N 1.324 -0.522 0 N-CA-C 109.665 -0.494 . . . . 0.0 109.665 179.92 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' CYS . . . . . . . . . . . . . 43.4 m -121.45 146.0 47.35 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.239 -179.899 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' ASN . . . . . . . . . . . . . 39.1 t30 -88.26 -23.45 23.5 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.154 -179.787 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' THR . . . . . 0.415 ' HB ' ' SG ' ' A' ' 1' ' ' CYS . 2.9 m -101.95 121.11 51.88 Favored Pre-proline 0 C--N 1.323 -0.582 0 CA-C-N 115.999 -0.546 . . . . 0.0 111.413 -178.977 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 22.2 Cg_exo -64.74 141.5 72.5 Favored 'Trans proline' 0 C--N 1.344 0.298 0 C-N-CA 123.021 2.48 . . . . 0.0 111.854 179.76 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . . . . . . . . . . . 101.62 -28.17 17.16 Favored Glycine 0 N--CA 1.445 -0.747 0 C-N-CA 120.687 -0.768 . . . . 0.0 111.615 -179.331 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.849 ' HB3' ' SG ' ' A' ' 22' ' ' CYS . 1.6 m -86.97 136.85 32.78 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 121.136 0.493 . . . . 0.0 110.191 179.446 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 14.2 m -105.26 140.18 38.8 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.596 -0.729 . . . . 0.0 109.314 -179.745 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' CYS . . . . . . . . . . . . . 53.9 t -72.37 112.33 8.34 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.482 0.658 . . . . 0.0 111.709 -178.887 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . . . . . . . . . 14.1 m -114.54 66.91 0.68 Allowed 'General case' 0 C--N 1.312 -1.052 0 N-CA-C 106.554 -1.647 . . . . 0.0 106.554 177.624 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' TRP . . . . . 0.472 ' HA ' ' HA ' ' A' ' 20' ' ' PRO . 0.2 OUTLIER -28.91 127.01 0.23 Allowed Pre-proline 0 N--CA 1.464 0.266 0 CA-C-N 114.24 -1.345 . . . . 0.0 112.833 -176.631 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' PRO . . . . . 0.511 ' O ' HG23 ' A' ' 4' ' ' THR . 62.2 Cg_endo -97.1 31.85 11.75 Favored 'Cis proline' 0 N--CA 1.46 -0.443 0 C-N-CA 123.627 -1.406 . . . . 0.0 114.213 0.968 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . . . . . . . . . 43.0 pt -138.56 133.61 42.53 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-O 121.663 0.744 . . . . 0.0 112.025 -179.174 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.849 ' SG ' ' HB3' ' A' ' 15' ' ' CYS . 8.0 t -83.54 140.1 32.47 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-N 115.927 -0.578 . . . . 0.0 109.547 179.011 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' THR . . . . . 0.569 HG22 ' HA ' ' A' ' 28' ' ' PRO . 7.9 p -148.76 135.5 19.76 Favored 'General case' 0 C--N 1.313 -0.982 0 CA-C-N 115.274 -0.875 . . . . 0.0 111.342 -178.104 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' ARG . . . . . 0.499 ' HG3' ' O ' ' A' ' 24' ' ' ARG . 4.8 ptm180 -93.92 126.29 39.04 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 178.576 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 58.52 27.23 15.32 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.36 0.6 . . . . 0.0 109.404 -179.069 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 77.57 9.31 86.94 Favored Glycine 0 C--N 1.333 0.392 0 CA-C-N 115.504 -0.771 . . . . 0.0 112.251 -178.885 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 88.4 mt -108.07 131.12 21.96 Favored Pre-proline 0 C--O 1.24 0.558 0 CA-C-O 121.092 0.472 . . . . 0.0 111.091 -179.724 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.569 ' HA ' HG22 ' A' ' 23' ' ' THR . 74.2 Cg_endo -76.14 64.3 7.01 Favored 'Trans proline' 0 C--N 1.341 0.158 0 C-N-CA 123.269 2.646 . . . . 0.0 112.48 179.946 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 55.5 t . . . . . 0 C--N 1.324 -0.532 0 CA-C-O 121.285 0.564 . . . . 0.0 110.163 -179.759 . . . . . . . . 0 0 . 1 stop_ save_